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Abstract	
	
Over	a	million	men	world-wide	are	affected	by	prostate	cancer,	with	the	disease	particularly	prevalent	in	Australia,	with	more	than	20,000	men	diagnosed	annually	across	the	country.	There	remain	significant	clinical	challenges	in	diagnosis	and	treatment.	A	family	history	is	a	major	risk	factor,	indicating	an	underlying	genetic	component,	yet	the	majority	of	inherited	factors	contributing	to	disease	remain	to	be	elucidated.		Identifying	this	unaccounted	heritable	contribution	will	extend	our	understanding	of	prostate	cancer	development	and	progression,	and	has	the	potential	to	improve	diagnosis	and	treatment.		
It	is	becoming	evident	that	high-risk	genetic	variants	often	occur	in	regulatory	regions	of	genes,	the	primary	sites	of	epigenetic	regulation,	therefore	mapping	epigenetic	changes	may	shed	some	light	on	missing	heritiability.	Epigenetic	marks	are	chemical	modifications	to	DNA	or	it’s	associated	proteins,	that	do	not	alter	the	genomic	sequence,	yet	play	a	key	role	in	regulating	gene	expression.	DNA	methylation,	the	most	frequently	studied	epigenetic	mark,	is	influenced	by	a	range	of	intrinsic	and	external	factors	including	diet,	lifestyle	and	age.	However,	it	is	becoming	increasingly	apparent	that	genetic	drivers	may	have	the	greatest	influence	on	epigenetic	patterns.	While	genetically	driven	epigenetic	profiles	contribute	to	natural	phenotypic	variation,	such	alterations	may	also	underpin	part	of	the	unexplained	inherited	contribution	to	complex	disease	risk.		
Large	pedigrees	with	clusters	of	affected	individuals	can	provide	invaluable	insight	into	complex	diseases,	affording	reduced	genetic	complexity.			As	such,	this	study	utilises	the	unique	Tasmanian	Familial	Prostate	Cancer	Resource	to	
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further	understand	the	inherited	drivers	of	epigenetic	change	that	can	pre-dispose	men	to	prostate	cancer.	Particularly,	this	study	focuses	on	identifying	genetic	variants	that	may	trigger	DNA	methylation	changes	in	regulatory	regions	of	the	genome.	Such	variants	have	been	termed	methylation	quantitative	trait	loci,	or	meQTLs,	and	can	be	examined	in	a	similar	manner	to	expression	quantitative	trait	loci.	
Clusters	of	affected	men,	representing	dense	aggregates	of	prostate	cancer	incidence	often	spanning	up	to	five	generation,	were	selected	from	four	large	families	in	the	Tasmanian	Familial	Prostate	Cancer	Study.	Samples	were	analysed	for	genotype	and	methylation	profiles,	initially	using	array	based	techniques	which	were	then	validated	and	extended	with	bisulphite	sequencing.	
Fundamental	to	analyses	of	methylome	data	is	normalization	and	batch	correction,	to	ensure	unwanted	technical	bias	is	removed	while	maintaining	the	biological	information	of	interest.	While	pre-processing	methodologies	were	available	for	analysis	of	matched	disease	and	control	samples,	the	development	of	an	optomised	pre-processing	pipeline	for	the	analysis	of	famililal	data	was	required.	Specifically,	this	included	testing	a	range	of	normalisation	methods	with	qualitative	and	quantitative	performance	metrics	to	determine	which	method	was	the	most	appropriate	and	effective	on	familial	data.			
Potential	meQTLs	of	interest	were	then	identified	through	two	distinct	approaches.	The	first	approach	prioritised	the	most	variable	methylation	sites	between	individuals,	while	the	second	approach	examined	methylation	surrounding	previously	identified	prostate	cancer	risk	loci.	To	test	the	selected	meQTLs,	methylation	data	was	combined	with	genotype	using	a	generalized	
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linear	model	accounting	for	kinship.	After	adjusting	for	multiple	testing	error,	significant	associations	were	prioritised	using	the	following	criteria;	proximity	to	prostate	cancer	relevant	genes	and	the	presence	of	key	regulatory	elements.	Through	bisulphite	sequencing,	prioritised	meQTLs	were	initially	validated,	followed	by	finer	mapping	of	the	influence	of	meQTLs	on	surrounding	methylation	profiles.		Additionally,	unaffected	controls	were	drawn	from	the	Tasmanian	Prostate	Cancer	Case	Control	Study	to	examine	differential	methylation	patterns	between	affected	and	unaffected	individuals,	with	the	aim	of	identifying	predisposing	variants.		Using	this	approach	an	meQTL	associated	with	the	tumour	suppressor	gene	CASZ1	was	identified.	This	meQTL,	located	at	1p36.22,	showed	genetically	driven	methylation	patterns	at	the	SNP,	which	extended	approximately	150bp	either	side,	to	two	additional	CpGs.	Distinct	differential	methylation	profiles	were	also	observed	between	cancer	and	control	groups	for	the	CASZ1	region.	This	meQTL	provides	an	intriguing	basis	for	further	investigation	as	dysregulation	of	the	gene	has	been	associated	with	an	aggressive	prostate	cancer	phenotype.		
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Chapter	1	-	Introduction	
	
	
1.1	Prostate	Cancer	Incidence	and	Mortality	
Prostate	cancer	considerably	impacts	on	the	life	expectancy	and	quality	of	life	of	
millions	of	men	and	their	families	world-wide.	Globally,	prostate	cancer	is	the	second	
most	common	cancer	in	men	with	around	1.1	million	men	diagnosed	in	2012	(Ferlay	
et	al.	2015),	as	shown	in	Figure	1.1A,	which	depicts	global	incidence	and	mortality	
rates	of	prostate	cancer	relative	to	other	common	cancers.	The	disease	affects	a	
significant	number	of	Australian	men,	with	just	over	20,000	men	diagnosed	in	2012	
and	17,250	new	cases	estimated	to	have	been	diagnosed	in	2015,	comprising	almost	
a	quarter	of	all	male	cancer	cases	that	year	(AIHW,	2016).	Figure	1.1B	highlights	
Australia-specific	incidence	rates	relative	to	other	common	cancers.	A	considerable	
number	of	men	die	from	prostate	cancer	in	Australia,	with	3,112	deaths	reported	in	
2013,	accounting	for	13%	of	all	cancer	deaths	that	year,	making	it	the	second	
deadliest	cancer	after	lung	cancer	(AIHW,	2014),	as	depicted	in	Figure	1.1B,	
illustrating	Australia-specific	mortality	rates	relative	to	other	common	cancers.		
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Figure	1.1	Incidence	and	mortality	rates	for	various	cancers	in	2012.	
Estimated	age-standardised	incidence	and	mortality	rates	for	men	across	various	
cancer	sub-types	(A)	globally	and	(B)	specific	to	Australia	and	New	Zealand.	Adapted	
from	the	World	Health	Organisation’s	GLOBOCAN	project,	2012.		 ASR	(W):	Age-
standardised	rates	(world	population)
A
B
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Due	to	the	widespread	practise	of	prostate	specific-antigen	testing	and	subsequent	
biopsies,	Australia	and	New	Zealand	have	the	highest	reported	incidence	of	prostate	
cancer	worldwide,	with	111.6	men	per	100,000	diagnosed	annually	((Ferlay	et	al.	2015),	see	Figure	1.1B).	Prostate	cancer	is	particularly	pertinent	for	Tasmania	men,	
with	446	men	diagnosed	in	2012,	at	an	incidence	of	174.6	per	100,000,	compared	to	
the	Australia-wide	incidence	of	162.7	(111.6	as	standardised	to	WHO	world	standard	
population)	per	100,000	in	the	same	year	(AIHW,	2016).	Tasmanian	men	also	had	a	
slightly	higher	mortality	rate	in	2012	at	28.2	per	100,000	compared	to	27.8	Australia-
wide.	
	
	
1.2	Limitations	of	Prostate	Cancer	Diagnosis	and	Treatment	
Diagnosis	for	prostate	cancer	is	currently	performed	by	digital	rectal	examination	
(DRE),	serum	levels	of	prostate-specific	antigen	(PSA)	and	prostate	tissue	biopsy.	
Tumours	are	graded	using	the	Gleason	score,	measuring	1-10	depending	on	the	
abnormality	of	biopsied	cells,	however,	for	the	majority	of	tumours	with	a	mid-range	
score	it	is	difficult	to	determine	treatment	course	(DeWeerdt	2015).	There	is	
considerable	debate	regarding	the	utility	of	PSA	testing,	a	blood	test	measuring	
levels	of	a	protein	normally	produced	by	the	prostate	gland	but	often	present	in	
higher	concentrations	in	men	with	prostate	cancer	(Sohn	2015).	The	test	was	
originally	developed	in	the	mid	1980s	to	assess	cancer	progress	post-treatment	and	
was	used	in	this	manner	until	the	mid	1990s	when	high	mortality	rates	from	prostate	
cancer	necessitated	an	additional	diagnostic	to	DRE.	PSA	was	chosen	as	it	was	found	
to	improve	early	detection	by	78%	(Catalona	et	al.	1994).	Thus,	from	1994	until	
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recently,	the	test	has	been	used	as	the	gold	standard	for	diagnosis	of	new	prostate	
cancer	cases.		
	
However,	conflicting	evidence	surrounding	effect	or	influence	on	mortality	and	the	
propensity	for	over	diagnosis	has	led	to	much	controversy	surrounding	the	use	of	
PSA	as	a	diagnostic	measure	(Roobol	2015).	Levels	of	the	antigen	can	vary	
substantially	between	cancer-free	men	due	to	infection,	inflammation,	benign	
prostatic	hyperplasia	or	age	and	have	also	been	shown	to	decline	in	later	stages	of	
cancer	(Sohn	2015).	Thus	as	an	initial	diagnostic	measure,	the	test	has	low	
specificity	with	substantial	false	positive	rates	at	around	40-60%,	and	poor	
sensitivity,	with	over	30%	false	negatives	reported	(Brawer	and	Lange	1989).	
Evidence	for	the	limitations	of	the	PSA	test	is	provided	by	the	USA	National	Cancer	
Institute’s	figures;	for	every	1,000	men	who’s	PSA	was	tested	regularly	over	ten	
years,	around	120	will	return	false-positive	results	with	only	110	receiving	an	
accurate	cancer	diagnosis,	and	of	those	correctly	diagnosed	five	will	die	of	the	cancer	
despite	screening	and	nearly	half	will	develop	complications	from	treatment.	Only	
one	death	will	be	avoided	(Sohn	2015).	
	
Consequently,	a	watchful	waiting	approach	is	now	more	frequently	chosen	if	the	
cancer	is	of	a	low	grade,	symptoms	are	not	present	or	the	man	is	of	an	age	or	health	
status	where	he	is	more	likely	to	die	from	comorbidities.	This	approach	is	becoming	
increasingly	common	with	only	around	50%	of	men	diagnosed	with	prostate	cancer	
now	being	treated	in	the	USA	as	opposed	to	90%	ten	years	ago	(Sohn	2015).	
However,	early	treatment	is	life	saving	for	men	with	aggressive	cancer.	It	is	thus	
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crucial	to	be	able	to	distinguish	between	indolent	and	aggressive	forms	of	prostate	
cancer,	with	much	research	continuing	into	developing	biomarkers	that	can	facilitate	
early	and	accurate	diagnosis	and	identify	those	at	high	risk	of	metastasis.		
	
A	biomarker	is	a	biological	molecule	found	in	body	fluid	or	tissue	that	can	objectively	
distinguish	normal	from	abnormal	biology	or	healthy	and	disease	states.	An	ideal	
biomarker	would	be	detectable	in	blood	or	urine,	yet	be	solely	expressed	in	the	
neoplastic	prostate	(DeWeerdt	2015).	While	the	traditional	PSA	test	is	still	the	most	
widely	used	biomarker	for	prostate	cancer,	two	other	biomarkers	are	currently	
approved	by	the	United	States	Food	and	Drug	Administration	(FDA).	The	Prostate	
Health	Index	(PHI)	uses	a	combination	of	free	and	bound	PSA	and	improves	cancer	
detection	in	men	with	high	Gleeson	scores	as	well	as	improving	prognostic	accuracy	
at	biopsy	(Saini	2016).	Prostate	Cancer	Antigen	3	(PCA3)	is	a	long	non-coding	RNA	
gene	that	is	overexpressed	in	prostate	tumours.	The	antigen	test	exhibits	improved	
specificity	and	predictive	value	compared	to	PSA	testing,	yet	has	extremely	variable	
sensitivity	ranging	between	20-90%	and	is	thus	preferentially	used	in	conjunction	
with	PSA	and	DRE	(Saini	2016).		
	
A	plethora	of	additional	biomarkers	for	both	diagnostic	and	prognostic	purposes	
have	been	commercially	developed	but	are	yet	to	be	FDA-approved.	The	
Transmembrane	Protease,	serine	2-ETS-related	gene (TMPRSS2-ERG)	gene	fusion	
occurs	in	around	50%	of	prostate	tumours,	however	as	a	diagnostic	test	it	lacks	
sensitivity	and	specificity.	This	is	at	least	partially	a	result	of	tumour	heterogeneity	
and	varying	gene-fusion	frequencies	between	populations.	The	utility	of	the	marker	
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when	used	in	isolation	is	limited,	however	in	combination	with	PCA3	and	PSA	it	has	
been	shown	to	increase	diagnosis	and	prognosis	accuracy	(Leyten	et	al.	2014).	The	
Phosphatase	and	Tensin	Homolog	(PTEN)	tumour-suppressor	gene	deletion	is	also	
used	as	a	prognostic	marker,	often	in	combination	with	TMPRSS2-ERG	to	determine	
a	patient’s	response	to	therapy,	as	the	combination	of	these	genomic	aberrations	is	
associated	with	poor	patient	outcome	(Boström	et	al.	2015).		
	
Many	of	the	other	diagnostic	and	prognostic	tests	being	developed	utilise	panels	of	
genomic	or	protein	markers,	see	(Prensner	et	al.	2012;	Cary	and	Cooperberg	2013;	Saini	2016)	for	further	detail.	Unfortunately	poor	design	of	clinical	trials	and	the	
long	process	of	FDA-approval	has	hindered	the	availability	of	these	tests	in	the	clinic	(Prensner	et	al.	2012).	Despite	this	recent	surge	in	the	development	of	diagnostic	
and	prognostic	markers,	these	tests	only	examine	some	of	the	alterations	
underpinning	prostate	cancer	and	in	order	to	continue	to	improve	diagnostic	and	
prognostic	tools	much	still	remains	to	be	understood	about	the	molecular	drivers	of	
prostate	cancer.		
	
A	central	driver	for	improving	these	diagnostic	measures	and	enabling	early	and	
accurate	diagnosis,	is	the	fact	survival	rates	dramatically	diminish	once	prostate	
cancer	has	metastasised.	Five-year	survival	rates	for	men	with	metastatic	prostate	
cancer	are	only	a	third	of	the	rate	for	those	men	diagnosed	with	a	localised	disease	(Hodson	2015).	For	metastatic	prostate	cancer	hormone	therapy	is	the	first	line	of	
treatment,	with	the	aim	of	suppressing	prostate-stimulating	androgens,	particularly	
testosterone.	Such	treatments	may	be	effective	for	several	years	before	the	tumours	
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become	resistant,	by	which	stage	treatment	merely	adds	months	to	a	patient’s	life	(Savage	2015).	Thus	once	prostate	cancer	has	metastasised	it	is	ultimately	
incurable.	By	understanding	what	drives	prostate	cancer	to	metastasise	in	some	men	
and	not	others	we	may	be	able	to	further	understand	the	mechanism	by	which	
cancers	become	resistant	to	chemotherapy	and	develop	treatments	that	circumvent	
this.	
	
Moreover,	the	ability	to	distinguish	men	with	an	indolent,	slow-growing	form	of	
prostate	cancer	would	reduce	un-necessary	treatment,	as	often	men	suffering	this	
form	of	cancer	will	die	from	other	causes	(Patrikidou	et	al.	2014).	This	is	highlighted	
in	the	high	ten-year	and	fifteen-year	survival	rates	for	localised	prostate	cancer	at	
93%	and	77%	respectively	(AIHW,	2012).		Since	prostate	cancer	treatments	such	as	
radio-	or	chemotherapy	and	prostatectomy	can	often	lead	to	infection,	incontinence,	
impotence	or	even	death,	minimising	treatment	to	only	those	men	who	require	it	
will	help	to	ensure	quality	of	life	is	preserved	(Penson	et	al.	2005).	Reducing	over-
treatment	would	also	diminish	the	medical	and	financial	burden	on	these	men	and	
on	the	health	care	system,	allowing	more	resources	to	be	directed	to	men	with	
aggressive	cancer	so	that	these	individuals	have	improved	access	to	life-saving	
treatment.		
	
1.3	Prostate	Cancer	Risk	Factors	
Risk	factors	for	prostate	cancer	include	environmental	exposures,	lifestyle,	diet,	age,	
ancestry	and	genetic	and	epigenetic	predisposition.		Environmental	exposure	to	
chemicals	such	as	Vinclozolin,	an	agricultural	antifungal	that	disrupts	endocrine	
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function,	and	the	hormone	bisphenol	A	(BPA),	commonly	found	in	food	and	
beverage	packaging,	have	also	been	associated	with	prostate	abnormalities	and	a	
heightened	risk	of	prostate	cancer	respectively	(Anway	and	Skinner	2008;	Tarapore	et	al.	2014).	Higher	urinary	BPA	levels	have	been	found	in	prostate	cancer	
affected	men,	particularly	those	over	65,	and	animal	studies	indicate	the	hormone	
may	induce	abnormalities	at	the	centrosome	(Tarapore	et	al.	2014).		
	
As	with	many	complex	diseases,	chronic	inflammation,	obesity	and	physical	inactivity	
are	linked	to	a	higher	risk	of	prostate	cancer,	although	the	underlying	
pathophysiological	mechanisms	are	yet	to	be	fully	understood	(Koul	et	al.	2010;	Rhee,	Vela	and	Chung	2016).	Similarly,	the	effect	of	diet	on	prostate	cancer	risk	has	
been	inconsistently	reported.	Consequently	a	recent	consortium	pooled	15	cohort	
studies	of	over	842,000	men	including	more	than	52,000	prostate	cancer	cases,	to	
further	investigate	possible	associations	(Wu	et	al.	2016).	Examining	the	link	
between	processed	and	un-processed	red	meat,	poultry,	seafood	and	egg	intake,	the	
study	found	only	a	modest	positive	correlation	between	red	meat	of	any	kind	and	
advanced	prostate	cancer.	Consumption	of	seafood	was	not	found	to	have	an	effect	
while	poultry	was	negatively	associated	with	risk	of	advanced	and	fatal	cancers	and	a	
higher	consumption	of	eggs	was	linked	to	an	increased	risk	of	advanced	and	fatal	
cancers.	Supporting	this	association,	an	earlier	study	in	2011	found	that	men	who	
ate	more	than	2.5	eggs	a	week	had	an	81%	increased	risk	of	developing	a	lethal	form	
of	prostate	cancer	than	those	who	ate	less	than	0.5	eggs	per	week	(Richman	et	al.	2011).	Conversely	a	diet	high	in	folate	and	other	nutrients	involved	in	one-carbon	
metabolism	such	as	methionine	and	vitamin	B6	has	been	shown	to	be	protective	
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against	prostate	cancer,	especially	high-grade	clinically	relevant	forms	(Shannon	et	
al.	2009).	Additionally,	dietary	interventions	such	as	selenium	supplementation,	
increased	vegetable	intake,	ibuprofen	and	aspirin	have	been	found	to	attenuate	the	
growth	of	cancer	in	some	tumour	stages	in	a	subset	of	men.	While	this	study	
provides	evidence	that	prostate	cancer	risk	posed	by	genetic	factors	may	be	
ameliorated	in	a	some	individuals	by	diet,	there	exists	a	very	complex	interaction	
between	genetic	risk	and	environmental	factors,	the	details	of	which	are	still	not	well	
understood	(Loeb	et	al.	2015).	To	fully	appreciate	the	contribution	and	interaction	
of	environmental	and	genetic	risk	factors,	it	may	first	be	imperative	to	understand	
the	underlying	mechanistic	link	between	the	two	–	namely	epigenetic	regulation.	
	
Ancestry	also	influences	the	risk	of	prostate	cancer,	with	the	highest	incidence	in	
affluent	regions	such	as	North	America,	Oceania	and	western	and	northern	Europe	
and	the	highest	mortality	rates	in	less	developed	regions	such	as	South	America,	sub-
Saharan	Africa	and	the	Caribbean	(Center	et	al.	2012).	While	part	of	this	risk	
variation	may	be	driven	by	environment,	lifestyle	or	screening	practises,	USA	and	
foreign	born	Chinese,	Japanese,	Vietnamese	and	Filipino	men	living	in	the	USA	all	
had	higher	unfavourable	risk	profiles	at	diagnosis	than	Non-Hispanic	Whites	in	a	
recent	study	(Lichtensztajn	et	al.	2014).	The	heightened	risk	was	also	not	
associated	with	diagnosis	at	a	later	clinical	stage	and	varied	by	ethnic	group,	
indicating	these	men	had	biological	differences	predisposing	them	to	a	more	severe	
disease	progression	(Lichtensztajn	et	al.	2014).		
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The	disparity	in	incidence	between	races	suggests	genetic	factors	may	be	important	
contributors	to	risk.	Numerous	studies	have	consistently	reported	a	family	history	to	
be	a	major	risk	factor	for	the	disease	(Carter	et	al.	1992;	Keetch	et	al.	1995;	Gronberg,	Damber	and	Damber	1996;	Ghadirian	et	al.	1997),	with	the	association	
between	family	history	and	increased	risk	of	prostate	cancer	found	to	be	1.45	(95%	
CI	=	1.12-1.89)	in	a	large	consortium	examining	the	risk	of	family	history	on	several	
cancer	types	(Jacobs	et	al.	2010).			
	
1.3.1	Genetic	Risk	Factors	
With	an	estimated	heritability	of	60%	prostate	cancer	is	one	of	the	most	heritable	
cancers	(Hjelmborg	et	al.	2014).	Accordingly,	the	relative	risk	of	prostate	cancer	is	
2.48	if	a	first	degree	relative	has	been	diagnosed	(Kicinski,	Vangronsveld	and	Nawrot	2011),	with	an	increased	risk	if	a	man	has	an	affected	brother	rather	than	
father.	The	relative	risk	rises	again	if	two	or	more	first-degree	relatives	are	affected	
(Relative	Risk:	4.39,	(Kicinski,	Vangronsveld	and	Nawrot	2011)).	Despite	this	well-
established	familial	link,	a	comprehensive	understanding	of	how	genetic	variation	
contributes	to	prostate	cancer	predisposition	is	yet	to	be	elucidated.		
	
Early	familial	studies	using	linkage	analysis	examined	the	segregation	of	disease	
variants	within	families,	identifying	risk	associated	loci	in	many	genes	including	
RNASEL,	a	putative	tumour	suppressor	gene	which	regulates	proliferation	and	
apoptosis	(Carpten	et	al.	2002)	and	MSR1,	a	macrophage	scavenger	receptor	(Xu	et	
al.	2002).	However,	the	restricted	genomic	coverage	of	the	available	technology	at	
the	time	limited	the	success	of	familial	linkage	studies	and	there	was	a	persistent	
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failure	in	replicating	results	(Edwards	et	al.	2003).	More	recently,	the	large	
consortiums	such	as	the	International	Consortium	for	Prostate	Cancer	Genetics	
(ICPCG)	have	utilised	evolving	technology	to	validate	previous	findings	and	discover	
new	risk	loci.		Examining	1,233	pedigrees	in	2010	the	consortium	replicated	evidence	
for	eleven	previously	identified	regions	and	found	risk	associations	at	two	novel	
regions	(Christensen,	Bonnie	and	George	2010).	Two	years	later	the	ICPCG	
consortium	validated	eight	prostate	cancer	risk	loci	previously	identified	through	
genome-wide	association	studies	(GWAS)	(Jin	et	al.	2012),	and	this	year,	having	
conducted	GWAS	analysis	on	over	5	million	exon	single	nucleotide	polymorphisms	
(SNPs)	in	2511	unrelated	familial	prostate	cancer	cases	and	1382	controls,	the	
consortium	validated	a	further	six	previously	identified	risk	loci	(Teerlink	et	al.	2016).		
	
The	success	of	combining	next-generation	genomic	technology	and	familial	studies	
to	discover	and	validate	prostate	cancer	risk	loci	has	been	demonstrated	by	the	
identification	of	HOXB13.	Familial	linkage	studies	had	implicated	a	region	on	
chromosome	17	(q21-22)	as	potentially	containing	a	prostate-cancer	risk	gene	(Lange	et	al.	2003).	Further	next	generation	sequencing	studies	examining	the	200	
genes	in	this	region	found	a	recurrent	G84E	mutation	in	HOXB13	which	segregated	
with	disease	and	was	significantly	more	common	in	men	with	familial	prostate	
cancer	than	sporadic	cases	(carrier	frequency	of	3.1%	compared	to	0.6%)	(Ewing	et	
al.	2012).	Additional	studies	confirmed	the	rare	mutation	(Breyer	et	al.	2012)	and	
found	it	explained	around	1%	of	the	familial	risk	of	prostate	cancer	in	the	UK	(Kote-Jarai	et	al.	2015).	
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Population	based	GWAS,	which	examine	differences	in	genotype	between	large	
numbers	of	unrelated	affected	and	unaffected	individuals,	have	identified	over	100	
prostate	cancer	risk	loci	(Eeles	et	al.	2009;	2013;	Olama	et	al.	2014).	However,	as	is	
the	case	for	many	complex	diseases,	together	these	common	variants	explain	only	a	
fraction	of	the	population	burden	of	disease.	For	prostate	cancer,	only	33%	of	the	
inherited	risk	of	disease	is	explained	by	these	loci	across	various	populations	(Olama	
et	al.	2014).	Many	explanations	have	been	proposed	for	the	unexplained	genetic	
component	of	complex	disease	susceptibility.	For	example,	the	impact	of	large	
deletions,	inversions	or	copy	number	variants	may	not	be	detected	in	GWAS	
examining	single	nucleotide	variations.		Complex	gene-gene	and	gene-environment	
interactions,	overestimating	heritability,	poor	modelling	and	statistical	application	
could	further	create	a	mismatch	between	the	expected	heritability	of	prostate	
cancer	and	the	heritability	explained	by	known	variants	(Eichler	et	al.	2010).		
	
There	is	also	debate	as	to	whether	this	“missing	heritability”	is	due	to	many	common	
variants	of	low	penetrance	acting	in	an	additive	manner	or	if	rare	variants	of	high	
penetrance,	difficult	to	detect	in	GWAS,	contribute	significantly	to	disease	
predisposition.	To	help	answer	this	question	and	comprehensively	catalogue	
variation	in	the	human	genome,	the	1000	genomes	project	(1KGP)	was	launched	in	
2008	and	completed	in	2015,	mapping	genetic	variants	down	to	a	frequency	of	1%	(Auton	et	al.	2015).	Numerous	ongoing	ventures	have	since	sequenced	hundreds	of	
thousands	of	human	genomes	and	exomes,	examining	natural	variation	and	variants	
linked	to	common	and	rare	diseases.	Some	of	the	most	prominent	include	the	
100,000	Genome	Project	(http://www.genomicsengland.co.uk/the-100000-
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genomes-project)	and	the	Exome	Aggregation	Consortium	
(http://exac.broadinstitute.org).	Together	these	projects	have	shown	the	importance	
of	rare	variants	in	understanding	complex	disease	aetiology.	
	
However,	the	computational	load	of	examining	rare	variants	in	these	large	studies	is	
still	immense.	The	advent	of	affordable	next	generation	sequencing	has	allowed	for	a	
revival	of	familial	studies,	where	pedigree	structures	and	enrichment	of	rare	variants	
allows	transmission	to	be	tracked	down	generations,	providing	greater	discovery	
power,	a	much	more	manageable	computational	task	to	examine	rare	disease-linked	
variation.	An	early	example	of	the	power	of	familial	studies	can	be	seen	in	the	
discovery	of	the	association	between	cardiovascular	disease,	hypercholesterolemia	
and	LDL	receptor	mutations	in	familial	studies	(reviewed	in	(Endo	2010)).	The	
resultant	improvement	in	the	understanding	of	the	molecular	biology	underlying	
hypercholesterolemia	lead	to	the	development	of	statins,	a	drug	therapy	with	huge	
benefit	to	the	general	population,	not	only	those	families	affected	by	the	rare	
mutations.	Similarly,	laboratory	exploration	of	rare	mutations	discovered	in	familial	
prostate	cancer	studies	could	improve	the	molecular	understanding	of	disease	
aetiology,	improving	diagnosis	and	treatment	options	for	a	wider	population	of	men.		
	
1.4	The	Role	of	Non-coding	Variants	in	disease		
The	debate	between	the	common	and	rare	variant	hypotheses	has	traditionally	
focused	on	“functional”	variation	in	coding	regions	of	the	genome.	The	key	to	
explaining	the	remaining	inherited	component	of	disease	burden	may	come	from	
further	understanding	the	role	of	“regulatory”	variants;	those	variants	outside	gene-
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coding	regions	yet	involved	in	controlling	gene	expression.	Evidence	for	the	
molecular	importance	of	non-coding	variation	is	indicated	by	the	proportion	of	non-
coding	disease-associated	SNPs	identified	in	GWAS,	with	over	90%	located	outside	of	
genes	(Hindorff	et	al.	2009).	At	least	some	of	these	SNPs	affect	gene	regulatory	
mechanisms,	modifying	gene	expression	by	altering	transcription	factor	binding	or	
directing	altered	epigenetic	profiles	(Furey	and	Sethupathy	2013).	Accordingly,	it	
has	been	suggested	that	cancer	is	not	only	the	result	of	the	accumulation	of	genetic	
mutations	with	age	but	also	a	disruption	in	epigenetic	reprogramming	(Feinberg	and	Tycko	2004).		
	
	
1.5	Epigenetics		
1.5.1	Epigenetics	at	a	Glance	
Conrad	Waddington	first	coined	the	term	‘epigenetics’	in	the	early	1940s	to	integrate	
the	existence	of	two	related	phenomenon;	that	genetically	identical	cells	possess	the	
capacity	to	differentiate	into	tissue	specific	structures	with	correlated	functions	and	
that	gene-environment	interactions	can	affect	phenotypes	(reprinted	in	(Waddington	2012)).	The	term	epigenetics	has	since	come	to	refer	to	the	
environment	surrounding	the	DNA,	with	a	current	working	definition	characterising	
an	epigenetic	trait	as	“a	stably	heritable	phenotype	resulting	from	changes	in	a	
chromosome	without	alterations	in	the	DNA	sequence”	(Berger	et	al.	2009).	This	
term	is	most	often	used	in	reference	to	the	inheritance	of	traits	to	a	daughter	cell	
during	mitosis,	but	there	is	evidence,	although	still	controversial,	of	germ	line	
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transmission	of	epigenetic	traits	between	generations	(Skinner	2011;	Pembrey	et	
al.	2014).	For	a	timeline	of	key	advances	in	the	field	of	epigenetics	see	Figure	1.2.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.2	Timeline	of	key	advances	in	the	field	of	epigenetics.		
Adapted	from	(Cazaly	et	al.	2015).	
1940s 1970s Key*epigenetic*milestones 2000s 2014
Conrad*Waddington*coins*
the*term*'epigenetics’
1975:*Holliday*and*
Pugh*first*describe*
cytosine*methylation**
1977:*Effect*of*
azanucleosides on*
cell*differentiation*
first*described*
1978:*Metastable*
epialleles first*described*
in*mice*
1999H2006:*Human*epigenome
project*(HEP):*generation*of*
genomeHwide*tissue*specific*
DNA*methylation*profiles
http://www.epigenome.org
Next*generation*sequencing*&*advances*in*
data*analysis/visualisation*revolutionise
genetic*and*epigenetic*fields*
2009:*First*epigenetic*
drug,*5HAzacitidine
approved*by*FDA*for*
treatment*of*MDS
2002:*First*‘constitutional*
epimutation’*identified*in*
MLH1*gene*in*subset*of*
Lynch*syndrome*cases
2003:*ENCODE*launched*by*
NHGRI*to*identify*functional*
elements*of*the*genome
www.genome.gov/100051074
2010:*NCBI*creates*Epigenomics
Program*encompassing*epigenome
mapping*and*characterisation
http://www.ncbi.nlm.nih.gov/geo
2000:*First*FANTOM*
consortium*on*functional*
genomic*annotation
fantom.gsc.riken.jp
2007:*Roadmap*Epigenomics
project*by*the*NIH*begun*as*a*
reference*of*normal*epigenomes
www.roadmapepigenomics.org
2008:*Promoter*hypermethylation
used*as*biomarkers*to*screen*for*
colorectal*cancer*
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1.5.2	Epigenetic	Modifications	
Eukaryotic	DNA	is	assembled	into	chromatin;	repeating	units	of	nucleosomes	
consisting	of	approximately	147	base	pairs	of	DNA	wrapped	around	an	octamer	of	
histones.	Chromatin	is	then	configured	into	higher	order	structures	that	play	
functional	roles	in	regulating	the	accessibility	of	DNA	to	the	transcriptional	
machinery.	Mechanisms	that	influence	the	genomic	environment	and	chromatin	
structure	include	modifications	to	the	DNA	itself,	absence	/	presence	of	histone	
modifications	and	histone	variants,	and	processes	involving	non-coding	RNA	and	
chromatin	remodelling	complexes	(Dawson	and	Kouzarides	2012).	At	one	
extreme,	tightly	packaged,	transcriptionally	inactive	heterochromatin	is	
characterized	by	DNA	methylation,	de-acetylated	histones	and	tightly	packed	
nucleosomes,	with	non-coding	RNA	such	as	repressive	miRNA	involved	in	targeting	
and	maintaining	heterochromatin.	At	the	other	extreme,	euchromatin	contains	
unmethylated	DNA,	acetylated	histones	and	active	histone	variants	with	DNA	
exposed	to	the	transcription	machinery	(Richards	and	Elgin	2002).	Epigenetic	
modifiers	including	epigenetic	writers,	readers	and	erasers,	communicate	with	
chromatin	remodelling	complexes	to	move	and	modify	nucleosomes,	opening	or	
compacting	chromatin.	See	Figure	1.3	for	detail	on	the	different	epigenetic	marks	
present	in	hetero-	and	euchromatin.	
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Figure	1.3	Epigenetic	marks	involved	in	chromatin	regulation.		
Higher	order	chromatin	structures	play	a	functional	role	in	regulating	the	
accessibility	of	DNA	to	transcriptional	machinery.	(A)	Tightly	packaged	
heterochromatin	is	characterized	by	DNA	methylation	(filled	black	circles),	de-
acetylated	histones	(clear	purple	stars)	and	tightly	packed	nucleosomes.	(B)	
Alternatively,	euchromatin	contains	unmethylated	cytosines	(unfilled	circles)	and	
acetylated	histones	(purple	stars),	with	DNA	exposed	to	the	transcription	machinery	
(green).	Epigenetic	modifiers	including	writers,	readers	and	erasers,	communicate	
with	chromatin	remodelling	complexes	to	move	and	modify	nucleosomes,	opening	
or	compacting	chromatin.	Adapted	from	(Cazaly	et	al.	2015).	
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More	than	a	dozen	post-translational	modifications	of	histone	proteins	have	been	
reported	to	date,	including	methylation,	acetylation,	phosphorylation	and	
ubiquitination	(Dawson	and	Kouzarides	2012),	and	technological	advances	have	
made	it	possible	to	map	these	modifications	genome-wide	(Barski	et	al.	2007;	Consortium	et	al.	2015).	These	modifications	have	together	been	proposed	to	form	
a	‘histone	code’	which	can	be	interpreted	by	cellular	proteins	to	specify	downstream	
functions	(Allis	2008).	In	addition,	chromatin	structure	is	altered	by	the	actions	of	
ATP-dependent	chromatin	remodelling	enzymes	and	the	exchange	of	canonical	
histones	with	histone	variants.	This	creates	a	highly	dynamic,	adaptable	epigenetic	
landscape	that	plays	a	key	role	in	regulating	genome	function	and	provides	an	
interface	between	the	environment	and	the	genome.		
	
In	recent	years	the	existence	of	a	complex	network	of	non-coding	RNAs	(ncRNAs)	
transcribed	from	the	human	genome	has	become	apparent.	These	ncRNAs	have	
regulatory	functions	and	play	a	key	role	in	the	establishment	and	maintenance	of	
other	epigenetic	marks	(Daxinger	and	Whitelaw	2012),	with	evidence	that	they	
constitute	a	mechanism	for	epigenetic	inheritance	through	generations	(Liebers,	Rassoulzadegan	and	Lyko	2014).	There	is	also	mounting	evidence	for	the	
involvement	of	ncRNAs	in	disease	development,	particularly	in	cancer	(Kasinski	and	Slack	2011).	
	
1.5.3	DNA	Methylation	
DNA	methylation,	the	covalent	addition	of	a	methyl	group	to	a	cytosine	residue,	
usually	in	a	cytosine-guanine	pair	(CpG),	is	the	most	widely	studied	epigenetic	
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modification.	CpGs	are	enriched	in	clusters	referred	to	as	CpG	islands	(CGIs),	
associated	with	the	promoter	regions	of	up	to	60%	of	genes	(Cedar	and	Bergman	2012).	While	various	criteria	can	be	used	to	define	CGIs,	originally	they	were	
described	as	regions	larger	than	200	base	pairs	with	more	than	50%	GC	content	and	
an	observed/expected	ratio	of	CpGs	greater	than	0.6	(Wang	and	Leung	2004).	
While	around	70%	of	CpGs	are	methylated	in	mammals,	when	clustered	in	CGIs	they	
are	generally	unmethylated	(Suzuki	and	Bird	2008),	with	DNA	methylation	in	these	
islands	typically	associated	with	gene	silencing.	This	transcriptional	repression	by	
DNA	methylation	is	brought	about	by	the	recruitment	of	chromatin	condensing	
proteins	and	to	a	lesser	extent	by	physically	blocking	transcription	factor	binding	(Cedar	and	Bergman	2012).	Although	CGIs	have	been	well-established	to	co-
localise	with	transcription	start	sites,	a	2010	study	found	around	half	of	CGIs	are	
located	away	from	transcription	start	sites,	at	non-traditional,	poorly	characterised	
promoters	which	they	termed	“orphan	CGIs”	(Illingworth	et	al.	2010;	Jones	2012).		
	
Less	extensively	studied	but	potentially	more	relevant	to	disease,	is	the	regulatory	
role	of	methylation	extending	from	CGIs	and	within	gene	bodies	(intragenic),	as	
these	regions	have	been	found	to	be	more	variably	methylated	between	tissue	types	
and	in	cancerous	tissue	compared	to	normal	tissue	(Irizarry	et	al.	2009;	Gertz	et	al.	2011).	Regions	2Kb	either	side	of	CGIs	have	been	designated	island	shores	and	
regions	a	further	2Kb	outside	as	shelves	(Irizarry	et	al.	2009).	Methylation	further	
away	from	these	regions,	in	CpG	poor	areas	has	been	termed	“open	seas”	(Sandoval	
et	al.	2011).	For	a	schematic	on	the	genomic	landscape	of	DNA	methylation	see	
Figure	1.4.		
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Figure	1.4	Depiction	of	the	epigenetic	landscape.		
The	upper	panel	provides	a	schematic	of	a	typical	intergenic	and	genic	landscape	including	CpG	distribution	(lollipop	figures)	and	
methylation	patterns	(black	for	methylated,	white	for	unmethylated)	across	exonic	regions	and	promoter/enhancer	regulatory	regions.		
The	transcription	start	site	is	indicated	by	the	black	arrows	labelled	‘TSS’.	The	lower	panel	depicts	the	most	common	annotation	of		
genomic	CpG	density,	with	north	(N)	and	south	(S)	shores	2kB	either	side	of	CpG	dense	islands	and	north	(N)	and	south	(S)	shelves	a	
further	2kB	outside	these.	Further	out,	Open	Seas	denote	CpG	poor	regions.	Adapted	from	(Stirzaker	et	al.	2014).	
<"""#2kB#""">######<"""#2kB#""">############# # # ######<"""#2kB#""">##<"""#2kB#"""># ##
Open#Sea#######N#Shelf########N#Shore# CpG$island$$$$$ $S#Shore#######S#Shelf##### #Open#Sea#
"""""""""#intergenic#"""""""}#{"""""""""""#genic#""""""""""}{"""""""""""""""""#intergenic#"""""""""""""""""}#{""#genic#""##
Exon1# Exon3#Exon2#Promoter# Promoter#Enhancer# Exon1#
TSS#TSS#
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Genome-wide,	intragenic	methylation	patterns	have	been	described	as	a	bell-curve	
shape,	with	high	methylation	in	genes	of	moderate	expression	levels	and	low	
methylation	in	genes	with	either	high	or	low	gene	expression	(Jjingo	et	al.	2012).	
These	differences	have	been	attributed	to	varying	chromatin	accessibility	during	
transcription,	with	the	idea	being	that	at	a	low	level	of	gene	expression	nucleosomes	
are	tightly	packaged	and	DNA	methyltransferases	(DNMTs)	are	unable	to	access	CpG	
sites.	At	moderate	levels	of	transcription,	nucleosomes	are	repositioned	to	allow	
RNA	polymerase	II	access	to	the	DNA,	coincidentally	allowing	DNMT	access.	However	
once	RNA	polymerase	II	density	peaks	with	high	gene	expression,	DNMT	access	is	
again	restricted	and	methylation	levels	drop	(Jjingo	et	al.	2012).	Methylation	at	
gene	bodies	may	contribute	to	transcriptional	elongation	by	inactivating	alternate	
intragenic	promoters	or	non-coding	transcripts	(Maunakea	et	al.	2010).	This	may	
help	to	explain	the	DNA	methylation	paradox,	whereby	methylation	appears	to	have	
opposing	effects	on	gene	expression	depending	on	whether	it	is	present	in	promoter	
or	gene	body	regions	(Jones	1999;	2012).		
		
1.5.4	Establishing	and	Maintaining	Epigenetic	Patterns	
The	establishment	and	maintenance	of	epigenetic	patterns	is	influenced	by	a	range	
of	intrinsic	and	extrinsic	factors	including	environment,	diet,	stochastic	changes	and	
the	underlying	genetic	sequence	(Aguilera	et	al.	2010;	McKay	et	al.	2012)	.	The	
various	epigenetic	marks	and	mechanisms	work	collectively	to	create	divergent	
epigenetic	patterns	across	tissue	and	loci,	which	vary	across	populations	and	with	
age	(ENCODE	Project	Consortium	et	al.	2012).		
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Environmental	influences	on	epigenetic	patterns	include	pesticides	such	as	
vinclozolin	(Anway	et	al.	2005),	which	is	used	to	kill	fungal	growth	on	crops	but	also	
acts	as	an	endocrine	disrupter	in	humans	and	is	a	known	risk	factor	for	prostate	
cancer,	as	discussed	above.	Another	known	environmental	risk	factor	for	prostate	
cancer,	BPA	a	synthetic	estrogen,	has	also	been	shown	to	influence	DNA	methylation	
patterns	(Dolinoy,	Huang	and	Jirtle	2007).	There	is	evidence	that	at	least	some	of	
these	environmentally	driven	changes	can	be	passed	down	through	meiosis	as	
transgenerational	epigenetic	inheritance	(Guerrero-Bosagna	and	Skinner	2011;	Daxinger	and	Whitelaw	2012;	Veenendaal	et	al.	2013).	However,	the	evidence	for	
this	inheritance	and	the	mechanisms	involved	still	remain	to	be	fully	elucidated,	
partly	as	they	require	escape	of	epigenetic	reprogramming,	a	two	phase	process	
discussed	below	which	would	normally	act	to	eliminate	transmission	of	epigenetic	
marks	down	generations.	Such	inheritance	is	beyond	the	scope	of	this	thesis;	
however	a	detailed	discussion	of	the	current	understanding	of	transgenerational	
epigenetic	inheritance	is	reviewed	in	Pembrey	et	al.	(Pembrey	et	al.	2014).	
	
While	the	effect	of	environment	on	epigenetic	profiles,	particularly	DNA	methylation	
is	widely	acknowledged,	stochastic	changes	may	in	fact	be	more	common	than	
environmentally	induced	changes,	with	one	study	examining	4000	human	genes	in	
clonal	cell	lines,	observing	300	to	have	random	monoallelic	expression	(Gimelbrant	
et	al.	2007).	Epigenetic	stochasticity	can	be	defined	as	a	combination	of	epigenetic	
variation	in	the	germline	and	somatic	instability.	Similar	to	Richards’	‘facilitated	
epigenetic	variation’	model	(Richards	2006),	Feinberg	and	Irizarry’s	‘inherited	
stochastic	variation	model’	proposes	genetic	sequence	variation	underlies	the	
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propensity	for	epigenetic	variation,	as	certain	DNA	sequences	are	not	only	directly	
responsible	for	particular	traits	but	also	increase	natural	methylation	variation	for	
that	trait	(Feinberg	and	Irizarry	2010).	Various	stochastic	and	environmental	
factors	then	influence	DNA	methylation	at	these	variably	methylated	regions	
(VMRs),	resulting	in	increased	phenotypic	differences,	which	are	then	acted	on	by	
Darwinian	selection	in	a	similar	manner	to	selection	pressures	affecting	purely	
genetic	traits.	In	subsequent	studies	they	found	the	sites	of	greatest	DNA	
methylation	variability	in	colon	cancer	corresponded	to	the	sites	of	greatest	
variability	in	other	cancers	including	lung,	breast	and	ovarian	cancers,	with	these	
sites	normally	having	distinct	tissue	specific	DNA	methylation	patterns	(Hansen	et	al.	2011).	Thus	heritable	DNA	methylation	variation	could	provide	some	contribution	to	
the	unexplained	heritable	genetic	component	of	common	complex	diseases.		
	
Once	DNA	methylation	patterns	are	established,	DNA	methyltransferases	(DNMTs)	
ensure	tissue	specific	methylation	patterns	are	maintained	through	mitosis	with	high	
precision	and	fidelity	(Cedar	and	Bergman	2012).	In	contrast,	at	a	global	level,	
methylation	is	substantially	‘wiped	clean’	during	gametogenesis	to	provide	the	
developing	embryo	the	capacity	for	totipotency	and	prevent	accumulation	of	
epigenetic	changes	from	previous	generations	(Seisenberger	et	al.	2012).	This	
epigenetic	reprogramming	occurs	in	two	waves,	firstly	during	pre-implantation	and	
secondly	after	primordial	germ	cell	migration,	including	the	removal	of	imprinted	
marks	(Sasaki	and	Matsui	2008).		
	
Epigenetic	reprogramming	involves	both	active	and	passive	demethylation,	which	
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has	long	perplexed	the	scientific	community	due	to	their	inability	to	identify	the	
enzyme	responsible	for	this	demethylation.	Insight	into	this	process	has	been	gained	
only	recently	following	the	discovery	of	the	additional	DNA	modification,	
hydroxymethylation	(5hmC),	enriched	in	Purkinje	cells	in	the	brain	(Kriaucionis	and	Heintz	2009)	and	also	embryonic	stem	cells	(Ito	et	al.	2010;	Cimmino	et	al.	2011).	
The	ten-eleven	translocation	(TET)	family	of	proteins	are	responsible	for	this	
modification,	and	there	is	evidence	that	it	is	an	intermediate	in	the	process	of	active	
demethylation	(Hackett	et	al.	2013).	High	levels	of	the	modification,	particularly	in	
neural	cells	and	during	embryonic	development	suggests	that	it	may	have	a	yet	to	be	
elucidated	role	in	regulating	the	genome.		Interestingly,	5hmC	levels	have	been	
shown	to	be	reduced	in	cancers	including	prostate	cancer	(Haffner	et	al.	2011)	and	
it	has	been	suggested	that	this	reduction	may	be	an	early	event	in	prostate	cancer	
development,	possibly	due	to	TET	down-regulation	as	a	result	of	environmental	
stress	and	aging	(Chia	et	al.	2014).		
	
1.5.4.1	Sequence	driven	methylation	variation:	meQTLs	
Genomic	sequence	variation	may	have	the	greatest	impact	on	epigenetic	patterns,	
as	one	study	examining	a	three	generation	family	estimated	that	genotype	explained	
around	80%	of	the	variation	in	DNA	methylation	(Gertz	et	al.	2011).	There	has	since	
been	much	research	into	‘methylation	quantitative	trait	loci’	or	meQTLs;	sequence	
variants	across	the	genome	that	drive	methylation	patterns	(Drong	et	al.	2013).	
These	meQTLs	have	been	mapped	in	a	variety	of	tissues,	stages	of	development,	
populations	and	across	different	organisms	(Gibbs	et	al.	2010;	Bell	et	al.	2011;	Drong	et	al.	2013;	Smith	et	al.	2014).	MeQTLs	can	occur	at	the	CpG	site	itself	
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(meSNP),	in	close	proximity	(cis)	(Drong	et	al.	2013)	or	distantly	(trans)	(Lemire	et	
al.	2015).	Arguably	the	greatest	effect	on	methylation	is	mediated	through	meSNPs	
as	these	can	directly	create	or	remove	a	CpG	site,	immediately	influencing	
methylation	at	that	site	and	possibly	in	neighbouring	regions.	Indeed	Zhi	and	
colleagues	found	that	two	thirds	of	the	strongest	meQTL	signals	in	their	study	were	
due	to	meSNPs	and	that	80%	of	generic	variants	at	meSNPs	were	meQTLs	(Zhi	et	al.	2013).	They	also	found	that	the	CpG	disrupting	SNP	significantly	affected	
methylation	at	CpG	sites	within	45bp	and	continued	up	to	10kb,	likely	in	associated	
with	linkage	disequilibrium.	Providing	further	evidence	for	the	importance	of	
meSNPs,	a	recent	study	examining	publicly	available	data	found	23%	of	common	
variants	were	meSNPs	and	that	these	SNPs	were	significantly	enriched	in	meQTLs	
and	more	likely	to	be	trait-associated	cancer	loci	(Zhou	et	al.	2015).		
	
DNA	sequence	variants	not	only	drive	methylation	changes	but	also	histone	
modifications,	with	three	recent	studies	pointing	to	an	important	role	of	genetic	
variants	in	determining	histone	modification	patterns	(McVicker	et	al.	2013;	Kilpinen	et	al.	2013;	Kasowski	et	al.	2013).	In	these	studies,	hundreds	of	variants	
were	associated	with	changes	to	histone	modifications	and	gene	expression,	with	
the	underlying	mechanism	thought	to	be	altered	transcription	factor	binding.	
Various	other	mechanisms	have	been	proposed	for	the	altered	gene	expression	
associated	with	meQTLs,	including	altered	binding	of	proteins	such	as	the	CTCF	
transcription	factor	which	has	different	affinities	for	methylated	and	unmethylated	
DNA	(Shukla	et	al.	2011),	and	altered	transcription	elongation,	splicing	and	
recombination	rates	(Olsson	et	al.	2014).	
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1.5.5	Genetically	driven	Epigenetic	Disease	Susceptibility	
Inherited	genetic	variants	have	been	shown	to	drive	methylation	changes	in	disease	
with	meQTLs	associated	with	osteoarthritis	(Rushton	et	al.	2015),	neuropsychiatric	
diseases	 (Taqi	 et	 al.	 2011)	 and	 complex	 diseases	 such	 as	 diabetes	 and	 cancer.	 A	
recent	study	examining	40	previously	identified	diabetes	risk	SNPs	found	nearly	half	
introduced	or	removed	a	CpG	site	(Dayeh	et	al.	2013),	while	an	extensive	genome-
wide	 association	 study	 between	 genetic	 variation,	 methylation	 patterns,	 mRNA	
expression	and	insulin	secretion	identified	SNP-CpG	pairs	in	several	genes	involved	in	
proliferation	and	apoptosis	of	pancreatic	ß-cells	(Olsson	et	al.	2014).		
	
DNA	methylation	was	the	first	epigenetic	mark	to	be	linked	to	cancer	(Feinberg	and	Tycko	2004)	in	the	early	1980s	and	since	then	the	global	hypomethylation	and	
regional	specific	hypermethylation	has	been	well	characterised	in	tumour	tissue.	
Global	hypomethylation	due	to	loss	of	methylation	at	repetitive	sequences	and	
retrotransposons	often	occurs	in	prostate	cancer	(Yegnasubramanian	et	al.	2008)	
with	the	level	of	hypomethylation	correlated	to	cancer	severity	(Bedford	and	van	Helden	1987).	In	contrast,	hypermethylation	has	been	particularly	seen	at	promoter	
CGIs	of	tumour	suppressor	genes	such	as	Glutathione	S-Transferase	Pi	1	(GSTP1),	Ras	
Association	Domain	Family	Member	1	(RASSF1A)	and	O6-alkylguanine	DNA	
alkyltransferase	(MGMT)	where	aberrant	methylation	leads	to	gene	silencing	(Song	
et	al.	2002;	Kang	et	al.	2004).	More	recent	cancer	research	efforts	have	focussed	on	
methylation	at	shores	and	shelves	where	most	(up	to	76%)	tissue-specific	differential	
methylation	occurs	and	interestingly,	the	majority	of	differential	methylation	
changes	in	cancer	also	occur	at	these	regions	(Irizarry	et	al.	2009).		
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A	key	example	of	a	genetically	driven	methylation	abnormality	in	the	cancer	field	is	
Lynch	syndrome;	an	autosomal	dominant	cancer	susceptibility	condition	where	two	
thirds	of	cases	result	from	heterozygous	loss-of-function	mutations	in	DNA	mismatch	
repair	genes,	most	commonly	MutL	Homolog	1	(MLH1)	and	MutS	Homolog	2	(MSH2)	(Ward	et	al.	2013).	However,	such	mutations	are	not	apparent	in	around	one-third	
of	Lynch	Syndrome	cases,	some	of	which	(~4%	for	MLH1	(Ward	et	al.	2013))	can	be	
explained	by	epimutations	in	MLH1	and	MSH2.	These	epimutations	lead	to	
transcriptional	inactivation	of	the	gene,	essentially	having	the	same	effect	as	a	
genomic	sequence	mutation	seen	in	other	Lynch	syndrome	cases.	One	possible	
mechanism	underlying	these	epimutations	involves	‘primary’	DNA	methylation	
changes	independent	of	any	sequence	change,	resulting	in	labile	epimutations,	
which	can	be	reversed	in	the	germline	and	are	therefore	inherited	in	an	
unpredictable,	non-Mendelian	manner	or	not	passed	on	at	all.		
	
Alternatively,	‘secondary’	epimutations	may	result	from	underlying	sequence	
changes,	including	promoter	deletions	and	SNPs	(Hitchins	and	Lynch	2014).	For	
example,	the	c.-27C>A	germline	variant	in	the	5’UTR	of	the	MLH1	gene	has	been	
linked	to	cancer	susceptibility	through	transcriptional	silencing	(Hitchins	et	al.	2011).	In	these	cases	the	disease	follows	a	more	predictable	inheritance	pattern	as	
the	epimutation	is	driven	by	a	genetic	variant.	As	yet	undiscovered	sequence	
mutations	may	also	be	the	underlying	carcinogenic	mechanism	in	subsets	of	cancers	
such	as	Cowden	syndrome,	where	some	individuals	have	hypermethylation	
epimutations	in	the	absence	of	known	sequence	mutations	(Bennett,	Mester	and	Eng	2010).		
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Underlying	genetic	drivers	have	also	been	linked	to	epimutations	in	sporadic	cases	of	
renal	cell	cancer	(RCC)	where	SNPs	were	associated	with	promoter	hypermethylation	
of	the	Von	Hippel-Lindau	Tumor	Suppressor	(VHL)	gene	in	tumour	tissue,	a	gene	
previously	shown	to	be	genetically	altered	in	individuals	with	the	familial	form	of	the	
cancer	(Moore	et	al.	2011).	Similarly,	in	colorectal	cancer,	a	C>T	point	mutation	at	
an	enhancer	element	of	the	mismatch	repair	gene	MGMT,	has	been	linked	to	
aberrant	promoter	methylation	and	gene	silencing	(Ogino	et	al.	2007).	Finally,	Shen	
et	al	(Shen	et	al.	2013)	have	demonstrated	that	susceptibility	SNPs	at	the	HNF1	
Homeobox	B	(HNF1B)	locus	in	ovarian	cancer	are	associated	with	altered	
methylation	and	consequent	expression	of	HNF1B.		
	
Evidence	for	genetically	driven	aberrant	methylation	patterns	in	prostate	cancer	is	
provided	by	a	2013	study	examining	DNA	methylation	changes	in	prostate	cancer	
metastases	(Aryee	et	al.	2013).	While	the	authors	found	substantial	methylation	
alteration	differences	between	individuals,	methylation	changes	were	often	
maintained	in	the	same	individual	across	various	anatomically	distinct	metastases	
compared	to	matched	normal	non-prostatic	tissue,	in	a	similar	manner	to	copy	
number	alterations.	These	abnormally	methylated	regions	within	the	same	individual	
across	metastases	were	often	located	in	cancer-related	genes,	as	were	regions	that	
were	similarly	hypermethylated	between	individuals.	Despite	less	intra-individual	
tumour	methylation	heterogeneity	than	between	individuals,	clonal	evolution	still	
created	noticeable	intra-individual	methylation	differences	between	metastases.	The	
authors	attributed	this	mainly	to	stochastic	factors	as	these	tumours	pass	through	a	
“very	narrow	individual-specific	clonal	gate”	after	which	minimal	heterogeneity	
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occurs.	In	a	more	loci-specific	study,	Ianni	et	al.	examined	genetically	driven	
methylation	alterations	in	several	genes	including	Glycine	N-Methyltransferase	
(GNMT),	a	gene	coding	for	an	enzyme	involved	in	regulating	synthesis	and	
availability	of	methyl	groups.		The	T	allele	genotype	at	one	SNP	in	the	GNMT	
promoter	was	linked	to	altered	DNA	methylation,	decreased	gene	expression	and	
heightened	prostate	cancer	risk	(Ianni	et	al.	2012).	Together	these	studies	point	to	
the	importance	of	examining	genetically	driven	methylation	changes	in	further	
understanding	prostate	cancer	development.	
	
Thus	there	is	now	considerable	interest	in	mapping	inherited	methylation	changes	
influencing	disease	susceptibility	and	disease	course.	Given	the	recent	technological	
advances	that	are	enabling	integration	of	genetic,	epigenetic	and	phenotypic	data	it	
is	likely	that	more	examples	of	diseases	resulting	from	genetic	drivers	of	epigenetic	
change	will	be	described	in	the	future.		
	
1.5.6	The	promise	of	epigenetic	diagnosis	and	therapy	
Aberrant	methylation	has	been	suggested	as	a	diagnostic	and	prognostic	marker	for	
various	cancers	for	nearly	a	decade.	GSTP1,	the	most	commonly	altered	gene	in	
prostate	cancer,	improves	specificity	and	sensitivity	of	PSA	diagnosis,	particularly	on	
recurrence	(Hopkins,	Burns	and	Routledge	2007;	Woodson	et	al.	2008;	Maldonado	et	al.	2014),	while	promoter	methylation	at	the	MGMT	gene	predicts	
response	to	chemotherapy	in	glioblastoma	(Wiewrodt	et	al.	2007).	More	recently,	a	
2012	prospective	study	of	cervical	neoplasia	further	demonstrated	the	utility	of	
harnessing	our	heightened	understanding	of	epigenetic	predisposition	in	improving	
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diagnostic	tests.	Examining	DNA	methylation	variability	between	epithelial	samples	
predicted	the	risk	of	cancer	three	years	prior	to	morphological	changes	(Teschendorff	and	Widschwendter	2012;	Teschendorff	et	al.	2012).		Feinberg	
suggests	that	using	such	tests	to	identify	subgroups	for	further	traditional	follow-up	
screening	could	increase	the	positive	predictive	value	of	these	more	invasive	and	
expensive	tests	by	over	90%	and	greatly	reduce	cancer	deaths	(Feinberg	2014).				
	
Furthermore,	epigenetic	therapy	offers	the	exciting	possibility	of	resetting	gene	
expression	in	a	way	not	yet	possible	for	genomic	mutations,	since	unlike	genetic	
variation	and	chromosomal	defects	that	permanently	alter	the	genome,	epigenetic	
patterns	are	more	dynamic	and	pharmaceutically	adaptable.	Several	epigenetic	
drugs	have	been	approved	for	treatment	of	other	cancers	in	the	USA,	with	many	
more	in	clinical	trials	(Bojang	and	Ramos	2014).	However,	these	drugs	are	designed	
to	correct	the	epigenetic	alterations	acquired	during	disease	development	(Sharma,	Kelly	and	Jones	2010)	with	the	assumption	that	these	acquired	epigenetic	
alterations	are	driven	by	the	disease	process	itself.	More	recently	it	has	been	
hypothesised	that	inherited	genetic	variation	can	drive	epigenetic	alterations	and	
further,	that	these	contribute	to	disease	susceptibility	or	disease	course.	A	greater	
understanding	of	these	drivers	of	disease	would	allow	for	more	effective,	
personalised	medical	treatment	of	prostate	cancer.	
	
1.6	Project	Rational	 	
The	focus	of	this	study	is	to	adopt	a	new	approach	to	elucidate	the	underlying	
molecular	mechanisms	driving	prostate	cancer	development	by	using	the	Tasmanian	
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Familial	Prostate	Cancer	resource	to	examine	inherited	determinants	of	methylation	
patterns.	This	resource	contains	genealogical	and	pathology	records	for	over	one	
thousand	people	from	fifty	large	families,	with	archived	blood,	buccal	and	prostate	
tissue	samples	for	individuals	diagnosed	with	prostate	cancer	and	their	close	
relatives.		
	
1.6.1	Hypothesis	
The	hypothesis	for	this	study	is	that	DNA	sequence	changes	in	non-coding	regions	of	
the	genome	can	alter	transcriptional	activity,	triggering	epigenetic	changes	in	
regulatory	regions,	which	lead	to	gene	silencing	and	contribute	to	prostate	cancer	
development	and	progression.	It	is	hypothesised	that	these	can	be	identified	by	
examining	germline	DNA	of	individuals	from	families	exhibiting	a	dense	aggregation	
of	prostate	cancer	cases.	
	
1.6.2	Aims	
Two	broad	aims	were	developed	to	examine	this	hypothesis:	
Aim	1:	To	utilise	the	Tasmanian	Familial	Prostate	Cancer	Resource,	containing	dense	
aggregations	of	prostate	cancer	cases,	to	examine	the	association	between	
genotype,	as	measured	by	SNPs,	and	epigenotype,	as	measured	by	DNA	methylation.	
Aim	2:	To	utilise	the	Tasmanian	Familial	Prostate	Cancer	Resource	and	the	
Tasmanian	Prostate	Cancer	Case	Control	Study	to	examine	the	association	between	
epigenotype	and	prostate	cancer	occurrence.			 	
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Chapter	2	–	Features	of	the	Tasmanian	Familial	Prostate	
Cancer	Resource	guiding	study	design	
	
	
2.1	Introduction		
2.1.1	Employing	familial	data	to	examine	disease-relevant	meQTLs	
Population-based	GWAS	studies	have	successfully	identified	part	of	the	common	
variation	linked	to	disease,	yet	the	effect	size	of	variants	is	often	small	and	difficult	
to	verify	(Hindorff	et	al.	2009;	Marjoram,	Zubair	and	Nuzhdin	2014).	As	it	
becomes	clearer	that	common	SNPs	do	not	explain	a	large	portion	of	the	genetic	risk	
of	complex	disease,	rare	variants	are	being	examined	in	more	detail	to	help	further	
understand	inherited	risk	of	disease	(Manolio	et	al.	2009;	Wijsman	2012).	Family	
studies	provide	one	of	the	best	opportunities	to	examine	rare	deleterious	variants,	
as	these	variants	are	often	enriched	in	families	with	clusters	of	affected	individuals	(Curran,	Meikle	and	Blangero	2011).	The	inclusion	of	pedigree	structures	in	these	
studies	also	provides	additional	analysis	advantages,	including	imputation	for	family	
members	where	genetic	material	is	unavailable	and	interpretation	and	ranking	of	
disease	segregating	variants	(Thomas	2012).	Decreased	genetic	complexity	
combined	with	shared	environments	also	allow	for	greater	confidence	in	detecting	
true	genetic	differences	over	confounding	factors	(Pattaro	and	Saint-Pierre	2013).	
Additionally,	certain	statistical	challenges	are	reduced	in	familial	studies;	pedigrees	
inherently	lack	population	stratification	which	can	create	off	target	associations,	and	
a	much	smaller	sample	size	is	required	to	achieve	the	same	power,	assuming	the	
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pedigree	has	an	appropriate	trait	distribution.	There	is	a	lower	risk	of	false	positives	
as	less	statistical	tests	are	required	once	specific	regions	of	interest	are	identified	(Wijsman	2012).		
	
The	power	of	familial	study	designs	can	be	observed	in	the	recent	success	of	two	
familial	studies	identifying	functional	variants	linked	to	disease,	one	examining	
autism	risk	and	the	other	renal	function	(Marchani	et	al.	2012;	Park	et	al.	2013).	
This	utility	is	further	exemplified	by	the	divergent	results	of	two	late-onset	
Alzheimer’s	disease	studies,	one	familial	and	the	other	case-control.	While	both	
studies	evaluated	the	same	four	candidate	genes,	the	success	of	each	study	was	
markedly	different.	The	population-based	case-control	study	of	17,313	individuals,	
had	a	sample	size	forty	times	greater	than	the	familial	approach,	yet	was	unable	to	
find	any	significant	disease-linked	SNPs	(Gerrish	et	al.	2012).	Contrastingly,	the	
familial	study	which	sequenced	pooled	samples	from	449	unrelated	affected	
individuals	from	families	with	clusters	of	Alzheimer’s	disease,	identified	numerous	
disease-segregating	rare	variants	(Cruchaga	et	al.	2012).		
	
Similar	success	has	been	seen	in	familial	studies	examining	prostate	cancer	risk,	for	
example	in	the	case	of	Homeobox	B13	(HOXB13)	as	discussed	in	Chapter	1	under	
section	1.3.1.	In	this	case,	family	studies	were	key	to	discovering	a	risk	region	on	
chromosome	17	and	also	subsequent	elucidation	of	the	disease-segregating	
mutation.	Unlike	the	above	Alzheimer’s	disease	case,	possibly	due	to	the	
heterogeneous	nature	of	prostate	cancer	predisposition,	HOXB13	was	later	validated	
in	population	based	studies	and	found	to	explain	around	1%	of	the	familial	risk	of	
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prostate	cancer	in	the	UK	population	(Kote-Jarai	et	al.	2015).	Additionally,	work	
from	our	laboratory	using	the	same	familial	prostate	cancer	data	set	as	utilised	in	the	
current	project,	discovered	novel	risk	SNPs	associated	with	Integrin	alpha	2	(ITGA2),	
a	gene	not	previously	associated	with	prostate	cancer	risk	(FitzGerald	et	al.	2009).	
	
While	familial	studies	have	traditionally	been	applied	to	analyse	genetic	risk	for	
complex	diseases,	advances	in	technology	and	analysis	tools	have	recently	allowed	
for	epigenetic	risk	to	also	be	investigated.	In	a	similar	manner	to	examining	the	
effect	of	genetic	variation	on	gene	expression	or	quantitative	traits	(eQTLs/QTLs),	
the	effect	of	genetic	variation	on	methylation	and	subsequently	gene	expression	and	
quantitative	traits	(meQTLs)	can	now	also	be	explored,	using	similar	laboratory	
techniques	and	data	analysis	algorithms	(Gaunt	et	al.	2016).	Sequence	and	array-
based	technologies	are	now	capable	of	measuring	epigenetic	variation	as	well	as	
genetic	variation,	with	DNA	methylation	a	particular	disease	focus.		
	
The	majority	of	these	next	generation	methylation	techniques	depend	upon	a	key	
innovation	from	the	Kanematsu	laboratories	in	1992,	bisulphite	conversion	(Frommer	et	al.	1992).	The	process	takes	advantage	of	the	selective	deamination	
by	bisulphite	of	cytosine	residues	over	other	nucleotides.	Critically,	methylation	of	
the	cytosine	residue	protects	it	from	this	conversion	and	as	such	methylated	
residues	can	be	distinguished	from	those	that	are	unmethylated.	Unmethylated	
cytosines	are	converted	to	uracil	and	then	thymine	during	PCR	amplification,	as	
demonstrated	in	Figure	2.1	(Patterson	et	al.	2011).		
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Recent	studies	have	demonstrated	the	utility	of	exploiting	familial	resources	to	
examine	the	effect	of	meQTLs	in	both	cis	and	trans	(Lemire	et	al.	2015;	Kulkarni	et	
al.	2015).	The	current	study	similarly	aims	to	harness	the	power	of	a	familial	study	
design	in	combination	with	next	generation	epigenetic	technologies	to	examine	the	
association	between	genotype,	epigenotype	and	prostate	cancer	occurrence.	Whilst	
this	strategy	has	now	been	adopted	by	several	researchers	in	the	field	of	familial	
genetics,	at	the	commencement	of	this	project,	this	approach	was	new	to	the	field.	
To	achieve	this	larger	aim,	two	specific	objectives	first	needed	to	be	addressed.	
Firstly,	clusters	of	individuals	from	the	Tasmanian	Familial	Prostate	Cancer	Resource	
with	high	disease	burden	needed	to	be	identified,	and	secondly	high	quality	genome-
wide	genotype	and	methylation	data	needed	to	be	generated	from	these	individuals.		
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Figure	2.1	Bisulphite	Conversion	of	DNA	
Genomic	DNA	is	denatured	(Step	1)	before	unmethylated	cytosines	undergo	
bisulphite	conversion	with	sodium	bisulphite	(Step	2).		A	desulphonation	step	
removes	the	sulphite	moiety,	generating	uracil	(Step	3).		During	subsequent	PCR	
amplification	uracil	is	replaced	with	thymine.		Alternatively,	the	methyl	group	
protects	methylated	cytosines	from	bisulphite	conversion	and	these	nucleotides	
remain	as	cytosines,	and	can	thus	be	distinguished	from	unmethylated	cytosines	
which	have	been	converted	to	thymine.		Adapted	from	New	England	BioLabs	
EpiMark®	Bisulfite	Conversion	Kit	Protocol.	
	
	 DNA	 
amplification 
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2.2	Sample	Selection	Strategy	and	Evaluation	of	Data	Quality	
2.2.1	Sample	Selection	from	the	Tasmanian	Familial	Prostate	Cancer	Resource	
The	Tasmanian	Familial	Prostate	Cancer	Resource	provides	a	rare	opportunity	to	
further	examine	the	underlying	mechanisms	of	prostate	cancer	development.	It	was	
initially	established	in	the	1990s	from	large	families	with	multiple	cases	of	prostate	
cancer.	The	families	were	identified	from	the	records	of	the	Tasmanian	Cancer	
Registry.	As	PSA	testing	had	not	been	widely	adopted	in	Tasmania	at	the	time,	these	
original	affected	men	were	recruited	to	the	study	having	presented	with	a	
symptomatic	form	of	the	disease,	with	all	cases	being	histologically	confirmed.	The	
Tasmanian	Cancer	Registry	and	the	Menzies	Institute	for	Medical	Research	
genealogical	database	has	since	been	utilised	to	expand	this	original	database	to	
include	additional	men	diagnosed	with	prostate	cancer	as	well	as	their	close	
relatives.	Many	families	extend	to	five	or	six	generations.	This	unique	resource	now	
contains	genealogical	and	pathology	records	for	over	one	thousand	people	from	
sixty	large	families.	As	well	as	whole	blood	and	buccal	samples,	over	75%	of	cases	
have	archived	pathology	specimens	in	the	form	of	paraffin	embedded	prostate	
tissue.	These	are	stored	at	one	of	three	locations;	pathology	laboratories	at	the	
Royal	Hobart	Hospital,	the	Cancer	Genetics	laboratory	at	the	Menzies	Institute	for	
Medical	Research	and	private	pathology	laboratories	in	Hobart.	
	
The	current	study	focuses	on	four	large	families	from	this	resource,	Prostate	Cancer	
Families	9,	11,	22	and	72,	with	abridged	pedigrees	shown	in	Figures	2.2-5.	For	this	
study	sixty-two	individuals	were	selected	primarily	from	these	four	large	families	and	
their	DNA	subjected	to	genome-wide	methylation	and	/	or	genotype	analysis.	
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Selection	of	individuals	was	based	on	disease	burden,	as	determined	by	the	number	
of	affected	first	and	second	degree	relatives	and	the	proband’s	age	at	diagnosis.	
Selected	individuals	were	of	Caucasian	descent,	ranging	in	age	from	23	to	89	years	
and	represented	clusters	of	densely	aggregated	cases	of	affected	men	and	close	
relatives.	These	individuals	included	thirty-four	men	affected	by	prostate	cancer,	
fifteen	unaffected	men,	ten	females	(including	one	diagnosed	with	another	cancer)	
and	three	men	diagnosed	with	another	form	of	cancer.	Female	samples	were	chosen	
if	they	had	at	least	one	first	degree	relative	affected	by	prostate	cancer.	These	
samples	were	used	to	provide	additional	statistical	power	in	the	genotype-
methylation	analysis	described	in	Chapter	4.		
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Figure	2.2	Tas	PCa	Family	9	abridged	pedigree.			
A	section	of	the	larger	pedigree	for	Family	9	highlights	the	high	rate	of	prostate	cancer	within	the	family,	particularly	in	the	later	generations.		Males	are	shown	as	squares	and	females	circles.		Men	affected	by	prostate	cancer	are	represented	by	filled	in	black	squares,	unaffected	men	by	
unfilled	squares	and	individuals	diagnosed	with	other	cancers	are	indicated	by	a	small	filled	box	in	the	top	left	corner.		A	subset	of	samples	analysed	for	methylation	data	are	indicated	by	red	arrow	heads.	Family	9	extends	over	nine	generations	and	contains	fifty-three	men	affected	by	
prostate	cancer.		The	blue	line	indicates	where	the	same	individual	has	been	included	twice	in	the	pedigree,	once	in	his	own	lineage	on	the	far	right	and	again	towards	the	left	of	the	pedigree	where	he	has	married	a	woman	who	has	descended	from	the	left	branch	of	the	family.	
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Figure 2.2 Tas PCa Family 9 abridged pedigre .   
A section of the larger pedigree for Family 9 highlights the high rate of prostate cancer within the family, particularly in the later generations.  Males are shown as squares and females circles.  Men affected by prostate cancer are represented by filled in black squares, unaffected men by unfilled 
squares and individuals diagnosed with other cancers are indicated by a small filled box in the top left corner.  A subset of  samples analysed for methylation data are indicated by red arrow heads. Family 9 extends over nine generations and contains fifty-three men affected by prostate cancer.  The 
blue line indicates where the same individual has been included twice in the pedigree, once in his own lineage on the far right and again towards the left of the pedigree where he has married a woman who has descended from the left branch of the family. 
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Figure	2.3	Tas	PCa	Family	11	abridged	pedigree.	
Two	branches	of	the	larger	pedigree	for	Family	11	are	illustrated,	with	men	represented	as	squares	and	females	circles.		Men	affected	by	prostate	cancer	are	filled	in	black,	unaffected	men	are	unfilled	and	
individuals	diagnosed	with	other	cancers	are	indicated	by	a	small	filled	box	in	the	top	left	corner.	A	subset	of	samples	analysed	for	methylation	data	are	indicated	by	red	arrow	heads.	These	abridged	
pedigrees	for	Family	11	cover	five	generations	and	include	twelve	affected	men.	
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Figure 2.3 Tas PCa Family 11 abridged pedigree. 
Two branches of the larger pedigree for Family 11 are illustrated, with men represented as squares and females circles.  Men affected by prostate cancer are filled in black, unaffected men are unfilled and individuals diagnosed 
with other cancers are indicated by a small filled box in the top left corner. A subset of samples analysed for methylation data are indicated by red arrow heads. These abridged pedigrees for Family 11 cover five generations and 
include twelve affected men. 
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Figure	2.4	Tas	PCa	Family	22	abridged	pedigree.	
Two	branches	of	the	larger	pedigree	for	Family	22	are	illustrated,	with	men	represented	as	squares	and	females	circles.		Men	affected	by	prostate	cancer	are	filled	in	black,	unaffected	are	unfilled	and	
individuals	diagnosed	with	other	cancers	are	indicated	by	a	small	filled	box	in	the	top	left	corner.	A	subset	of	samples	analysed	for	methylation	data	are	indicated	by	red	arrow	heads.	The	abridged	Family	22	
pedigrees	cover	six	generations,	including	eighteen	affected	men. 40 
 
 
 
 
Figure 2.4 Tas PCa Family 22 abridged pedigree. 
Two branches of the larger pedigree for Family 22 are illustrated, with men represented as squares and females circles.  Men affected by prostate cancer are filled in black, unaffected are unfilled and individuals diagnosed with 
other cancers are indicated by a small filled box in the top left corner. A subset of samples analysed for methylation data are indicated by red arrow heads. The abridged Family 22 pedigrees cover six generations, including 
eighteen affected men.
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Figure	2.5	Tas	PCa	Family	72	abridged	pedigree.	
A	section	of	the	larger	pedigree	for	Family	72	is	illustrated,	with	men	represented	as	squares	and	females	circles.	Men	affected	by	prostate	cancer	are	filled	in	black,	unaffected	are	unfilled	and	individuals	
diagnosed	with	other	cancers	are	indicated	by	a	small	filled	box	in	the	top	left	corner.	A	subset	of	samples	analysed	for	methylation	data	are	indicated	by	red	arrow	heads.	The	abridged	family	72	pedigree	
depicts	twelve	affected	men	over	six	generations.
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Figure 2.5 Tas PCa Family 72 abridged pedigree. 
A section of the larger pedigree for Family 72 is illustrated, with men represented as squares and females circles. Men affected by prostate cancer are filled in black, unaffected are unfilled and individuals diagnosed with other 
cancers are indicated by a small filled box in the top left corner. A subset of samples analysed for methylation data are indicated by red arrow heads. The abridged fami ly 72 pedigree depicts twelve affected men over six 
generations.
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Overall,	twenty-seven	individuals	selected	had	at	least	two	first-degree	relatives	
affected	by	prostate	cancer,	and	often	had	three	or	four	affected	relatives	(ten	
samples).	Twenty-six	had	one	affected	first-degree	relative	and	only	eight	had	none,	
of	which	six	had	prostate	cancer	themselves.	In	addition	to	the	number	of	first	
degree	relatives	affected	by	prostate	cancer,	samples	were	also	selected	to	generate	
clusters	of	closely	related	individuals,	with	fourteen	father-son	pairs,	seven	brother	
pairs	and	six	sibling	trios	included.	One	three-generation	cluster	from	Family	72	was	
also	selected,	comprising	two	first	generation	affected	brothers,	three	second-
generation	children	(two	men	affected	by	prostate	cancer	and	their	sister)	and	a	
third	generation	male	affected	by	another	cancer.	Figure	2.6	A-D	displays	the	familial	
clusters	(from	families	9,	11,	22	and	72)	and	abridged	pedigrees	for	the	individuals	
selected	for	analysis.		Some	additional	individuals	were	chosen	for	analysis	from	
smaller	pedigrees	to	ensure	statistical	power	was	maintained.	These	individuals	were	
also	prioritised	on	the	number	of	first	degree	relatives	affected	by	prostate	cancer,	
and	are	shown	in	Figure	2.6	E.
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Figure	2.6	Pedigree	clusters	from	the	Tasmanian	Familial	Prostate	Cancer	study.	
A)	Four	clusters	from	Family	9	were	selected	for	analysis.	Circles	represent	women	
and	squares	men,	with	individuals	affected	by	prostate	cancer	filled	in	black,	those	
unaffected	unfilled	and	individuals	affected	by	other	cancers	quarter	filled.		Samples	
with	methylation	data	are	indicated	by	an	arrow-head,	green	for	good	quality	
samples	and	red	for	poor	quality.	Samples	with	genotype	data	are	indicated	by	
diamonds,	green	for	good	quality	and	red	for	poor	quality.		Replicate	samples	are	
indicated	by	square	brackets	around	the	sample	name,	and	the	batch	for	
methylation	array	data	is	indicated	underneath	the	sample	name.	
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Figure	2.6	Pedigree	clusters	from	the	Tasmanian	Familial	Prostate	Cancer	study.	
B)	Two	clusters	from	Family	11	were	selected	for	analysis.	Circles	represent	women	
and	squares	men,	with	individuals	affected	by	prostate	cancer	filled	in	black,	those	
unaffected	unfilled	and	individuals	affected	by	other	cancers	quarter	filled.		Samples	
with	methylation	data	are	indicated	by	an	arrow-head,	green	for	good	quality	
samples	and	red	for	poor	quality.	Samples	with	genotype	data	are	indicated	by	
diamonds,	green	for	good	quality	and	red	for	poor	quality.		Replicate	samples	are	
indicated	by	square	brackets	around	the	sample	name,	and	the	batch	for	
methylation	array	data	is	indicated	underneath	the	sample	name.	
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Figure	2.6	Pedigree	clusters	from	the	Tasmanian	Familial	Prostate	Cancer	study.	
C)	Three	clusters	from	Family	22	were	selected	for	analysis.	Circles	represent	women	
and	squares	men,	with	individuals	affected	by	prostate	cancer	filled	in	black,	those	
unaffected	unfilled	and	individuals	affected	by	other	cancers	quarter	filled.		Samples	
with	methylation	data	are	indicated	by	an	arrow-head,	green	for	good	quality	
samples	and	red	for	poor	quality.	Samples	with	genotype	data	are	indicated	by	
diamonds,	green	for	good	quality	and	red	for	poor	quality.		Replicate	samples	are	
indicated	by	square	brackets	around	the	sample	name,	and	the	batch	for	
methylation	array	data	is	indicated	underneath	the	sample	name.	
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Figure	2.6	Pedigree	clusters	from	the	Tasmanian	Familial	Prostate	Cancer	study.	
D)	Five	clusters	from	Family	72	were	selected	for	analysis.	Circles	represent	women	
and	squares	men,	with	individuals	affected	by	prostate	cancer	filled	in	black,	those	
unaffected	unfilled	and	individuals	affected	by	other	cancers	quarter	filled.		Samples	
with	methylation	data	are	indicated	by	an	arrow-head,	green	for	good	quality	
samples	and	red	for	poor	quality.	Samples	with	genotype	data	are	indicated	by	
diamonds,	green	for	good	quality	and	red	for	poor	quality.		Replicate	samples	are	
indicated	by	square	brackets	around	the	sample	name,	and	the	batch	for	
methylation	array	data	is	indicated	underneath	the	sample	name.		
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Figure	2.6	Pedigree	clusters	from	the	Tasmanian	Familial	Prostate	Cancer	study.	
E)	One	cluster	from	each	of	families	1,	2,	3,	4,	12	and	75	were	selected	for	analysis.	
Circles	represent	women	and	squares	men,	with	individuals	affected	by	prostate	
cancer	filled	in	black,	those	unaffected	unfilled	and	individuals	affected	by	other	
cancers	quarter	filled.		Samples	with	methylation	data	are	indicated	by	an	arrow-
head,	green	for	good	quality	samples	and	red	for	poor	quality.	Samples	with	
genotype	data	are	indicated	by	diamonds,	green	for	good	quality	and	red	for	poor	
quality.		Replicate	samples	are	indicated	by	square	brackets	around	the	sample	
name,	and	the	batch	for	methylation	array	data	is	indicated	underneath	the	sample	
name.	
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2.2.2	DNA	isolation,	preparation	and	initial	quality	control	
Peripheral	 blood	 samples	were	 collected	with	 informed	 consent	 obtained	 from	 all	
participants,	 following	 ethics	 approval	 from	 the	 University	 of	 Tasmania	 (H9999,	
Human	Research	 Ethics	 Committee	 Tasmanian	Network).	 DNA	was	 extracted	 from	
whole	blood	using	the	Nucleon	BACC3	(GE	Healthcare)	DNA	extraction	kit,	following	
the	manufacturer’s	instructions.	DNA	was	initially	quantified	on	the	Nanodrop	8000	
(Thermo	Scientific)	and	samples	with	a	260:280	ratio	of	less	than	1.80	were	further	
purified	 using	 the	 Zymo	 Clean	 &	 Concentrator	 (TM)-5	 Kit	 (Zymo).	 DNA	 was	 then	
quantified	 using	 a	 Qubit®	 Flourometer.	 To	 ensure	 selected	 samples	 had	 sufficient	
quantity	 and	 quality	 of	 DNA	 to	 perform	 methylation	 and	 genotype	 arrays,	 each	
sample	was	quantified	on	the	Nanodrop	8000	(Thermo	Scientific)	and	samples	with	
sufficient	 DNA	 quantity	 (at	 least	 1.5µg)	 and	 purity	 (A260/280	 above	 1.8)	 were	
interrogated	via	electrophoresis	on	a	2%	agarose	gel	to	further	assess	DNA	quality.	
Samples	with	poor	quality	DNA,	as	indicated	by	small	DNA	fragments	detected	by	gel	
electrophoresis,	were	excluded	from	further	analysis.		
	
2.2.3	Genome-wide	DNA	methylation	analysis		
The	launch	of	Illumina’s	Infinium	HumanMethylation	450k	BeadChip	(hereafter	
referred	to	as	the	‘methylation	array’)	in	2012	has	been	central	to	the	rapid	advance	
in	our	understanding	of	epigenetic	risk	factors	of	disease.	This	cost-effective	
platform	delivers	a	single	“snapshot”	of	over	480,000	CpG	sites	throughout	the	
genome.	Adopted	by	many	researchers,	it	ensured	the	continued	popularity	of	
epigenomic	array-based	technology,	as	earlier	array	technology	lacked	the	same	
depth	of	genomic	coverage	(ie.	the	previous	Illumina	methylation	array	contained	
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only	27,000	CpG	sites)	and	bisulphite	sequencing	costs	at	the	time	were	prohibitive	
and	indeed	still	surpass	the	cost	and	ease	of	laboratory	processing	of	the	
methylation	array.		
	
Briefly,	the	methylation	array	involves	denaturing	and	bisulphite	converting	DNA,	
followed	by	amplification	and	hybridization	to	a	bead	chip	containing	hapten	
labelled	dideoxynucleotides.	There	are	two	types	of	probes	on	the	array;	one	quarter	
are	Infinium	I	probes	which	use	a	single	colour	channel	but	have	a	different	bead	for	
methylated	or	unmethylated	DNA,	while	the	remaining	75%	are	Infinium	II	probes,	a	
novel	design	from	the	previous	27k	array,	with	a	single	bead,	using	two	different	
colour	signals	for	detection,	green	for	methylated	(labelled	with	biotin)	and	red	for	
unmethylated	(labelled	with	2,4-dinitrophenol).	While	Infinium	II	probes	require	only	
one	bead	per	locus,	increasing	genomic	coverage,	they	can	only	tolerate	a	maximum	
of	three	CpGs	in	the	probe	body.	Infinium	I	probes	can	tolerate	more	CpGs,	allowing	
for	coverage	of	CpG	dense	regions.		
	
While	this	technology	is	powerful	and	reproducible	there	are	several	factors	that	
must	be	considered	in	experimental	design	and	quality	control	to	ensure	reliable,	
high	quality	data	is	generated	and	ensure	observed	differences	are	true	biological	
differences,	not	simply	technical	bias	(Sun	et	al.	2011;	Harper,	Peters	and	Gamble	2013).	Firstly,	the	platform	is	prone	to	batch	effects,	introduced	either	during	
bisulphite	conversion	or	downstream	processing,	which	may	require	normalization	
despite	a	strong	study	design.	Secondly,	although	the	two-probe	biochemistry	
greatly	increases	genomic	coverage,	it	necessitates	further		
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within-array	normalization	to	allow	signals	from	both	probe	types	to	be	analysed	
together	(Dedeurwaerder	et	al.	2011).	Familial	data	requires	particular	attention	in	
choosing	the	most	appropriate	normalisation	method,	and	this	is	discussed	in	detail	
in	Chapter.3.	
	
Fifty-eight	samples,	including	fifty	unique	samples	and	eight	biological	replicates,	as	
specified	in	Figure	2.6	(indicated	by	arrow	heads)	and	Table	2.1,	were	subjected	to	
methylation	analysis.	One	microgram	of	DNA	from	each	sample	was	bisulphite	
converted,	using	the	EZ	DNA	Methylation-Gold	(TM)	kit	(Zymo	Research),	according	
to	the	manufacturer’s	instructions.	Bisulphite	converted	DNA	(400ng)	was	then	used	
for	analysis	of	DNA	methylation	using	the	methylation	array	BeadChips,	according	to	
the	manufacturer’s	instructions.	The	samples	were	analysed	over	five	plates,	with	
replicate	samples	analysed	across	the	plates	to	allow	for	monitoring	and	adjustment	
of	potential	technical	bias.	Forty-eight	of	the	fifty-eight	samples	selected	for	
interrogation	on	the	methylation	array	were	analysed	in-house,	while	ten	were	
performed	using	a	service	provider,	Service	XS	(Leiden,	The	Netherlands).	These	ten	
samples	were	analysed	using	a	service	provider	as	they	were	analysed	prior	to	the	
installation	of	Illumina	HiScan	Technology	within	our	laboratory.	BeadChips	analysed	
in-house	were	imaged	on	the	Illumina	HiScan	reader.	Upon	scanning,	the	florescent	
signals	are	excited	by	a	laser	and	Illumina’s	iControl	software	records	these	signals	as	
IDAT	files	containing	the	raw	intensity	signals	from	both	red	and	green	colour	
channels	(Illumina	2012).	For	each	of	the	480,000	loci	on	the	array,	a	beta	value	
between	0-1	is	then	generated,	indicating	the	proportion	of	methylation	at	that	site	
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for	the	population	of	cells	analysed	(0	indicative	of	no	methylation,	1	completely	
methylated).		
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Sample'ID Sex
Disease'
Status 'Rel'
+' Quality M RepM Quality G RepG Age$*
1 PC1)03 M Affected 1 NA NA Good No 82
2 PC2)01 M Affected 2 NA NA Good No 52
3 PC2)02 M Affected 2 NA NA Good No 53
4 PC2)03 M Affected 2 NA NA Good No 58
5 PC3)01 M Affected 3 NA NA Good No n/a
6 PC4)01 M Affected 0 NA NA Good No 74
7 PC9)01$ M Affected 2 Good No Good No 64
8 PC9)04$ M Affected 0 Good No Good No 65
9 PC9)12$ M Affected 0 Good No Good No 72
10 PC9)121$ M Unaffected 1 Good No Good No 48
11 PC9)129 F NA 1 Good No Good No 61
12 PC9)24$ F NA 1 Good No Good No 45
13 PC9)286 M Unaffected 1 Good No Good No 47
14 PC9)29 F NA 1 Good No Good No n/a
15 PC9)338 M Affected 0 Good No Good No 63
16 PC9)357 M Unaffected 1 Good No Good No 42
17 PC9)477$ M Affected 1 Good No Good No 52
18 PC11)03 M Affected 1 Good No Good No 89
19 PC11)04 M Affected 1 Good No Good No 73
20 PC11)09 M Affected 2 Good No Good No 83
21 PC11)147 M Affected 1 Good No Good No 61
22 PC11)180 M Unaffected 1 Good No Good No 42
23 PC11)213 M Affected 0 Poor x2 NA NA 62
24 PC11)233 M Unaffected 3 Poor x2 NA NA 92
25 PC11)234 M Unaffected 1 Good No Good No 55
26 PC11)415 M Unaffected 1 Good No NA NA 61
27 PC12)04 M Affected 2 NA NA Good No n/a
28 PC22)02 M Affected 2 Good No NA NA 64
29 PC22)03 M Affected 2 Good No Good No 74
30 PC22)04 M Affected 1 Good No Good No 62
31 PC22)16 M Affected 3 Good x2 Good No 76
32 PC22)162 M Unaffected 2 Good No Good No 56
33 PC22)17 M Affected 3 Good x4 Good x2 63
34 PC22)195 F NA 1 Good No NA NA 40
35 PC22)203 M Affected 3 Good No Good No 75
36 PC22)21 M Affected 2 Good No Good No 70
37 PC22)210 F NA 4 Good No Good No 73
38 PC22)274 M Unaffected 1 Good No Good No 45
39 PC22)386 F NA 1 Good No NA NA 56
40 PC22)387 M Affected 2 Good No Good No 79
Table&2.1&Samples&selected&from&the&Tasmanian&Familial&Prostate&Cancer&Resource&
for&methylation&and&genotype&array&analysis
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41 PC22)388 M Unaffected 3 Good No Good No 73
42 PC22)393$ F NA 1 Good No Good No 44
43 PC22)414 F NA 3 Good No Good No 66
44 PC22)416 M Affected 2 Good No Good No 61
45 PC22)418 M Unaffected 3 Good No Good No 54
46 PC22)468 M Affected 0 Good No NA NA 69
47 PC22)476 M Unaffected 1 Good No Good No 36
48 PC27)01 M Affected 1 NA NA Good No 64
49 PC72)02 M Affected 1 NA NA Good No 85
50 PC72)03 M Affected 3 Good No Good No 70
51 PC72)04 M Affected 4 Good No Good x2 78
52 PC72)106 M Unaffected 2 Good No Good No 46
53 PC72)126 M Affected 1 Good No Good No 49
54 PC72)136 M Other$Cancer 0 Good No NA NA 57
55 PC72)187 F NA 2 Good No Good No 41
56 PC72)188 M Other$Cancer 1 Good No Good No 23
57 PC72)213 M Unaffected 0 Good x2 NA NA 41
58 PC72)291 M Unaffected 1 Poor x2 NA NA 42
59 PC72)77 M Affected 0 Good No NA NA 75
60 PC72)94 M Other$Cancer 1 NA NA Good No 61
61 PC72)97 F Other$Cancer 2 NA NA Good No n/a
62 PC75)01 M Affected 2 NA NA Good No 65
Rel+$:$number$of$affected$first$degree$relatives
RepM:$analsyed$as$a$replicate$sample$on$the$methylation$array
*$Age$at$sample$collection
RepG:$analsyed$as$a$replicate$sample$on$the$genotype$array
n/a:$not$available
NA:$Non)applicable
QualityG:$quality$of$genotype$$data
QualityM:$quality$of$methylation$data
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2.2.4	Genome-wide	methylation	data	extraction,	pre-processing	and	initial	quality	
control	analysis	
Raw	 data	was	 combined	 from	 all	 batches	 generated	 in	 both	 the	 overseas	 and	 in-
house	 laboratories,	 and	 analysed	 together.	 Illumina’s	 GenomeStudio	 software	
package	provides	only	basic	quality	control	and	pre-processing,	which	is	insufficient	
to	 analyse	 familial	 methylation	 data,	 as	 this	 type	 of	 data	 requires	 specialised	
normalisation	methods	to	remove	technical	bias.	As	such,	IDAT	files	were	analysed	in	
the	R	environment	 (R	Core	Team,	2014).	A	combination	of	 three	R	packages,	minfi	(Aryee	 et	 al.	 2014),	 methylumi	 (Davis,	 S	 et	 al.,	 2012)	 and	 ChAMP	 (Morris	 et	 al.	2014),	were	used	to	load	IDAT	files	into	R	and	perform	basic	quality	control	analysis.	
Different	normalization	methods	require	the	data	to	be	in	different	formats	and	it	is	
often	 difficult	 or	 impossible	 to	 change	 the	 format	 of	 the	 data	 between	 packages	
once	 it	 is	 loaded	 in	R.	As	 such,	 a	number	of	 different	packages	were	used	 to	 load	
data,	 with	 the	 chosen	 package	 dependent	 on	 the	 normalization	 method	 tested.	
Methylumi	 was	 used	 to	 read	 data	 into	 R	 in	 the	 correct	 format	 for	 Quantile	
Normalisation	in	the	lumi	R	package.		
	
The	minfi	package	provides	a	quality	control	report	based	on	inbuilt	control	probes	
on	 the	 array	 (such	 as	 staining,	 hybridization,	 bisulphite	 conversion	 and	 negative	
controls)	as	well	as	the	ability	to	exclude	probes	and	samples	based	on	probe	signal	
intensity.	 Samples	 failing	 this	 initial	 quality	 control	 were	 excluded	 from	 further	
analysis	 according	 to	 the	 recommendations	 of	 the	 minfi	 package	 authors.	
Specifically,	 samples	 were	 excluded	 if	 the	 sample	 profile	 deviated	 markedly	 from	
that	of	the	other	samples	on	both	the	density	plot	and	bean	plot.		
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Biological	 replicate	 samples	 were	 included	 across	 batches	 to	 allow	 assessment	 of	
quality	control	and	technical	bias.	Of	the	50	unique	blood	samples	and	8	replicates	
initially	 interrogated,	 47	 unique	 and	 5	 replicate	 samples	 passed	 quality	 control	
metrics	and	were	used	 for	 further	analysis,	as	 indicated	 in	Figure	2.6	 (green	arrow	
heads	indicating	samples	for	which	good	quality	data	was	generated	and	red	arrow	
heads	 indicating	 samples	 which	 generated	 poor	 quality	 data)	 and	 in	 Table	 2.1.	
Following	 sample	 quality	 control,	 the	 default	 quality	 thresholds	 in	 ChAMP	 were	
employed	to	exclude	poor	quality	probes,	with	a	minimum	detection	p-value	of	0.05	
in	more	than	one	sample	removing	6740	probes	and	a	bead	count	threshold	of	<3	in	
5%	of	samples	removing	a	further	478	probes,	leaving	478,293	probes.			
	
To	 account	 for	 sex	 differences	 in	methylation,	 driven	 particularly	 by	 X-inactivation	
dosage	 compensation,	 probes	 on	 the	 sex	 chromosomes	 were	 removed	 prior	 to	
normalisation.	While	ChAMP	includes	this	option	as	default	when	loading	data,	most	
packages	 require	 manual	 separation,	 normalisation	 and	 recombination	 of	 sex	
chromosomes	 or	 their	 complete	 manual	 removal.	 Thus	 to	 permit	 appropriate	
comparison	of	normalization	methods,	a	homogenous	set	of	loci	across	all	packages	
was	required	and	therefore	sex	chromosomes	were	removed	at	this	stage	of	analysis	
and	 not	 re-introduced.	 There	 is	 debate	 as	 to	 whether	 all	 probes	 containing	 SNPs	
ought	to	be	removed	from	datasets	during	pre-processing	(Shoemaker	et	al.	2010;	Chen	et	al.	2013;	Zhi	et	al.	2013).	This	decision	will	vary	between	studies	depending	
on	the	nature	of	the	data	and	the	research	question	at	hand.	 In	the	current	study,	
SNP	probes	were	not	excluded	during	the	pre-processing,	as	the	aim	of	the	study	is	
to	examine	the	effect	of	genetic	variation	on	methylation	profiles.	However,	a	subset	
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of	 SNP	 probes	 previously	 shown	 to	 introduce	 technical	 bias	were	 removed	 during	
down-stream	analysis,	as	discussed	in	Chapter.4	sections	4.1	&	4.3.4.			
	
2.2.5	Genome-wide	SNP	genotyping	of	familial	samples		
Between	2008	and	2015	the	1000	Genomes	Project	(1KGP)	mapped	approximately	
85	million	single	nucleotide	variants	across	2,500	individuals	from	26	populations,	
down	to	a	minor	allele	frequency	of	1%	(Auton	et	al.	2015).	Drawing	on	this	public	
catalogue	of	human	variation,	the	Illumina	Human	Omni2.5	array	is	the	first	of	
Illumina’s	SNP	arrays	to	include	broad	coverage	of	1KGP	data.	Integration	of	data	
from	the	catalogue	enabled	the	array	to	capture	much	of	this	human	variation,	by	
including	2.5	million	common	and	rare	variants	down	to	a	minor	allele	frequency	of	
2.5%.		
	
Fifty-one	unique	samples	were	selected	from	the	Tasmanian	Familial	Prostate	Cancer	
Resource	and	interrogated	on	Illumina's	Omni2.5	array.	Thirty-two	samples	were	
interrogated	in-house	and	twenty-one	(including	two	replicate	samples)	were	
generated	by	the	Illumina	Genome	Network	commercial	service	(USA).	Two	samples,	
PC22-17	and	PC72-04	were	analysed	in	both	locations	to	provide	an	opportunity	to	
compare	sample	quality	and	examine	technical	bias.	The	thirty-two	samples	selected	
for	genotyping	analysis	in-house	were	interrogated	across	four	of	Illumina’s	Human	
Omni2.5	BeadChips,	hereafter	referred	to	as	the	‘genotype	array’.	DNA	at	a	quantity	
of	200	ng	per	sample	was	processed	across	four	BeadChips	according	to	the	
manufacturer’s	instructions.	Briefly,	DNA	was	amplified,	fragmented	and	hybridised	
to	BeadChips	before	being	washed,	stained	and	imaged	on	an	Illumina	HiScan.	
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Similar	to	the	methylation	BeadChips,	the	genotype	BeadChips	were	imaged	using	an	
Illumina	HiScan	in	combination	with	iControl	software	to	generate	IDAT	files	
containing	the	raw	intensity	signals	from	red	and	green	colour	channels.	The	raw	
data	intensity	files	for	the	combined	fifty-one	samples	performed	in-house	and	those	
analysed	through	the	commercial	service	were	uploaded	together	to	Illumina’s	
GenomeStudio	software	package.		
	
2.2.6	Extraction,	pre-processing	and	quality	control	analysis	of	genotype	data	
Raw	data	from	both	laboratories	was	combined	and	analysed	in	GenomeStudio,	with	
initial	quality	control	performed	in	accordance	with	Illumina’s	recommendations.	
Specifically,	internal	sample	dependent	and	independent	controls	on	the	genotype	
array	were	used	to	visualise	sample	and	probe	quality.	Sample-dependant	controls	
included	hybridisation	stringency,	non-specific	binding	and	non-polymorphic	controls	
while	sample-independent	controls	included	staining,	extension,	target	removal,	
hybridisation	and	sample	restoration.		
	
A	score	indicating	the	quality	of	each	genotype	call	(GenCall	Score,	ranging	from	0.0	
to	1.0)	was	calculated	for	each	genotype	using	a	sample-clustering	algorithm.	
Genotype	clustering	at	each	SNP	was	examined	by	the	angle,	dispersion	and	overlap	
of	the	clusters	together	with	signal	intensity.	Lower	GenCall	Scores	were	allocated	to	
genotypes	located	furthest	from	a	cluster	center	(See	Figure	2.7	for	an	example	of	a	
high	(A)	and	low	(B)	scoring	genotype).		
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Figure	2.7	Comparison	of	good	and	poor	quality	SNP	clusters	on	the	genotype	
array.	
Intensity	signals	for	two	different	loci	are	presented.		A)	represents	a	good	quality	
SNP	call	as	samples	are	clustered	in	one	of	three	tightly	grouped	distributions.		Firstly	
2	homozygous	samples	in	pink,	followed	by	5	heterozygous	samples	in	purple	and	
finally	9	homozygous	samples	in	blue.		All	samples	are	within	or	on	the	cluster	
boundaries.		Contrastingly,	B)	represents	a	poorly	scored	locus	as	all	samples	fall	
outside	the	boundary	of	the	cluster	centre.		Black	samples	are	unable	to	be	classified	
into	any	genotype.
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Several	GenCall	Score	thresholds	were	tested	to	find	an	optimal	cut-off	that	would	
eliminate	poorly	performing	SNP	probes	without	removing	probes	of	high	quality.	
The	default	GenCall	Score	threshold	of	0.15	was	selected	as	it	optimised	the	call	rate	
without	compromising	reproducibility	or	Mendelian	consistency.	Using	this	
threshold,	between	2,252	and	79,204	probes	were	removed	per	sample.	Table	2.2	
shows	aspects	of	the	DNA	quality	report	generated	in	GenomeStudio,	detailing	the	
number	of	genotype	calls	made	at	each	loci,	the	number	that	were	unable	to	be	
called	due	to	poor	clustering	(no	calls)	and	the	call	rate	or	proportion	of	good	calls.	
The	high	quality	of	data	generated	across	all	samples	on	the	genotype	array	is	
indicated	by	the	high	call	rates	for	each	sample,	as	such	no	samples	were	excluded	
from	downstream	analysis.	
	
To	further	inspect	sample	quality	and	reliability,	a	heritability	report	was	generated	
in	GenomeStudio	for	a	subset	of	samples	with	at	least	one	parent	present	on	the	
genotype	array.	Table	2.3	shows	that	for	all	thirteen	samples	measured,	a	parent-
child	heritability	frequency	of	well	over	99%	was	achieved,	aligning	with	expected	
values	for	parent-child	first	degree	relatives,	providing	further	evidence	of	the	
reliability	of	the	data.	
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Table&2.2&Genotype&array&DNA&Quality&Report
Number'of'loci'='2,391,739
Low'GenCall'Score'Cutoff'='0.15
Row Sample&ID No&Calls Calls
Call&
Rate Row Sample&ID No&Calls Calls
Call&
Rate
1 PC2@01 8389 2383350 0.997 28 PC22@418 63055 2328684 0.974
2 PC2@02 3738 2388001 0.998 29 PC11@234 64334 2327405 0.973
3 PC2@03 9141 2382598 0.996 30 PC9@04 35040 2356699 0.985
4 PC22@03 3311 2388428 0.999 31 PC9@29 13796 2377943 0.994
5 PC22@04 4275 2387464 0.998 32 PC27@01 10986 2380753 0.995
6 PC22@16 3963 2387776 0.998 33 PC11@04 9259 2382480 0.996
7 PC22@17_a 14596 2377143 0.994 34 PC22@393 6633 2385106 0.997
8 PC22@21 4360 2387379 0.998 35 PC72@04_b 21515 2370224 0.991
9 PC22@162 6119 2385620 0.997 36 PC22@476 5537 2386202 0.998
10 PC22@203 6875 2384864 0.997 37 PC9@129 19829 2371910 0.992
11 PC22@274 12465 2379274 0.995 38 PC9@01 2895 2388844 0.999
12 PC22@387 2252 2389487 0.999 39 PC22@210 4130 2387609 0.998
13 PC22@388 2870 2388869 0.999 40 PC12@04 39723 2352016 0.983
14 PC72@106 6116 2385623 0.997 41 PC4@01 44277 2347462 0.982
15 PC72@188 3577 2388162 0.999 42 PC75@01 44266 2347473 0.982
16 PC72@02 2993 2388746 0.999 43 PC11@09 19405 2372334 0.992
17 PC72@03 3552 2388187 0.999 44 PC9@286 19285 2372454 0.992
18 PC72@04_a 3569 2388170 0.999 45 PC9@338 6608 2385131 0.997
19 PC72@94 2544 2389195 0.999 46 PC3@01 38797 2352942 0.984
20 PC72@97 4048 2387691 0.998 47 PC22@414 79204 2312535 0.967
21 PC72@126 2417 2389322 0.999 48 PC11@147 53769 2337970 0.978
22 PC9@477 63674 2328065 0.973 49 PC11@03 39124 2352615 0.984
23 PC22@17_b 16957 2374782 0.993 50 PC72@187 48661 2343078 0.980
24 PC1@03 7542 2384197 0.997 51 PC9@12 12555 2379184 0.995
25 PC9@121 10428 2381311 0.996 52 PC22@416 56758 2334981 0.976
26 PC11@180 57113 2334626 0.976 53 PC9@24 16873 2374866 0.993
27 PC9@357 51992 2339747 0.978
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Table&2.3&Heritability&Report&for&a&subset&of&genotype&array&data
Number'of'loci'='2,391,739
Low'GenCall'Score'Cutoff'='0.15
Child&ID &Parent&ID &Correct &Errors &Total
&Parent?Child
Heritability&Freq
1 PC22@274 PC22@21 2375467 188 2375655 0.9999
2 PC72@106 PC72@04 2382249 156 2382405 0.9999
3 PC72@188 PC72@126 2385723 162 2385885 0.9999
4 PC72@94 PC72@02 2386361 155 2386516 0.9999
5 PC72@97 PC72@02 2384796 177 2384973 0.9999
6 PC72@126 PC72@04 2385891 136 2386027 0.9999
7 PC9@121 PC9@04 2347202 616 2347818 0.9997
8 PC11@180 PC11@04 2325376 2186 2327562 0.9991
9 PC9@357 PC9@338 2331699 2144 2333843 0.9991
10 PC11@234 PC11@09 2306769 2863 2309632 0.9988
11 PC22@476 PC22@416 2327717 2715 2330432 0.9988
12 PC72@187 PC72@04 2337712 2186 2339898 0.9991
13 PC9@24 PC9@12 2362774 291 2363065 0.9999
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Additional	sample	and	SNP	error	checking	was	then	performed	in	PLINK	(Purcell	et	
al.	2007)	on	the	remaining	2,391,739	SNPs.	For	sample	quality,	sex	assignment	was	
confirmed	and	a	threshold	of	10%	was	applied	for	the	proportion	of	missing	
genotypes	per	sample.	All	samples	passed	these	quality	measures	and	progressed	to	
the	next	stage	of	quality	control,	SNP	error	checking.	Poor	quality	SNPs	were	
excluded	from	further	analysis	based	on	three	stepwise	quality	checks;	firstly,	
missing	genotype	calls,	secondly	failing	to	reach	Hardy-Weinberg	equilibrium	and	
finally	minor	allele	frequency	(MAF).	As	a	result	of	a	missing	genotype	in	more	than	
5%	of	samples,	61,217	SNP	probes	were	removed,	leaving	2,330,522	loci	for	analysis.	
A	Hardy-Weinberg	equilibrium	test	was	applied	to	the	data	with	a	threshold	p-value	
of	0.001,	with	no	SNPs	failing	this	test.	A	MAF	of	0.1%	was	applied	to	the	data	
removing	713,	687	SNPs,	leaving	1,616,835	with	a	total	genotyping	rate	in	remaining	
individuals	of	0.993.	Good	quality	data	were	generated	for	all	samples	analysed	for	
genotype,	as	indicated	by	green	diamonds	in	Figure	2.6	and	as	detailed	in	Table	2.1.	
	
	
2.2.7	High	quality	methylation	and	genotype	data	was	attained	for	thirty-nine	
samples	
Of	the	samples	analysed	for	both	methylation	and	genotype,	good	quality	data	was	
generated	for	thirty-nine	samples,	as	specified	in	italics	in	Table	2.1.	These	samples	
are	also	highlighted	by	green	arrow	heads	and	diamonds	in	Figure	2.6.	Data	for	three	
of	the	replicate	pairs	(PC11-213,	PC11-233	and	PC11-191)	interrogated	on	the	
methylation	array	failed	to	pass	quality	control	metrics	and	were	excluded	from	
further	analysis.	No	samples	were	excluded	from	the	genotype	analysis	as	all	
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samples	passed	minimum	quality	control	thresholds.	Overall,	for	the	thirty-nine	
samples	with	good	quality	methylation	and	genotype	data,	there	were	eleven	father-
son	pairs,	seven	brother	pairs	and	four	sibling	trios,	including	the	three-generation	
cluster	in	Family	72.	
	
	
2.3	Discussion	
The	utility	of	founder	populations	to	study	complex	disease	genetics	has	been	widely	
demonstrated,	such	as	the	identification	of	BRCA1/2	as	a	disease	susceptibility	gene	
in	the	Ashkenazi	Jewish	population	(Kirchhoff	et	al.	2004).	In	addition,	genetic	
studies	conducted	in	the	Icelandic	population	(deCODE	Genetics	(Amundadottir	et	
al.	2004))	and	in	the	Mormon	population	in	Utah	(Christensen,	Bonnie	and	George	2010)	have	made	important	contributions	to	our	understanding	of	a	number	of	
complex	diseases.	These	populations	share	similar	features,	where	the	current	
population	has	descended	from	a	reduced	number	of	founders	due	to	the	restricted	
population	or	bottleneck	at	some	point	in	history.	The	Tasmanian	population	shares	
a	number	of	features	of	these	types	of	populations,	in	that	the	population	has	been	
relatively	stable,	the	majority	having	descended	from	founder	population	originating	
from	the	UK	as	either	convicts	or	settlers	in	the	1800s.	Further,	it	has	been	
demonstrated	that	large	families	can	be	identified	and	traced	back	to	their	common	
founders.	This	is	exemplified	by	the	contributions	that	have	been	made	to	
understanding	the	genetic	basis	of	disease	using	the	Tasmanian	population,	
including	contributions	to	Huntington's	disease	(Brothers	1964),	multiple	endocrine	
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neoplasia	(Burgess	et	al.	2000),	glaucoma	(Fingert	et	al.	1999),	congenital	cataract	(Burdon	et	al.	2003)	and	most	recently	prostate	cancer	(Eeles	et	al.	2009).		
	
The	utlilisation	of	the	Tasmanian	Familial	Prostate	Cancer	Resource	here,	is	
particularly	pertinent	to	highly	penetrant	disease	variants	as	the	original	affected	
men	were	recruited	to	the	study	after	presenting	with	symptomatic	disease.	This	is	
in	contrast	to	other	prostate	cancer	studies	that	were	initiated	subsequent	to	wide-
spread	introduction	of	PSA	testing	which	faced	the	widely	recognized	issue	that	PSA-
detected	disease	does	not	necessarily	equate	to	clinicaly	relevant	prostate	cancer		(Saini	2016).	Additionally,	the	Tasmanian	resource	now	contains	genealogical	and	
pathology	records	for	over	one	thousand	people	from	sixty	large	families,	often	
extending	over	five	or	six	generations.	Thus,	this	resource	provides	a	rich	source	
from	which	to	draw	genomic	and	epigenomic	data	to	help	understand	the	underlying	
mechanisms	contributing	to	prostate	cancer	predisposition.	
	
Familial	genetic	resources	such	as	the	one	used	here	are	relatively	rare,	particularly	
in	prostate	cancer	where	disease	onset	is	late	and	thus	multiple	generational	
families	are	rare.	However,	there	are	a	few	comparable	resources	for	examining	
prostate	cancer	risk,	comprising	very	large	multiple	affected	generation	families	
which	can	be	traced	back	to	their	founders.	Rich	genealogical	data	is	available	in	
Iceland	(deCODE	(Amundadottir	et	al.	2004))	and	Utah	populations	(Christensen,	Bonnie	and	George	2010)and	this	has	facilitated	the	generation	of	valuable	genetic	
resources	for	complex	disease	research	including	studies	into	prostate	cancer.	Other	
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familial	resources	exist	in	Finland,	Sweden	and	the	US	(Seattle,	Washington	State)	(FitzGerald	et	al.	2013).	
	
While	these	types	of	familial	resources	have	the	potential	to	provide	invaluable	
insight	into	disease	processes,	samples	must	be	carefully	selected	from	extensive	
pedigrees	to	provide	the	most	informative	data	(Ziegler	and	Sun	2012).	
Additionally,	there	are	several	limitations	associated	with	familial	study	design.	
Samples	may	not	be	available	for	all	individuals	of	interest,	as	samples	are	frequently	
collected	over	extended	time	periods,	often	spanning	many	decades.	This	long	
acquisition	time	can	also	lead	to	degradation	of	sample	material.	Additionally,	there	
is	often	a	limited	quantity	of	genomic	material	available,	especially	if	many	family	
members	in	extended	pedigrees	are	deceased,	as	is	often	the	case	in	generations	
deceased	prior	to	the	pedigree	being	ascertained.	There	were	three	main	phases	
throughout	the	design	of	this	study	where	samples	were	excluded	due	to	poor	
quality.	Initially,	samples	with	insufficient	genomic	material	or	inappropriate	quality	
were	excluded.	Secondly,	data	generated	for	each	sample	through	methylation	and	
genotype	analysis	were	required	to	pass	quality	control	thresholds	for	each	
individual	platform,	as	described	in	sections	2.2.4	and	2.2.6.	A	further	limitation	of	
this	study	was	the	removal	of	probes	located	on	the	sex	chromosomes.	These	probes	
were	excluded	for	consistency	as	not	every	R	package	used	in	the	methylation	array	
analysis	allowed	for	separate	normalisation	of	sex	chromosomes	and	autosomes.	
This	procedure	is	imperative	as	X-inactivation	dosage	compensation	leads	to	high	
methylation	levels	on	the	X	chromosome.	Finally,	samples	were	only	able	to	be	used	
to	examine	the	association	between	genotype	and	methylation	if	data	of	high	quality	
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was	generated	across	both	platforms.	Thirty-nine	samples	passed	both	quality	
control	thresholds	and	were	thus	used	for	this	subsequent	analysis,	as	described	in	
Chapter	4.		
	
Despite	these	limitations,	familial	data	sets	present	an	exciting	opportunity	to	
examine	rare	deleterious	variants	(Williams	and	Blangero	1999).	This	chapter	has	
described	the	rationale	used	to	prioritise	samples	from	the	Tasmanian	Familial	
Prostate	Cancer	Resource	for	use	in	this	study,	as	well	as	detailing	the	creation	of	
high	quality	genome-wide	genotype	and	epigenomic	data	for	subsequent	analysis.	
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Chapter	3	–	Development	of	appropriate	normalisation	
strategies	for	the	analysis	of	germline	familial	methylation	
data	
	
	
3.1	Introduction	
To	 date,	 genome-wide	 epigenetic	 studies	 have	 largely	 focused	 on	 epigenetic	
alterations	 that	 occur	 in	 diseased	 tissues,	 where	 epigenetic	 changes	 across	 the	
genome	 are	 mapped	 through	 comparing	 ‘normal’	 and	 affected	 tissues	 from	 the	
same	 individual.	 Indeed	 epigenetic	 drugs,	 currently	 in	 clinical	 use	 are	 designed	 to	
correct	 the	 epigenetic	 alterations	 acquired	 during	 disease	 development	 (Sharma,	Kelly	 and	 Jones	 2010);	 the	 assumption	 being	 that	 these	 acquired	 epigenetic	
alterations	 are	 driven	 by	 the	 disease	 process	 itself.	 More	 recently	 it	 has	 been	
hypothesised	 that	 inherited	 genetic	 variation	 can	 drive	 epigenetic	 alterations	 and	
further	that	these	contribute	to	disease	susceptibility	or	disease	course.	To	date	the	
large	 majority	 of	 genome-wide	 methylation	 studies	 and	 consequently	 the	
bioinformatics	 pipelines	 used	 to	 interpret	 these	 data	 have	 been	 designed	 to	
compare	diseased	tissue	with	‘normal’	tissue,	in	order	to	map	epigenetic	changes	in	
the	diseased	 tissue	 itself.	 This	 analysis	necessarily	 screens	out	 inherited	epigenetic	
changes	 that	 are	 evident	 both	 in	 the	normal	 tissue	 and	 the	diseased	 tissue	of	 the	
same	affected	individual.	There	remains	a	need	to	explore	inter-individual	variation	
of	the	epigenome	and	it’s	contribution	to	disease,	as	evidence	suggests	genotype	is	
one	of	the	greatest	influences	on	epigenetic	patterns	(Gertz	et	al.	2011).	For	a	more	
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detailed	 description	 on	 the	 inherited	 drivers	 of	 methylation	 patterns	 see	 section	
1.5.4.1	in	Chapter	1.		
	
A	powerful	approach	for	examining	the	role	of	inherited	variation	driving	epigenetic	
change,	is	to	examine	large	families	where	inheritance	and	methylation	patterns	can	
be	 tracked	 through	 generations.	 A	 number	 of	 challenges	 exist	 in	 the	 analysis	 of	
genome-wide	 methylation	 mapping	 in	 samples	 and	 these	 include	 technical	
challenges	dealing	with	batch	effects	and	the	underlying	biochemistry	employed	by	
the	 array	 methods.	 This	 has	 necessitated	 the	 development	 of	 numerous	 pre-
processing	quality	control	methods	to	ensure	reliable,	high	quality	data	generation.	
As	 mentioned	 above,	 most	 studies	 examining	 epigenetic	 profiles	 typically	 assess	
differences	between	two	distinct	groups	(normal	tissue	versus	tumour	tissue	or	case	
vs	control	status),	and	as	such	the	majority	of	normalisation	methods	for	the	analysis	
of	 methylation	 array	 data	 are	 designed	 for	 these	 types	 of	 comparisons.	 These	
methods	 frequently	 require	 two	 data	 groups	 to	 normalise	 negative	 and	 positive	
control	 probes	 or	 genomic	 regions.	 Such	methods	 are	 incompatible	with	 pedigree	
data,	which	lack	a	distinct	second	comparison	group	for	normalisation.	While	other	
methods	 such	 as	 BMIQ	 (Teschendorff	 et	 al.	 2013)	 do	 not	 rely	 on	 cancer-normal	
differences,	 they	 often	 focus	 on	 intra-array	 normalisation	 and	 do	 not	 necessarily	
address	technical	bias	between	samples.	To	avoid	unwanted	technical	noise	such	as	
batch	 affects,	 it	 may	 therefore	 be	 necessary	 to	 combine	 such	 intra-array	
normalisation	methods	with	an	inter-array	correction	method	such	as	ComBat	from	
the	sva	R	package	(Leek	et	al.	2012).	In	the	absence	of	appropriate	strategies	for	pre-
processing	familial-based	methylation	array	data,	there	is	a	need	to	develop	a	‘fit	for	
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purpose’	pipeline,	which	can	be	used	as	a	guide	to	remove	poor	quality	samples	and	
probe	 signals,	 adjust	 for	 technical	 bias	 and	 prepare	 data	 for	 analysis	 of	 biological	
differences.	 As	 such,	 the	 aim	 of	 this	 chapter	 is	 to	 establish	 and	 test	 a	 pipeline	 to	
remove	 technical	 bias	 whilst	 maintaining	 biological	 information	 in	 familial	 data	
generated	on	the	methylation	array.	
	
3.2	Method	
	
3.2.1	Normalisation		
To	determine	the	best	normalisation	method	for	 familial	data,	eight	techniques,	as	
described	in	Table	3.1,	were	applied	to	familial	clusters	of	samples	selected	from	the	
larger	pedigrees,	 as	detailed	 in	 Figure	2.6	of	Chapter	2.	 Section	2.2.1	of	Chapter	2	
contains	a	detailed	description	of	the	laboratory	processing	of	the	methylation	array	
and	initial	quality	control.		
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Table	3.1	Normalisation	methods	tested.		The	table	includes	a	brief	description	of	
each	method,	the	relevant	R	package	and	reference	for	further	information.	
	
	
Normalisation	method	 Package	 Reference	
Quantile	Normalisation	
The	distributions	of	probe	intensities	for	different	samples	
are	made	identical.		Often	used	in	microarray	analysis.	
lumi	 (Du,	Kibbe	and	Lin	2008)	
Stratified	Quantile	Normalisation	
Probes	are	stratified	by	genomic	region	then	quantile	
normalised	with	sex	chromosomes	normalised	separately	
when	male	and	female	samples	are	present.	No	background	
correction,	zeros	removed	by	outlier	function.	Not	
recommended	for	cancer-normal	comparisons	or	other	
groups	with	global	differences.	
minfi	 (Aryee	et	al.	2014)	
Beta-Mixture	Quantile	Dilation	(BMIQ)		
Adjusts	type	II	probes	to	type	I	distribution.		Recommended	
for	all	datasets.	
ChAMP	 (Teschendorff	et	al.	2013)	
Subset-quantile	Within	Array	Normalisation	(SWAN)	
A	quantile	distribution	is	created	using	a	subset	of	probes,	
with	subsetting	based	on	the	number	of	CpGs	in	the	probe	
body.		Separate	subsets	are	created	for	type	I	and	II	probes.		
The	remaining	probes	are	then	adjusted	to	the	subsets.	
minfi	
(Maksimovic,	Gordon	and	Oshlack	2012)	
Functional	Normalisation	(FunNorm)	
Uses	control	probes	to	remove	unwanted	technical	
variation.		Also	diminishes	batch	effects	in	some	datasets.		
Suitable	for	use	in	cancer-normal	studies	or	where	global	
methylation	changes	occur.	
minfi	 (Fortin	et	al.	2014)	
Dasen	
Background	adjustment	and	between-array	normalisation	
are	performed	separately	on	type	I	and	II	probes.	
wateR-	
melon	
(Pidsley	et	al.	2013)	
Noob	
Uses	type	I	probe	design	to	measure	non-specific	
fluorescence	in	opposite	colour	channel.	
minfi	 (Triche	et	al.	2013)	
Remove	Unwanted	Variation	(RUV)	
Previously	used	with	microarray	data	to	normalise	via	
negative	control	genes.		Requires	distinct	groups	such	as	
cancer-normal	to	normalise	on.	
RUV-	
normalize	
(Gagnon-Bartsch,	Jacob	and	Speed	2012)	
Batch	Correction:		ComBat	
Adjusts	for	known	or	unknown	batches	using	an	empirical	
Bayesian	framework.	
sva	 (Leek	et	al.	2012)	
	 72	
The	probe	sub-set	chosen	for	each	analysis	was	selected	following	the	instructions	of	
each	 individual	 normalisation	 package,	 which	 had	 different	 requirements.	 This	
dictated	 whether	 normalisation	 methods	 were	 compatible	 and	 could	 be	 used	 in	
conjunction.	The	methods	 involve	various	degrees	of	 type	 I	and	 II	probe	scaling	 to	
account	 for	underlying	 technical	differences	between	 the	probe	 types,	background	
and	dye	bias	 correction	and	 initial	batch	correction	between	arrays.	Depending	on	
the	 normalisation	 method,	 data	 was	 either	 used	 in	 the	 red/green	 signal	 format	
(RGset),	 converted	 into	 methylated	 and	 unmethylated	 values	 (MethylSet)	 or	
converted	 to	 β	 values	 by	 the	 function	 β	 =	 M/	 (M	 +	 U	 +100),	 where	 M	 is	 the	
methylated	signal	and	U,	unmethylated.	In	some	normalisation	methods,	the	offset	
of	 100	 is	 included	 to	 regularize	 scores	 when	 both	 methylated	 and	 unmethylated	
values	are	very	low.	While	the	β	value	is	more	biologically	intuitive	(it	ranges	from	0-
1	 indicating	 the	 proportion	 of	methylation	 at	 that	 site	 for	 the	 population	 of	 cells	
analysed),	it	suffers	from	severe	heteroskedasticity	at	very	high	or	low	values	(Du	et	
al.	 2010).	 Logit	 transforming	 to	 an	M-value	 removes	 this	 unequal	 variance.	 Thus	
wherever	possible,	calculations	in	this	study	have	been	performed	on	the	M-values	
and	 transformed	 back	 to	 β	 values	 if	 required	 for	 biological	 interpretation.	 Eight	
performance	 metrics	 were	 then	 used	 to	 compare	 methods	 and	 determine	 the	
optimal	normalisation	approach	for	familial	datasets.	Visual	tools	such	as	density	and	
MDS	 plots	 and	 unsupervised	 hierarchical	 clustering	 were	 used	 to	 compare	 the	
various	methods	between	all	samples	and	particularly	replicate	samples.		See	Table	
3.2	 for	 a	 description	 of	 each	 metric	 employed	 to	 assess	 performance	 of	
normalisation	methods.	
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Table	 3.2	 Qualitative	 and	 Quantitative	 metrics	 used	 to	 assess	 normalisation	
efficacy.	 	 The	 table	 includes	 a	 brief	 description	 of	 each	 metric	 and	 which	 figures	
describe	the	results	for	that	method.	
	
	
	
	 Method	 Description	 Figure	
1	 Density	Plot:	all	samples	
Bimodal	distribution	of	Beta	values	as	methylated	and	
unmethylated	signals.		Each	sample	is	represented	by	a	
single	line.		A	batch	effect	is	indicated	when	samples	
performed	in	the	same	batch	have	a	similar	
distribution.	
Figure	3.2	
(A,C,E);	
Figure	3.3	
	
Density	Plot:	
3	groups	of	
replicate	samples	
Bimodal	distribution	of	Beta	values	as	methylated	and	
unmethylated	signals.		Samples	are	coloured	by	
replicate	group.		As	each	replicate	group	contain	the	
same	biological	information,	differences	in	sample	
distribution	within	groups	indicate	technical	bias.	
Figure	3.4	
(A,C,E)	
	
Density	Plot:	
Probe	I	and	II	
distribution	
Bimodal	distribution	of	Beta	values	as	methylated	and	
unmethylated	signals	separated	by	Infinium	I	and	II	
probe	types.		Provides	information	about	probe	
normalisation	which	is	required	for	Infinium	I	and	II	
signals	to	be	combined	in	the	same	analysis.	
Figure	3.2		
(B,	D,	F)	
2	 MDS	plot:	all	samples	
Multi-dimensional	scaling	plots	show	a	2-d	projection	
of	distances	between	samples.		For	these	plots	the	
1000	most	variable	sites	have	been	selected	as	they	are	
the	most	biologically	relevant	for	this	type	of	analysis.		
Samples	cluster	by	similarity	and	as	such	batch	effects	
and	familial	clustering	can	be	clearly	discerned.	
Figure	3.1;	
Figure	3.5	
	
MDS	plot:	
3	groups	of	
replicate	samples	
1000	most	variable	sites	are	again	selected,	with	
samples	coloured	by	replicate	group.		As	each	replicate	
group	contains	the	same	biological	information,	close	
within	group	clustering	indicates	minimal	technical	bias	
while	distantly	clustered	replicate	samples	indicate	
heightened	technical	bias.	
Figure	3.4	
(B,D,F)	
3	
ANOVA	of	the	first	
principal	
component	for	
MDS	plots	
Provides	a	quantitative	value	for	MDS	plots.			A	lower	p-
value	indicates	the	clustering	is	more	significantly	
explained	by	batch,	with.	a	larger	p-value	after	
normalisation	indicating	a	reduction	in	batch	effect.	
P-values	
displayed	
on	Figure	
3.1	
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4	
Median	Absolute	
Differences	
between	
replicate	samples	
For	each	replicate	group	the	median	M	value	(log	of	
Beta	values)	across	all	probes	was	calculated	and	the	
absolute	difference	compared	between	replicate	groups	
after	various	normalisation	methods.		A	smaller	absolute	
difference	indicates	improved	normalisation	as	more	
techincal	bias	is	removed.	
Table	3.3	
5	
Imprinted	
regions:	
Density	plots	
227	probes	mapping	known	imprinted	hemi-methylated	
regions	can	be	used	as	a	standard	to	measure	changes	in	
methylation	levels	after	normalisation.		Density	plots	
have	a	single	distribution	peak	since	there	is	roughly	
50%	methylation	at	these	sites.	
Figure	3.7	
	
Differentially	
Methylated	
Region	Standard	
Error	(DMRSE)	
	
The	DMRSE	measures	how	each	sample	varies	from	the	
expected	50%	methylation.		Smaller	error/deviation	
from	50%	indicates	less	technical	bias.	
Table	3.4;	
Figure	3.7	
(A,C,E)	
6	 Cluster	Dendorgram	
Another	tool	to	measure	clustering	by	sample	similarity.		
Samples	are	labelled	by		
batch	with	batch	effects	clearly	seen	before	
normalisation	and	diminished	after.		Red	stars	indicate	
replicate	samples	that	are	expected	to	cluster	most	
closely.	
Figure	3.6	
7	 meQTL	Association	
Association	between	methylation	at	cg17749961	and	
SNPs	in	a	2Mb	window.			
A	significant	association	is	maintained	after	
normalisation	and	batch	correction.	
Figure	3.8	
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3.2.2	Batch	Correction	
Since	 an	 obvious	 batch	 effect	 remained	 after	 normalisation,	 the	 ComBat	 function	
from	the	sva	package	(Frommer	et	al.	1992)	was	used	to	further	remove	technical	
bias	 introduced	 by	 interrogating	 samples	 on	 the	 methylation	 array	 in	 different	
batches.	
	
3.2.3	Statistical	Analysis	
Eight	methods,	as	described	in	Table	3.2,	were	used	to	compare	the	efficacy	of	the	
various	 normalisation	methods.	 In	 addition	 to	 density	 and	MDS	 plots,	 the	 ANOVA	
test	 and	 quantitative	measures,	mean	 absolute	 difference	 between	 replicates	 and	
the	 differentially	methylated	 region	 standard	 error	 (DMRSE)	measures	were	 used.	
Additionally,	 two	 approaches	 were	 taken	 to	 test	 the	 underlying	 biological	
information	 was	 preserved	 between	 samples;	 namely,	 an	 association	 analysis	
between	 genotype	 and	 methylation	 at	 a	 previously	 identified	 meQTL	 and	 an	
epigenome-wide	association	analysis	with	age.		
	
For	a	qualitative	measure	to	examine	effectiveness	of	between	array	normalisation,	
hierarchical	 cluster	 dendrograms	 were	 generated	 using	 all	 probes	 with	 the	 hclust	
function	 using	 the	 Euclidean	 distance	 method	 from	 the	 default	 R	 package,	 stats.	
Cluster	 dendrograms	 group	 samples	 by	 differences,	with	 similar	 samples	 grouping	
together.		
	
MDS	 plots	 were	 clustered	 by	 batch	 or	 family,	 then	 analysis	 of	 variance	 was	
performed	 on	 the	 first	 principal	 component	 from	 a	 principal	 component	 analysis	
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(PCA)	on	the	1000	most	variable	beta	values	using	the	aov	and	prcomp	functions	in	
the	stats	core	R	package.	 	P-values	are	displayed	on	 the	MDS	plots	 in	Figure	3.1	A	
lower	p-value	indicates	clustering	is	more	significantly	explained	by	batch	or	family,	
with	a	larger	p-value	after	normalisation	indicating	a	reduction	in	technical	bias.		
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Figure	3.1		Multidimensional	scaling	plots	of	M-values	by	batch	and	family.		
Multidimensional	scaling	plots	for	Raw	(A,	B),	Stratified	QN	(C,	D)	and	ComBat	
Stratified	QN	(E,	F)	M-values.		For	each	plot	the	1000	most	variable	probes	were	
selected.		In	A,	C	and	E	numbers	represent	batches	and	are	coloured	accordingly,	
with	clustering	by	batch	clearly	seen	in	A,	to	a	lesser	extent	in	C	and	removed	in	E.		In	
B,	D	and	F	numbers	represent	family	groups	and	are	coloured	accordingly	with	the	
clearest	clustering	present	in	F	after	the	batch	effect	has	been	removed.			
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Six	replicate	sample	pairs	were	used	to	quantitatively	assess	the	performance	of	the	
normalisation	 methods,	 as	 one	 sample	 from	 each	 pair	 was	 interrogated	 on	 a	
separate	batch.	 The	median	absolute	difference	between	each	pair	was	 calculated	
by	first	taking	the	absolute	difference	at	each	probe	between	the	two	replicates	and	
then	taking	the	median	of	the	differences.	A	lower	median	difference	indicates	less	
technical	bias,	as	the	samples	are	biologically	identical.	
	
There	are	227	known	imprinted	regions	(iDMRs)	on	the	methylation	array,	and	these	
have	previously	been	employed	in	analysis	packages	such	as	wateRmelon	as	a	quality	
control	 metric	 (Pidsley	 et	 al.	 2013).	 These	 regions	 are	 expected	 to	 have	 allele-
specific	methylation	and	a	β	value	of	0.5,	and	therefore	deviation	from	this	value	can	
be	examined	as	a	standard	error-type	measure,	denoted	DMRSE	in	the	wateRmelon	
package.	 	The	dmrse_row	 function	was	used	 to	measure	dispersion	of	methylation	
between	 samples	 for	 each	 normalisation	 method.	 A	 lower	 value	 indicates	
methylation	values	are	more	tightly	aligned	with	expected	methylation	levels.	
	
Whilst	 evidence	 of	 clustering	 according	 to	 familial	 relationships	 following	
normalisation	 correction	 provides	 some	 confidence	 that	 biological	 integrity	 of	 the	
data	 is	 preserved,	 to	 further	 test	 the	 preservation	 of	 biologically	 relevant	
information,	 we	 examined	 detectable	 associations	 of	 known	meQTLs	 in	 our	 data.	
Shoemaker	and	colleagues	have	previously	identified	736	CpG	sites	to	be	associated	
with	 SNPs	 in	 cis	 (Zhang	 et	 al.	 2010).	 Here,	 cg17749961,	 one	 of	 the	 ten	 most	
significant	hits	reported	by	Shoemaker	et	al.,	was	examined	in	a	subset	(22	males)	of	
the	 39	 individuals,	 for	 whom	 both	 methylation	 and	 genotyping	 SNP	 data	 was	
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available.	 Association	 analysis	 was	 performed	 between	 this	 probe	 site	 and	 SNPs	
located	 within	 a	 2Mb	 window	 adjacent	 to	 this	 site,	 using	 linear	 regression,	 and	
assuming	an	additive	disease	model.	Relatedness	was	adjusted	for	by	fitting	a	linear	
mixed	model	on	the	methylation	of	cg17749961	and	a	kinship	matrix,	determined	by	
the	 Identity-by-State	 function	 in	 the	 GenABEL	 R	 package	 (GenABEL	 project	
developers,	 2013).	 The	 residuals	 from	 this	model	were	 then	 used	 as	 the	 outcome	
variable	in	the	linear	regression	model	with	SNPs	drawn	from	a	370K	Illumina	array.	
Bonferroni	correction	was	used	to	correct	for	multiple	testing	error.	
	
	
3.3	Results		
In	the	previous	chapter,	high	quality	methylation	data	was	generated	for	forty-seven	
unique	and	five	replicate	samples	from	four	families	using	the	methylation	array	 in	
three	 separate	 batches	 (see	 Chapter	 2	 Table	 2.1	 for	 a	 list	 of	 these	 samples).	 The	
analysis	described	here	has	endeavoured	to	determine	the	most	suitable	method	of	
removing	technical	bias	in	familial	studies,	by	evaluating	eight	normalisation	metrics.	
Both	qualitative	and	quantitative	analysis	was	used	to	examine	these	methods	and	
furthermore,	 the	data	was	tested	to	determine	 if	 true	biological	associations	could	
still	be	identified.	
	
3.3.1	Evaluation	of	normalisation	methods	to	address	technical	bias	
Data	 generated	 from	 whole	 genome	 methylation	 analysis	 employing	 array	
technology	generates	an	output	necessitating	application	of	normalisation	methods	
to	correct	for	possible	bias	arising	from	within	and	between	array	variation.	Herein	
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eight	different	methodologies	(Table	3.1)	were	examined	and	visual	and	quantitative	
metrics	were	employed	to	evaluate	their	comparative	performance.	A	minimum	of	
one	 sample	 in	 each	 of	 the	 three	 batches	 was	 replicated,	 providing	 five	 technical	
replicates	 in	 addition	 to	 the	 three	 unique	 samples	 on	 each	 batch,	 to	 permit	
generation	 of	 data	 from	 analysis	 of	 the	 same	 biological	 sample.	 In	 data	 lacking	
technical	 bias,	 replicate	 samples	 would	 be	 expected	 to	 generate	 the	most	 similar	
methylation	 profiles,	 while	 methylation	 profiles	 generated	 from	 closely	 related	
individuals	should	also	cluster	tightly	compared	to	distantly	or	unrelated	individuals.	
However,	 if	 technical	bias	such	as	a	batch	effect	has	been	 introduced,	 this	distorts	
the	 profiles	 and	 samples	 no	 longer	 cluster	 by	 biological	 similarity	 but	 instead	 the	
most	evident	grouping	would	be	by	batch.		
	
Batch	 effect	 (between	 array	 variation)	 was	 initially	 examined	 using	 density	
distribution	plots	(Figure	3.2).	Figure	3.2A	comprising	raw	values	from	all	3	batches	
reveals	 significant	 bias.	 The	 greatest	 contributor	 to	 batch	 effect	 was	 the	 date	 on	
which	the	BeadChips	were	processed,	with	bisulphite	conversion	performed	on	the	
same	 day	 as	 BeadChip	 processing.	 Employing	 a	 stratified	 QN	 (Figure	 3.2C)	 and/or	
ComBat	 normalisation	 (Figure	 3.2E)	 dramatically	 reduced	 this	 observed	 effect.	 For	
between	array	biases,	Figure	3.2	shows	the	density	distribution	of	β	values	for	raw	
data	 samples	 (A),	 after	 Stratified	 QN	 (C)	 and	 after	 Stratified	 QN	 combined	 with	
ComBat	 correction	 (E).	 This	 is	 particularly	 evident	 when	 comparing	 the	 B	 value	
density	plots	of	3	groups	of	replicate	samples	(Figure	3.4	A,	C	and	E).		
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Figure	3.2		Density	distribution	of	β 	values.		Density	plot	and	probe	distribution	of	β	
values	for	Raw	pre-normalisation	data	(A,	B),	after	Stratified	QN	(C,	D)	and	with	
Stratified	QN	and	ComBat	batch	correction	(E,	F).		For	density	plots	(A,	C,	E)	a	single	
line	represents	a	sample,	with	samples	coloured	by	batch.	A	clear	batch	effect	is	
present	in	A,	lessened	in	C	and	removed	in	E.		For	the	probe	distribution	(B,	D,	F)	one	
sample	has	been	chosen	with	the	red	dashed	line	indicating	type	I	probe	distribution,	
the	blue	dashed	line	type	II	and	the	solid	black	line	the	combined	probe	distribution.		
The	probe	type	distribution	is	also	improved	after	normalisation,	as	type	I	and	II	are	
more	closely	aligned	in	D	and	F	compared	to	B.	
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Stratified	QN	also	performs	best	at	removing	within	array	biases	as	the	distribution	
of	 probe	 I	 and	 II	 types	 become	more	 uniform	 (Figure	 3.2	 B,	 D	 and	 F).	 This	 bias	 is	
driven	 by	 the	 differing	 biochemistry	 of	 the	 probes,	with	 type	 I	 employing	 a	 single	
colour	 channel	 with	 a	 different	 bead	 for	 methylated	 and	 unmethylated	 DNA	 and	
type	II	containing	one	bead	in	two	colour	channels.			The	underlying	biology	targeted	
by	each	probe	 is	 confounded	by	 this	 technical	bias,	 as	 type	 I	measures	CpG	dense	
regions	(such	as	 islands)	while	type	 II	can	only	tolerate	three	CpGs	 in	the	 length	of	
the	 probe.	 As	 such,	 type	 I	 interrogate	 a	 greater	 proportion	 of	 unmethylated	 to	
methylated	 DNA,	 while	 type	 II	 perform	 the	 opposite.	 Removing	 the	 probe	 bias	 is	
imperative	 for	 accurate	 comparisons	 between	 these	 probe	 types	 when	 pooling	
probe	 I	 and	 II	 data,	 which	 is	 necessary	 for	 accurate	 genome-wide	 methylation	
information	of	both	CpG	rich	and	poor	regions.	
	
In	 contrast,	 the	 density	 plots	 of	 β	 values	 for	 other	 normalisation	 (SWAN	 and	
FunNorm)	methods	do	not	 improve	to	the	same	degree	and	 in	some	cases	greater	
variation	is	introduced	(Figure	3.3C-G).	For	example,	a	worsening	of	the	batch	effect	
is	 seen	 for	 SWAN	normalisation	 (Figure	3.3D),	 compared	 to	 raw	data	 (Figure	3.3A)	
and	 the	 distribution	 of	methylated	 and	 unmethylated	 signals	 is	 inverted	 following	
FunNorm	(Figure	3.3E).		
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Figure	3.3		Density	distribution	of	β 	values	for	all	normalisation	methods.		Density	
plots	of	β	values	for	various	normalisation	methods:	raw	pre-normalisation	data	(A),	
Quantile	Normalisation	(B),	BMIQ	(C),	SWAN	(D),	FunNorm	(E),	Dasen	(F),	Noob	(G),	
Stratified	QN	(H),	Raw	with	ComBat	correction	(I)	and	Stratified	QN	with	ComBat	
correction	(J).		A	single	line	represents	a	sample	with	samples	coloured	by	batch.		
The	batch	effect	present	in	the	raw	data	(A)	remains	after	the	majority	of	
normalisation	methods	with	Dasen	(F)	and	Stratified	QN	(H)	showing	the	most	
uniform	distributions.		Some	methods	such	as	quantile	normalisation	(B)	and	
FunNorm	(E)	flip	the	methylated	and	unmethylated	signal	distribution.		ComBat	is	
effective	at	removing	batch	effects	in	both	raw	(I)	and	normalised	(J)	data,	with	the	
best	outcome	seen	with	Stratified	QN	with	ComBat	batch	correction	(J).	
	
	 	
	 85	
The	 second	 approach	 employed	 to	 examine	 the	performance	of	 the	normalisation	
methods	 was	 to	 generate	multi-dimensional	 scaling	 (MDS)	 plots.	 These	 permitted	
the	 visualization	 of	 the	 two-dimensional	 projection	 of	 the	 differences	 between	
samples.	 For	 each	 plot	 the	 1000	 most	 variable	 probes	 were	 selected,	 as	 these	
represent	the	most	pertinent	biological	differences	between	samples.	M-values	were	
used	as	opposed	to	β–values,	the	latter	of	which	have	been	shown	to	suffer	severe	
heteroskedasticity	at	very	high	and	low	values	(Du	et	al.	2010).	Again	a	strong	batch	
effect	 is	observed	in	the	raw	data	(Figure	3.1A)	as	expected	and	this	 is	removed	or	
significantly	 reduced	 following	 normalisation	 using	 Stratified	QN	 (Figure	 3.1C)	 and	
Combat	 (Figure	 3.1E)	 corrected	 data.	 The	 strong	 batch	 effect	 masks	 the	 familial	
relationships	 in	the	raw	data,	however	following	correction,	clustering	according	to	
kinship	 is	 clearly	 evident	 (Figure	 3.1F).	 Similarly	 the	 replicate	 samples	 (Figure	 3.4)	
which	group	disparately	 in	 the	raw	data	 (A,B),	co-locate	or	cluster	 tightly	 following	
Stratified	QN	(C,D)	and	ComBat	(E,F).	The	MDS	plots	for	each	normalisation	method	
(Figure	 3.5)	 also	 show	 Stratified	QN	 followed	 by	 ComBat	 to	 be	 the	most	 effective	
method	for	removing	clustering	by	batch.	
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Figure	3.4			Density	distribution	of	β 	values	and	Multidimensional	scaling	plots	of	
M-values	for	replicate	samples.	
Density	(A,	C,	E)	and	MDS	(B,	D,	F)	plots	of	three	replicate	sample	groups	for	Raw	(A,	
B),	Stratified	QN	(C,	D)	and	Stratified	QN	ComBat	corrected	(E,	F)	data.		For	all	plots	
samples	are	coloured	by	batch	1-3	as	labelled.		Density	plots	show	the	distribution	of	
β	values,	which	become	more	uniform	after	Stratified	QN	(C)	and	Stratified	QN	plus	
Combat	(E).		MDS	plots	show	clustering	of	the	1000	most	variable	sites	by	M-value,	
highlighting	the	decreasing	variance	between	replicate	groups	after	Stratified	QN	
and	Combat	(F).		
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Figure	3.5	Multidimensional	scaling	plots	of	M-values	by	batch	for	all	normalisation	
methods.		Multidimensional	scaling	plots	for	Raw	(A),	Quantile	Normalisation	(B),	
BMIQ	(C),	SWAN	(D),	FunNorm	(E),	Dasen	(F),	Noob	(G),	Stratified	QN	(H),	Raw	with	
ComBat	correction	(I)	and	Stratified	QN	with	ComBat	correction	(J).		For	each	plot	
the	1000	most	variable	probes	were	selected.		Batches	are	numbered	and	coloured,	
with	clustering	by	batch	clearly	seen	in	the	raw	data	(A)	and	removed	to	varying	
degrees	with	different	normalisation	methods.		ComBat	correction	following	
Stratified	QN	provides	optimal	batch	correction	removal	as	the	samples	no	longer	
cluster	according	to	batch.		
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MDS plot: Raw with ComBat correction 
labeled by batch
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MDS plot: Stratified QN with ComBat correction 
labeled by batch
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This	 efficacy	 of	 normalisation	methods	 in	 reducing	 clustering	 of	 samples	 by	 batch	
was	 assessed	 quantitatively	 by	 ANOVA	 to	 test	 the	 effect	 of	 batch	 on	 the	 first	
principal	 component.	 The	 ANOVA	 was	 repeated	 for	 each	 normalisation	 method,	
using	M-values	from	the	top	1000	most	variable	sites.	Consistent	with	the	visualized	
MDS	 plot,	 the	 p-value	 was	 highly	 significant	 demonstrating	 the	 significant	
association	of	batch	 in	M	value	 in	raw	and	Stratified	QN	data	(P<0.01)	but	was	not	
significant	following	correction	using	ComBat	(p=0.97).		
	
For	 a	 final	 qualitative	 measure	 to	 examine	 effectiveness	 of	 between	 array	
normalisation,	 hierarchical	 cluster	 dendrograms	 were	 generated.	 Application	 of	
Stratified	QN	and	ComBat	 (Figure	3.6),	 again	demonstrated	 superior	normalisation	
when	visualized	by	this	method,	with	raw	data	samples	clearly	clustering	into	three	
distinct	groups	(Figure	3.6A),	stratified	QN	resulting	in	improved	clustering	(B)	while	
ComBat	 batch	 correction	 following	 Stratified	 QN	 completely	 removes	 the	 batch	
effect	 (C)	 permitting	 the	 desired	 outcome	 with	 related	 individuals	 clustering	
together	 in	 familial	 groups.	 	 Furthermore,	 replicate	 samples	 cluster	 more	 clearly	
after	ComBat	normalisation	(C,	red	stars)	indicating	removal	of	batch	effects	without	
perturbing	biologically	relevant	information.			
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Figure	3.6	Hierarchical	cluster	dendrogram	for	Raw,	Stratified	QN	and	Combat	
corrected	data.		Samples	are	clustered	by	similarity	and	labelled	by	batch.		Raw	data	
samples	(A)	clearly	cluster	into	three	distinct	batches	while	Stratified	QN	(B)	partially	
adjusts	clustering	by	batch	and	Stratified	QN	combined	with	Combat	considerably	
diminishes	the	batch	effect	(C).		Red	stars	indicate	replicate	samples	which	cluster	
more	clearly	in	(C),	indicating	removal	of	batch	effects.	
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To	 quantitatively	 assess	 the	 performance	 of	 these	 normalisation	 methods,	 the	
median	absolute	difference	in	M-values	was	calculated	for	6	replicate	pairs,	with	one	
sample	from	each	pair	interrogated	on	a	separate	batch.	With	the	exception	of	one	
pair,	 Stratified	 QN	 with	 ComBat	 was	 found	 to	 have	 the	 lowest	 absolute	 median	
difference	 between	 technical	 replicate	 pairs,	 corresponding	 to	 the	 highest	
correlation	 between	 replicate	 pairs	 (see	 Table	 3.3).	 Whilst	 others	 such	 as	 SWAN	
introduced	an	increase	in	the	error	rate	relative	to	the	Raw	data	values.		
	
	
	
	
Table	3.3	Median	absolute	difference	between	technical	replicate	pairs.			
	
Normalisation	Method	 Pair.1	 Pair.2	 Pair.3	 Pair.4	 Pair.5	 Pair.6	
Raw	 0.557	 0.397	 0.639	 0.255	 0.974	 0.721	
Quantile	Normalisation	 0.335	 0.612	 0.378	 0.322	 0.610	 0.414	
Stratified	Quantile	
Normalisation	 0.258	 0.377	 0.309	 0.268	 0.381	 0.330	
BMIQ	 0.569	 0.414	 0.646	 0.271	 0.980	 0.726	
SWAN	 0.676	 0.375	 0.751	 0.247	 1.003	 0.808	
Functional	Normalisation	 0.334	 0.511	 0.378	 0.312	 0.590	 0.398	
Dasen	 0.250	 0.399	 0.290	 0.253	 0.399	 0.313	
Noob	 0.414	 0.646	 0.410	 0.411	 0.916	 0.621	
Raw	with	ComBat	 0.263	 0.268	 0.258	 0.236	 0.336	 0.261	
Stratified	Quantile	
Normalisation		with	ComBat	 0.193	 0.313	 0.218	 0.210	 0.270	 0.223	
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Finally,	 standard	 error	 measures	 for	 imprinted	 regions	 were	 calculated	 and	
compared	 between	methods	 as	 described	 in	 the	 statistical	 analysis	 section	 of	 the	
methods.	 	 Smaller	 values	 indicate	 lower	errors	and	more	 reliable	data.	A	 standard	
error	measure	 (DMRSE)	of	0.0048	was	 calculated	 for	 the	 raw	data,	with	 this	 value	
increasing	 with	 following	 normalisations	 using	 QN	 (0.0052),	 Noob	 (0.0052)	 and	
Functional	Normalisation	(0.0056).	The	remaining	normalisation	methods	generated	
reduced	 DMSRE	 values	 with	 Stratified	 QN	 with	 ComBat	 batch	 correction	 again	
producing	the	smallest	error	values	at	0.0012.	See	Table	3.4	for	a	full	list	of	DMRSE	
values	and	Figure	3.7	for	the	density	plots	of	these	probes.	
	
	
	
Table	3.4	Standard	error	measures	for	imprinted	differentially	methylated	regions	
for	the	various	normalisation	methods.	
	
Normalisation	Method	 DMRSE	*	
Raw	 0.0048	
Quantile	Normalisation	 0.0052	
Stratified	Quantile	Normalisation	 0.0028	
BMIQ	 0.0048	
SWAN	 0.0046	
Functional	Normalisation	 0.0056	
Dasen	 0.0043	
Noob	 0.0052	
Raw	with	ComBat	 0.0028	
Stratified	Quantile	Normalisation	+	ComBat	 0.0012	
	
	
*Differentially	Methylated	Region	Standard	Erro
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Figure	3.7			Density	distribution	of	β 	values	for	imprinted	differentially	methylated	
regions.		Density	plots	for	Raw	(A),	Stratified	QN	(C)	and	Stratified	QN	with	ComBat	
(E)	for	227	probes	mapping	known	imprinted	differentially	methylated	regions.		Each	
line	represents	a	sample,	with	samples	coloured	by	batch.		As	methylation	at	these	
loci	is	allele-specific	there	is	a	single	density	distribution	rather	than	the	bimodal	
distribution	seen	in	Figures	3.2,	3.3	and	3.4A,C,E.	The	standard	error	type	measure	
(DMRSE)	diminishes	with	Stratified	QN	and	Combat,	indicating	more	reliable	data.	B,	
D	and	F	show	the	Infinium	I	and	II	probe	distributions,	which	becomes	more	uniform	
with	Stratified	QN	and	Combat.	 	
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3.3.2	Increased	power	for	determining	true	biological	associations	
Critical	 to	 any	 normalisation	 method	 is	 the	 maintenance	 of	 true	 biological	
differences	between	samples.	As	described	 in	 the	 statistical	analysis	 section	of	 the	
methods,	 a	 previously	 identified	 meQTL	 (cg17749961,	 	 (Zhang	 et	 al.	 2010))	 was	
selected	 to	perform	association	analysis	with	prior	 to	 and	 following	normalisation.	
Following	 Bonferoni	 correction,	 a	 significant	 association	 was	 detected	 in	 the	 raw	
data	(Figure	3.8A,	p-value=7.29e-06),	increasing	markedly	after	Stratified	QN	(Figure	
3.8B,	p-value=3.53e-07).	After	ComBat	(C)	there	was	a	drop	in	significance	compared	
to	 Stratified	 QN	 and	 Raw	 data,	 yet	 the	 p-value	 was	 still	 highly	 significant	 (p-
value=1.05e-05)	indicating	preservation	of	the	biological	information	of	interest.	The	
drop	in	significance	after	batch	correction	may	be	explained	as	confounding	between	
batch	 and	 family,	 which	 is	 removed	 after	 ComBat.	 Ideally,	 samples	 would	 be	
randomised	across	experiments,	however	the	nature	of	familial	studies	is	such	that	
this	 is	not	always	possible,	as	 samples	are	collected	at	different	 time	points,	often	
across	 generations.	 To	 maintain	 maximum	 power,	 the	 inclusion	 of	 all	 available	
samples	is	essential	and	therefore,	data	processing	methods	capable	of	dealing	with	
non-ideal	datasets	are	required.		
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Figure	3.8		Association	plot	between	SNPs	and	methylation.				
Association	between	methylation	at	cg17749961	and	SNPs	in	a	2Mb	window	
promimal	to	the	LYCAT	gene.	There	is	a	significant	association	in	the	raw	data	(A,	p-
value=7.29e-06)	which	increases	after	stratified	QN	(B,	p-value=3.53e-07)	and	drops	
slightly	after	ComBat	correction	(C,	p-value=1.05e-05).
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3.4	Discussion	
There	is	currently	a	plethora	of	pre-processing	methods	and	R	packages	available	for	
analysis	 of	 methylation	 array	 data,	 and	 comprehensive	 review	 articles	 evaluating	
their	utility	have	been	published	(Touleimat	and	Tost	2012;	Marabita	et	al.	2013;	Pidsley	et	al.	2013;	Morris	and	Beck	2015).	The	majority	of	these	are	designed	for	
specific	 types	 of	 sample	 sets,	 particularly	 those	 comprised	 of	 two	 distinct	 groups	
such	 as	 case-control	 or	 cancer-normal	 with	 substantial	 methylation	 differences	
between	the	two	groups.	For	different	data	sets,	such	as	those	from	familial	studies,	
which	 include	 complex	 pedigree	 structures	 instead	 of	 two	 distinct	 groups,	 these	
methods	 may	 be	 ineffective	 or	 even	 worse,	 detrimental	 in	 that	 they	 introduce	
technical	bias,	as	identified	with	selected	methods	in	the	analysis	reported	here.	To	
correctly	 normalise	 data,	 it	 is	 critical	 to	 choose	 the	most	 appropriate	method,	 yet	
there	 has	 been	 little	 focus	 on	 developing	 appropriate	 processing	 pipelines	 for	
familial	methylation	array	analysis,	despite	the	current	interest	in	inherited	drivers	of	
methylation	patterns.	Further	barriers	are	the	various	format	requirements	and	the	
lack	of	 integration	 to	provide	 a	 seamless	 processing	pipeline.	Here,	 eight	 different	
methods	have	been	tested	and	a	best-practice	pre-processing	pipeline	presented	for	
familial	data	(depicted	 in	Figure	3.9).	This	pipeline	creates	a	template	to	guide	and	
expedite	 the	 analysis	 of	 familial	 datasets,	 particularly	 generated	 using	 the	
methylation	array	data.		
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Figure	3.9	Pipeline	for	familial	data	processed	on	Illumina’s	450K	methylation	
array.		Each	box	indicates	a	stage	of	the	pipeline	including	the	R	package	and	the	
data	format	required/created	in	italics.		
Pre$processing,pipeline,for,familial,450k,data,
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Detect,variably,or,diﬀeren<ally,methylated,regions,&,CNVs,
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Cell,type,correc<on,(If%required) , ,,,,
RefFreeEWAS:%%β"Values"!""adjusted"β"Values"
"
Normalisa<on,,
,
•  Stra@ﬁed%Quan@le%Normalisa@on:%probes%are%stra@ﬁed%by%region,%then%type%I%and%II%
probes%are%scaled%with%normalisa@on%applied%separately%to%methylated%and%
unmethylated%signals.%%Sex%chromosomes%are%also%normalised%separately.%
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A	 fundamental	 requirement	 for	 processing	 methylation	 array	 data	 is	 effective	
adjustment	 for	 technical	 bias,	 including	 batch	 effects	 and	 adjusting	 for	 the	 two-
probe	biochemistry	of	the	array.	Batch	effects	may	be	introduced	through	bisulphite	
conversion	or	downstream	processing	or	variation	in	array	quality.	Various	methods	
have	 been	 developed	 to	 adjust	 for	 these	 effects,	 mostly	 involving	 variations	 in	
quantile	 normalisation,	 a	 technique	 commonly	 used	 in	 analysis	 of	 microarray	
datasets	 to	 align	 two	 different	 distributions	 so	 they	 result	 in	 identical	 statistical	
properties	(Sun	et	al.	2011;	Teschendorff	et	al.	2013;	Aryee	et	al.	2014).		
	
BMIQ	and	Functional	Normalisation	have	been	advocated	as	the	preferred	methods	
for	analysis	of	cancer	study	data,	as	they	are	more	specific	 in	design	than	Quantile	
Normalisation	 and	 have	 been	 shown	 to	 be	more	 effective	 at	 removing	 unwanted	
technical	bias	(Teschendorff	et	al.	2013;	Fortin	et	al.	2014).	However,	while	these	
methods	were	not	specifically	developed	for	such	a	purpose,	they	have	been	shown	
to	work	most	effectively	on	case-control	or	tumour-normal	datasets	respectively.	To	
the	 best	 available	 knowledge,	 optimal	 pre-processing	 methods	 for	 familial	 based	
data,	 such	 as	 performed	 here,	 have	 not	 been	 previously	 reported.	 Normalisation	
methods	 necessarily	 make	 assumptions	 about	 data,	 with	 the	 accuracy	 of	 these	
assumptions	 varying	 for	different	data	 sets.	 	 Thus	 the	 same	normalisation	method	
can	have	a	vastly	different	effect	on	different	types	of	data	and	conversely,	as	shown	
here,	different	normalisation	methods	can	have	vastly	different	effects	on	the	same	
data.	It	is	therefore	key	to	select	the	right	normalisation	method	for	the	data-set	of	
interest.	Of	the	eight	methods	tested,	Stratified	QN	was	consistently	identified	as	the	
best	normalisation	method	across	all	visual	and	quantitative	evaluation	metrics	 for	
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use	in	this	context.	The	principle	underpinning	this	normalisation	is	stratification	by	
genomic	 region	and	 is	 thus	 ideal	 for	data	where	 the	differences	between	adjacent	
genomic	 loci	 are	maintained.	 This	 is	 in	 contrast	 to	 tumour-normal	 tissue	 datasets	
where	 there	 are	 large	 blocks	 of	 dramatically	 altered	 methylation	 patterns	
throughout	the	tumour	genome	(Timp	et	al.	2014).	Again	not	surprisingly,	packages	
that	utilize	differences	 in	negative	control	methylation	patterns	between	cases	and	
controls	such	as	FunNorm	were	not	found	to	be	effective	on	familial	datasets	where	
no	“normal”	control	is	available.		
	
The	inherent	strengths	of	familial	data	could	be	further	exploited	by	a	normalisation	
technique	that	accounts	 for	known	relationships	between	samples.	Such	a	method	
could	draw	on	pedigree	information	to	ensure	normalisation	has	effectively	removed	
technical	 bias	 while	 maintaining	 known	 biologically	 relevant	 information	 such	 as	
relatedness	 and	 familial	 clustering	 by	methylation.	 A	 diagnostic	metric	 accounting	
for	 a	 known	 relationship	 could	 be	 used	 to	 test	 the	 efficacy	 of	 pre-processing	
methods	 in	 a	 similar	 manner	 to	 the	 standard	 error	 associated	 with	 imprinted	
differentially	methylated	regions	(iDMRs)	from	the	wateRmelon	package.		
	
It	may	also	be	of	 importance	 for	 researchers	 to	 consider	 the	undesirable	effect	of	
non-specific	binding	and	the	presence	of	SNPs	in	the	probe	body.	A	study	from	the	
Weksberg	 lab	 found	 around	 6%	 of	 probes	 on	 the	 array	 cross-hybridised	 to	 non-
targeted	 genomic	 regions	 (Chen	 et	 al.	 2013).	 They	 have	 catalogued	 these	 probes	
and	 suggest	 removing	 them	 prior	 to	 downstream	 analysis.	 Their	 study	 also	
demonstrates	SNPs	in	the	probe	body	can	interfere	with	probe	binding,	altering	the	
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methylation	 signal	 at	 around	 14%	 of	 sites.	 Illumina	 recommends	 all	 probes	
containing	 a	 SNP	within	 10bp	 of	 the	 interrogated	 CpG	 site	 ought	 to	 be	 removed,	
while	 others	 suggest	 the	 ‘probe	effect’	 continues	 to	 the	 entire	 50bp	 length	of	 the	
probe	 (Zhi	et	 al.	 2013).	 The	 removal	 of	 all	 such	 probes	would	 be	 undesirable	 for	
studies	examining	the	effect	of	genotype	on	methylation,	as	evidence	suggests	 the	
vast	majority	of	these	SNPs	occur	either	at	the	CpG	site	 itself	(meSNPs)	or	close	by	(Shoemaker	et	al.	2010;	Zhi	et	al.	2013).		
	
To	overcome	this	issue,	Zhi	and	colleagues	suggest	an	elegant	approach	to	examine	
the	effect	of	meSNPs	on	methylation	without	the	potential	bias	introduced	by	SNPs	
altering	probe	binding	(Zhi	et	al.	2013).	The	 type	 II	probes	contain	only	one	bead	
type	 for	both	methylated	and	unmethylated	sites	of	 interest,	with	 the	methylation	
status	of	the	loci	designated	by	the	addition	of	a	different	coloured	nucleotide	(red	
or	 green)	 at	 the	 single	 base	 extension.	 As	 type	 II	 probes	 terminate	 one	 base	 pair	
before	the	cytosine	of	the	CpG	dinucleotide,	a	mutation	at	the	cytosine	itself	would	
not	 affect	 probe	 binding.	 As	 such,	 probes	 without	 SNPs	 in	 the	 probe	 body	 but	
present	 at	 the	 single	base	extension	 can	 reliably	be	used	 to	examine	 the	effect	of	
meSNPs	 on	 methylation,	 a	 very	 useful	 technique	 for	 examining	 the	 effect	 of	
inherited	variation	on	methylation	patterns.			
	
Preservation	of	the	biological	integrity	of	information	from	methylation	array	data	is	
imperative	 and	 requires	 appropriate	 pre-processing	 to	 minimize	 technical	 errors,	
which	will	be	dictated	by	the	type	of	data.	Stratified	QN	in	combination	with	ComBat	
batch	 correction	 performed	 the	 best	 of	 those	 methods	 tested	 for	 normalising	
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familial	 data	 interrogated	 on	 methylation	 array.	 This	 method	 was	 observed	 to	
remove	technical	biases	while	maintaining	biologically	relevant	information;	allowing	
true	 biological	 differences	 and	 similarities	 to	 inform	 the	 search	 for	 the	 role	 of	
methylation	 patterns	 driving	 disease	 processes.	 The	workflow	 presented	 in	 Figure	
3.9	outlines	the	methodology	adopted	to	pre-process	familial	data	in	this	study.	This	
may	 also	 be	 instructive	 for	 other	 studies	 using	 familial	 data,	 including	 longitudinal	
studies	 where	 the	 same	 individuals	 are	 repeatedly	 measured	 over	 time.		
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Chapter.4	Identification	and	prioritisation	of	me-QTLs	
	
	
4.1	Introduction	
Although	many	factors	influence	DNA	methylation	patterns,	including	diet,	
environment	and	random	factors;	genetic	variation	has	possibly	the	greatest	effect	
on	methylation,	and	this	is	observed	when	comparing	different	cell	types,	during	
development	and	across	populations	(Smith	et	al.	2014).	Genetic	variation	is	known	
to	influence	methylation	patterns	in	a	number	of	ways.	Firstly,	it	has	been	observed	
for	many	years	that	coding	variants	in	DNA	methylating	enzymes	or	chromatin	
remodelling	factors	affect	epigenetic	patterns	across	numerous	diseases,	particularly	
cancer	(You	and	Jones	2012).	Such	coding	variants	in	genes	regulating	the	
epigenetic	environment	alter	protein	function,	impacting	on	the	removal	or	addition	
of	methylation	marks	across	the	genome.	Secondly,	variants	in	non-coding	regions	
can	affect	DNA	methylation	patterns,	although	these	regions	have	been	less	
extensively	studied,	as	their	effect	on	gene	regulation	is	more	challenging	to	unravel	(Barr	and	Misener	2016).	As	research	efforts	increasingly	turn	to	understanding	
these	regulatory	elements,	numerous	studies	are	providing	evidence	for	the	
contribution	of	non-coding	genetic	variants	on	DNA	methylation	patterns	in	various	
cancer	types	(Heyn	2016).	
	
The	mechanisms	by	which	non-coding	variants	influence	methylation	patterns	are	
complex.	The	variants	termed	methylation	quantitative	trait	loci	(meQTLs),	may	
occur	in	three	distinct	locations,	as	indicated	in	Figure	4.1	below.	Cis-meQTLs	occur	
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in	close	proximity	to	the	CpG	site	(within	1Megabase	(Mb))	(Gamazon	et	al.	2012;	Heyn	et	al.	2014;	Rushton	et	al.	2015)	while	trans-meQTLs	are	located	distally	to	
the	CpG	site,	influencing	methylation	over	1Mb	away	on	the	same	chromosome	or	
on	different	chromosomes,	through	3-dimensional	chromatin	structures	(Lemire	et	
al.	2015).	Finally,	variants	can	also	occur	at	the	CpG	sites	themselves	(CpG-SNPs)	
with	numerous	studies	suggesting	these	may	have	the	strongest	effect	on	
methylation	patterns(Shoemaker	et	al.	2010;	Zhi	et	al.	2013;	Zhou	et	al.	2015).	
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Figure	4.1	Location	of	meQTLs.		
SNPs	affecting	CpG	methylation	(meQTLs)	have	been	described	as	occurring	in	cis	
within	1Mb	of	the	CpG,	at	the	CpG	itself	(CpG-SNP)	or	further	than	1Mb	from	the	
CpG,	in	trans.		 	
GAGAT...ATCGATAGGTTACTTAGTGGTG...AGACGAGGATAGAGTGGCGTAGACTGG
CTCTA...TAGCTATCCAATGAATCTCCAC...TCTGCTCCTATCTCACCGCATCTGACC
CH3
cis$$$$ CpG$SNP trans
DNA*
methylation
<1Mb >1Mb
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The	location	at	which	the	meQTL	occurs	determines	how	it	may	affect	methylation	
patterns.	Most	directly,	CpG-SNPs	can	physically	modify	the	cytosine	of	a	CpG	site	to	
another	nucleotide,	most	frequently	thymine,	removing	the	possibility	of	cytosine	
methylation	(Hellman	2010;	Gertz	et	al.	2011).	Alternatively,	variants	may	alter	
transcription	factor	binding	sites,	leading	to	inhibition	of	transcription	factor	binding	
and	the	recruitment	of	the	transcription	machinery	(Kasowski	et	al.	2010),	with	
altered	transcription	factor	binding	frequently	shown	to	alter	nearby	methylation	
patterns	(Kasowski	et	al.	2010;	Banovich	et	al.	2014).	The	mechanism	by	which	
these	altered	methylation	patterns	occur	is	less	well	understood.	However,	it	is	now	
know	that	a	transient	decrease	in	expression	is	all	that	is	required	to	initiate	more	
permanent	epigenetic	silencing	(Oyer	et	al.	2009).	Lack	of	gene	expression,	
including	diminished	occupancy	at	the	DNA	by	the	transcription	machinery,	leads	to	
altered	chromatin,	namely	a	depletion	of	acetylated	histones	and	methylated	
histone-3-lysine-4	(H3K4),	and	an	enrichment	of	the	methylated	histone-3-lysine-9	
(H3K9)	histone	mark	(Yan	et	al.	2003).	These	altered	histone	modifications	are	then	
followed	by	increased	DNA	methylation,	which	facilitates	a	more	permanently	
silenced	gene	expression	state	(Yan	et	al.	2003;	Oyer	et	al.	2009).	
	
Linked	to	this	aberrant	silencing,	is	the	‘seeding	hypothesis’,	which	postulates	that	
abnormal	promoter	methylation	is	seeded	or	extended	from	methylation	in	flanking	
regions	such	as	shores	and	shelves	(Graff	et	al.	1997;	Deng	et	al.	1999;	Hesson,	Hitchins	and	Ward	2010).	Such	seeding	of	aberrant	methylation	has	been	
described	at	the	promoters	of	several	tumour	suppressor	genes	in	various	cancer	
types,	including	MutL	Homolog	1(MLH1)	in	sporadic	colorectal	cancers	and	Ras	
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Associated	Domain	Family	1	Isoform	A	(RASSF1A)	in	sporadic	breast	cancer	(Deng	et	
al.	1999;	Yan	et	al.	2003).	
	
Another	mechanism	by	which	aberrant	methylation	patterns	can	be	generated	is	
through	alterations	in	methyl-binding	protein	domains.	This	can	affect	the	binding	
affinity	of	certain	transcription	factors	such	as	the	transcriptional	repressor	CCCTC-
Binding	Factor	(CTCF)	(Shukla	et	al.	2011),	leading	to	the	effects	described	above,	or	
affect	binding	of	factors	like	methyl-CpG	binding	protein	2	(MeCP2)	and	subsequent	
recruitment	of	chromatin	remodelling	complexes,	which	can	lead	to	aberrant	3-
dimensional	chromatin	structures.	Aberrant	binding	of	MeCP2	can	also	affect	
alternative	splicing,	with	a	decrease	in	intragenic	DNA	methylation	associated	with	
altered	splicing	of	transcripts	(Maunakea	et	al.	2013).		
	
Interestingly,	CpG	methylation	is	a	significant	driver	of	human	polymorphisms,	as	
methylated	cytosines	are	highly	vulnerable	to	deamination	to	thymine	(Cooper	and	Youssoufian	1988;	Rideout	et	al.	1990;	Tomso	and	Bell	2003).	As	early	as	1988,	
CpG-SNPs	were	described	to	play	a	key	role	in	mutagenesis,	accounting	for	35%	of	
coding	mutations	in	one	particular	study,	with	90%	of	these	Cà	T	or	GàA	
transitions	(Cooper	and	Youssoufian	1988).	Over	a	decade	later,	when	non-coding	
variation	was	beginning	to	be	examined,	Tomso	et	al.	surveyed	two	million	non-
coding	SNPs	for	polymorphism	“hotspots”,	and	found	that	such	variation	was	
enriched	outside	CpG	islands.	They	found	that	methylated	CpGs	outside	islands,	
which	are	normally	methylated,	were	6.7	times	more	likely	to	contain	SNPs	than	
expected	and	that	CpGs	in	islands	(normally	unmethylated)	contained	6.8	fold	less	
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variation	than	expected	by	chance.	Finding	comparable	levels	of	CàT	and	GàA	
variants	(80%),	they	concluded	that	methylated	cytosine	deamination	plays	a	strong	
role	in	human	variation	and	that	variation	within	islands	is	supressed	as	these	
regions	are	normally	un-methylated	(Tomso	and	Bell	2003).		
	
Genetic	variation	and	CpG	methylation	are	thus	intrinsically	linked,	with	the	
underlying	genetic	sequence	establishing	a	‘propensity	to	methylate’;	a	
predisposition	or	tendency	towards	a	particular	epigenetic	pattern	in	the	context	of	
a	certain	genotype	(Hesson,	Hitchins	and	Ward	2010).	These	patterns	are	not	
solely	dependent	on	genotype	as	they	are	also	influenced	by	environmental	and	
random	factors,	as	described	in	Richard’s	‘facilitated	epigenetic	variation	model’	(Richards	2006).	This	genotype-epigenotype	interaction	is	further	described	in	
Feinberg	and	Irizarry’s	‘inherited	stochastic	variation	model’	which	proposes	genetic	
sequence	variation	underlies	the	propensity	for	epigenetic	variation,	as	certain	DNA	
sequences	are	not	only	directly	responsible	for	particular	traits	but	also	increase	
natural	methylation	variation	for	that	trait	(Feinberg	and	Irizarry	2010).	Various	
stochastic	and	environmental	factors	then	influence	DNA	methylation	at	these	
variably	methylated	regions	(VMRs),	resulting	in	increased	phenotypic	differences,	
which	are	then	acted	on	by	Darwinian	selection	in	a	similar	manner	to	selection	
pressures	affecting	purely	genetic	traits.	This	model	is	supported	by	further	studies	
examining	distinct	methylation	patterns	across	different	populations.	For	example,	
Heyn	et	al.	found	one-third	of	differential	inter-individual	methylation	patterns	to	be	
independent	of	genotype,	suggesting	genetic	and	epigenetic	evolutionary	blueprints	
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are	established	and	acted	on	by	divergence	and	selection	pressures	resulting	in	
phenotypic	variation	(Heyn	et	al.	2013).		
	
A	complete	atlas	of	the	influence	of	environmental	and	genomic	variation	on	DNA	
methylation	requires	many	more	studies	across	various	populations,	tissue	types	and	
disease	models.	In	the	present	study,	genome-wide	methylation	and	SNP	profiles	
have	been	generated	as	described	in	Chapter	2.	An	appropriate	pre-processing	
pipeline	was	developed	to	permit	analysis	of	the	genome-wide	methylation	profiles	
of	familial	prostate	cancer	cases	and	family	members	(Chapter	3,	Cazaly	et	al,	2016).	
These	pipelines	have	produced	high	quality	methylation	and	genotype	data	for	
thirty-nine	samples	representing	ten	families.	The	output	methylation	profiles	of	
these	samples	show	significant	familial	grouping	(Chapter	3	Figure.1F),	indicative	of	
the	underlying	inheritance	of	genetic	drivers	in	these	cohorts	of	families	with	high	
prostate	cancer	incidence.		
	
Herein,	these	data	will	be	interrogated	to	identify	and	prioritise	prostate	cancer	
relevant	meQTLs.	As	the	most	influential	variants	are	likely	to	be	the	CpG-SNPs	
themselves,	this	study	focuses	on	these	variants,	adapting	an	elegant	approach	
described	by	Zhi	and	colleagues	who	examined	cis-meQTLs	in	the	Genetics	of	Lipid	
Lowering	Drugs	and	Diet	Network	data	(Zhi	et	al.	2013).	Specifically,	Zhi	et	al.	
demonstrated	that	although	the	Infinium	HumanMethylation	450k	BeadChip	was	
not	designed	to	examine	CpG-SNPs,	careful	selection	of	probes	and	analysis	allows	
for	accurate	measurements	at	these	sites.	While	SNPs	located	within	probe	bodies	
on	the	methylation	array	can	interfere	with	binding	of	the	probe	to	target	DNA,	
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probes	with	a	SNP	at	the	single	base	extension	(SBE)	for	Infinium	type	II	probes	can	
be	reliably	used	to	examine	CpG-SNPs.	Only	Infinium	type	II	probes	are	suitable	for	
examining	CpG-SNPs	as	the	probes	themselves	do	not	cover	the	SBE.	In	contrast,	
Infinium	type	I	probe	bodies	do	cover	the	SBE	and	ought	to	be	excluded.	The	authors	
report	that	more	than	80%	of	genetic	variants	at	CpGs	(CpG-SNPs)	are	meQTLs	and	
that	the	influence	of	these	variants	extends	beyond	the	CpG-SNP,	concluding	these	
are	important	determinants	genotype-linked	epigenetic	changes.	
	
	
4.2	Methods	
Two	distinct	approaches	have	been	employed	to	determine	prostate	cancer	relevant	
meQTLs,	adopting	several	key	strategies.	The	first	approach	prioritises	CpG	sites	with	
highly	variable	methylation	between	individuals,	which	is	predicted	to	vary	with	
genotype.	It	is	hypothesised	that,	as	the	samples	are	drawn	from	families	with	
elevated	rates	of	prostate	cancer	incidence,	the	variants	driving	predisposition	will	
be	enriched	in	the	affected	men,	influencing	aberrant	methylation	patterns	and	will	
be	distinguishable	from	their	unaffected	relatives.	The	second	approach	draws	on	
previously	identified	regions	of	the	genome	associated	with	prostate	cancer	risk,	
with	the	hypothesis	that	a	proportion	of	the	unexplained	risk	variants	previously	
identified	in	both	familial	and	sporadic	prostate	cancer	studies,	may	be	due	to	non-
coding	variants	driving	aberrant	methylation	profiles.	The	pipeline	for	identifying	
variants	of	interest	from	each	approach,	together	with	subsequent	meQTL	testing	
and	prioritisation	can	be	seen	in	Figure	4.2.	
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Figure	4.2	The	pipeline	employed	in	this	study	to	identify	prostate	cancer	relevant	
meQTLs.		Two	distinct	approaches	were	taken	to	identify	meQTLs.	Regions	of	
interest	from	both	approaches	were	analysed	in	the	same	manner	with	the	GenABEL	
R	package	and	prioritised	using	the	same	metrics	as	described	in	Figure	4.9.	
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4.2.1.	Identification	of	CpG	sites	with	highly	variable	methylation		 	
Allele-specific	methylation	profiles	consist	of	three	distinct	methylation	levels,	
namely	clusters	of	high,	mid	and	low	methylation	levels,	corresponding	to	
homozygous	genotypes	driving	high	and	low	methylation	and	heterozygous	
genotypes	driving	intermediate	methylation	(Deng	et	al.	2009).	A	heterozygous	
genotype	has	approximately	50%	methylation	as	one	allele	is	methylated	and	the	
other	un-methylated	across	a	population	of	cells.	As	such,	variable	CpG	sites	in	this	
study	were	selected	by	choosing	those	displaying	three	distinct	clusters	of	
methylation	between	samples,	with	the	aim	of	examining	genotype	driven	meQTLs.		
	
Given	that	it	has	been	reported	that	CpG-SNPs	are	likely	important	drivers	of	
methylation	changes,	7,049	probes	on	the	methylation	array	interrogating	a	known	
CpG-SNP	were	selected	and	then	prioritised	on	methylation	variability	at	the	CpG-
SNP.	This	method	ranked	CpG	sites	by	standard	deviation	from	the	mean	
methylation	value	across	individuals	at	each	site	(base	stats	R	package,	R	Core	Team	
2016).	This	identification	was	enabled	through	the	annotation	function	in	the	minfi	R	
package	(Aryee	et	al.	2014),	which	annotates	genomic	information,	including	CpG-
SNPs,	to	the	methylation	data.	Specifically,	the	standard	deviation	at	each	CpG-SNP	
was	calculated	between	individuals,	and	the	100	CpG-SNPs	with	the	greatest	
standard	deviation	were	selected	for	meQTL	analysis.	Appendix	4.5	contains	details	
of	the	R	code	used	in	this	analysis.	
	
Secondly,	to	more	widely	examine	variable	methylation	outside	CpG-SNPs,	an	
alternative	method	was	used	on	all	probes.	In	this	approach	the	central	distribution	
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of	methylated	values	was	captured	for	each	CpG	site	using	the	quantile	function	
from	the	stats	R	package	by	selecting	the	95%	Reference	Range.	This	method	has	
previously	been	described	by	Lemire	and	colleagues	to	examine	trans-meQTLs	in	
lymphocytes	(Lemire	et	al.	2015).	Specifically,	the	difference	between	the	97.5%	
quintile	and	the	2.5%	quintile	is	calculated	at	a	given	CpG	site.	Adopting	this	
approach	is	equivalent	to	calculating	the	range	of	methylation	values,	after	the	
upper	and	lower	2.5%	of	values	are	discarded.	This	is	to	limit	the	effect	of	outliers,	
which	may	skew	results	if	included.	
	
4.2.2.	Selection	of	prostate	cancer	risk	loci	for	meQTL	analysis		
In	this	approach,	the	association	between	loci	within	previously	identified	prostate	
cancer	risk	regions	and	neighbouring	CpG	methylation	was	examined.	Previously	
examined	prostate	cancer	risk	regions	were	selected	from	three	different	sources;	1)	
regions	previously	identified	through	modified	linkage	analysis	in	this	laboratory	
using	the	Tasmanian	Familial	Prostate	Cancer	Resource,	2)	other	published	familial	
prostate	cancer	risk	loci	from	the	OMIM	resource,	and	3)	risk	SNPs	identified	by	
GWAS	published	on	NCBI’s	GWAS	Catalogue.	
	
4.2.2.1	Risk	loci	identified	through	the	Tasmanian	Familial	Prostate	Cancer	Study		
A	previous	modified	linkage	analysis	in	this	laboratory	using	BEAGLE	(Browning	and	Browning	2011)	on	the	Tasmanian	Familial	Prostate	Cancer	Study,	identified	four	
regions	generating	modified	logarithm	of	the	odds	(LOD)	scores	.	These	regions	were	
of	nominal	genome-wide	significance	(unpublished).	Figure	4.3	illustrates	the	
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Manhattan	plot	for	this	study,	showing	the	significance	of	prostate	cancer	risk	loci	
genome-wide.		
	
	
	
	
	
	
	
Figure	4.3	Manhattan	Plot	highlighting	prostate	cancer	linkage	regions.	
A	 SNP	 genome	 wide	 scan	 using	 the	 Affymetrix	 CNV370	 array	 using	 Tasmanian	
Familial	 Prostate	 Cancer	 dataset	 comprising	 265	 individuals	 of	 which	 171	 were	
affected	cases,	and	one	or	two	offspring	of	deceased	cases	representing	a	further	71	
cases.	Plot	generated	using	IBD	sharing	calculated	using	the	fast	IBD	sharing	option	
in	 BEAGLE	 for	 265	 individuals	 representing	 prostate	 cancer	 cases	 and	 children	 of	
diseases	cases.	A	reference	group	of	373	unrelated	Tasmanian	controls	was	used	as	a	
control	 dataset.	 Each	 individual	 chromosome	 is	 numbered.	 Note,	 the	 major	
histocompatibility	 complex	 (MHC)	 region	 has	 been	 removed	 in	 this	 graph	 due	 to	
complexity	and	linkage	disequilibrium	in	this	region	causing	false	signal.	
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These	nominal	linkage	regions,	also	listed	in	Appendix	4.1	contain	143	SNPs	on	four	
chromosomes;	fifty	on	chromosome	2,	forty-nine	on	chromosome	6,	twenty-nine	on	
chromosome	15	and	fifteen	on	chromosome	22.	Modified	LOD	scores	ranged	from	
1.98	to	4.8,	with	the	majority	of	scores	over	3,	indicating	an	increased	probability	of	
genetic	linkage	to	disease.	As	these	loci	were	annotated	to	a	previous	genome	build,	
SNPnexus	(http://www.snp-nexus.org)	was	used	to	convert	the	genomic	positions	to	
the	hg19	build	co-ordinates	so	comparison	to	methylation	array	data	and	other	
prostate	cancer	risk	data	could	be	conducted.		
	
4.2.2.2	Risk	Loci	identified	through	published	familial	prostate	cancer	studies	
Thirty-two	prostate	cancer	risk	regions	were	selected	from	the	Online	Mendelian	
Inheritance	in	Man	(OMIM)	database	(http://www.ncbi.nlm.nih.gov/omim).	OMIM	is	
a	freely	available	compendium	of	human	genes	and	phenotypes.	This	database	is	
regularly	updated	and	curated	by	the	McKusick-Nathans	Institute	of	Genetic	
Medicine	at	the	Johns	Hopkins	University.	As	the	regions	were	already	annotated	to	
the	hg19	genome	build	no	genome	conversion	was	required.	Unlike	the	risk	loci	from	
the	two	other	databases,	which	could	be	used	to	generate	a	50Kb	window	for	
analysis,	this	dataset	contained	large	genomic	regions	requiring	a	sliding	window	
approach	to	allow	all	loci	in	the	regions	to	be	sequentially	tested	without	inflating	
the	multiple	testing	burden	within	each	window.	See	Figure	4.4	below	for	a	
schematic	of	the	sliding	window	design.		
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4.2.2.3	Risk	Loci	identified	through	published	prostate	cancer	GWAS		
A	list	of	320	prostate	cancer	risk	SNPs	from	published	GWAS	was	generated	using	
the	GWAS	catalogue	(https://www.ebi.ac.uk/gwas/),	a	joint	venture	founded	in	2008	
by	the	National	Human	Genome	Research	Institute	and	the	European	Bioinformatics	
Institute.	The	resource	is	a	manually	curated	and	quality	controlled	collection	of	
published	GWAS	with	over	100,000	SNPs	and	associated	traits.	Sixty-three	duplicate	
SNPs	from	multiple	studies	were	removed,	along	with	1	SNP	with	no	annotation	
information	on	UCSC,	leaving	256	unique	SNPs.		As	these	SNPs	were	annotated	to	
the	latest	genome	build,	hg38,	they	were	then	passed	through	SNPnexus	to	generate	
hg19	genomic	co-ordinates.		
	
4.2.3	Filtering	of	CpG	probes	prior	to	meQTL	association	
As	discussed	in	section	4.1,	SNPs	located	in	the	probe	body	on	the	methylation	array	
can	interfere	with	binding	of	the	probe	to	target	DNA,	creating	an	artificial	
methylation	signal	and	technical	bias	in	the	data	(Chen	et	al.	2013).	As	such,	these	
probes	were	removed	from	further	analysis.		
	
4.2.4	Association	between	SNPs	and	CpGs	in	identified	risk	windows	
For	each	method	of	determining	variable	CpG	sites	(standard	deviation	and	95%	
reference	range),	the	100	most	variable	CpGs	were	selected	for	meQTL	analysis.	
Genomic	windows	of	250Kb	were	generated	around	each	CpG,	with	SNPs	located	
within	each	genomic	window	extracted	from	the	genotype	array	using	PLINK	(Purcell	et	al.	2007)	and	the	GenABEL	R	package	(GenABEL	project	developers	
2013).	These	SNPs	were	then	analysed	against	one	variable	CpG	per	window.		
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For	previously	identified	prostate	cancer	risk	loci	identified	from	the	Tasmanian	
Familial	Prostate	Cancer	Study	and	published	GWAS,	a	50Kb	window	was	drawn	
around	each	SNP	of	interest	with	all	CpG	sites	falling	within	that	genomic	range	
drawn	from	the	methylation	array	using	the	minfi	R	package	(Aryee	et	al.	2014).	
These	were	analysed	against	all	SNPs	from	the	genotyping	array	in	the	same	window	
(instead	of	only	the	risk	SNP),	to	allow	for	the	possibility	that	the	previously	
identified	SNP	was	not	the	causative	risk	SNP,	but	was	in	linkage	disequilibrium	with	
the	nearby	risk	SNP.	The	approach	for	the	risk	loci	identified	through	published	
familial	prostate	cancer	studies	was	slightly	different	as	this	data	covered	large	
genomic	windows,	rather	than	single	nucleotide	variants.	For	this	approach	a	sliding	
window,	as	described	in	Figure	4.4	below	was	used,	with	every	SNP	and	CpG	within	
each	window	extracted	from	the	methylation	and	genotype	arrays	as	discussed	
above.	
	
The	window	sizes	were	carefully	chosen	to	include	as	many	informative	SNPs	and	
CpGs	as	possible	without	being	unduly	large	to	limit	discovery	power	by	excessive	
statistical	tests.	Window	sizes	were	selected	in	accordance	with	previous	studies,	
which	have	found	meQTL	associations	typically	extend	10-15Kb	(Zhi	et	al.	2013;	Smith	et	al.	2014).	Luijk	and	colleagues	also	suggest	windows	between	10-50Kb,	as	
larger	windows	of	several	hundred	base	pairs	can	lead	to	prohibitive	false	discovery	
rates	as	the	number	of	statistical	tests	are	extremely	high	(Luijk	et	al.	2015).		
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Figure	4.4	Sliding	window	design.		
A	sliding	window	strategy	was	used	to	analyse	prostate	cancer	associated	genetic	regions	identified	through	the	familial	linkage	
approach	to	generate	genomic	regions	for	association	analysis.	A	unique	region	of	30Kb	with	a	10Kb	overlap	either	side	was	chosen	to	
create	a	50Kb	window.	
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A	polygenic	model	using	a	hierarchical	generalized	linear	model	accounting	for	
kinship	was	used	from	the	GenABEL	package	to	examine	the	association	between	
each	SNP	and	each	CpG	in	each	window.	Kinship	coefficients	for	the	thirty-nine	
samples	(listed	in	Table	2.1)	were	calculated	with	the	Identity-by-State	function	in	
the	GenABEL	R	package	using	a	direct	IBS	computation.	Negative	log10	
transformations	of	the	p-values	were	taken	to	create	more	interpretable	values,	as	
the	differences	between	p-values	are	more	apparent.	Using	a	negative	log10	
transformation,	a	significant	p-value	of	0.05	translates	to	1.3.	However,	as	there	are	
many	statistical	tests	required	in	genomic	studies,	convention	is	to	correct	for	
multiple	testing	error	across	the	genome	adjusting	the	significance	threshold	to	
<5x10^(-8)	which	equates	to	a	negative	log10	p-value	of	7.3	(Panagiotou,	Ioannidis	and	Project	2012).		
	
In	the	current	study,	the	significance	threshold	was	adjusted	by	Bonferroni	
Correction,	with	a	typical	significant	p-value	of	0.05	divided	by	the	number	of	
statistical	tests	(ie.	SNP	x	CpG	combinations)	in	each	window.	These	adjusted	
thresholds	are	displayed	on	the	association	plots	in	this	chapter.	However,	a	more	
stringent	cut-off	was	employed	when	considering	meQTLs	for	the	prioritisation	
pipeline.	To	qualify	for	the	pipeline,	only	meQTLs	with	transformed	negative	log10	p-
value	above	10	(which	is	much	higher	than	the	conventionally	used	genome-wide	
significance	adjustment)	were	considered.	Given	that	the	total	number	of	tests	
carried	out	in	this	study	is	smaller	than	the	number	of	tests	in	a	genome	wide	
association	study,	all	meQTLS	that	were	considered	for	the	prioritisation	pipeline	
were	significant	after	adjusting	for	multiple	testing.	Regions	were	then	plotted	in	a	
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similar	manner	to	GWAS	Manhattan	plots	using	the	generic	plot	function	in	R.	
Appendices	4.5	and	4.6	detail	the	R	code	used	to	perform	the	identification	and	
prioritisation	of	meQTLs.	
	
4.2.5	meQTL	Prioritisation		
MeQTLs	were	considered	for	the	prioritisation	pipeline	if	the	association	between	
SNPs	and	methylation	was	above	the	adjusted	significance	threshold	of	10	for	
negative	log10	p-values.	Four	filtering	steps	were	then	applied	to	the	significant	
associations	as	detailed	below.			
	
	
	
4.3	Results	
Appropriate	quality	methylation	and	genotype	data	obtained	from	thirty-nine	
samples	was	analysed	to	identify	and	prioritise	prostate	cancer	relevant	meQTLs.	
Samples	included	in	these	analyses	are	indicated	by	orange	stars	in	Figure	4.5	below,	
and	listed	in	Table	2.1	of	Chapter	2	(sex	and	disease	status	information	is	included).		
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Figure	4.5	Pedigree	Information	for	samples	included	in	meQTL	Analysis	.		
Four	clusters	from	Family	9	(A),	two	from	Family	11	(B),	four	from	Family	22	(C),	and	
five	from	Family	72	(D)	were	selected	for	meQTL	analysis.	Circles	represent	women	
and	squares	men,	with	individuals	affected	by	prostate	cancer	filled	in	black,	those	
unaffected	unfilled	with	individuals	affected	by	other	cancers	quarter	filled.	Samples	
analysed	are	indicated	by	an	arrow-head	with	thirty-nine	samples	with	both	good	
quality	methylation	and	Genotype	data	indicated	by	orange	stars.		
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4.3.1	Identification	of	CpG	sites	with	highly	variable	methylation		
To	determine	the	most	variable	methylation	sites	between	individuals,	two	
approaches	were	taken.	Firstly,	the	standard	deviation	of	methylation	values	at	
probes	containing	CpG-SNPs	was	examined,	with	the	100	most	variable	CpGs	tested	
for	genotype-methylation	associations.	Significant	meQTL	associations	(threshold	
adjusted	by	Bonferroni	Correction)	were	detected	in	each	of	the	100	windows	
analysed,	with	93	windows	containing	a	–log10(p-value)	above	the	stringent	adjusted	
significance	threshold	of	10.	The	most	variable	100	CpG	sites	together	with	their	–
log10(p-values)	and	the	number	of	significant	associations	per	window	are	presented	
in	Appendix	4.2,	with	summary	statistics	provided	in	Table	4.1.		
	
Table	4.1	Summary	of	prioritisation	and	association	analysis	for	the	variable	
methylation	approach	
	
Variable	Methylation	Approach	 Standard	Deviation	
95%-Reference	
Range	
Number	of	windows	from	each	approach	 100	 100	
Windows	for	which	an	meQTL	association	was	generated	 100	 98	
Windows	with	–log10(p-value)	above	the	adjusted	
significance	threshold	using	Bonferroni	Correction	 100	 96	
Mean	number	of	significant	associations	per	window	
using	Bonferroni	Correction	 22	 23	
Number	of	CpG-SNPs	with	a	–log10(p-value)	above	the	
adjusted	significance	using	Bonferroni	Correction	 100	 90	
Highest	–log10(p-value)	 33.8	 30.25	
Mean	–log10(p-value)	 22	 19	
Windows	with	a	–log10(p-value)	above	the	adjusted	
significance	threshold	of	10	 93	 85	
Number	of	CpG-SNPs	with	a	–log10(p-value)	above	the	
adjusted	significance	threshold	of	10	 93	 81	
Overlap	with	alternate	variable	methylation	approach	 67	 67	
Overlap	with	risk	loci	approach	 3	 3	
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A	second	approach	was	then	taken	to	examine	the	influence	of	meQTLs	outside	of	
CpG-SNPs	and	to	provide	validation	of	CpGs	identified	in	the	first	method.	The	95%	
Reference	Range	was	calculated	for	all	probes	as	described	in	section	4.3.1,	with	
ninety-eight	genomic	windows	successfully	generated.	The	vast	majority	of	these	
(ninety-six)	produced	–log10(p-values)	above	the	Bonferroni	adjusted	significance	
threshold,	with	eighty-five	above	the	stringent	adjusted	significance	threshold	of	10.	
The	ninety-six	CpGs	with	–log10(p-values)	above	the	Bonferroni	adjusted	significance	
threshold,	together	with	the	–log10(p-values)	and	the	number	of	significant	
associations	per	window	are	detailed	in	Appendix	4.3,	while	summary	statistics	
presented	in	Table	4.1.		
	
Sixty-seven	of	the	identified	meQTLs	were	identified	by	both	methods,	(highlighted	
in	orange	in	Appendix	4.2).	Both	methods	also	had	analogous	maximum	–log10(p-
values)	(33.80	for	Standard	Deviation	and	30.25	for	95%-Reference)	and	mean	–
log10(p-values)	(22	for	Standard	Deviation	and	19	for	95%-Reference)	as	well	as	a	
similar	number	of	significant	associations	above	the	adjusted	Bonferroni	Correction	
per	window	(mean	of	22	for	Standard	Deviation	and	23	for	95%-Reference	Range).	
There	were	thirty-three	CpGs	that	did	not	overlap	between	the	two	methods,	
including	the	most	significant	cg13387643	which	had	a	–log10(p-value)	of	33.80.	This	
CpG	was	identified	as	highly	variable	by	the	standard	deviation	approach,	yet	was	
only	included	in	the	top	200	most	variable	sites	determined	by	the	95%	Reference	
Range.	As	such,	meQTL	analysis	would	not	have	been	performed	on	this	CpG	if	it	had	
not	been	detected	in	the	standard	deviation	approach.	Additionally,	only	ten	of	the	
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top	twenty	most	variable	CpGs	identified	by	the	standard	deviation	method	were	
ranked	in	the	top	100	CpGs	identified	by	the	95%	Reference	Range	method.	
	
4.3.2	Selection	of	prostate	cancer	risk	loci	for	meQTL	analysis	
To	identify	genomic	regions	pertinent	to	prostate	cancer	predisposition,	three	data	
sources	of	previously	identified	prostate	cancer	risk	loci	were	utilised	to	create	6108	
genomic	windows.		
	
A	previous	linkage	analysis	in	our	laboratory	using	the	Tasmanian	Familial	Prostate	
Cancer	Resource,	identified	four	regions	with	nominally	significant	modified	LOD	
scores	associated	with	prostate	cancer	risk	and	a	summary	of	the	statistically	
significant	associations	is	presented	in	Table	4.2,	Risk	Loci1.		Additionally,	thirty-two	
prostate	cancer	risk	regions	previously	associated	with	familial	prostate	cancer	were	
examined	and	these	are	presented	in	Table	4.2,	Risk	Loci2.	There	is	evidence	that	
prostate	cancer	susceptibility	variants	identified	by	GWAS	also	contribute	to	
hereditary	prostate	cancer	(Teerlink	et	al.	2014).	As	such,	previously	identified	
prostate	cancer	risk	SNPs	from	GWAS	were	also	examined	in	this	approach	(Table	
4.2,	Risk	Loci3).		Pooling	the	putative	prostate	cancer	susceptibility	loci	identified	
from	the	three	sources	generated	6108	windows	and,	association	analysis	between	
methylation	and	genotype	was	successfully	performed	in	4994	windows.	Three-
hundred	and	seventy-two	windows	contained	meQTL	–log10(p-value)	above	the	
adjusted	significance	threshold.	The	fifty	most	significant	associations	identified	from	
the	three	prostate	cancer	risk	loci	methods	is	presented	in	Appendix	4.4.	
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Table	4.2	Summary	of	prioritisation	and	association	analysis	for	the	prostate	
cancer	risk	loci	approach	
	
	
	 	 	 	 	
Prostate	Cancer	Risk	Loci	Approach	 Risk	Loci	1	
Risk	
Loci	2	
Risk	
Loci	3	 Total	
Number	of	windows	 143	 5723	 242	 6108	
Windows	for	which	an	meQTL	association	was	generated	 143	 4613	 238	 4994	
Windows	with	a	–log10(p-value)	above	the	adjusted	
significance	using	Bonferroni	Correction	
13	
(9%)	
228	
(5%)	
131	
(55%)	 372	
Windows	with	a	–log10(p-value)	above	the	adjusted	
significance	threshold	of	10	 4	 8	 36	 48	
Number	of	CpG-SNPs	with	a		–log10(p-value)	above	the	
adjusted	significance	using	Bonferroni	Correction	 6	 16	 30	 52	
Number	of	CpG-	with	a		–log10(p-value)	above	the	
adjusted	significance	threshold	of	10	 4	 7	 22	
33		
(69%)	
Overlap	with	variable	methylation	approach	 0	 3	 0	 3	
	
	
	
	
	
1	Risk	loci	identified	through	the	Tasmanian	Familial	Prostate	Cancer	Study	
2	Risk	Loci	identified	through	published	familial	prostate	cancer	studies-	taken	from	
OMIM	database	
3	Risk	Loci	identified	through	published	prostate	cancer	GWAS-	taken	from	GWAS	
Catalogue	 	
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4.3.3	Association	between	genotype	and	methylation		
Following	generation	of	genomic	windows	encompassing	the	selected	CpGs	or	SNPs	
(as	detailed	previously),	association	analyses	were	performed	in	each	window	using	
a	polygenic	linear	model	to	identify	meQTLs.	MeQTLs	with	a			
-log10(p-value)	above	the	adjusted	significance	threshold	of	10	were	subsequently	
prioritised	through	several	filtering	steps	as	described	below.	
	
To	determine	if	meQTL	associations	were	associations	detected	by	chance	or	
possibly	an	artefact	of	the	methodology	employed,	ten	genomic	regions	were	
chosen	at	random	across	the	genome,	and	tested	for	association	between	genotype	
and	methylation.	The	10	plots	are	presented	in	Figure	4.6	(A-J)	together	with	the	
number	of	associations	above	the	adjusted	significance	threshold.	Of	these	regions,	
one	showed	a	statistically	significant	association	(Figure	4.6	F)	while	the	remainder	
contained	no	significant	associations,	providing	evidence	that	the	significant	
associations	generated	by	the	analyses	outlined	here	are	true	biological	associations	
and	not	the	result	of	methodological	bias.	Additionally,	the	region	that	returned	a	
significant	association	was	found	to	contain	a	SNP	in	the	probe	body,	which	may	
have	affected	the	probe	binding,	inflating	the	methylation	signal.	For	the	ongoing	
analyses,	all	such	probes	with	potentially	spurious	binding	were	removed	during	the	
prioritisation	pipeline.	
	
	In	contrast,	many	significant	associations	were	generated	from	both	variable	
methylation	approaches	and	the	risk	loci	approaches.	A	visual	representation	of	a	
significant	association	analysis	is	shown	in	Figure	4.7.	As	indicative	on	the	smaller	
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inset	plot,	methylation	levels	at	the	variable	CpG	of	interest	are	clustered	by	
genotype.	Methylation	at	three	neighbouring	CpGs	either	side	of	the	variable	CpG	
was	examined,	yet	no	altered	methylation	pattern	was	observed	(see	Figure	4.8).
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Figure	4.6	Association	between	Methylation	and	Genotype:	Negative	control	plots.		
Ten	genomic	regions	of	250Kb	were	chosen	at	random	and	association	analysis	was	
performed	between	SNPs	and	CpGs	in	the	regions.	Genomic	location	in	Mb	is	
presented	on	each	x-axis	with	the	–log10(p-value)	on	the	y-axis.	The	location	of	each	
CpG	is	indicated	by	a	red	triangle	with	0.05	p-value	(–log10	of	1.3)	and	Bonferroni	
adjusted	p-value	thresholds	indicated	with	dashed	horizontal	lines.	Only	F	shows	a	
significant	genotype-methylation	association.	
A B
C D
E F
G H
I J
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Figure	4.7	Visualisation	of	association	between	methylation	and	genotype:	Significant	association	at	cg13387643.		
In	this	250Kb	region,	genotypes	at	169	SNPs	were	compared	to	methylation	levels	at	one	variable	CpG	located	in	the	centre	of	the	
region,	indicated	by	the	blue	triangle.	10	SNPs	had	–log10(p-values)	above	the	Bonferroni	adjusted	significance	p-value	threshold.	The	
smaller	inset	plot	shows	methylation	level	at	this	CpG	with	samples	grouped	by	genotype	at	the	closest	SNP.	
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Figure	4.8	Methylation	surrounding	the	most	significant	CpG-SNP.	Methylation	levels	at	three	neighbouring	CpGs	either	side	of	the	
most	significant	CpG-SNP	(cg13387643).	Samples	in	each	of	the	surrounding	CpG	sites	have	high	levels	of	methylation	tightly	clustered	
together.
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4.3.4	meQTL	Filtering	and	Prioritisation		
To	prioritise	the	most	disease-relevant	variants,	four	levels	of	filtering	were	applied	
to	significantly	associated	loci.	Figure	4.9	highlights	the	four	filtering	stages,	together	
with	the	number	of	CpGs	progressing	through	each	level.	In	the	first	instance,	
meQTLs	with	a	–log10(p-value)	below	the	adjusted	significance	threshold	of	10	were	
removed	from	further	analysis,	leaving	the	111	most	significant	associations,	with	
forty-eight	unique	CpGs	from	the	risk	loci	approach	and	sixty-six	from	the	variable	
methylation	approach,	with	three	CpGs	overlapping	between	the	variable	
methylation	and	risk	loci	approaches.		
	
To	maintain	the	focus	on	CpG-SNPs,	loci	lacking	a	CpG-SNP	were	removed.	Ninety-
nine	CpGs	remained,	sixty-six	from	the	variable	methylation	approach	and	thirty-
three	from	the	risk	loci	approach.	For	each	of	these	ninety-nine	CpGs	the	function	of	
the	nearest	gene	was	examined.	While	CpG	methylation	and	other	regulatory	motifs	
do	not	always	affect	expression	at	the	most	proximal	gene,	instead	influencing	
expression	at	distal	regions	(in	trans),	current	analysis	tools	make	it	extremely	
challenging	to	accurately	examine	regulatory	function	outside	proximal	genes.	Genes	
with	a	reported	role	as	a	tumour	suppressor	or	oncogene,	a	role	in	proliferation,	cell	
cycle	regulation,	angiogenesis	or	gene	regulation	were	included.	Illumina’s	genomic	
annotation	on	the	methylation	array	was	used	to	determine	the	most	proximal	gene,	
namely	if	CpGs	were	located	within	a	gene	or	within	1,500bp	of	a	transcription	start	
site.	These	annotations	were	then	confirmed	using	the	UCSC	genome	browser.	CpG	
sites	that	were	not	annotated	to	a	gene	on	the	methylation	array	were	excluded	
from	further	analysis.	Thirty-seven	CpG	sites	remained	after	this	filtering,	and	are	
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presented	in	Table	4.3	together	with	a	subset	of	the	annotation	information	and	
reported	functionality	of	the	nearest	gene.		
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Table	4.3	The	37	most	significant	associations	from	all	approaches.	
CpGs	are	filtered	by	significance	of	p-value,	presence	of	CpG-SNP,	absence	of	probe	SNP	and	gene	function.	CpG	sites	prioritised	for	
validation	are	highlighted	in	orange	with	three	CpG	sites	prioritised	from	both	approaches	highlighted	in	yellow.	
	
A)	meQTLs	identified	throughstandard	deviation	
		 CpG	Name	
In	other	
variable	
approach	
CpG-SNP	 Gene	 Gene	Function	
1	 cg13387643	 no	 rs284310	 CASZ1	 Zinc	finger	transcription	factor,	may	function	as	tumor	suppressor	
2	 cg09084244	 no	 rs1109559	 CDK2AP1		
Possible	regulatory	role	in	DNA	replication.	Forms	core	subunit	of	NURD	
complex;	epigenetically	regulates	embryonic	stem	cell	differentiation.	
Associated	with	oral	cancer	
3	 cg25013753	 no	 rs1051508	 ARHGAP22	 Regulates	cell	motility	&	angiogenesis.	May	be	involved	in	transcription	regulation	via	interaction	with	VEZF1	
4	 cg08210706	 no	 rs10135403	 SERPINA5	 Inhibits	urinary-type	plasminogen	activator-dependent	tumor	cell	invasion	and	metastasis	
5	 cg00231519	 no	 rs36101953	 C10orf46	 Cell	cycle	associated	protein	capable	of	promoting	cell	proliferation	
6	 cg02978201	 no	 rs737008	 PRM1	 Protamines	substitute	for	histones	in	the	chromatin	of	sperm	during	the	haploid	phase	of	spermatogenesis	
7	 cg00345083	 no	 rs7517857	 AJAP1	 Plays	a	role	in	cell	adhesion	and	cell	migration	
8	 cg08238375	 no	 rs4705795	 MCC	 Candidate	colorectal	tumor	suppressor	gene	thought	to	negatively	regulate	cell	cycle	progression	
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B)	meQTLs	identified	through	95%	Reference	Range	
	
		 CpG	Name	
In	other	
variable	
approach	
CpG-SNP	 Gene	 Gene	Function	
9	 cg20592836	 yes	 rs2378256	 TP53INP2	 Dual	role	as	transcription	factor	&	in	autophagy	
10	 cg02464073	 no	 rs1721	 ITGB2	 Important	role	in	immune	response.	Defects	in	gene	cause	leukocyte	adhesion	deficiency	&	gastrointestinal	carcinoma	
11	 cg08146865	 yes	 rs3197223	 NME6		 Inhibitor	of	p53-induced	apoptosis	
12	 cg23698271	 no	 rs11199030	 TIAL1	 RNA-binding	protein,	regulates	various	activities	including	translational	control,	splicing	&	apoptosis	
13	 cg21927991	 yes	 rs5025124	 ZFAT	 Puatively	binds	DNA	&	functions	as	a	transcriptional	regulator	involved	in	apoptosis	and	cell	survival	
14	 cg07240846	 yes	 rs10906142	 CAMK1	
Activates	transcription	factor	CREB1	in	hippocampal	neuron	
nuclei,	possible	involvement	in	apoptosis	of	erythroleukemia	
cells	
15	 cg06330797	 yes	 rs7357046	 RPS6KA2		 Implicated	in	cell	growth	&	differentiation,	may	function	as	tumor	suppressor	in	ovarian	cancer		
16	 cg19360212	 yes	 rs11200296	 NSMCE4A		
Involved	in	DNA	double-strand	breaks	by	homologous	
recombination,	required	for	telomere	maintenance,	involved	in	
positive	regulation	of	response	to	DNA	damage	stimulus	
17	 cg05331763	 no	 rs79974293	 FOXK2	
Related	pathways:	Cell	Cycle	/	Checkpoint	Control	and	Wnt	/	
Hedgehog	/	Notch.	GO	annotations	include	sequence-specific	
DNA	binding	transcription	factor	activity	&	magnesium	ion	
binding	
18	 cg01891583	 yes	 rs2304466	 USP7		 May	induce	p53/TP53-dependent	cell	growth	repression	&	apoptosis	
19	 cg05161773	 yes	 rs426439	 S	EPT9	 Involved	in	cytokinesis	&	cell	cycle	control,	possible	ovarian	tumor	suppressor	gene.	Chromosomal	translocation	results	in	
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acute	myelomonocytic	leukemia	
20	 cg11251367	 yes	 rs12403072	 FMN2	 Role	in	organization	of	cytoskeleton	&	cell	polarity.	Involved	in	responses	to	DNA	damage		
21	 cg09993319	 yes	 rs7898151	 MGMT		 Involved	in	Cell	Cycle	&	DNA-methyltransferase	activity	
22	 cg04610028	 yes	 rs2967607	 RAB11B		 Involved	in	regulating	exocytotic	and	endocytotic	pathways		
23	 cg05338731	 no	 rs5751591	 RAB36	 Associated	with	rhabdoid	cancer	
24	 cg02658043	 yes	 rs7465214	 NRBP2	 Associated	with	medulloblastoma	
25	 cg26365090	 yes	 rs11700304	 TOX2	 RNA	polymerase	II	transcription	factor	binding.	Putative	transcriptional	activator	
26	 cg17662493	 yes	 rs6006744	 SMC1B	 Involved	in	chromatid	cohesion	and	DNA	recombination	during	meiosis	and	mitosis		
27	 cg03796003	 yes	 rs117229426	 KCTD5		 Associated	with	rectal	neoplasm		
28	 cg09289202	 yes	 rs6757649	 STK25		 Possible	role	in	response	to	environmental	stress	and	cell	migration	
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C)	meQTLs	identified	through	the	Tasmanian	Familial	Prostate	Cancer	Study	
		 CpG	Name	 Variable	
Approach	
CpG-SNP	 Gene	 Gene	Function	
29	 cg03036702	 No	 rs4714482	 FOXP4	 Transcription	factor,	may	play	a	role	in	tumors	of	the	kidney	&	larynx	
30	 cg16995742	 No	 rs7577630	 COPS8	 Important	regulator	in	multiple	signaling	pathways	
	 	
	
	
	
	
	
	D)	meQTLs	identified	through	published	familial	prostate	cancer	studies	
		 CpG	Name	 Variable	Approach	 CpG-SNP	 Gene	 Gene	Function	
		 cg11251367	 Yes	 rs12403072	 FMN2		 Role	in	organization	of	actin	cytoskeleton	&	cell	polarity.	Involved	in	responses	to	DNA	damage,	cellular	stress	&	hypoxia		
31	 cg00069771	 No	 rs17452776	 C1orf57	 Involved	in	purine	metabolism		
32	 cg23209941	 No	 rs12137417	 DISC1-TSNAX	 DISC1:	involved	in	neurite	outgrowth	&	cortical	development	
33	 cg07134368	 No	 rs12034296	 TSNAX-DISC1	
TSNAX:	Interacts	with	DNA-binding	protein	that	binds	consensus	
sequences	at	breakpoint	junctions	of	chromosomal	translocations	
	 	 	 	 	 		
E)	meQTLs	identified	through	published	prostate	cancer	GWAS		
		 CpG	Name	 Variable	Approach	 CpG-SNP	 Gene	 Gene	Function	
34	 cg23069046	 No	 rs6920276	 REXO2	 Possible	role	in	DNA	repair,	replication,	recombination	
		 cg03036702	 No	 rs4714482	 FOXP4	 Transcription	factor,	implicated	in	kidney	&	larynx	tumors	
35	 cg09349613	 No	 rs72828989	 CTBP2	 One	alternative	transcript	is	a	transcriptional	repressor	
36	 cg13301327	 No	 rs11696871	 ZBTB46	 Zinc	Finger,	GO	annotations	include	nucleic	acid	binding	
37	 cg13284789	 No	 rs4508746	 SIDT1	 GO	annotations	include	RNA	transmembrane	transporter	activity	
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To	further	prioritise	prostate	cancer	relevant	meQTLs,	the	presence	of	putative	
regulatory	elements	were	examined	500	bp	either	side	of	the	identified	meQTLs.	
Again,	the	UCSC	genome	browser	was	used	for	this	approach,	specifically	to	
determine	the	presence	of	regulatory	elements	such	as	transcription	factor	and	
miRNA	binding	sites,	active	histone	and	chromatin	marks	and	DNase	hypersensitivity	
regions.	Concurrently	considered,	was	the	CpG	density	of	each	region,	with	regions	
containing	too	few	CpGs	(less	than	ten)	excluded	and	regions	containing	dense	CpG	
islands	also	excluded,	as	recent	evidence	suggests	the	greatest	inter-individual	
variability	occurs	outside	CpG	islands,	at	shores	and	shelves.	Utilising	this	filtering	
strategy,	twenty-three	CpGs	were	prioritised	for	further	analysis	and	these	are	
highlighted	in	orange	in	Table	4.3.		
	
	
	
	
	
	
	
	
	
	
	
	
	 136	
	
	
	
	
	
	
	
Figure	4.9	MeQTL	filtering	steps.		
The	five	levels	of	filtering	applied	to	the	significant	associations	are	presented	
together	with	the	number	of	CpGs	prioritised	after	each	step.	
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4.5 Discussion	
In	order	to	identify	inherited	meQTLs	associated	with	disease	in	this	familial	dataset,	
two	distinct	yet	complementary	approaches	(Figure	4.2),	were	used.	Following	
filtering	as	described,	twenty-three	meQTLs	were	prioritised	for	further	follow	up.	
These	represent	the	most	statistically	significant	associations	identified,	those	in	
predicted	regulatory	regions	and	close	to	genes	likely	to	be	of	functional	relevance	
to	prostate	cancer.			
	
Of	the	fifty	significant	associations	with	a	-log10(p-value)	greater	than	10,	there	was	a	
substantial	enrichment	of	CpG-SNPs,	with	thirty-three	meQTLs	containing	a	CpG-
SNP.	This	represented	68.8%	of	the	most	significant	associations	and	is	consistent	
with	previous	findings	pertaining	to	the	influential	role	of	CpG-SNPs.	For	example,	
Zhi	and	colleagues	found	two	thirds	(or	66%)	of	the	strongest	meQTLs	in	their	study	
were	in	fact	CpG-SNPs	(Zhi	et	al.	2013),	while	Shoemaker	et	al.	observed	38-88%	of	
allele-specific	methylation	occured	at	CpG-SNPs.			
	
While	the	detection	of	significant	associations	between	genotype	and	methylation	is	
consistent	with	previous	published	studies,	this	does	not	necessarily	indicate	
association	with	disease.		The	variability	detected	between	individuals	may	simply	be	
‘normal’	epigenetic	variability	and	not	contribute	to	prostate	cancer	predisposition.	
To	prioritise	the	most	disease	relevant	CpGs,	filtering	was	undertaken	based	on	co-
localisation	to	cancer-relevant	genes.	Of	the	thirty-seven	meQTLs	prioritised,	
seventeen	have	previously	been	linked	to	regulation	of	the	cell	cycle,	apoptosis	or	
cell	growth	and	are	therefore	reasonable	candidates	to	contribute	to	cancer.	Nine	
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genes	are	putative	tumour	suppressor	genes,	eleven	are	involved	in	transcriptional	
activation	or	repression	and	nine	have	been	associated	with	at	least	one	form	of	
cancer,	with	genes	associated	with	multiple	categories.		
	
For	the	variable	methylation	approach,	thirty-four	CpGs	identified	as	highly	variable	
by	the	standard	deviation	method	were	not	ranked	in	the	top	100	variable	sites	
identified	by	the	95%	Reference	Range.	This	included	the	most	significant	meQTL,	
cg13387643	as	well	as	another	nine	of	the	top	twenty	most	significant	meQTLs	
identified	from	the	standard	deviation	approach.	This	may	be	due	to	the	fact	that	
the	95%	Reference	Range	excluded	samples	with	very	high	or	very	low	methylation	
levels	as	these	were	considered	outliers,	while	the	standard	deviation	approach	
included	all	methylation	values.	As	it	is	difficult	to	discern	whether	outlying	
methylation	values	are	technical	errors	or	real	biological	signals,	it	is	important	at	
this	stage	to	include	all	highly	variable	sites	for	subsequent	biological	analysis.	
Interestingly,	of	the	sixty-seven	CpGs	that	overlapped	the	two	methods,	fifteen	were	
still	prioritised	in	Stage.3	(twenty-seven	CpGs	remaining)	and	thirteen	of	the	final	
twenty-three	selected	for	validated	were	prioritised	by	both	methods.	These	results	
support	the	use	of	a	number	of	different	statistical	approaches	for	identifiying	
potential	meQTLs.	
	
Overall,	the	variable	methylation	approach	identified	the	greatest	number	of	highly	
significant	associations	with	ninety-three	for	the	standard	deviation	approach	and	
eighty-five	for	the	95%-Reference	Range	approach.	The	design	of	the	450k	array	is	
focused	on	promoter	and	regulatory	regions	of	the	genome,	and	as	such	aligns	with	
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the	overall	hypothesis	of	this	study;	that	non-coding	variation	can	trigger	epigenetic	
changes	in	regulatory	regions,	leading	to	gene	silencing,	predisposing	men	to	
prostate	cancer.	It	is	therefore	not	surprising	that	the	approaches	aimed	at	variant	
prioritisation	by	initially	examining	methylation	profiles	generated	more	significant	
meQTLs	than	variants	prioritised	by	other	means.	Additionally,	the	variable	
methylation	approaches	directly	identify	methylation	patterns	of	interest;	allele-
specific	methylation	clusters,	in	three	distinct	methylation	levels,	driven	by	
genotype.		
	
Examination	of	the	genetic	regions	previously	associated	with	prostate	cancer	in	
familial	studies	revealed	forty-eight	of	the	prostate	cancer	risk	windows	with	a	
statistical	significant	-log10(p-value)	greater	than	10.		The	windows	associated	with	
the	risk	loci	through	the	Tasmanian	Familial	Prostate	Cancer	Study	were	selected	for	
meQTL	analysis	as	it	was	hypothesised	that	meQTL	SNPs	may	have	underpinned	a	
portion	of	the	linkage	signal	observed	and	thus	be	most	relevant	to	this	analysis	of	
the	same	dataset.	For	thoroughness,	risk	loci	identified	in	other	published	familial	
prostate	cancer	studies	were	also	included	in	a	second	analysis.	Heterogeneity	in	
prostate	cancer	is	well	recognised	and	there	is	evidence	that	different	sets	of	genes	
contribute	to	hereditary	prostate	cancer	predisposition	(Lange	et	al.	2003).	The	
underpinning	susceptibility	genes	for	many	of	these	large	familial	prostate	cancer	
linkage	regions	remains	unknown.	Many	of	these	linkage	regions	are	large,	spanning	
many	megabases	and	it	was	hypothesised	that	identified	non-coding	meQTLs	in	
these	regions	could	underpin	the	prostate	cancer	risk.	Comparison	of	the	two	
sources	of	putative	prostate	cancer	susceptibility	loci	revealed	that	within	regions	
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surrounding	the	risk	loci	identified	through	the	Tasmanian	Familial	Prostate	Cancer	
Study,	a	greater	proportion	of	significant	and	highly	significant	associations	were	
identified,	with	9%	of	associations	remaining	significant	(after	adjustment	for	
multiple	testing	error).	In	comparison,	5%	of	loci	identified	through	other	published	
familial	prostate	cancer	linkage	regions	generated	significant	associations.	This	is	
consistent	with	the	hypothesis	that	inherited	determinants	of	methylation	changes	
are	detectable	in	our	dataset	which	may	be	associated	with	prostate	cancer	risk.		
	
It	is	notable	that	for	both	of	these	analyses,	the	linkage	regions	were	large,	incurring	
substantial	multiple	testing	correction.	Further,	the	association	method	tests	each	
SNP	within	each	linkage	region	and	thus	assumes	each	has	an	equal	likelihood	of	a	
potential	association,	whereas	there	is	likely	to	be	a	single	or	few	real	associations	in	
each	region.	Loci	identified	by	modified	linkage	analysis	of	familial	prostate	cancer	
cases	only	tested	for	association	in	four	genomic	regions	and	this	data	was	
generated	using	the	Affymetrix	370	SNP	chip,	a	low	density	array	compared	with	
those	available	today,	developed	before	much	of	the	common	or	rare	variation	
associations	with	disease	had	been	discovered.	Similarly,	familial	prostate	cancer	
susceptibility	loci	identified	from	other	published	studies	only	examined	a	subset	of	
the	genome.	It	should	also	be	considered	that	a	proportion	of	the	risk	loci	previously	
associated	with	prostate	cancer	may	not	be	linked	to	meQTLs,	instead	affecting	
prostate	cancer	risk	through	other	molecular	mechanisms	such	as	mutating	the	
coding	regions	of	genes	or	affecting	other	forms	of	gene	regulation.		
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In	contrast,	the	approach	of	using	prostate	cancer	susceptibility	SNPs	identified	by	
GWAS	detected	a	large	number	of	significant	associations,	with	55	in	total.	Each	of	
the	SNPs	tested	has	been	previously	significantly	associated	with	prostate	cancer	
risk,	further	each	of	the	SNPs	tested	were	relatively	common	in	the	population,	thus	
the	higher	success	in	identifying	significant	associations	is	not	unexpected.	
Interestingly	it	could	also	indicate	that	susceptibility	variants	identified	through	
GWAS	are	more	likely	to	be	acting	to	influence	disease	through	altering	methylation	
patterns.	The	majority	of	meQTLs	identified	in	the	current	study	were	found	in	non-
coding	or	intergenic	regions.	The	evidence	that	a	portion	of	prostate	cancer	risk	SNPs	
identified	through	GWAS	also	contribute	to	familial	prostate	cancer	risk	(Jin	et	al.	2012;	Teerlink	et	al.	2014),	and	that	the	fact	non-coding	variation	consistently	
identified	in	GWAS	may	be	underpinned	by	meQTls	in	non-coding	regions	(Barr	and	Misener	2016),	suggests	that	a	portion	of	the	SNPs	identified	through	this	
differential	methylation	approach	may	be	located	at	loci	previously	identified	as	
associated	with	prostate	cancer	susceptibility.	Examination	of	this	question	revealed	
that	three	CpG	sites	overlapped	in	the	list	of	significant	sites	generated	through	both	
the	methylation	and	prostate	cancer	risk	loci	approaches	(highlighted	in	yellow	on	
Table	4.3)	and	these	were	selected	to	be	taken	forward	in	further	analyses.		
	
The	observed	influence	of	genotype	on	methylation	levels	at	the	meQTLs	was	also	of	
interest	here.	As	described	previously	and	in	section	4.3.3,	methylation	levels	were	
found	to	cluster	by	genotype,	as	visualised	on	the	smaller	inset	plot	of	Figure	4.7.	It	
was	also	of	interest	to	examine	the	effect	of	these	meQTLs	on	neighbouring	
methylation	patterns,	as	Smith	et	al.	have	demonstrated	the	effect	of	cis-meQTLs	
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extends	up	to	1500	Kb	(Smith	et	al.	2014),	with	an	earlier	study	observing	the	most	
significant	meQTL	associations	for	CpG-SNPs	are	within	45bp	(Zhi	et	al.	2013).	While	
Figure	4.8	does	not	show	any	perturbance	in	methylation	patterns	in	the	three	CpGs	
either	side	of	the	variable	CpG,	this	may	be	due	to	the	limited	coverage	of	the	
methylation	array,	as	there	are	often	large	genomic	distances	between	CpG	sites	
represented	on	the	array.	Whilst	this	technology	provides	an	excellent	“snapshot”	of	
the	human	methylome,	it	covers	less	than	2%	of	all	genomic	CpGs	and	as	such,	an	
alternative	method	of	examining	methylation	patterns	must	also	be	utilised.	A	
method	such	as	bisulphite	sequencing,	capable	of	examining	every	CpG	within	a	
selected	region,	will	allow	the	lack	of	variation	surrounding	meQTLs	to	be	
investigated	in	closer	detail,	aiding	in	the	understanding	of	whether	the	uniform	
profiles	observed	are	the	result	of	a	gap	in	analysis	power	on	the	methylation	array,	
or	a	true	biological	phenomenon.	In	addition	to	allowing	for	a	more	complete	picture	
of	the	methylation	landscape	surrounding	meQTLs	to	be	examined,	bisulphite	
sequencing	will	provide	an	independent	platform	to	validate	the	meQTLs	of	interest	
identified	here.	
	
While	many	studies	now	examine	CpG-SNPs	and	meQTLs	relative	to	cancer	
predisposition,	at	the	commencement	of	this	study	there	was	a	paucity	of	
methodologies	and	analysis	for	such	investigations,	particularly	for	pedigree-
structured	datasets.	As	such,	two	innovative	approaches	were	developed	to	examine	
the	association	between	genotype,	methylation	and	prostate	cancer.	Herein	the	
genetic	drivers	of	the	most	variable	methylation	sites,	in	conjunction	with	
methylation	surrounding	genomic	regions	previously	linked	to	prostate	cancer	risk	
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were	examined	and	twenty-three	regions	were	prioritized	to	be	taken	forward	for	
validation	and	more	detailed	examination.	
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Chapter	5	–	The	influence	of	meQTLs	on	the	surrounding	
epigenomic	landscape	and	prostate	cancer	risk		
	
	
5.1	Introduction	
The	role	of	CpG	island	function	at	promoters	has	been	established	for	many	years,	
with	high	levels	of	methylation	at	promoter	islands	consistently	linked	to	gene	
silencing	through	establishment	of	a	condensed	chromatin	state	(Jones	2012).	
However,	more	recently	attention	has	turned	to	the	functional	relevance	of	
methylation	at	other	regions	of	the	genome.	While	gene	body	methylation	has	been	
less	comprehensively	studied,	over	the	past	two	decades	an	understanding	of	the	
influence	of	gene	body	methylation	on	gene	expression	has	emerged.	Interestingly,	
gene	body	methylation	has	a	contrasting	effect	on	gene	expression	to	that	of	
promoter	methylation,	with	low	methylation	linked	to	higher	gene	repression	(Maunakea	et	al.	2010;	Kulis	et	al.	2012;	Varley	et	al.	2013).	Yet,	the	function	of	
gene	body	methylation	remains	to	be	fully	understood,	with	recent	studies	only	
beginning	to	elucidate	the	underlying	mechanisms	controlling	the	effect	of	gene	
body	methylation	on	gene	expression	(Yang	et	al.	2014).		
	
Accompanying	the	growing	interest	in	methylation	at	gene	bodies,	is	a	heightened	
appreciation	for	the	role	of	methylation	at	shores	and	shelves,	regions	surrounding	
islands	(see	Chapter	1,	Figure	1.4	for	a	schematic	of	a	typical	intergenic	and	genic	
landscape).	This	interest	results	from	the	observation	that	much	of	the	variability	
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between	tissue	types	and	disease	states	occurs	in	these	regions	(Irizarry	et	al.	2009).	As	these	regions	are	observed	to	be	the	sites	of	greatest	variability	between	
cancer	and	normal	tissue,	there	is	now	considerable	interest	in	both	the	molecular	
basis	for	this	variability	and	also	its	functional	consequences.	One	of	the	influences	
on	these	variable	methylation	patterns	are	meQTLs	(methylation	quantitative	traits),	
which	have	been	observed	to	alter	methylation	patterns	across	tissues	and	ancestry	(Smith	et	al.	2014).	MeQTLs	are	enriched	in	non-coding	regions	of	the	genome,	
where	they	impact	on	binding	of	transcription	factors	and	chromatin	remodellers	(Heyn	et	al.	2014).	
	
While	a	proportion	of	meQTLs	contribute	to	disease	burden,	up	to	a	third	may	simply	
contribute	to	natural	human	variation	(Heyn	et	al.	2013)	and	the	challenge	is	
thefore	to	identify	those	that	relate	to	disease.	Much	of	the	work	in	the	epigenetic	
cancer	field	to	date	has	focussed	on	examining	the	aberrant	methylation	changes	
that	occur	in	cancerous	tissue,	and	the	distinctive	global	hypomethylation	and	
regional	specific	hypermethylation	observed	in	tumour	tissues	have	been	well	
documented	(Jones	2012;	Sproul	and	Meehan	2013).	However,	there	has	been	
limited	analysis	of	inherited	predisposing	epigenetic	factors	that	may	be	present	
throughout	multiple	tissues	in	the	body,	contributing	to	tumorigenesis.	Rather	than	
simply	a	consequence	of	the	molecular	dysregulation	observed	in	tumours,	if	these	
aberrant	methylation	profiles	are	driven	by	inherited	genetic	variation,	present	in	
the	germline	and	distributed	throughout	all	tissues,	the	aberrant	methylation	
profiles	themselves	may	be	contribute	to	cancer	development	(Hesson,	Hitchins	and	Ward	2010).	To	investigate	this	potential	role	of	meQTLs	in	driving	prostate	
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cancer	predisposition,	the	final	aim	of	this	study	is	to	assess	differential	methylation	
levels	at	specific	loci	in	peripheral	blood	of	men	affected	by	prostate	cancer	
compared	to	unaffected	individuals.		
	
The	greatest	effect	of	meQTLs	are	often	observed	within	close	proximity	to	the	
genetic	variant	(Shoemaker	et	al.	2010;	Zhi	et	al.	2013;	Zhou	et	al.	2015)	and	
therefore	the	methylation	patterns	immediately	proximal	to	meQTLs	are	of	interest.	
While	the	methylation	array	technology	utilised	to	prioritise	meQTLs	in	this	study	
provides	a	valuable	‘snapshot’	across	the	genome,	enabling	disease-relevant	regions	
of	interest	to	be	selected	and	prioritised,	it	captures	only	2%	of	CpGs	genome-wide	(Fan	et	al.	2016),	and	therefore	is	not	able	to	provide	fine	mapping	methylation	
data.	Bisulphite	sequencing	was	therefore	used	to	generate	fine	detailed	mapping	of	
methylation	profiles	in	the	regions	proximal	to	selected	meQTLs.			
	
	
5.2	Methods	
5.2.1.	Sample	Selection	
DNA	samples	for	bisulphite	sequencing	were	selected	from	the	Tasmanian	Familial	
Prostate	Cancer	Resource.	Samples	analysed	in	Chapter	2	with	high	quality	and	
quantity	of	DNA	were	selected,	together	with	an	additional	twelve	affected	men	
from	the	familial	resource.	Thirty-seven	of	the	familial	samples	(Appendix	5.1,	
highlighted	in	orange)	were	used	to	validate	methylation	data	generated	at	earlier	
stages	in	this	study	and	then	further,	to	examine	the	influence	of	genotype	on	
methylation	profiles	surrounding	meQTLs.	In	addition,	thirty-two	age-matched	
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unaffected	individuals	were	also	selected	from	a	second	genetic	resource,	the	
Tasmanian	Prostate	Cancer	Case	Control	Study,	to	compare	methylation	patterns	
between	affected	men	from	the	familial	resource	(n=31)	and	unaffected	population	
controls.	A	description	of	the	sample	set	in	this	study	can	be	found	at	(FitzGerald	et	
al.	2009).	As	prostate	cancer	is	markedly	associated	with	age,	unaffected	men	with	
the	oldest	age	at	sample	collection	were	chosen	for	analysis.	The	unaffected	men	
have	been	cross-checked	with	the	Tasmanian	Cancer	Registry	which	records	all	
cancers	diagnosed	in	Tasmania,	as	required	under	legislation	in	Australia.	The	eighty-
one	individuals	included	in	this	analysis	are	listed	in	Appendix	5.1,	together	with	
their	disease	status,	sex	and	age	and	median	age	for	each	of	the	unaffected	and	
affected	groups	of	individuals.	To	determine	if	such	sample	sizes	would	be	sufficient	
to	detect	significant	associations	between	epigenotype	and	cancer	status,	power	
calculations	were	conducted	with	the	pwr	R	package.		Various	effect	sizes	(20%,	35%,	
75%)	were	tested	with	a	sample	size	of	thirty	samples	per	group.	Various	sample	
sizes	(n=20-40	in	each	group)	were	then	tested	with	the	conservative	effect	size	of	
20%	methylation	difference.	All	tests	were	calculated	for	a	significance	level	of	0.05,	
with	all	returning	a	power	value	above	0.999.	These	calculations	thus	indicate	the	
sample	size	of	thirty-two	unaffected	controls	and	thirty-one	affected	men	would	be	
sufficient	to	detect	a	significant	difference	between	the	groups.		
	
5.2.2	PCR	optimisation	
Bisulphite	converted	DNA	(see	section	2.2.3	of	Chapter.2	for	details	of	bisulphite	
conversion)	was	diluted	to	10ng/µL	in	the	m-Elution	Buffer	provided	in	the	EZ	DNA	
Methylation	Gold	Kit™.	Bisulphite	PCR	primers	were	designed	in	methPrimer	(Li	and	
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Dahiya	2002)	to	cover	1Kb	regions	of	interest	identified	in	Chapter	4.	These	primers	
either	covered	the	entire	region	or	for	larger,	more	CpG	dense	regions,	two	
overlapping	fragments	were	selected	to	encompass	the	majority	of	CpG	sites.	See	
Appendix	5.2	for	a	list	of	the	primers	utilised	in	this	analysis.	Common	SNPs	were	
annotated	to	the	converted	reference	sequences	through	the	UCSC	genome	browser	(Kent	et	al.	2002)	and	potential	primer	binding	sites	containing	these	SNPs	were	
excluded.	 
	
Primers	were	first	optimised	using	control	placental	DNA	(Bioline	Pty	Ltd),	then	
conditions	were	tested	on	individual	DNA	samples	of	highest	quantity/quality.	Post	
bisulphite	conversion,	amplification	was	performed	using	a	Veriti	thermal	cycler	
(Applied	Biosystems).	Optimisation	of	each	primer	pair	was	achieved	+/-	Q-solution	
(Qiagen)	and/or	Magnesium	Chloride	and	a	temperature	gradient.	In	addition	a	
variety	of	Taq	polymerase	mixtures	(MyTaqTM	HS	mix,	BiolinePty	Ltd	and	GoTaq®	Green	
master	mix,	Promega)	were	tested.	See	Appendix	5.3	for	a	list	of	final	PCR	conditions	
for	each	fragment.	A	subset	of	PCR	amplified	fragments	were	examined	by	gel	
electrophoresis	on	a	2%	agarose	gel	to	ensure	amplification	products	were	of	
expected	size.	Amplified	fragments	were	stored	at	-80˚C	prior	to	sequencing.		
	
5.2.3	Nextera	DNA	and	library	preparation	
DNA	fragments	from	all	regions	were	pooled	for	each	individual,	with	a	subset	of	the	
samples	quantified	on	the	Qubit®	Flourometer	(Invitrogen).	Concentrations	were	
adjusted	as	per	manufacturer’s	instructions	in	preparation	for	fragmentation	and	
tagging.	
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A	5µL	volume	of	0.2ng/µL	genomic	DNA	per	sample	was	used	as	the	input	for	
Illumina’s	Nextera	XT	Library	Preparation	kit.	According	to	manufacturer’s	
instructions,	the	DNA	was	‘tagmentated’	(simultaneously	fragmented	and	tagged	
with	adapters),	amplified	through	PCR	and	cleaned.	Using	a	bead-based	protocol,	the	
libraries	were	normalised	and	pooled	to	ensure	equivalent	concentrations	of	each	
library	was	sequenced.	Illumina’s	MiSeq	was	used	to	sequence	the	libraries.	
	
5.2.4	Data	generation,	quality	control	and	analysis	
Standard	quality	control	pipelines	were	employed	to	process	next	generation	
sequencing	data.	Low	quality	base	calls	and	adapter	fragments	were	removed	using	
the	adapter	trimming	tool	Cutadapt	(Martin	2011)	with	the	wrapper	Trim	Galore	
(Krueger		2015).	Quality	scores	on	the	trimmed	data	were	then	examined	with	
FastQC	(Andrews	2011)	with	high	quality	reads	retained.	Reads	were	aligned	to	a	
bisulphite	Hg19	reference	sequence	using	Bismark	(Krueger	and	Andrews	2011)	
generating	BAM	and	text	files.	Sequencing	data	was	extracted	from	the	BAM	files	
with	Bismark,	and	off	target	amplified	regions	removed,	leaving	678	CpG	sites	in	13	
genomic	regions	of	interest.	Data	was	then	uploaded	to	R	with	the	BiSeq	package	(Hebestreit	and	Klein	2013),	and	additional	quality	control	thresholds	were	
manually	established	using	the	mean	number	of	CpGs	covered	per	sample	and	the	
median	coverage	depth	at	these	sites.	Samples	failing	to	reach	a	median	coverage	
depth	of	ten	reads	across	CpG	sites	were	removed	from	further	analysis,	as	were	
CpG	sites	exceeding	a	maximum	quality	threshold	of	10%	“no	call”	values	across	
samples.	Appendix	5.4	details	the	script	used	to	generate	the	data	and	perform	
quality	control.	
	 150	
5.3	Results	
Using	array-based	analysis	of	samples	from	individuals	sourced	from	the	Tasmanian	
Familial	Prostate	Cancer	meQTLs	were	identified	and	prioritised	for	further	analysis	
(as	detailed	in	Chapter	4).	However,	as	the	array	based	technology	captures	only	2%	
of	the	CpGs	genome-wide,	an	additional	approach	was	required	to	generate	fine-
mapping	of	the	regions	surrounding	the	meQTLs	in	order	to	determine	the	effect	of	
the	meQTL	on	the	epigenetic	profile	of	the	surrounding	region.	Bisulphite	
sequencing	was	therefore	performed	on	forty-nine	peripheral	blood	samples	from	
individuals	in	the	Tasmanian	Familial	Prostate	Cancer	Study.	To	investigate	the	
influence	of	these	meQTLs	on	prostate	cancer	risk,	samples	from	thirty-one	of	the	
affected	men	from	the	familial	resource	were	then	combined	with	an	additional	
thirty-two	samples	from	an	independent	resource,	the	Tasmanian	Prostate	Cancer	
Case	Control	Study.	Due	to	time	constraints,	data	generated	from	the	analysis	of	
twelve	of	the	prioritised	regions	will	be	presented	herein.	These	regions	were	those	
that	were	successfully	amplified	from	bisulphite	converted	DNA	and	sequenced,	as	
detailed	in	Table	5.1,	which	also	provides	genomic	and	epigenomic	annotation	data	
for	these	regions.		
	
MeQTLs	are	located	across	a	range	of	chromosomes	and	genomic	locations,	with	
variants	located	at	either	the	cytosine	or	guanine	of	CpG	pairs.	This	includes	six	CàT	
variants,	five	GàA	variants	and	one	CàA	variants	with	the	minor	allele	frequencies	
of	these	variants	indicated	in	Table	5.1.	Eight	meQTLs	are	proximal	to	genes	involved	
in	regulation	of	cell	growth,	proliferation	and	migration,	while	four	have	frequently	
observed	or	putative	tumour	suppressor	roles	(Chapter	4,	Table	3	has	further	detail	
	 151	
on	the	function	of	these	genes).	Six	genes	proximal	to	prioritised	meQTLs	have	
previously	been	associated	with	prostate	cancer	as	indicated	in	Table	5.1.		
	
Most	of	the	regions	examined	appeared	within	gene	introns	(nine),	while	one	
represents	an	exonic	region	and	two	are	located	in	untranslated	regions	(UTRs).	Of	
the	two	meQTLs	in	UTRs,	one	is	within	1500	bp	of	a	transcription	start	site,	as	is	
another	intronic	meQTL.	Relative	to	CpG	island	annotations,	six	meQTLs	are	located	
in	“open	seas”	distant	to	islands	while	five	are	located	in	shores,	regions	flanking	
islands.	Of	note,	none	of	these	regions	represent	CpG	islands,	and	contain	between	
11	and	51	CpGs.	
	
	 152	
	
	
Gene $Size*
Chr
** CpG$number RS$number$ Variant
Genotype$
Data
Proxy$SNP
available
MAF
***
CpG$
Annotation
Gene$
Annotation
Coding$
Annotation
$CpGs$in$
1Kb$ $PC$link
+ ++
1 CASZ1 930 2 cg13387643 rs284310 C/00>/T No Yes T=0.30 OpenSea Body intron 29 YES 34
2 ITGB2 1217 21 cg02464073 rs1721 C/00>/T Yes NA T=0.46 Shore TSS1500 UTR 16 YES 27
3 NME6 751 3 cg08146865 rs3197223 C/00>/T Yes NA T=0.18 OpenSea 3'UTR UTR 11 NO/ 27
4 C10orf46 946 10 cg00231519 rs36101953 C/00>/T No Yes T=0.26 Shore TSS1500 intron 12 NO 24
5 PRM1 680 16 cg02978201 rs737008 C/00>/A Yes NA A=0.49 OpenSea Body exon/+++ 27 NO 22
6 FOXK2 880 17 cg05331763 rs79974293 G/00>/A No No A=0.03 Shore Body intron 33 NO 22
7 USP7 817 16 cg01891583 rs2304466 G/00>/A Yes NA A=0.42 OpenSea Body intron 28 YES 22
8 SEPT9 1183 17 cg05161773 rs426439 C/00>/T No Yes T=0.33 OpenSea Body intron 20 YES 21
9 MGMT= 945 10 cg09993319 rs7898151 /G/00>/A/ No Yes G=0.43 OpenSea Body intron 21 YES 19
10 RAB11B 782 19 cg04610028 rs2967607 C/00>/T No No T=0.36 Shore Body intron 51 NO 19
11 AJAP1 735 1 cg00345083 rs7517857 G/00>/A Yes NA G=0.50 Shore Body intron 22 NO 15
12 MCC 1058 5 cg08238375 rs4705795 G/00>/A No Yes A=0.43 OpenSea Body intron 13 YES 12
**/Chromosome/Number
***/Minor/allele/frequency/as/established/by/the/1000/genomes/project
+/Previously/associated/with/prostate/cancer
++/Significance/as/measured/by/0LOG10(p0value)
+++/Synonymous/coding/mutation
5'UTR:/5'/Untranslated/Region
NA:/not/applicable
Table$5.1$MeQTL$regions$successfully$amplified$by$bisulphite$sequencing
TSS1500:/within/1500bp/of/the/transcription/start/site
*/PCR/product/size
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5.3.1	Validation	of	methylation	array	data	with	bisulphite	sequencing	data	
To	validate	methylation	data	generated	earlier	in	this	study	(Chapters	2-4),	values	at	
the	prioritised	meQTLs	between	the	methylation	array	and	bisulphite	sequencing	
data	were	compared.	The	absolute	difference	in	methylation	proportion	(between	0-
1,	with	0	indicating	no	difference)	between	array	and	bisulphite	sequencing	values	
for	sample	PC22-16	were	calculated	at	each	meQTLs	of	interest.	This	sample	had	
been	separately	interrogated	across	two	batches	on	the	methylation	array.	The	
average	of	the	two	values	from	each	batch	on	the	array	was	calculated	at	eleven	of	
the	twelve	meQTLs	(there	was	no	sequencing	data	for	the	meQTL	within	the	SEPT9	
gene)	and	then	subtracted	from	the	average	of	the	bisulphite	sequencing	values	at	
corresponding	meQTLs.	The	absolute	difference	between	the	two	methylation	array	
values	as	well	as	between	the	two	platforms	were	plotted	at	each	meQTL,	as	
displayed	in	Figure	5.1	below.		
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Figure	5.1	Absolute	difference	between	methylation	measures	across	meQTLs	in	
sample	PC22-16.		
The	absolute	difference	(0	representing	identical	values)	between	methylation	
values	obtained	from	the	array	and	bisulphite	sequencing	data	are	presented	in	red	
bars	across	11	of	the	meQTLs,	while	blue	bars	represent	the	difference	between	
technical	replicates	of	sample	PC22-16	on	different	array	batches.	 	
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Nine	of	the	meQTLs	had	differences	lower	than	0.3	between	the	two	platforms	(red	
bars),	indicative	of	a	consistent	biologically	relevant	methylation	pattern	between	
the	platforms.	This	is	within	the	validation	range	reported	by	(Bibikova	et	al.	2011).	
Namely,	if	genotype	drives	methylation	profiles	in	allele-specific	clusters,	as	
hypothesised	in	this	study,	then	ten	out	of	twelve	meQTLs	for	this	sample	have	
consistent	biological	methylation	patterns	across	the	platforms.	Furthermore,	as	
highlighted	by	the	blue	bars	in	Figure	5.1,	the	two	technical	replicates	generated	
using	the	methylation	array	did	not	produce	identical	results,	with	three	meQTLs	
demonstrating	a	greater	difference	within	the	array	platform	than	between	
platforms.	These	differences	highlight	the	variability	often	present	within	the	same	
platform,	demonstrating	the	need	to	examine	methylation	profiles	by	multiple	
methods.			
	
An	additional	comparison	of	the	two	datasets	was	performed	by	comparing	the	
differences	between	methylation	values	at	each	CpG	across	forty-three	samples	
interrogated	on	both	platforms.	The	absolute	difference	at	each	CpG	value	per	
sample	was	calculated	then	averaged	across	the	samples	per	CpG.	The	absolute	
mean	difference	for	each	meQTL	is	plotted	in	Figure	5.2	below,	together	with	error	
bars	indicating	the	standard	error	of	the	mean.	Excluding	SEPT9,	which	had	a	much	
lower	number	of	successfully	sequenced	samples	at	the	meQTL	(n=24),		the	
differences	between	the	technologies	were	consistent	across	the	meQTL	regions,	
with	discrepancies	between	the	platforms	possibly	the	result	of	the	heightened	
sensitivity	in	bisulphite	sequencing.		
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Figure	5.2	Mean	absolute	differences	between	array	and	bisulphite	sequencing	
data.	
The	mean	absolute	difference	(0	representing	identical	values)	between	methylation	
values	obtained	from	the	array	and	bisulphite	sequencing	data	are	presented	across	
12	genes	containing	meQTLs	of	interest.	43	samples	were	sequenced	for	each	
meQTL,	with	successful	data	generated	for	35-43	samples	at	11	meQTLs.	SEPT9	was	
the	exception,	with	lowever	sample	coverage	(n=24).	Error	bars	are	indicative	of	the	
standard	error	of	the	mean.	
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5.3.2	Exploring	the	influence	of	meQTLs	on	the	methylation	landscape.	
To	examine	the	influence	of	genotype	on	methylation	patterns	in	cis,	samples	drawn	
from	the	familial	resource	were	divided	into	three	groups	based	on	genotype	at	the	
CpG-SNP.	SNPs	were	either	located	at	the	cytosine	or	guanine	of	CpG	pairs.	Only	
samples	with	genotype	data	(n=37)	were	examined	here.	For	five	meQTLs,	the	CpG-
SNP	was	included	in	the	genotype	data,	and	as	such	genotypes	were	directly	
extracted	using	the	GenABEL	R	package.	Genotypes	at	the	CpG-SNP	were	also	
confirmed	through	whole	genome	sequencing	(WGS)	data	for	a	subset	of	samples	
(n=15)	across	all	genotypes.	For	the	remaining	seven	meQTLs,	the	CpG-SNP	itself	was	
not	present	in	the	genotype	data,	(see	Table	5.1	for	details	on	which	meQTLs	had	
genotype	data	and	which	could	be	imputed).	For	five	of	these	meQTLs,	genotype	at	
the	CpG-SNP	was	imputed	from	neighbouring	proxy	SNPs	in	linkage	disequilibrium	
(LD).	The	online	tool	SNAP	(Johnson	et	al.	2008)	was	used	for	imputation.	Data	was	
drawn	from	the	Northern	European	population	of	the	Hapmap	project.	Following	
imputation	Four	of	the	selected	SNPs	had	R2	values	greater	that	0.95	and	a	D’	of	1,	
and	the	fifth	had	R2	0.83	and	D’	1.	For	the	remaining	two	SNPs,	no	appropriate	
tagging	SNP	could	be	imputed.	Thus	genotype	data	was	available	for	ten	meQTLs.	
The	remaining	two	meQTLS	for	which	genotype	data	was	not	available	were	not	
considered	further.	
	
Ten	meQTL	regions	were	qualitatively	analysed	for	genetically	driven	methylation	
patterns,	by	examining	the	median	methylation	per	genotype	group	at	each	CpG	
within	the	amplified	1Kb	region	surrounding	the	meQTL.	All	meQTL	regions	displayed	
distinct	methylation	clusters	corresponding	to	genotype.	To	quantitatively	examine	
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the	effect	of	genotype	on	methylation	in	these	regions,	the	meQTL	with	the	largest	
effect	size	(CASZ.1,	as	determined	by	the	qualitative	analysis)	was	tested	with	a	
linear	model.	This	meQTL	was	not	significant	and	it	was	concluded	that	the	sample	
size	was	not	large	enough	to	detect	significance	at	any	of	the	meQTLs.	The	effect	
sizes	for	the	meQTLs	are	presented	in	Figures	5.3	and	5.4	and	can	be	used	for	power	
analyses	to	determine	the	sample	size	needed	to	detect	significance	in	subsequent	
studies.	
	
To	examine	the	influence	of	meQTLs	on	prostate	cancer	predisposition,	methylation	
at	the	regions	of	interest	were	compared	between	affected	individuals	(n=31)	
selected	from	the	Tasmanian	Familial	Prostate	Cancer	Resource	and	age-matched	
unaffected	individuals	(n=32)	drawn	from	the	Tasmanian	Prostate	Cancer	Case	
Control	Study.	The	median	methylation	level	within	each	group	was	calculated	at	
every	CpG	per	meQTL	region	and	plotted	across	the	genomic	region.		
	
	
5.3.3	Genetic	variation	driving	aberrant	methylation	profiles:	A	proof	of	principle	
at	the	meQTL	proximal	to	CASZ1		
The	meQTL	associated	with	the	CASZ1	gene,	was	located	in	a	intron	within	the	gene	
body.	Methylation	status	at	this	CpG-SNP	was	strongly	influenced	by	genotype,	with	
individuals	of	the	CC	genotype	displaying	high	levels	of	methylation	(median	
methylation	proportion	0.79),	while	those	with	TT	genotype	display	low	methylation	
(median	methylation	proportion	0.11)	and	heterozygous	individuals	display	50%	
methylation	(median	methylation	proportion	0.50).	Genotype	groups	exhibited	
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expected	methylation	levels,	as	individuals	with	a	TT	genotype	lack	the	potential	for	
cytosine	methylation	in	the	CpG	context.	The	familial	distribution	of	genotype	
frequencies	was	examined	and	displayed	on	Figure	5.3A,	with	no	family	contributing	
overly	towards	one	certain	genotype.			
		
The	influence	of	the	CASZ1	meQTL	on	genotype	is	not	restricted	to	the	CpG-SNP	
itself	but	extends	to	at	least	one	neighbouring	CpG	either	side,	corresponding	to	
approximately	150	bp	either	side	of	the	CpG-SNP,	as	indicated	on	Figure	5.3A.	As	
data	is	not	displayed	for	every	CpG	in	the	region,	due	to	failure	to	reach	quality	
control	thresholds,	there	may	be	a	greater	influence	of	the	CpG-SNP	on	surrounding	
patterns	than	evident	here.		
	
A	similar	differential	methylation	profile	was	also	observed	between	affected	and	
unaffected	individuals	at	the	CASZ1	regions,	as	indicated	in	Figure	5.2B,	where	a	
substantial	difference	between	affected	and	unaffected	individuals	was	evident	at	
the	CpG-SNP.	Affected	individuals	have	lower	median	methylation,	at	0.18,	similar	to	
the	‘TT’	genotype	in	5.2A	at	0.11,	while	the	unaffected	individuals	display	mid-level	
methylation	at	0.63,	similar	to	heterozygous	allele-specific	methylation	in	Figure	
5.2A.	Strikingly,	the	extended	influence	of	the	meQTL	seen	in	Figure	5.2A,	can	also	
be	observed	in	Figure	5.2B,	where	the	affected	individuals	have	lower	methylation	
either	side	of	the	CpG-SNP	than	the	unaffected	individuals.	Intriguingly,	epigenetic	
dysregulation	of	this	gene	has	been	linked	to	neuroblastoma	and	prostate	cancer.	
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Figure	5.3	Median	methylation	profiles	surrounding	the	meQTL	of	interest		
Median	methylation	is	plotted	against	corresponding	genomic	positions	for	18	CpGs	
in	the	CASZ1	region.	A)	Samples	(n=37)	are	divided	into	genotype	groups,	as	
indicated	in	the	key,	with	median	methylation	per	group	plotted	at	each	CpG.	A	
black	vertical	line	represents	the	location	of	the	CpG-SNP,	with	the	corresponding	
genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	The	dashed	lines	
indicate	the	extent	of	the	influence	of	the	CpG-SNP	on	neighbouring	CpG	
methylation	levels.	B)	Median	methylation	for	unaffected	individuals	(n=32)	and	
affected	individuals	(n=31),	with	familial	distributions	of	the	affected	individuals	
indicated.
A)
B)
145'bp 159'bp
Affected'Individuals'(n=31)
Unaffected'Individuals'(n=32)
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5.3.4	Extension	of	methylation	profile	analysis	to	other	meQTL	regions	
The	remaining	nine	meQTL	regions	analysed	for	genetically	driven	methylation	
patterns	(as	detailed	in	Figure	5.4	(A,	C,	E,	G,	I,	K,	M,	O,	Q),	all	displayed	distinct	
methylation	clusters	corresponding	to	genotype.	In	the	differential	analysis	by	
prostate	cancer	status,	seven	showed	divergent	patterns	between	affected	and	
unaffected	individuals	at	the	CpG-SNP	(Figure	5.3	B,	D,	F,	H,	J,	P,	R)	while	two	(Figure	
5.3	L,	N)	had	similar	median	methylation	levels	between	the	two	groups.	Of	the	
seven	regions	with	dissimilar	profiles,	six	had	lower	methylation	in	the	affected	
individuals	with	only	one	(F)	displaying	lower	methylation	in	the	unaffected	
individuals.	The	methylation	profiles	between	the	genotype	stratified	plots	and	the	
disease	status	plots	at	each	meQTL	were	similar	for	all	regions	except	two	(Figure	5.3	
K&L,	M&N)	which	showed	clear	genotype	clustering	at	the	CpG-SNP,	yet	minimal	
differences	between	affected	and	unaffected	individuals	at	the	same	site.		
	
Specifically,	the	two	meQTL	regions	within	UTRs	(Figure	5.4	A&B	at	the	ITGB2	gene	
and	Figure	5.4	A&B	at	the	NME6	gene)	displayed	similar	methylation	profiles,	with	
high	methylation	levels	seen	throughout	the	region	and	interrupted	only	by	
methylation	changes	at	the	CpG-SNP.		MeQTLs	located	in	intronic	open	sea	regions	
(USP7	Figure	5.4	I&J,	MGMT	Figure	5.4	M&N,	MCC	Figure	5.4	Q&R)	displayed	
minimal	variation	in	methylation	profiles	between	individuals,	except	at	the	CpG-
SNPs.	The	region	annotated	to	AJAP	(Figure	5.4	O&J)	was	CpG	dense	and	displayed	
variable	methylation	levels	over	the	region,	which	were	most	divergent	at	the	CpG-
SNP.	This	variability	was	expected	as	the	region	is	located	in	and	intronic	island	
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shore.	The	sole	region	located	in	an	exon	at	PRM1	(Figure	5.4	G&H),	was	tightly	
clustered	between	individuals	with	distinct	variation	between	individuals	only	
present	at	the	CpG-SNP.	
	
Interestingly,	the	region	annotated	to	the	CDK2	associated	cullin	domain	1	(C10orf46	
or	CACUL1)	gene	shown	in	Figure	5.4	E&F,	is	located	approximately	150bp	
downstream	of	a	CpG	island.	While	methylation	patterns	at	the	CpG-SNP	were	
dependent	on	genotype	and	prostate	cancer	status,	the	region	further	upstream	and	
more	proximal	to	the	CpG	island	was	more	uniformly	methylated	between	all	
genotype	groups	and	between	individuals	with	different	cancer	status.	This	region	
displayed	lower	methylation	levels,	as	often	seen	at	CpG	islands	located	at	promoter	
regions.	Surprisingly,	the	region	annotated	to	MGMT,	a	gene	well	known	to	display	
aberrant	epigenetic	dysfunction	in	cancer	and	indeed	used	as	a	treatment	biomarker	
in	certain	types	of	brain	cancer	(Wiewrodt	et	al.	2007),	did	not	show	any	
differences	between	affected	and	unaffected	individuals	at	the	CpG-SNP	(Figure	5.4	
N),	despite	a	genotype	driven	methylation	pattern	at	the	CpG-SNP	(Figure	5.4A).		
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Figure	5.4	A	&	B	Median	methylation	profiles	surrounding	the	meQTL	of	interest	in	
ITGB2.	
Median	methylation	for	12	CpGs	in	the	ITGB2	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).
A)
B)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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Figure	5.4	C	&	D		Median	methylation	profiles	surrounding	the	meQTL	of	interest	in	
NME6.	
Median	methylation	for	11	CpGs	in	the	NME6	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).
C)
D)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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Figure	5.4	E	&	F		Median	methylation	profiles	surrounding	the	meQTL	of	interest	in	
C10orf46.	
Median	methylation	for	18	CpGs	in	the	C10orf46	region.	A)	Samples	(n=37)	are	
divided	into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	
group	plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-
SNP,	with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	
line.	The	black	indicates	a	CpG	island	is	150bp	upstream.	B)	Median	methylation	for	
unaffected	individuals	(n=32)	and	affected	individuals	(n=31).
E)
F)
150bp)to)CGI
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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Figure	5.4	G	&	H		Median	methylation	profiles	surrounding	the	meQTL	of	interest	
in	PRM1.	
Median	methylation	for	33	CpGs	in	the	PRM1	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).	
G)
H)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
	 167	
	
	
	
	
	
Figure	5.4	I	&	J		Median	methylation	profiles	surrounding	the	meQTL	of	interest	in	
USP7	
Median	methylation	for	17	CpGs	in	the	USP7	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).	
I)
J)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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Figure	5.4	K	&	L		Median	methylation	profiles	surrounding	the	meQTL	of	interest	in	
SEPT9.	
Median	methylationfor	24	CpGs	in	the	SEPT9	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).	
	
K)
L)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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Figure	5.4	M	&	N		Median	methylation	profiles	surrounding	the	meQTL	of	interest	
in	MGMT.	
Median	methylation	for	16	CpGs	in	the	MGMT	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).	
M)
N)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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Figure	5.4	O	&	J	Median	methylation	profiles	surrounding	the	meQTL	of	interest	in	
AJAP1.	
Median	methylation	for	34	CpGs	in	the	AJAP1	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).	
O)
P)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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Figure	5.4	Q	&	R		Median	methylation	profiles	surrounding	the	meQTL	of	interest	
in	MCC.	
Median	methylationfor	11	CpGs	in	the	MCC	region.	A)	Samples	(n=37)	are	divided	
into	genotype	groups,	as	indicated	in	the	key,	with	median	methylation	per	group	
plotted	at	each	CpG.	A	black	vertical	line	represents	the	location	of	the	CpG-SNP,	
with	the	corresponding	genomic	and	CpG	annotation	indicated	adjacent	to	the	line.	
B)	Median	methylation	for	unaffected	individuals	(n=32)	and	affected	individuals	
(n=31).
Q)
R)
Affected)Individuals)(n=31)
Unaffected)Individuals)(n=32)
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5.4	Discussion		
The	vast	majority	of	disease	risk	loci	identified	for	complex	disease	to	date	are	in	
non-coding	regions	where	the	functional	effect	on	the	underlying	mechanisms	of	
predisposition	are	difficult	to	elucidate	(Hindorff	et	al.	2009).	This	is	particularly	the	
case	for	prostate	cancer,	where	the	regulatory	mechanisms	surrounding	many	
identified	risk	SNPs	are	yet	to	be	fully	understood	(Whitington	et	al.	2016).	While	
these	variants	can	affect	a	range	of	regulatory	mechanisms,	including	non-coding	
RNA	(ncRNA)	(Jin	et	al.	2011;	Kumar	et	al.	2013;	Ramalho-Carvalho	et	al.	2016)	
and	histone	modifications	(Esteller	2007),	this	study	has	focussed	on	examining	the	
effect	of	non-coding	variation	on	the	well-established	epigenetic	regulatory	
mechanism;	DNA	methylation.		
	
Altered	methylation	profiles	are	a	molecular	hall-mark	of	cancer	(Jones	and	Baylin	2007;	Jones	2014),	with	numerous	aberrant	methylation	profiles	observed	at	key	
genes	associated	with	prostate	cancer	progression,	including	the	cell	growth	
regulatory	gene	G1	To	S	Phase	Transition	1	(GSTP1)	and	the	mismatch	repair	gene	
O6-methylguanine	DNA	methyltransferase	(MGMT)	(Kang	et	al.	2004;	Ellinger	et	al.	2008).	However,	as	previously	discussed,	these	observed	changes	often	occur	well	
into	the	tumorigenesis	process,	where	it	is	difficult	to	distinguish	driver	from	
passenger	epi-mutations.	Family	studies	have	emerged	as	a	powerful	tool	to	
overcome	this	challenge,	as	driver	mutations	can	be	more	readily	characterised	if	a	
variant	can	traced	through	a	family	pedigree,	where	genotypes	can	be	compared	
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As	such,	the	current	study	examines	genetically	driven	methylation	patterns	in	
individuals	drawn	from	a	rare	familial	resource.	These	pedigrees	are	likely	to	be	
enriched	for	deleterious	inherited	drivers	of	prostate	cancer,	as	the	resource	
contains	dense	aggregates	of	affected	men,	spanning	several	generations.	MeQTLs	
were	identified	and	prioritised	using	array-based	techniques	(Chapter	2-4),	with	the	
independent	method	of	bisulphite	sequencing	used	here	to	validate	this	data	and	
further	explore	the	methylation	landscape	surrounding	these	variants.	Twelve	
meQTLs	were	validated,	with	the	correlation	between	genotype	and	methylation	in	
related	individuals	examined.	It	is	hypothesised	that	meQTLs	in	non-coding	regions	
drive	these	aberrant	methylation	patterns,	interacting	with	other	regulatory	
mechanisms	to	bring	about	permanent	silencing	of	tumour	suppressor	genes,	
predisposing	men	to	prostate	cancer.		
	
The	effect	of	methylation	on	gene	expression	is	dependent	on	the	location	and	
distribution	of	CpG	sites	throughout	the	genome,	with	promoter	methylation	
associated	with	active	gene	expression	and	gene	body	methylation	associated	with	
the	opposite	(Jones	1999).	Thus,	the	location	of	CpGs	relative	to	genes	and	CpG	
islands	is	crucial	to	understanding	the	function	of	CpG	methylation	in	both	health	
and	disease	states.	Accordingly,	the	genomic	(for	example	whether	intergenic,	
intronic,	exonic)	and	epigenomic	(relation	to	CpG	island)	annotations	at	prioritised	
meQTLs	were	carefully	considered	during	the	current	analysis	and	are	detailed	in	
Table	5.1.	Seven	of	the	twelve	meQTLs	were	in	“open	sea”	regions,	representing	
isolated	CpGs,	located	further	than	4Kb	from	CpG	islands	(Sandoval	et	al.	2014).	It	is	
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not	surprising	that	these	regions	constituted	the	majority	of	identified	CpG	locations,	
as	the	greatest	proportion	of	annotated	CpGs	on	the	array	are	located	in	“open	seas”	
(36%).	The	remaining	five	meQTLs	were	located	in	CpG	island	shores,	which	are	2Kb	
either	side	of	islands,	comprising	23%	of	annotated	CpGs	on	the	array.	None	of	the	
twelve	meQTLs	were	located	in	CpG	islands	as	only	regions	with	lower	CpG	density	
were	prioritised	for	follow	up	in	Chapter	4.		
	
The	prioritised	meQTLs	were	enriched	in	regulatory	regions,	with	nine	of	the	twelve	
prioritised	meQTLs	located	in	introns,	two	in	untranslated	regions	and	only	one	in	an	
exon.	While	the	methylation	array	has	been	developed	with	a	focus	on	regulatory	
regions,	it	is	highly	enriched	for	promoter	regions,	with	intergenic	and	promoter	CpG	
sites	comprising	45%	of	regions	on	the	array	(Dedeurwaerder	et	al.	2011).	Thus	
meQTLs	may	be	naturally	enriched	outside	of	islands,	at	CpG	shores,	shelves	and	
open	seas,	and	may	explain	why	promoter	regions	were	not	prioritised	in	the	
pipeline	of	Chapter	4.	This	is	supported	by	the	methylation	profile	at	one	region,	
annotated	to	C10orf46	(Figure	5.4	E&F),	where	the	start	of	the	region,	located	
approximately	150bp	downstream	of	a	CpG	island	exhibited	more	uniform	
methylation	patterns	between	individuals	than	upstream	at	the	CpG-SNP.	This	lower	
variability	in	methylation	is	often	seen	at	CpG	islands	located	at	promoter	regions,	
with	Irizarry	and	colleagues	observing	island	shores	to	be	the	most	variable	CpG	
regions	during	development	and	across	multiple	cancer	types	(Irizarry	et	al.	2009).			
	
The	association	between	epigenotype	and	prostate	cancer	occurrence	was	then	
examined	in	the	affected	individuals	drawn	from	the	familial	resource	and	
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unaffected	individuals	from	an	independent	population-based	study.		While	seven	of	
the	twelve	genes	containing	prioritised	meQTLs	have	previously	been	associated	
with	prostate	cancer,	none	of	the	exact	risk	SNPs	have	previously	been	linked	to	the	
disease.	As	these	samples	were	drawn	from	families	enriched	for	prostate	cancer	
cases,	these	novel	variants	may	help	to	clarify	part	the	unexplained	inherited	
component	of	prostate	cancer	risk.		
	
The	most	striking	difference	in	gene	body	methylation	between	genotype	groups	
and	prostate	cancer	disease	status	was	observed	at	the	CASZ1	gene,	a	zinc	finger	
transcription	factor	involved	in	neuronal	cell	differentiation,	with	a	putative	tumour	
suppressor	role	(Liu	et	al.	2006).	At	the	CpG-SNP	a	TT	genotype	was	associated	with	
minimal	methylation.	This	was	expected,	as	a	CàT	mutation	removes	the	potential	
for	cytosine	methylation.	This	differential	methylation	profile	was	mirrored	in	the	
disease	status	plot,	where	samples	from	men	with	prostate	cancer	had	minimal	
methylation	levels	compared	to	unaffected	individuals.	Both	these	differential	
methylation	patterns	extended	approximately	150	bp	either	side	of	the	CpG-SNP.	
While	reduced	gene	body	methylation	has	been	previously	observed	to	result	in	a	
decrease	in	gene	expression	(Yang	et	al.	2014),	to	date,	no	studies	have	examined	
the	correlation	between	gene	body	methylation	and	gene	expression.	However,	
CASZ1	expression	has	been	found	to	be	decreased	in	aggressive	neuroblastoma	cells,	
with	the	ectopic	restoration	of	CASZ1	expression	inhibiting	tumour	cell	growth,	both	
in	vitro	and	in	vivo	(Carén	et	al.	2007;	Liu	et	al.	2011).	
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While	CASZ1	is	most	widely	known	to	be	involved	in	neuronal	cell	differentiation,	
with	the	majority	of	cancer	studies	examining	aberrant	CASZ1	expression	and	
function	in	brain	cancer,	there	is	often	overlap	between	genes	involved	in	various	
cancers	(Amundadottir	et	al.	2004).	Indeed,	this	may	occur	with	CASZ1,	as	lower	
CASZ1	expression	was	recently	associated	with	increased	prostate	cancer	cell	growth	
in	silico	(Chiyomaru	et	al.	2012).	This	study	found	several	genes	including	CASZ1,	
were	targets	of	the	oncogenic	micro	RNA,	miR-151.	MiR-151	is	highly	expressed	in	
prostate	cancer	cell	lines,	with	downregulation	through	the	isoflavone	genistein,	
found	to	supress	prostate	cancer	cell	growth	in	PC3	and	DU145	cell	lines	(Chiyomaru	et	al.	2012).	To	date	the	direct	effects	of	CASZ1	expression	on	prostate	
cancer	cell	lines	or	in	vivo	have	yet	to	be	examined.	
	
The	underlying	mechanism	for	the	involvement	of	CASZ1	in	prostate	cancer	or	
neuroblastoma	is	also	yet	to	be	understood,	with	no	tumour-associated	variation	in	
the	coding	region	of	the	gene	identified	(Wang	et	al.	2012).	As	such	it	has	been	
suggested	that	epigenetic	silencing	may	be	involved,	with	downregulation	of	the	
histone	methyltransferase	EZH2	associated	with	an	increase	in	CASZ1	expression	and	
a	decrease	in	neuroblastoma	growth	(Wang	et	al.	2012).	The	role	of	methylation	in	
this	regulatory	process	is	less	clear,	as	while	DNA	methylation	has	been	examined	at	
several	CpG	islands	associated	within	CASZ1	regulatory	regions,	no	difference	was	
observed	between	primary	tumour	DNA	and	the	blood	of	unaffected	individuals	(Carén	et	al.	2007).	It	may	be	that	alterations	in	expression	of	CASZ1	are	driven	by	
aberrant	methylation	patterns	outside	islands,	as	detailed	in	this	study.		
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Intriguingly,	a	rare	sub	group	of	prostate	cancers	(approximately	1%)	possess	a	
neuroendocrine	phenotype	(also	termed	small-cell	carcinoma),	which	are	more	likely	
to	develop	resistance	to	androgen	therapy	(Deorah	et	al.	2012)	(Grigore,	Ben-Jacob	and	Farach-Carson	2015).	Normal	prostate	epithelium	is	in	fact	interspersed	
with	neuroendocrine	cells.	These	cells	function	to	produce	specialized	peptides	to	
stimulate	the	release	of	normal	prostate	secretions.	Inappropriate	regulation	of	
these	cells	can	trigger	cellular	proliferation,	angiogenesis	and	migration	of	prostate	
cells	(Bok	and	Small	2002).	As	CASZ1	is	transcription	factor	involved	in	neuronal	
development	and	observed	to	be	dysregulated	in	both	neuroblastoma	and	prostate	
cancer.		This	represents	and	interesting	avenue	for	further	research	through	
investigation	of	whether	dysregulation	of	this	gene	could	in	turn	disrupt	the	
regulation	of	neuroendocrine	cells	and	contribute	to	prostate	cancer	development.	
Indeed,	data	from	a	recent	study	of	castration-resistant	neuroendocrine	prostate	
cancer	indicates	up	to	36%	of	this	prostate	cancer	phenotype	displays	alterations	in	
CASZ1	either	through	amplification,	upregulation	or	deep	deletion	(Beltran	et	al.	2016).	
	
This	study	has	validated	twelve	of	the	prioritized	meQTLs	(identified	in	Chapter	4)	
and	further	examined	the	methylation	landscape	surrounding	a	subset	of	these	
meQTLs.	All	ten	regions	examined	for	genetically	driven	methylation	patterns,	had	
genotype	dependent	methylation	profiles	at	the	CpG-SNP,	which	extended	in	cis	at	
the	CASZ1	meQTL	region.	Men	affected	by	prostate	cancer	had	lower	median	
methylation	levels	at	seven	of	the	nine	CpG-SNP	sites,	with	one	region,	at	the	CASZ1	
gene,	also	demonstrating	lower	methylation	either	side	of	the	CpG-SNP.	This	CpG-
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SNP	may	be	informative	in	further	understanding	the	complex	inherited	component	
of	prostate	cancer	as,	decreased	expression	of	the	gene	has	been	previously	
associated	in	silico	with	increased	prostate	cancer	cell	growth	(Chiyomaru	et	al.	2012).	Further	experimental	analysis	of	this	region	is	required	to	help	elucidate	the	
potential	molecular	mechanisms	involved.	Data	generated	in	this	study	has	
uncovered	a	large	number	of	meQTLs	potentially	involved	in	prostate	cancer	risk,	
with	twelve	validated	and	examined	in	further	detail	here	and	one	providing	an	
elegant	proof	of	principle	of	the	prioritisation	pipeline.	However,	there	remains	a	
wealth	of	information	to	be	further	examined,	both	bioinformatically	and	
experimentally	in	future	studies.	
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Chapter	6	–	Conclusions	
	
Prostate	cancer	is	one	of	the	most	prevalent	cancers	world-wide,	yet	significant	
clinical	challenges	in	diagnosis	and	treatment	persist.	Diagnostic	difficulties	are	
exacerbated	by	a	limited	understanding	of	underlying	molecular	mechanisms	
governing	the	development	and	progression	of	the	prostate	cancer.	This	is	
exemplified	by	our	ongoing	reliance	on	the	biomarker,	PSA	which	has	limited	
sensitivity	and	specificity.	Of	pressing	clinical	concern	is	our	inability	to	differentiate	
men	at	high	risk	of	metastasis	from	those	with	a	more	indolent	form	of	the	disease.	
This	is	exceedingly	pertinent	for	men	diagnosed	with	prostate	cancer,	as	while	
current	treatments	can	have	substantial	negative	impacts	on	quality	of	life,	early	
treatment	is	critical	for	men	with	an	aggressive	form	of	the	disease,	as	once	prostate	
cancer	has	metastasised	there	is	currently	no	cure,	and	limited	treatment	options.	
	
Prostate	cancer	is	one	of	the	most	heritable	cancers	(Hjelmborg	et	al.	2014),	yet	
the	majority	of	genetic	drivers	remain	to	be	elucidated,	with	only	a	third	of	predicted	
variants	thus	far	detected	(Olama	et	al.	2014).	A	key	to	unravelling	the	underlying	
molecular	mechanisms	of	prostate	cancer,	may	therefore	be	a	more	detailed	
understanding	of	the	underlying	inherited	component	of	the	disease.	One	way	to	
unravel	this	“missing	heritability”	is	through	pedigree-structured	studies,	which	
provide	a	powerful	tool	to	exploring	genetic	predisposition	to	many	complex	
diseases.	This	is	partly	due	to	the	ability	to	study	rare	variants,	which	are	often	
enriched	in	families	with	high	rates	of	certain	diseases,	together	with	diminished	
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genetic	noise.	The	additional	knowledge	about	relatedness	of	samples	and	
inheritance	patterns	of	genetic	markers	allows	other	computational	advantages	such	
as	imputation	(Saad	and	Wijsman	2014).		
	
Familial	studies	have	proven	successful	in	identifying	novel	risk	regions	and	variants	
in	prostate	cancer,	some	of	which	have	been	validated	in	larger	population	studies,	
and	importantly	have	been	applicable	to	men	outside	of	the	familial	disease	risk	
population	(Teerlink	et	al.	2014;	Kote-Jarai	et	al.	2015).	The	success	of	familial	
studies	in	unravelling	the	inherited	component	of	complexes	diseases	has	been	
particularly	evident	in	Tasmania,	where	the	population	has	been	relatively	stable	
since	the	1800s,	with	the	majority	of	the	current	populace	descended	from	a	
founder	population	of	settlers	and	convicts	from	the	UK.		Examining	extensive	
pedigrees	from	this	population,	where	many	large	families	can	be	identified	and	
traced	back	to	their	common	founders,	has	enabled	a	further	understanding	of	
disease	aetiology	in	complex	disorders	such	as	glaucoma	(Fingert	et	al.	1999),	
Huntington’s	disease	(Brothers	1964)	and	cancers	including	multiple	endocrine	
neoplasia	(Burgess	et	al.	2000)	and	more	recently,	prostate	cancer	(Eeles	et	al.	2009).	
	
Over	93%	of	disease-associated	SNPs	identified	to	date	are	in	non-coding	regions	of	
the	genome	(Hindorff	et	al.	2009;	Kumar	et	al.	2013),	and	focus	has	therefore	
more	recently	turned	to	investigation	of	the	role	of	non-coding	variants	in	gene	
regulation	and	complex	disease	aetiology	(Barr	and	Misener	2016)	,	which	has	
been	enabled	by	recent	advances	in	next	generation	molecular	technologies.		
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The	central	hypothesis	of	the	current	study	was	that	DNA	sequence	changes	in	non-
coding	regions	of	the	genome	can	alter	transcriptional	activity	and	trigger	epigenetic	
changes	in	regulatory	regions,	leading	to	gene	silencing	and	contributing	to	prostate	
cancer	development	and	progression.	Two	broad	aims	were	examined	to	investigate	
this	hypothesis.	Firstly,	to	use	the	Tasmanian	Familial	Prostate	Cancer	Resource	to	
examine	the	association	between	genotype,	as	measured	by	SNPs,	and	epigenotype,	
as	measured	by	DNA	methylation.	Secondly,	to	examine	the	association	between	
epigenotype	and	prostate	cancer	occurrence.	
	
The	major	findings	of	this	study	encompass	the	development	of	an	analysis	pipeline	
for	pre-processing	familial	methylation	data	and	performing	meQTL	with	an	
emphasis	on	identifying	meQTLs	linked	to	prostate	cancer	risk.	Through	this	pipeline,	
the	influence	of	genotype	on	methylation	profiles	and	subsequently	these	
methylation	profiles	on	prostate	cancer	risk	were	able	to	be	examined.	One	meQTL	
region,	at	the	CASZ1	gene,	exhibited	genotype	dependent	methylation	profiles	in	cis	
to	the	meQTL,	with	the	altered	methylation	profile	also	observed	in	men	affected	by	
prostate	cancer,	when	compared	to	unaffected	controls.	As	epigenetic	dysregulation	
has	previously	been	linked	to	neuroblastoma	and	prostate	cancer	it	acts	as	a	“proof	
of	principle”	for	the	pipeline.	Numerous	other	meQTL	regions	of	interest	requiring	
further	follow	up	were	also	identified,	however	these	are	outside	the	scope	of	this	
study.	
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Limited	methodologies	existed	for	meQTL	analysis	of	familial	data	at	the	
commencement	of	this	study,	with	a	major	outcome	of	the	study	being	the	
establishment	of	a	quality	control,	pre-processing	and	analysis	pipeline	for	meQTL	
data	generated	with	a	familial	study	design.	This	pipeline,	together	with	
recommendations	for	future	methylation	array-based	studies	utilising	familial	data	
are	described	in	Chapter	3	Figure	10	and	published	in	(Cazaly	et	al.	2016).	This	
pipeline	is	not	only	relevant	for	familial	studies	with	the	same	design	as	the	current	
study,	but	can	also	be	applicable	to	a	range	of	varied	study	designs,	including	
longitudinal	studies.	Longitudinal	studies	examining	differential	methylation	
between	twins	at	various	time	points	or	epigenetic	changes	within	the	same	
individual	over	time,	for	example	those	associated	with	age;	also	lack	two	distinct	
experimental	groups	on	which	to	perform	normalisation.	Additionally,	the	
methylation	differences	within	the	same	individual	over	time	may	be	much	subtler	
than	differences	between	cancerous	and	normal	tissue	and	thus	require	pre-
processing	methods	robust	at	removing	technical	bias.	As	such,	these	studies	would	
greatly	benefit	from	the	pipeline	developed	here.	
	
The	pipeline	enabled	prioritization	of	prostate	cancer	risk	meQTLs	(Chapter	4).		
After	validation	on	an	independent	platform	(targeted	bisulphite	sequencing,	
Chapter	5),	the	methylation	landscape	surrounding	twelve	of	these	meQTLs	was	
mapped	in	finer	detail.	Nine	meQTL	regions	exhibited	genotype	dependent	
methylation	patterns	at	the	CpG-SNP.		
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The	association	between	epigenotype	and	prostate	cancer	risk	was	then	examined	
by	comparing	the	methylation	profiles	between	affected	men	drawn	from	the	
familial	resource	and	age-matched	unaffected	controls	selected	from	an	
independent	case-control	study	(enabled	through	targeted	bisulphite	sequencing,	
Chapter	5).	Men	affected	by	prostate	cancer	displaying	lower	median	methylation	
levels	at	eight	of	the	twelve	prioritized	CpG-SNP	sites.		
	
One	meQTL	region,	encompassing	the	CASZ1	gene,	demonstrating	genotype	
dependent	methylation	levels	at	the	CpG-SNP	as	well	as	in	cis	either	side.	There	was	
also	lower	methylation	in	the	men	affected	by	prostate	cancer	than	in	unaffected	
controls,	with	the	pattern	extending	approximately	150bp	either	side	of	the	CpG-
SNP.	As	changes	in	expression	of	this	gene	have	been	previously	associated	with	
neuroblastoma	in	vitro	and	in	vivo	(Carén	et	al.	2007;	Liu	et	al.	2011)	and	with	
increased	prostate	cancer	cell	growth	in	silico	(Chiyomaru	et	al.	2012),	the	meQTL	
may	be	informative	in	further	understanding	the	complex	inherited	component	of	
prostate	cancer.	Specifically,	it	would	be	important	to	investigate	whether	the	DNA	
methylation	patterns	observed	in	peripheral	blood	in	this	study	extend	to	aberrant	
patterns	in	prostate	tissue.	Subsequent	investigations	would	examine	whether	the	
methylation	differences	do	affect	gene	expression,	and	if	differential	expression	is	
observed	between	unaffected	controls	and	affected	individuals.	Finally,	the	effect	of	
ectopically	altering	regions	of	the	CASZ1	gene	via	a	gene	editing	technique	such	as	
CRISPR/CAS9	could	be	examined.	The	rapid	development	of	such	gene	editing	
techniques	(Mali	et	al.	2013;	Cong	et	al.	2013)	now	facilitates	the	introduction	of	
specific	mutations	into	cells	and	the	examination	of	the	effects	of	such	mutations	on	
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cells.	This	technology	is	being	widely	used	to	introduce	cancer	associated	mutations	
in	vitro	and	in	vivo	studies	to	examine	effects	on	tumour	development.	As	such,	this	
region	provides	a	“proof	of	principal”	for	the	pipeline	developed	in	this	study,	as	it	
aimed	to	select	meQTLs	with	a	potential	role	in	prostate	cancer	predisposition	which	
could	then	be	validated	experimentally.	
	
At	the	commencement	of	the	current	study,	one	of	the	few	examples	of	the	
influence	of	meQTLs	on	cancer	predisposition	came	from	the	study	of	Lynch	
syndrome,	often	involving	mutations	to	DNA	mismatch	repair	genes	(Ward	et	al.	2013).	A	proportion	of	these	cases	are	attributed	to	‘secondary’	epimutations,	or	
aberrant	methylation	patterns	resulting	from	underlying	sequence	changes	such	as	
promoter	deletions	and	SNPs	(Hitchins	and	Lynch	2014).		
	
During	later	stages	of	the	current	study,	the	publication	of	additional	studies	have	
further	demonstrated	the	utility	of	employing	familial	resources	to	examine	the	
effect	of	genetic	drivers	on	epigenetic	patterns,	particularly	at	methylation	
quantitative	trait	loci	(meQTLs)	(Lemire	et	al.	2015;	Kulkarni	et	al.	2015).	Kulkarni	
and	colleagues	examined	epigenome-wide	methylation	in	850	Mexican-American’s	
from	the	San	Antonio	Family	Heart	Study,	noting	methylation	at	14%	of	CpGs	was	
associated	with	DNA	sequence	variation	in	cis	(Kulkarni	et	al.	2015).	A	subset	of	
this	methylation	was	also	associated	with	type	2	diabetes	phenotypic	traits,	
including	alterations	at	five	well	characterised	diabetes-associated	genes.	Such	
meQTL	mapping	may	provide	insight	into	the	underlying	molecular	mechanisms	of	
diabetes	and	aid	in	potential	treatment	targets	or	diagnostic	techniques.	Examining	
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more	distal	influences	of	meQTLs,	Lemire	et	al.	profiled	898	colon	cancer	patients	
and	850	controls	from	the	Ontario	Familial	Colon	Cancer	Registry	and	reported	1,919	
trans-meQTLs,	of	which	90%	replicated	in	at	least	one	independent	data	set.	Many	
of	these	trans-meQTLs	are	associated	with	epigenetic	regulators,	such	as	long	non-
coding	transcripts	and	zinc-finger	transcription	factors,	which	can	then	influence	
epigenetic	patterns	on	health	and	disease	(Lemire	et	al.	2015).	
	
Genetic	variation	can	affect	epigenetic	patterns	and	gene	expression	through	
numerous	interconnected	mechanisms,	including	DNA	methylation,	non-coding	
RNAs,	histone	modifications	and	transcription	factor	binding	(Furey	and	Sethupathy	2013;	Ramalho-Carvalho	et	al.	2016;	Whitington	et	al.	2016).	Advances	in	
technology	have	enabled	development	of	the	extensive	ENCODE	database	(ENCODE	Project	Consortium	et	al.	2012),	which	aims	to	catalogue	all	functional	elements	in	
the	human	genome.	The	current	study	has	focussed	on	one	aspect	of	epigenetic	
regulation-	DNA	methylation.	Specifically,	5-methylcytosine	has	been	examined,	and	
while	the	role	of	5-hydroxymethylcytosine	is	becoming	prominent	in	the	epigenetics	
field,	particularly	in	studies	of	the	brain	(Kriaucionis	and	Heintz	2009),	the	mark	is	
beyond	the	scope	of	the	current	study.	Additionally,	the	effect	of	meQTLs	in	this	
study	was	only	examined	in	cis,	at	regions	proximal	to	the	meQTLs	themselves.	It	is	
frequently	observed	that	these	variants	can	have	much	further	influences	on	gene	
regulation	in	trans	(Lemire	et	al.	2015)	however,	again,	these	aspects	of	gene	
regulation	are	outside	the	scope	of	the	current	study.	This	study	provides	insight	into	
one	aspect	of	epigenetic	regulation,	by	developing	an	analysis	strategy	for	
investigating	non-coding	variants	that	can	be	applied	to	other	familial	studies	and	
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diseases.	The	reality	of	the	epigenetic	landscape	is	far	more	complex,	comprising	
many	varied	mechanisms	working	in	concert	to	facilitate	gene	regulation.	A	
comprehensive	understanding	of	complex	disease	predisposition	requires	a	more	
extensive	understanding	of	the	interactions	between	these	mechanisms.	
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WHY EPIGENETICS AND WHY NOW?
The genomics era brought with it dra-
matic advances in our understanding of
the molecular basis of disease. High-
density genome mapping strategies
have proven particularly successful for
the identification of genes underlying
mendelian disorders, such as hemochro-
matosis, cystic fibrosis and muscular
dystrophy (1). The advent of genome-
wide association studies (GWAS) was
heralded with the promise of providing
a comprehensive map of genetic suscep-
tibility to complex disease. While un-
covering thousands of variants associ-
ated with disease risk, their promise is
yet to be fully realized, with a persistent
gap emerging between the fraction of
disease accounted for by genetic varia-
tion and the heritability estimates for
many traits (2). Several explanations
have been proposed for this unex-
plained genetic component to disease
susceptibility, including the impact of
large deletions, inversions or copy num-
ber variants, complex gene–gene and
gene–environment interactions, overes-
timated heritability, poor modeling and
statistical application and common vari-
ants masking rare variants or driving
synthetic association (2). Notably, dele-
terious variants occurring in coding re-
gions account for the minority of
 disease-associated single nucleotide
polymorphisms (SNPs), with estimates
that over 90% of variants identified in
GWAS are located in noncoding regions
of the genome (3). At least some of these
SNPs affect gene regulatory mecha-
nisms, modifying gene expression by al-
tering transcription factor binding and
directing altered epigenetic profiles (4).
Studies involving genetically identical
individuals such as monozygotic (MZ)
twins have been invaluable in investigat-
ing the role of genetics and environment
in complex disease. While providing in-
sight into the genetic basis of disease,
these studies have also strongly impli-
cated a nongenetic contribution to many
diseases. For example, MZ twins have
much less than 100% concordance rates
for common diseases such as Alz-
heimer’s disease and certain cancers (5).
The effect of the environment and ran-
dom factors on the epigenome poses a
possible explanation for this discordance,
since while MZ twin epigenetic profiles
show a high level of heritability early in
development, they diverge with age and
differing lifestyles and epigenetic marks
differ according to disease state (5).
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Our understanding of the factors affect-
ing the epigenome is increasing at a rapid
rate. The role of the underlying genetic se-
quence in determining epigenetic profiles
and the mechanisms by which environ-
mental and stochastic factors then modify
these epigenetic patterns are becoming
clearer. Our increased understanding of
these mechanisms and their role in dis-
ease processes is being driven by rapid
advances in laboratory and statistical
tools and the creation of extensive public
databases. This result makes it possible to
integrate genomic, epigenomic and phe-
notypic data with a greater level of detail
and scale than ever before (6) (see Figure 1
for a timeline of epigenetic milestones, in-
cluding the advent of online annotation
databases). This information is providing
a valuable resource for the investigation
of complex disease, revealing new oppor-
tunities for disease prevention in at-risk
individuals, identifying new therapeutic
targets and providing the prospect of in-
creased sensitivity and specificity of dis-
ease diagnosis (7).
A BRIEF HISTORY OF EPIGENETICS
Conrad Waddington first coined the
term “epigenetics” in the early 1940s to
integrate the existence of two related phe-
nomena: that genetically identical cells
possess the capacity to differentiate into
tissue-specific structures with correlated
functions and that gene–environment 
interactions can affect phenotypes
(reprinted in Waddington [8]). The term
“epigenetics” has since come to refer to
the environment surrounding the DNA,
with a current working definition charac-
terizing an epigenetic trait as “a stably
heritable phenotype resulting from
changes in a chromosome without alter-
ations in the DNA sequence” (9). This
term is most often used in reference to
the inheritance of traits to a daughter cell
during mitosis, but there is evidence, al-
though still controversial, of germ line
transmission of epigenetic traits between
generations (transgenerational inheri-
tance) (10,11).
Eukaryotic DNA is assembled into
chromatin; repeating units of nucleo-
somes consisting of 147 base pairs of
DNA wrapped around an octamer of his-
tones. Mechanisms that affect the ge-
nomic environment include modifications
to the DNA itself, absence/presence of hi-
stone modifications and histone variants,
and also processes involving noncoding
Figure 1. Timeline of key advances in the epigenetics field. Key milestones in the epigenetics field are shown.
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RNA and chromatin remodeling com-
plexes (12) (Figure 2). Although there is
contention over the extent of heritability
of the outcomes of many of these mecha-
nisms and whether they should therefore
strictly be regarded as epigenetic mecha-
nisms (9), it is clear that they all influence
genome function.
EPIGENETIC MECHANISMS
DNA Methylation
DNA methylation, the addition of a
methyl group to a cytosine residue im-
mediately preceding a guanine (CpG
dinucleotides), is the most widely stud-
ied epigenetic modification. CpG dinu-
cleotides are enriched in clusters called
CpG islands, associated with the pro-
moter regions of up to 60% of genes (13).
DNA methylation is generally associated
with gene silencing, inhibiting gene ex-
pression by recruiting proteins that facili-
tate chromatin condensation and to a
lesser extent by physically blocking tran-
scription factor binding (13).
DNA methylation patterns are influ-
enced by the underlying genetic se-
quence, stochastic changes, environmen-
tal factors and other epigenetic
mechanisms, resulting in differing
methylation patterns across populations,
age, tissue and loci (14). DNA methyl-
transferases (DNMTs) ensure tissue-spe-
cific DNA methylation patterns, once es-
tablished, are maintained through
mitosis with high precision and fidelity
(13). In contrast, at a global level, methy-
lation is substantially wiped clean during
gametogenesis to provide the developing
embryo the capacity for totipotency and
prevent accumulation of epigenetic
changes from previous generations (15).
This reprogramming occurs in two
waves: first, during pre-implantation
Figure 2. Epigenetic characteristics of heterochromatin and euchromatin. Nucleosome complexes consisting of eight core histone pro-
teins and 147 bp of DNA are configured in higher order structures that regulate the accessibility of DNA to the transcriptional machinery.
(A) Heterochromatin is characterized by DNA hypermethylation (filled black circles), de-acetylated histones (clear purple stars) and
tightly packed nucleosomes. Noncoding RNA is involved in maintaining heterochromatin structure. (B) Euchromatin contains unmethy-
lated CpGs (unfilled circles), acetylated histones (purple stars) and histone variants H2A.Z and H3.3 and is more accessible to the tran-
scription machinery (green). Writers, readers and erasers of epigenetic modifications work in concert with chromatin remodeling com-
plexes to move and modify nucleosomes, altering chromatin composition. TF, transcription factor; TSS, transcription start site.
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and, second, after primordial germ cell
migration, including the removal of im-
printed marks (16).
Genomic reprogramming involves
both active and passive demethylation,
which has long perplexed the scientific
community because of their inability to
identify the enzyme responsible for this
demethylation. Insight into this process
has been gained only recently after the
discovery of the additional DNA modifi-
cation, hydroxymethylation, enriched in
Purkinje cells in the brain (17) and also
embryonic stem cells (18,19). The ten-
eleven translocation (TET) family of pro-
teins are responsible for this modifica-
tion, and there is evidence that it is an
intermediate in the process of active
demethylation (20). However, the high
levels of the modification, particularly in
neural cells and during embryonic devel-
opment, suggests that it may have a yet-
to-be-elucidated role in regulating the
genome also.
Chromatin Conformation and
Structure
Packaging of the vast quantity of DNA
into the eukaryotic nucleus is facilitated
by the assembly of DNA into nucleo-
somes followed by their compaction into
higher-order structures. This structural
organization also plays a fundamental
role in regulating accessibility of the
DNA to the cellular transcription ma-
chinery (12) (Figure 2).
Up to a dozen posttranslational modi-
fications of histone proteins have been
reported to date, including methylation,
acetylation, phosphorylation and ubiqui-
tination (12), and technological advances
have made it possible to map these mod-
ifications genome-wide (21). These modi-
fications have together been proposed to
form a histone code, which can be inter-
preted by cellular proteins to specify
downstream functions (22). In addition,
chromatin structure is altered by the ac-
tions of ATP-dependent chromatin re-
modeling enzymes and the exchange of
canonical histones with histone variants.
This step creates a highly dynamic,
adaptable epigenetic landscape that
plays a key role in regulating genome
function and provides an interface be-
tween the environment and the genome.
Although histone modifications can be
subject to rapid turnover, there is also ev-
idence that they can be stably inherited
during cell division and thus contribute
to the maintenance of cellular identity.
However, this apparent epigenetic mem-
ory may be initiated by other factors
such as DNA methylation, noncoding
RNA (ncRNA), transcription factors or
the underlying DNA sequence (12).
Three recent studies point to an impor-
tant role of genetic variants in determin-
ing histone modification patterns
(23–25). In these studies, hundreds of
variants were associated with changes to
histones and gene expression, with the
underlying mechanism thought to be al-
tered transcription factor binding.
Noncoding RNA
In recent years, the existence of a com-
plex network of ncRNAs transcribed
from the human genome has become ap-
parent. These ncRNAs have regulatory
functions and play a key role in the es-
tablishment and maintenance of other
epigenetic marks (26), with evidence that
they constitute a mechanism for trans-
generational epigenetic inheritance (27).
There is also mounting evidence for the
involvement of ncRNAs in disease devel-
opment, particularly in cancer (28).
GENETIC DETERMINANTS OF
EPIGENETIC PATTERNS
Twin Studies
Diminished genetic noise and the in-
nate advantage of perfect age and often
sex matching, frequently coupled with
similar environmental and socioeco-
nomic upbringing, ensures twin studies
play an invaluable role in understanding
epigenetic mechanisms (29). The first
twin studies examining DNA methyla-
tion focused on X-chromosome inactiva-
tion, finding that the selection of which
X-chromosome is inactivated is not as
random as previously thought, but is in-
fluenced to a degree by underlying heri-
table patterns (30). Vickers et al. (30) also
showed that, with increasing age, there
was a greater skew in inactivation pat-
terns, suggesting twins become epigenet-
ically dissimilar with age. This result was
later reinforced by several larger studies
that found a high degree of epigenetic
heritability among MZ twins that de-
creased with age and that found larger
discrepancies between twins that lead
different lifestyles (5).
More recently, the advent of methyla-
tion array technology has enabled more
extensive studies that have found MZ
twins to be more epigenetically similar
than dizygotic twins. These studies also
found that the most heritable CpG sites
correlated with functional regions and
promoters, indicating these regions are
under tighter genetic control (31). Addi-
tionally, MZ DNA methylation patterns
may be influenced by the chorionicity of
the prenatal environment. Perhaps, sur-
prisingly, monochorionicity (a single
shared placenta) has been linked to more
divergent methylation patterns, yet
chorionicity is not always accounted for
in MZ twin studies (32). These studies
provide evidence for epigenetic differ-
ences in genetically identical individuals,
suggesting epigenetic metastability inde-
pendent of genotype can occur in hu-
mans, as has been previously shown in
mouse models (33). However, they also
point to certain regions where genetic in-
fluences exert greater control on the
epigenome.
Further evidence from studies examin-
ing DNA methylation patterns among
family members and unrelated individu-
als found SNPs induce subtle epigenetic
variation. One of the first studies to ex-
amine the relationship between genetic
variants and DNA methylation patterns
found evidence for allele-specific methy-
lation (ASM) outside imprinted regions,
some linked to allele-specific gene ex-
pression (34). Examination of the effect of
genetic variants on DNA methylation in
a three-generation family and among un-
related individuals found that heterozy-
gous SNPs associated with different
methylation patterns (35). This differen-
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tial methylation also correlated with
gene expression. Globally, genetic vari-
ants were found to be more influential
than imprinting, and most of the ASM
(75%) observed in the family was also
present in unrelated individuals, sug-
gesting genotype influences heritable re-
gions of differential methylation.
Other studies estimate around 20% of
heterozygous SNPs are linked to ASM
(36). Alternative terms have been pro-
posed for these variants, including
methylation-associated SNPs (mSNPs)
(37), CpG-SNPs (36) and methylation
quantitative trait loci (meQTL) (38). Hun-
dreds of these genetic variants have been
linked to DNA methylation patterns and,
similar to genetic quantitative trait loci,
these variants can affect gene expression
and phenotype (34,36–38). While SNPs in
the vicinity of CpG sites influence methy-
lation levels, the most obvious variant af-
fecting methylation is a mutation at the
CpG site itself. Indeed, most of the SNPs
linked to ASM are located at the CpG site
and are designated meSNPs (36,39).
These meSNPs also influence the methy-
lation levels of neighboring CpGs, partic-
ularly those close by (within 45 base pairs
[bp]) but have also been show to affect
CpGs up to 10 kb away (39).
GENETIC VARIANTS CAUSING
EPIGENETIC CHANGE IN DISEASE
Although there is no shortage of stud-
ies demonstrating a role for epigenetic
changes in driving disease, there are now
a number of examples in which cis-acting
variants have been clearly demonstrated
to drive the disease-associated epimuta-
tions. The term “epimutation” refers to an
altered epigenetic state resulting in altered
transcriptional activity of a gene. Such cis-
acting variants have been shown to alter
DNA methylation patterns and gene ex-
pression in a variety of human tissues
(34,36). These changes are likely an indi-
rect result of altered binding of transcrip-
tion factors, which can either lead to al-
tered recruitment of chromatin modifiers
and remodelers and subsequent epige-
netic changes or can cause changes in
gene expression that predispose the gene
to epigenetic silencing (40). Comprehen-
sive genetic analysis facilitated by im-
proved technology has revealed that sev-
eral diseases involving epigenetic
dysfunction have genetic origins.
One such example is the X-linked neu-
rodevelopmental disorder, fragile X syn-
drome. The genetic defect involves ex-
pansion of a trinucleotide repeat
sequence (CGG) at the promoter of the
fragile X mental retardation gene
(FMR1), with up to 45 repeats in unaf-
fected individuals and up to 200 in af-
fected individuals (41). The repeat ex-
pansion results in methylation of the
region and subsequent epigenetic silenc-
ing of the gene.
A more distally acting example of se-
quence variation contributing to disease
through altered gene regulation involves
the Myc transcription factor. Activation
of the Myc transcription factor is sug-
gested to occur in up to 70% of cancers,
arising through a range of mechanisms
including translocations, gene amplifica-
tion, enhanced protein translation and
stability, or indirectly through signaling
pathways that regulate Myc (42). In addi-
tion, a number of GWAS have found
multiple SNPs on chromosome 8q24 as-
sociated with different types of cancer
(43). These SNPs occur in a gene desert
but have since been found to influence
regulation of the Myc oncogene located
hundreds of kilobases away. These re-
gions have been shown to contain distal
enhancers of the Myc gene and highlight
that changes to long-range chromatin
structures can result in altered gene ex-
pression (44).
Imprinting Disorders
Imprinted genes escape the initial
phase of epigenetic reprogramming after
fertilization, retaining their parental
methylation marks and are expressed in
a parent of origin manner (45). Around
100 such imprinted genes are currently
known, with this number continuing to
increase (45). Imprinting provides clear
evidence that epigenetic modifications
can be inherited through meiosis, and
specific diseases ensue when there is an
abnormality in either the erasure of exist-
ing marks or reestablishment and main-
tenance of new marks (45). These dis-
eases can result from underlying genetic
defects or be due to epimutations (46).
Prader-Willi syndrome and Angelman
syndrome are neurological disorders with
distinct phenotypes that occur when the
same imprinted region on chromosome
15 is nonfunctional. While the vast major-
ity of cases are caused by a single gene
mutation or chromosomal deletion, be-
tween 1% (Prader-Willi syndrome) and
up to 4% in Angelman syndrome are due
to an imprinting defect, with the majority
of these being primary epimutations, oc-
curring in the absence of DNA sequence
mutations (47). Maternally inherited de-
fects lead to Angelman syndrome,
whereas paternal imprinting errors lead
to Prader-Willi syndrome (47).
Several different disorders result from
disruption of epigenetic regulation at the
IGF2/H19 locus, a region in which herita-
ble factors have been shown to have a
greater impact on DNA methylation than
the accumulation of stochastic and envi-
ronmental-induced changes (48). DNA
methylation at the imprinting control re-
gion upstream of the paternal H19 allele
normally silences H19 expression and ac-
tivates IGF2, whereas the maternal IGF2
allele is silenced (49). In the Silver-Rus-
sell syndrome, a rare developmental dis-
order, 45% of cases are attributed to an
epimutation in the imprinting control re-
gion of the paternal H19 allele (50).
Beckwith-Weidemann syndrome is a
congenital overgrowth syndrome with
83% of cases occurring sporadically, of
which around 60% are thought to in-
volve epimutations of two imprinting
control regions regulating H19, IGF2,
KCNQ1 and CDKN1C (51). Female MZ
twins represent a high proportion of
Beckwith-Weidemann syndrome cases,
and a study of five discordant female
MZ twins found that all affected twins
had a defect at the imprinted locus
KCNQ1OT1, which encodes a noncoding
RNA that regulates the expression of
other imprinted genes (52). Loss of im-
printing at the IGF2/H19 locus is also an
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epigenetic cause of around one-third of
Wilms tumor, the most common renal
cancer in children (49). The defect is also
associated with heightened colorectal
cancer risk (53) and esophageal squa-
mous cell carcinoma (54).
Lynch Syndrome
Whereas epigenetic changes are well
described in disease, particularly cancer,
there are now several clear examples of
cancer-associated epigenetic changes
being genetically driven. These types of
interactions can help to explain features
of these diseases such as late onset, envi-
ronmental effects, tissue specificity and
also familial associations that do not fol-
low mendelian inheritance patterns.
Combining genomic and epigenomic
data is also proving to be of value in the
search for prognostic signatures in cancer
(55), as seen in the Lynch syndrome, an
autosomal dominant cancer susceptibil-
ity condition. Approximately two-thirds
of Lynch syndrome cases result from het-
erozygous loss-of-function mutations in
DNA mismatch repair genes, most com-
monly mutL homolog 1 (MLH1) and
mutS protein homolog 2 (MSH2) (56).
However, such mutations are not ap-
parent in around one-third of Lynch syn-
drome cases, some of which (~4% for
MLH1 [56]) can be explained by epimu-
tations in MLH1 and MSH2. These
epimutations lead to transcriptional inac-
tivation of the gene, essentially having
the same effect as a genomic sequence
mutation seen in other Lynch syndrome
cases. One possible mechanism underly-
ing these epimutations involves primary
DNA methylation changes independent
of any sequence change, resulting in la-
bile epimutations, which can be reversed
in the germline and are therefore inher-
ited in an unpredictable, nonmendelian
manner or not passed on at all.
Alternatively, secondary epimutations
may result from underlying sequence
changes, including promoter deletions
and SNPs (57); for example, the c.-
27C>A germline variant in the 5′UTR of
the MLH1 gene has been linked to can-
cer susceptibility through transcrip-
tional silencing (58). In these cases, the
disease follows a more predictable in-
heritance pattern, since the epimutation
is driven by a genetic variant. As yet
undiscovered sequence mutations may
also be the underlying carcinogenic
mechanism in subsets of cancers such as
Cowden syndrome, where some indi-
viduals have hypermethylation epimu-
tations in the absence of known se-
quence mutations (59).
Underlying genetic drivers have also
been linked to epimutations in sporadic
cases of renal cell cancer, where SNPs
were associated with promoter hyperme-
thylation of the von Hippel-Lindau
(VHL) gene in tumor tissue, a gene previ-
ously shown to be genetically altered in
individuals with the familial form of the
cancer (60). Similarly, in colorectal cancer,
a C>T point mutation at an enhancer ele-
ment of the mismatch repair gene O(6)-
methylguanine-DNA methyltransferase
(MGMT) has been linked to aberrant pro-
moter methylation and gene silencing
(61). Given the recent technological ad-
vances that are enabling integration of
genetic, epigenetic and phenotypic data,
it is likely that more of examples of dis-
eases resulting from genetic drivers of
epigenetic change will be described in
the future.
Genetic Mutations in Epigenetic
Modifiers
Mutations in genes encoding epige-
netic modifiers also contribute to com-
plex diseases, again with cancer being
the best described example. Transloca-
tions, mutations or overexpression of
modifiers such as DNMTs, histone modi-
fying enzymes or chromatin remodeling
proteins are well documented in many
cancers (62). Aberrant epigenetic modi-
fiers can directly affect regulation of tar-
get genes as well as interacting with spe-
cific genetic variants of common
disease-causing SNPs (63). Whereas the
study of other complex diseases are at an
earlier stage, there is accumulating evi-
dence to suggest that disruption to epi-
genetic modifiers plays a role in a range
of other diseases, including diabetes, im-
mune diseases and intellectual disabili-
ties such as autism (63).
The simplest example of a genetic mu-
tation driving an epigenetic change and
contributing to disease is when the
change occurs in a gene encoding an epi-
genetic modifying enzyme. Some of the
more recently described examples in-
clude Kabuki syndrome with mutations
in the histone methyltransferase gene
MLL2 (64) and Coffin-Siris syndrome in-
volving mutations in SWI/SNF subunit
genes (65). Such disorders have been re-
cently reviewed (66). Another straightfor-
ward example of this is in the ICF syn-
drome (immunodeficiency, centromeric
instability and facial anomalies), which
usually arises because of biallelic muta-
tions in the gene encoding the DNMT3B
methylating enzyme (67). The syndrome
is a consequence of loss of DNMT activ-
ity resulting in genomic hypomethyla-
tion. Genomic hypomethylation is a rare
disease, which is invariably fatal in early
childhood. However, the disease displays
phenotypic variability, which is likely
due to the differing effects of individual
mutations on DNMT3B activity (67).
Rett syndrome, an X-linked neurode-
velopmental disorder usually affecting
girls, is also due to genetic defects in an
epigenetic modifier (in this case, the
methyl CpG binding protein MeCP2)
(68). The disease displays delayed onset,
with children developing normally until
1–2 years of age, when they present with
progressive neurological dysfunction.
The largely neurological phenotype of
this disease is likely a result of the re-
quirement for tight regulation of a num-
ber of important neural targets of MeCP2
(69). Variability in disease phenotype is
likely a function of the range of muta-
tions that give rise to the disease as well
as an effect of X-inactivation skewing.
THE EPIGENOME: AN INTERFACE
BETWEEN THE GENOME AND THE
ENVIRONMENT
While the underlying genome plays a
role in determining epigenetic profiles,
stochastic factors and environmental cues
including diet, exercise and toxins bring
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about subsequent changes in the
epigenome, as previously reviewed com-
prehensively (70). There is evidence that
at least some of these changes can then be
passed down through meiosis as trans-
generational epigenetic inheritance
(26,71,72). Whereas the evidence for this
and mechanisms involved are beyond the
scope of this article, they have recently
been comprehensively reviewed (11).
Stochastic Factors
It is now thought that randomly in-
duced epigenetic patterns may also con-
tribute to variation in development and
aging as well as providing a possible
mechanism for the rapid selection of
epigenotypes in response to environmen-
tal pressures. X-chromosomal inactivation
is a classic example of how epigenetic
profiles can be regulated by stochastic
factors. These factors may also explain
discordance between MZ twins (73).
While the effect of environment on
epigenetic profiles, particularly DNA
methylation, is widely acknowledged,
stochastic changes may in fact be more
common than environmentally induced
changes, with a study examining 4,000
human genes, finding 300 to have ran-
dom monoallelic expression (74). Epige-
netic stochasticity can be defined as a
combination of epigenetic variation in
the germline and somatic instability. Sim-
ilar to Richards’ “facilitated epigenetic
variation” model (75), Feinberg and
Irizarry’s “inherited stochastic variation
model” proposes genetic sequence varia-
tion underlies the propensity for epige-
netic variation, since certain DNA se-
quences are not only directly responsible
for particular traits but also increase nat-
ural methylation variation for that trait
(76). Various stochastic and environmen-
tal factors then influence DNA methyla-
tion at these variably methylated regions,
resulting in increased phenotypic differ-
ences, which are then acted on by Dar-
winian selection in a similar manner to
selection pressures affecting purely ge-
netic traits. Subsequent studies found the
sites of greatest DNA methylation vari-
ability in colon cancer corresponded to
the sites of greatest variability in other
cancers, including lung, breast and ovar-
ian cancers, with these sites normally
having distinct tissue-specific DNA
methylation patterns (77). Thus, heritable
DNA methylation variation could pro-
vide some contribution to the unex-
plained heritable genetic component of
common complex diseases.
THE PROMISE OF EPIGENETIC THERAPY
Whereas genetic mutations and chro-
mosomal defects permanently alter the
genome, epigenetic alterations, whether
driven by changes to the underlying ge-
nome or by environmental or stochastic
influences, can potentially be pharmaco-
logically reversed or modified, providing
the promise of restoring gene function,
altered as a result of epigenetic changes
in disease. There is currently consider-
able interest in the development and
clinical translation of pharmacological
agents that target either the writers or
the readers of the epigenetic code. Be-
cause these are mainly enzymes, they
provide an easier target than other gene
regulators such as transcription factors.
For obvious reasons, the use of such
agents is at the most progressed stage in
the treatment of cancers, with two
DNMT and two HDAC inhibiting com-
pounds approved for cancer treatment in
the United States and numerous others
in clinical trials (78) (Figure 3).
In 2004, 5-azacytidine (aza-C) became
the first U.S. Food and Drug Administra-
tion (FDA)-approved epigenetic drug
when it was approved for treatment of
myelodysplastic syndrome (79). An ana-
log of cytidine, the nucleoside is incorpo-
rated into nucleic acid of dividing cells
with a preference for RNA over DNA.
The presence of nitrogen at carbon-5
blocks the addition of a methyl group by
DNMTs, preventing the methylation of
the DNA after cell division. The bound
DNMTs, unable to detach due to the ni-
trogen, form permanent adducts with the
nucleic acid resulting in functional deple-
tion of DNMT from the cell (Figure 3C).
In addition, DNA replication is blocked
(80), and the DNA is functionally com-
promised, activating the p53 damage
pathway, leading to degradation of the
DNA (81) (Figure 3D).
Aza-2-deoxycytidine (decitabine) is
the deoxy form of aza-C and is solely in-
corporated into DNA, avoiding the indi-
rect effects on RNA and protein synthe-
sis of 5-aza-C. Approved in 2006 for
treatment of myelodysplastic syndrome,
it is the only other demethylating agent
currently approved by the FDA. Other
cytidine analogs such as zebularine and
5-fluoro-deoxycytidine are in clinical tri-
als, as are direct DNMT inhibitors in-
cluding procaine, procanamide and hy-
dralazine (78). The two other
FDA-approved epigenetic drugs fall
under the umbrella of histone deacety-
lase inhibitors. Both vorinostat in 2006
and romidepsin in 2009 were approved
for treatment of cutaneous T-cell lym-
phoma (78) (Figure 3A). Interest in tar-
geting epigenetic modifiers in cancer
and other diseases continues to grow,
with a wide range of targets now being
explored in both preclinical and clinical
trials. For example, inhibitors of several
histone methyltransferases, including
EZH2 and DOT1L are also in preclinical
trials for certain lymphomas and
leukemias, respectively (78) (Figure 3B).
Combining various epigenetic thera-
pies may prove to be the most effective
strategy because of the high degree of bi-
ological interaction between DNA
methylation, histone modifications and
chromatin remodeling complexes. In-
deed, clinical trials examining the syner-
gistic action of these therapies are prom-
ising (82). These therapies are also most
likely to be effective when combined
with conventional cancer treatments (78).
Epigenetic pharmaceuticals are still in
their infancy, and clearly more is to be
learned about the underlying mecha-
nisms determining epigenetic states,
since only some cancers can be repro-
grammed to a normal state and
demethylating agents and HDAC in-
hibitors are unable to bring about perma-
nent expression changes. This result is
particularly true if the abnormal epige-
netic state is driven by underlying ge-
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netic factors and would therefore require
ongoing pharmacological intervention to
prevent reversion of the epigenetic state.
Disease screening and diagnosis may
also be vastly improved with the inclu-
sion of epigenetic information. In 2012,
Teschendorff et al. (83,84) were able to
predict risk of cervical neoplasia 3 years
before morphological changes by examin-
ing DNA methylation variability. Feinberg
and Irizarry (85) suggest that if such tests
are used to identify subgroups for further
traditional follow-up screening (for exam-
ple, mammogram, colonoscopy), the posi-
tive predictive value of these more inva-
sive and expensive tests could rise to over
90% and greatly reduce cancer deaths.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Many questions remain regarding the
underlying mechanisms that determine
epigenetic patterns. Rapid improvements
in technology and our increasing ability
to effectively analyze and interpret the
immense quantities of data produced are
allowing the generation of comprehen-
sive epigenomic maps and characteriza-
tion of the differences in epigenetic state
between individuals and the changes
that occur during development, aging
and disease processes. This information
is also aiding in our understanding of
the underlying mechanisms involved, in-
cluding the relative contribution of envi-
ronmental influences, stochastic factors
and genetic variants. Numerous studies
across a range of tissue types and popu-
lations are providing strong evidence for
a key role for genetic variants in estab-
lishing inherited methylation patterns.
Over recent years, we have gained
considerable insight into the role of ge-
netic variants and epigenetic change in
diseases. Attention is now turning to un-
derstanding the interactions between ge-
netic and epigenetic factors and their
concerted roles in disease processes. This
Figure 3. Advances in epigenetic therapy. Epigenetic modifiers and modifications provide targets for therapeutic intervention in disease.
(A) Two histone deacetylase inhibitors are FDA approved for treatment of subtypes of leukemia. (B) Inhibitors of a range of epigenetic
modifiers, including histone methyltransferase enzymes, are in preclinical trials. (C) DNA demethylating agents decrease genomic methy-
lation, restoring aberrantly silenced gene expression by acting directly to inhibit methylating enzymes or as cytidine analogs are incorpo-
rated into nucleic acid of dividing cells, preventing methylation. (D) Cytidine analogs have the secondary effect of activating the p53
damage pathway and inducing apoptosis.
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approach is providing advances in dis-
ease prevention, diagnosis and surveil-
lance. It is also offering hope that a
heightened understanding of how inher-
ited factors regulate gene expression
through epigenetic mechanisms will 
provide more personalized diagnostic
tools and effective treatments for com-
plex disease.
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## Chapter.2 Appendix -- Analysis pipeline for initial quality 
control of Methylation Array Data ## 
#### Overview #### 
# 1. Read in data 
# 2. Remove failed samples 
# 3. Background correction & Control normalisation
# 4. Convert from RGset to MethylSet
# 5. Remove sex chr and normalise separately then recombine.  This 
is tricky for Methylumi objects as annotation seems impossible
#  ** Below 3 steps performed in next chapter --> normalisation **
### 5. Normalisation: swan, QN, BMIQ, Dasen
### 6. Remove failed probes based on detP- nonsignificant signal 
compared to background 0.05 threshold
### 7. Batch effect correction
####################################################################
##############################
################
# 1. Load data #
################
library(minfi)
baseDir <- file.path("/Users/ecazaly/Desktop/PhD_Analysis/450K/Raw 
data/Combined data IDAT files")
list.files(baseDir)
targets <- read.450k.sheet(baseDir)
# alternatively
# load("/Users/ecazaly/Dropbox/Analysis/workingDROP/RGsetE.RData")
RGsetE=read.450k.exp(base=baseDir,targets=targets, extended=TRUE) 
RGsetE<- updateObject(RGsetE)
############################
# 2. Remove failed samples #
############################
bad=c(9,17,22,24,27,29,40,42)
RGsetE2=RGsetE[,-c(bad)]
# which are the poor quality samples?
RGsetE[,bad]@phenoData$Sample_Name
# [1] "pc11-233a"     "PC11-213a"     "pc72-291a"    
# [4] "pc72-291b"     "PC9-4T (AH3)"  "PC9-12T (AH5)"
# [7] "PC11-233b"     "PC11-213b"  
densityPlot(RGsetE2,sampGroups=RGsetE2@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="RGsetE2")
mdsPlot(RGsetE2, numPositions=1000, sampNames=RGsetE2@phenoData
$Sample_Name, sampGroups=RGsetE2@phenoData$Batch,
        xlim=c(-4.5,9), ylim=c(-5,8),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2")
###################################################
# 3. Background correction, control normalisation #
###################################################
#preproIllumina will return a methylSet or bgcorrect.illumina and 
normalize.illumina.control will return an RGset
RGsetE2_bgcorrect=bgcorrect.illumina(RGsetE2)
densityPlot(RGsetE2_bgcorrect,sampGroups=RGsetE2_bgcorrect@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="RGsetE2_bgcorrect")
mdsPlot(RGsetE2_bgcorrect, numPositions=1000, 
sampNames=RGsetE2_bgcorrect@phenoData$Sample_Name, 
sampGroups=RGsetE2_bgcorrect@phenoData$Batch,
        xlim=c(-8.5,5), ylim=c(-5,8),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2_bgcorrect")
RGsetE2_control_norm=normalize.illumina.control(RGsetE2_bgcorrect, 
reference = 1)  # try with diff refs
RGsetE2_control_norm2=normalize.illumina.control(RGsetE2_bgcorrect, 
reference = 10)
RGsetE2_control_norm3=normalize.illumina.control(RGsetE2_bgcorrect, 
reference = 20)
RGsetE2_control_norm4=normalize.illumina.control(RGsetE2_bgcorrect, 
reference = 40)
densityPlot(RGsetE2_control_norm,sampGroups=RGsetE2_control_norm@phe
noData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref1")
densityPlot(RGsetE2_control_norm2,sampGroups=RGsetE2_control_norm2@p
henoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref2")
densityPlot(RGsetE2_control_norm3,sampGroups=RGsetE2_control_norm3@p
henoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref3")
densityPlot(RGsetE2_control_norm4,sampGroups=RGsetE2_control_norm4@p
henoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref4")
# These plots look identical
mdsPlot(RGsetE2_control_norm, numPositions=1000, 
sampNames=RGsetE2_control_norm@phenoData$Sample_Name, 
sampGroups=RGsetE2_control_norm@phenoData$Batch,
        xlim=c(-10.5,4.5), ylim=c(-8.5,5),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2_control_norm")
mdsPlot(RGsetE2_control_norm2, numPositions=1000, 
sampNames=RGsetE2_control_norm2@phenoData$Sample_Name, 
sampGroups=RGsetE2_control_norm2@phenoData$Batch,
        xlim=c(-10.5,4.5), ylim=c(-8.5,5),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2_control_norm2")
mdsPlot(RGsetE2_control_norm3, numPositions=1000, 
sampNames=RGsetE2_control_norm3@phenoData$Sample_Name, 
sampGroups=RGsetE2_control_norm3@phenoData$Batch,
        xlim=c(-5,10), ylim=c(-8.5,4),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2_control_norm3")
mdsPlot(RGsetE2_control_norm4, numPositions=1000, 
sampNames=RGsetE2_control_norm4@phenoData$Sample_Name, 
sampGroups=RGsetE2_control_norm4@phenoData$Batch,
        xlim=c(-10.5,4.5), ylim=c(-8.5,5),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2_control_norm4")
# As do these, although the 3rd one inverts
####################################################################
#########
# 4. Convert from RGset to MethylSet without normalisation or p-val 
removal #
####################################################################
#########
Raw_preprocess <- preprocessRaw(RGsetE2_control_norm)
# MethylSet (storageMode: lockedEnvironment)
# 485512 features, 52 samples  - this has lost 136887 sites
####################################################################
########
# 5. Remove X&Y chr and normalise these separately if using female 
samples #
####################################################################
########
Annotated=getAnnotation(Raw_preprocess, what="everything", 
drop=FALSE)  # this is a dataframe, could be an issue downstream
dim(Annotated) # 485512     33  - cuts it down to the same number of 
probes in Raw_preprocess.  
chrs=Annotated@listData$chr
Autosomes=Raw_preprocess[chrs!="chrX" & chrs !="chrY"]  # Methylset
dim(Autosomes) #  473864       52
dim(Raw_preprocess) # 485512       52  : have removed 11648 sex chr
Annotated_Autosomes=getAnnotation(Autosomes, what="everything", 
drop=FALSE)  #dataframe 
 #check:
dim(Annotated_Autosomes)  # [1] 473864     33
which(Annotated_Autosomes[,1]=="chrY") #integer(0)
which(Annotated_Autosomes[,1]=="chrX") #integer(0)
# normalise these automsomes separately to sex chr then somehow 
recombine
Raw_Male <- Raw_preprocess[,Raw_preprocess@phenoData$Sex=="M"]
Male_chr <- Raw_Male[chrs=="chrY" | chrs=="chrX"]
dim(Male_chr) # Features  Samples   11648       43
Raw_Female <- Raw_preprocess[,Raw_preprocess@phenoData$Sex=="F"]
Female_chr <- Raw_Female[chrs=="chrX"] 
dim(Female_chr) # Features  Samples 11232        9
## Chapter.2  Appendix.2  Analysis Pipeline for Omni2.5 genotyping 
array quality control using PLINK ##
# navigate to correct directory on HPC :  cd ~/Data/Omni25/
pipeline_omni
# ------ Add phenotype data -------
# To add phenotypes; transpose to t.ped and t.fam files and then 
manually edit t.fam files in VI or nano
plink --noweb --file All_Chips_1_5Cutoff_noReps --transpose --recode 
--out cutoff_15
# in nano modify final column with 2 (A), 1 (UA), 0 (NA) and then 
exit, will ask to save on exiting
nano cutoff_15.tfam  # 
# at this point there are 2,391739 SNPs
# 27534 heterozygous haploid genotypes; set to missing 
# haploid chromosomes are only counted once (i.e. male X and Y 
chromosome SNPs and all MT SNPs).
# genotypes have been set to missing if they are not valid (female Y 
genotype, heterozygous haploid chromosome)
# 192 SNPs with no founder genotypes observed
# ------- QC per individual -------
# 2,391739 SNPs
# 1. Check gender assignment
plink --noweb --tfile cutoff_15 --check-sex --out sexcheck_15
#look at the file, 5th column gives status as OK or otherwise.  All 
ok for my samples
less sexcheck_15.sexcheck
# 2. Missingness: remove indivs with >10% missing genotypes
# 2,391739 SNPs
plink --noweb --tfile cutoff_15 --mind 0.1 --make-bed --out 
cutoff_15_clean
# Check plink log. file to see if any excluded.  No all left in, so 
must have less than 10% which agrees
# with genomeStudio as call rates only down to 96% and mostly 99% 
# 3. Mendelian errors - can't use this as have no trios
#plink --noweb --bfile cutoff_15_clean --mendel --out 
cutoff_15_clean_mendel 
###Currently, PLINK only scans full trios for Mendel errors. 
Families with fewer than 2 parents in the dataset will not be 
tested.###
# ------- QC per SNP -------
# 1. Remove SNPs with high rate of missing genotype calls -more than 
10% missing genotypes... this is actually set at 5%  
# 2,391739 SNPs
plink --noweb --bfile cutoff_15_clean --geno 0.05 --make-bed --out 
cutoff_15_clean2
# 61217 SNPs failed missingness test ( GENO > 0.05 ), so now have 
2330522 SNPs
# 2330522 SNPs
# 2. Remove SNPs out of Hardy-Weinberg equilibrium
# 2330522 SNPs
###plink --noweb --bfile cutoff_15_clean2 --hardy --out 
cutoff_15_clean2_hardy
# 335 markers to be excluded based on HWE test ( p <= 0.001 )
#1303 markers failed HWE test in cases
#335 markers failed HWE test in controls
#Total genotyping rate in remaining individuals is 0.993477
# 2330187 SNPs
# is this too stringent? should I perhaps use 0.0001 which doesn't 
exclude any?
plink --noweb --bfile cutoff_15_clean2 --hwe 1E-4 --hardy --make-bed 
--out cutoff_15_clean_hwe_1E-4
# 0 markers to be excluded based on HWE test ( p <= 0.0001 )
# 419 markers failed HWE test in cases
# 0 markers failed HWE test in controls
# Total genotyping rate in remaining individuals is 
0.993679
# 2330522 SNPs
###plink --noweb --bfile cutoff_15_clean2 --hardy2 --out 
cutoff_15_clean2_hardy2
# --hardy2 is a lot more stringent and less accurate for rare 
genotypes, it takes out about 10 thousand more
#10522 markers to be excluded based on HWE test ( p <= 
0.001 )
#15887 markers failed HWE test in cases
#10522 markers failed HWE test in controls
#Total genotyping rate in remaining individuals is 0.993477
# check in R
hwe2 <- read.delim("cutoff_15_clean_hwe_1E-4.hwe", header=T, 
as.is=T, sep="")
str(hwe2)
hweALL2 <- hwe2[which(hwe2$TEST=="ALL"),]  # get rid of the rows 
that specify AFF, UNAFF
# order by p-val, p-vals are generated per SNP depending on the 
deviation from HWE, low p-values indicate a 
# SNP is out of HWE.  
hweOrderALL2 <- hweALL2[order(hweALL2$P),]
hwe2_less10_5 <- hweALL2[which(hweALL2$P<1E-5),]  # which SNPs have 
a p-val less than 1E-5? 289
hwe2_less10_4 <- hweALL2[which(hweALL2$P<1E-4),]  # 517 which is not 
quite the same as in PLINK as above
# 2. Set minimum MAF
plink --noweb --bfile cutoff_15_clean_hwe_1E-4 --maf 0.05 --out 
cutoff_15_clean3_maf
# 1,108728 SNPs failed frequency test ( MAF < 0.05 )
# 1221794 SNPs
# I think this is too stringent as it will cut of everything under 
5% frequency which could be quite 
# interesting for familial data.  will set to 0.01 and then 
investigate what ppl using set it to
plink --noweb --bfile cutoff_15_clean_hwe_1E-4 --maf 0.01 --out 
cutoff_15_clean3_maf_0.01
# 829,316 SNPs failed frequency test ( MAF < 0.01 )
plink --noweb --bfile cutoff_15_clean_hwe_1E-4 --maf 0.001 --make-
bed --out cutoff_15_clean3_maf_0.001
# 713,687 SNPs failed frequency test ( MAF < 0.001 )
# Use this cutoff. 
# 1,616835 SNPs remaining
# ---- final PLINK file:  cutoff_15_clean3_maf_0.001 ----------
# missingness, hwe, het
plink --noweb --bfile cutoff_15_clean3_maf_0.001 --missing --hwe 
1E-4 --hardy --het --make-bed --out cutoff_15_final
#1616835 SNPs
#12543 heterozygous haploid genotypes; set to missing
#Total genotyping rate in remaining individuals is 0.993451
plink --noweb --bfile cutoff_15_final --het --out cutoff_15_final
# create the individual (missingness vs homozygosity) and per SNP 
(missingness vs hwe) plots using this
# ------- Per Individual ---------
# plot homozygosity against errors per individual 
het_1.5 <- read.delim("cutoff_15_final.het",as.is=T,header=T,sep="")
imiss_1.5 <- 
read.delim("cutoff_15_final.imiss",as.is=T,header=T,sep="")
snp_1.5 <- 
read.delim("cutoff_15_final.lmiss",header=T,as.is=T,sep="")
png("Individual 1.5 cutoff Post QC.png")
plot(het_1.5$O.HOM./
het_1.5$N.NM.,imiss_1.5$F_MISS,ylab="missingness",xlab="Homozygosity
",
     main="Summary per individual, Post QC (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
# compare this to pre-QC
plink --noweb --tfile cutoff_15 --het --missing --out 
cutoff_15_preQC
#2391739 SNPs
#Total genotyping rate in remaining individuals is 0.991194
het_1.5pre <- 
read.delim("cutoff_15_preQC.het",as.is=T,header=T,sep="")
imiss_1.5pre <- 
read.delim("cutoff_15_preQC.imiss",as.is=T,header=T,sep="")
snp_1.5pre <- 
read.delim("cutoff_15_preQC.lmiss",header=T,as.is=T,sep="")
png("Individual 1.5 cutoff Pre QC.png")
plot(het_1.5pre$O.HOM./het_1.5pre$N.NM.,imiss_1.5pre
$F_MISS,ylab="missingness",xlab="Homozygosity",
     main="Summary per individual, Pre QC (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
# ----- heterozygosity ------
# plot missingness against heterozygosity
png("Individual 1.5 cutoff Post QC, heterozygosity.png")
plot(1-(het_1.5$O.HOM./
het_1.5$N.NM.),imiss_1.5$F_MISS,ylab="missingness",xlab="Heterozygos
ity",
     main="Summary per individual, Post QC, 
     heterozygosity (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
png("Individual 1.5 cutoff Pre QC, heterozygosity.png")
plot(1-(het_1.5pre$O.HOM./het_1.5pre$N.NM.),imiss_1.5pre
$F_MISS,ylab="missingness",xlab="Homozygosity",
     main="Summary per individual, Pre QC, 
     heterozygosity (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
# ------- per SNP -------- 
hardy_1.5post=read.delim("cutoff_15_final.hwe", header=T, as.is=T, 
sep="")
hardy_1.5postb <- hardy_1.5post[seq(1,nrow(hardy_1.5post),3),] 
# take out dodge ones 1614455 1614479
hardy_1.5postb <- hardy_1.5postb[-c(1614455,1614479),]
p_postb <- hardy_1.5postb$P
snp_1.5post <-snp_1.5[-c(1614455,1614479),]
#png("Missing per SNP vs HWE Post QC 
zoomC.png",width=800,height=500)
#par(mar=c(6,5,4,2)+0.1)
plot(-1*log10(snp_1.5post$F_MISS),-1*log10(p_postb),ylab="-log10(HW-
pval)",xlab="-log10(missingness)",main="Missingness vs HWE p-value, 
Post QC",ylim=c(-3/75,2))
abline(v=-1*log10(0.05),col=2)
text(-1*log10(0.05),-3/75,"5%",col=2)
abline(v=-1*log10(0.1),col=3)
text(-1*log10(0.1),-3/75,"10%",col=3)
abline(v=-1*log10(0.025),col=4)
text(-1*log10(0.025),-3/75,"2.5%",col=4)
lines(lowess(-1*log10(snp_1.5post$F_MISS[snp_1.5post$F_MISS!=0 & !
is.na(p_postb) & !is.na(snp_1.5post
$F_MISS)]),-1*log10(p_post[snp_1.5post$F_MISS!=0 & !is.na(p_postb) 
& !is.na(snp_1.5post$F_MISS)]),f=0.1),col="red",lwd=2)
#### This still doesn't work!!!!!! -- maybe several points there
#identify(-1*log10(snp_1.5post$F_MISS),-1*log10(p_postb), n=2)
# [1] 1614455 1614479
#dev.off()
# compare this to pre-QC
plink --noweb --tfile cutoff_15 --hardy --missing --out 
cutoff_15_preQC
hardy_1.5pre=read.delim("cutoff_15_preQC.hwe", header=T, as.is=T, 
sep="")
p_pre <- hardy_1.5pre$P[3*(1:(length(hardy_1.5pre$P)/3))-2]
png("Missing per SNP vs HWE Pre QC zoomC.png",width=800,height=500)
par(mar=c(6,5,4,2)+0.1)
plot(-1*log10(snp_1.5pre$F_MISS),-1*log10(p_pre),ylab="-log10(HW-
pval)",xlab="-log10(missingness)",main="Missingness vs HWE p-value, 
Pre QC",ylim=c(-3/75,2))
abline(v=-1*log10(0.05),col=2)
text(-1*log10(0.05),-3/75,"5%",col=2)
abline(v=-1*log10(0.1),col=3)
text(-1*log10(0.1),-3/75,"10%",col=3)
abline(v=-1*log10(0.025),col=4)
text(-1*log10(0.025),-3/75,"2.5%",col=4)
lines(lowess(-1*log10(snp_1.5pre$F_MISS[snp_1.5pre$F_MISS!=0 & !
is.na(p_pre) & !is.na(snp_1.5pre$F_MISS)]),-1*log10(p_pre[snp_1.5pre
$F_MISS!=0 & !is.na(p_pre) & !is.na(snp_1.5pre
$F_MISS)]),f=0.1),col="red",lwd=2)
dev.off()
identify(-1*log10(snp_1.5pre$F_MISS),-1*log10(p_pre), n=2)
# [1] 2386673 2386736
# get rid of these and then recheck graph 
snp_1.5pre2 <-snp_1.5pre[-c(2386673,2386736),]
plot(-1*log10(snp_1.5preb$F_MISS),-1*log10(p_pre),ylab="-log10(HW-
pval)",xlab="-log10(missingness)",main="Missingness vs HWE p-value, 
Pre_b QC",ylim=c(-3/75,2))
abline(v=-1*log10(0.05),col=2)
text(-1*log10(0.05),-3/75,"5%",col=2)
abline(v=-1*log10(0.1),col=3)
text(-1*log10(0.1),-3/75,"10%",col=3)
abline(v=-1*log10(0.025),col=4)
text(-1*log10(0.025),-3/75,"2.5%",col=4)
lines(lowess(-1*log10(snp_1.5preb$F_MISS[snp_1.5preb$F_MISS!=0 & !
is.na(p_pre) & !is.na(snp_1.5pre$F_MISS)]),-1*log10(p_pre[snp_1.5pre
$F_MISS!=0 & !is.na(p_pre) & !is.na(snp_1.5pre
$F_MISS)]),f=0.1),col="red",lwd=2)
save.image("myPipeline_15cutoff.RData")
#######################################################
#  cutoff 5
~/Data/Omni25/pipeline_omni
plink --noweb --file All_Chips_5_0Cutoff --transpose --recode --out 
cutoff_50
nano cutoff_50.tfam
plink --noweb --tfile cutoff_50 --check-sex --out sexcheck_50
plink --noweb --tfile cutoff_50 --mind 0.1 --geno 0.1 --make-bed --
out cutoff_50_clean
plink --noweb --bfile cutoff_50_clean --maf 0.001 --make-bed --out 
cutoff_50_clean_maf_0.001
plink --noweb --bfile cutoff_50_clean_maf_0.001 --missing --hwe 1E-4 
--hardy --het --make-bed --out cutoff_50_final
plink --noweb --bfile cutoff_50_final --het --out cutoff_50_final
# plot homozygosity against errors per individual 
R
setwd("~/Data/Omni25/pipeline_omni")
het_50 <- read.delim("cutoff_50_final.het",as.is=T,header=T,sep="")
imiss_50 <- 
read.delim("cutoff_50_final.imiss",as.is=T,header=T,sep="")
snp_50 <- 
read.delim("cutoff_50_final.lmiss",header=T,as.is=T,sep="")
png("Individual 5.0 cutoff Post QC.png")
plot(het_50$O.HOM./
het_50$N.NM.,imiss_50$F_MISS,ylab="missingness",xlab="Homozygosity",
     main="Summary per individual, Post QC (51 samples 5.0 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
## Chapter.3 Appendix_1 -- perform normalisation ##
## Overview ## 
____________________________________________________________________
_________________
# first 5 steps performed in ch.2 as part of QC protocol
## 1. Read in data 
## 2. Remove failed samples 
## 3. Background correction & Control normalisation
## 4. Convert from RGset to MethylSet
## 5. Remove sex chr and normalise separately then recombine.  This 
is tricky for Methylumi objects as annotation seems impossible
# 6. Normalisation: swan, QN, BMIQ, Dasen
# 7. Remove failed probes based on detP- nonsignificant signal 
compared to background 0.05 threshold
# 8. Batch effect correction: limma + RUV, Combat
____________________________________________________________________
_________________
####################################################################
###############
# 6. Normalisation:   Compare RAW to StratQN, FunNorm, SWAN, QN, 
BMIQ, Dasen, RUV #
####################################################################
###############
# use Autosomes object as need to normalise sex chr separately, 
still need to put RGsetE2 argument but make the mset the Autosomes 
object and then do the same for both sex chr
### 1. RAW ###   
Raw_preprocess
Autosomes
Male_chr
Female_chr
autosomes_RGsetE2 <- RGsetE2[chrs!="chrX" & chrs !="chrY"]
dim(autosomes_RGsetE2 )
###  2. Stratified Quantile Normalisation ###
#Stratified quantile normalization for Illumina amethylation arrays. 
This function implements stratified quantile normalization 
preprocessing for Illumina methylation microarrays. Probes are 
stratified by region (CpG island, shore, etc.) This function 
implements stratified quantile normalization preprocessing for 
Illumina methylation microarrays. If removeBadSamples is TRUE we 
calculate the median Meth and median Unmeth sig- nal for each 
sample, and remove those samples where their average falls below 
badSampleCutoff. The normalization procedure is applied to the Meth 
and Unmeth intensities separately. The distri- bution of type I and 
type II signals is forced to be the same by first quantile 
normalizing the type II probes across samples and then interpolating 
a reference distribution to which we normalize the type I probes. 
Since probe types and probe regions are confounded and we know that 
DNAm dis- tributions vary across regions we stratify the probes by 
region before applying this interpolation. For the probes on the X 
and Y chromosomes we normalize males and females separately using 
the gender information provided in the sex argument. If gender is 
unspecified (NULL), a guess is made using by the getSex function 
using copy number information. Background correction is not used, 
but very small intensities close to zero are thresholded using the 
fixMethOutlier. Note that this algorithm relies on the assumptions 
necessary for quantile normalization to be applicable and thus is 
not recommended for cases where global changes are expected such as 
in cancer-normal comparisons. 
Note that this normalization procedure is essentially similar to one 
previously presented (Touleimat and Tost, 2012), but has been 
independently re-implemented due to the present lack of a released, 
supported version. 
library(minfi)
StratQN <- preprocessQuantile(Autosomes, fixOutliers=TRUE, 
removeBadSamples=FALSE, quantileNormalize=TRUE, stratified=TRUE, , 
mergeManifest=TRUE, sex=Autosomes@phenoData$Sex, verbose=TRUE)
# can't use RGset as get an error saying subset out of bounds
# dont actually need to use the autosome object as the function 
normalised sex chr separately when sex is provided
type_autosomes <- data.frame(row.names(StratQN), 
getProbeType(StratQN))
colnames(type_autosomes) <- c("Name", "Type")
StratQN_betas <- getBeta(StratQN)
StratQN_all <- preprocessQuantile(Raw_preprocess, fixOutliers=TRUE, 
removeBadSamples=FALSE, quantileNormalize=TRUE, stratified=TRUE, , 
mergeManifest=TRUE, sex= Raw_preprocess@phenoData$Sex, verbose=TRUE)
### 3. Functional Normalisation ### 
library(minfi)
FunNorm <- preprocessFunnorm(RGsetE2, nPCs=2, sex=RGsetE2@phenoData
$Sex, bgCorr=TRUE, dyeCorr=TRUE, verbose=TRUE)
FunNorm_betas <- getBeta(FunNorm)
#FunNorm_autosomes <- preprocessFunnorm(autosomes_RGsetE2, nPCs=2, 
sex=autosomes_RGsetE2@phenoData$Sex, bgCorr=TRUE, dyeCorr=TRUE)
# Error in getGreen(object)[IRed$AddressA, ] : subscript out of 
bounds
# Also can't use Autosomes as needs to be RGset object not methylset
probeTypes_FunNorm <- data.frame(row.names(FunNorm), 
getProbeType(FunNorm))
colnames(probeTypes_FunNorm) <- c("Name", "Type")
par(mfrow=c(1,2))
plotBetasByType(getBeta(FunNorm)[,7], probeTypes=probeTypes_FunNorm, 
main="FunNorm by probe")
plotBetasByType(swan2[,7], probeTypes=probeTypes_FunNorm, 
main="RGsetE2 by probe")
# These look quite different, there is a greater skew towards 
unmethylated for the normalised data whereas the RGset has much more 
methylated
### 4. SWAN ###
swan=preprocessSWAN(RGsetE2, mSet=Raw_preprocess)  
# will perform preprocessRaw on the RGset if NULL for mset, this 
looks diff between my Raw_preprocess which I've done background 
correction on and the default, don't use default
#swan2=preprocessSWAN(RGsetE2) #default
#par(mfrow=c(1,2))
#plotBetasByType(swan[,7], main="SWAN by probe, my Raw")
#plotBetasByType(swan2[,7], main="SWAN by probe, default")
swan_autosomes <- preprocessSWAN(RGsetE2, mSet=Autosomes)
swan_maleChr <- preprocessSWAN(RGsetE2, mSet=Male_chr)
swan_femaleChr <- preprocessSWAN(RGsetE2, mSet=Female_chr)
par(mfrow=c(1,3))
plotBetasByType(swan_autosomes[,7], main="SWAN by probe, autosomes")
plotBetasByType(swan_maleChr[,7], main="SWAN by probe, male chr")
plotBetasByType(swan_femaleChr[,7], main="SWAN by probe, female 
chr")
# female chr look pretty odd, guessing this is a reflection of X 
inactivation
### 5. QN ###
library(methylumi)
library(IlluminaHumanMethylation450kanno.ilmn12.hg19) 
library(FDb.InfiniumMethylation.hg19)
pdat=read.csv("/Users/ecazaly/Desktop/R Dec14/Raw IDATs/Methylumi/
Methylumi_pdat2.csv")
MethylumiSet=methylumIDAT(barcodes = pdat$barcodes, pdat = pdat, 
parallel = F, n = F, n.sd=F, oob = T, idatPath=file.path("/Users/
ecazaly/Desktop/R Dec14/Raw IDATs/Methylumi"))
bad_methylumi=c(9,17,22,24,27,29,40,42)
MethylumiSet2=MethylumiSet[,-c(bad_methylumi)]
## Background and colour correction ##
library(lumi)
methylumi_prepro <- 
normalizeMethyLumiSet(methylumi.bgcorr(MethylumiSet2))
# For HumanMethylation450 data, the function delegates to 
normalizeViaControls() the task of scaling red and green intensities 
against a reference array (chip) which defaults to the first chip in 
a set. The code to do this is based on code from the 'minfi' package 
and uses the built-in normalization controls to scale the #channels 
of the samples, so that a consistent degree of dye bias is 
maintained for Infinium II probes across an experiment or set of 
experiments.
### QN ###
lumiQN_prepro=normalizeMethylation.quantile(methylumi_prepro)
lumiQNbetas=betas(lumiQN_prepro)
type_methylumi <- data.frame(row.names(lumiQN_prepro), 
lumiQN_prepro@featureData@data$DESIGN)
colnames(type_methylumi) <- c("Name", "Type")
plotBetasByType(lumiQNbetas[,1], probeTypes=type_methylumi, 
main="lumiQNbetas by probe")
 
### 6. BMIQ ###
library(wateRmelon)
library(RPMM)
# BMIQ_autosomes=BMIQ(getBeta(Autosomes), probeTypes_autosomes) # 
this doesn't work, looks like you need all the probes, 
Raw_preprocess and RGset also don't either  
BMIQ=BMIQ(methylumi_prepro) # just have to do it with all 
chromosomes
BMIQ_betas <- betas(BMIQ)
type_BMIQ <- data.frame(row.names(BMIQ), BMIQ@featureData@data
$DESIGN)
colnames(type_BMIQ) <- c("Name", "Type")
### 7. Dasen ###
Dasen=as.matrix(dasen(methylated(Raw_preprocess),unmethylated(Raw_pr
eprocess),onetwo= getProbeType(Raw_preprocess), fudge=100))
probeTypes_Dasen <- data.frame(row.names(Raw_preprocess), 
getProbeType(Raw_preprocess))
⁃ colnames(probeTypes_Dasen) <- c("Name", "Type")
Dasen_autosomes=as.matrix(dasen(methylated(Autosomes),unmethylated(A
utosomes),onetwo=getProbeType(Autosomes), fudge=100))
probeTypes_autosomes2 <- data.frame(row.names(Autosomes), 
getProbeType(Autosomes))
colnames(probeTypes_autosomes2) <- c("Name", "Type")
plotBetasByType(Dasen[,1], probeTypes= probeTypes_autosomes2, 
main="Dasen by probe, autosomes")
probeTypes_male <- getProbeType(Male_chr)
Dasen_male=as.matrix(dasen(methylated(Male_chr),unmethylated(Male_ch
r),onetwo= probeTypes_male, fudge=100))
probeTypes_autosomes2_male <- data.frame(row.names(Male_chr), 
getProbeType(Male_chr))
colnames(probeTypes_autosomes2_male) <- c("Name", "Type")
plotBetasByType(Dasen_male[,1], probeTypes= 
probeTypes_autosomes2_male, main="Dasen by probe, male chr")
# the plot works for Dasen but not male/female chr for some reason
probeTypes_female <- getProbeType(Female_chr)
Dasen_female=as.matrix(dasen(methylated(Female_chr),unmethylated(Fem
ale_chr),onetwo= probeTypes_female, fudge=100))
probeTypes_autosomes2_female <- data.frame(row.names(Female_chr), 
getProbeType(Female_chr))
colnames(probeTypes_autosomes2_female) <- c("Name", "Type")
plotBetasByType(Dasen_female[,1], probeTypes= 
probeTypes_autosomes2_female, main="Dasen by probe, female chr")
### 8. RUV ###
library(minfi)
library(methylumi)
#library(RUVnormalize)
source("naiveRandRUV.R") 
source("missMethylRUVFunctions.R")
mValues_autosomes = getMvals(Autosomes,RGsetE2) 
ctl_autosomes <- !(rownames(mValues_autosomes) %in% 
featureNames(Autosomes))  ## create logical vector marking NCPs, 613 
probes from 479078- 479690 
mValues_raw <- getMvals(Raw_preprocess, RGsetE2)
ctl_raw <- !(rownames(mValues_raw) %in% 
featureNames(Raw_preprocess))
result_autosomes= naiveRandRuv(t(mValues_autosomes), ctl_autosomes, 
nuCoeff=1e-3, k=ceiling(ncol(mValues_autosomes)/4)) ## perform 
normalization 
RUV_autosomes=t(result_autosomes)
BetaRUV_autosomes=ilogit2(RUV_autosomes)
densityPlot(BetaRUV_autosomes,sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Autosomes")
type=data.frame(cbind(rownames(Autosomes),getProbeType(Autosomes))) 
colnames(type)=c("Name","Type")
type_male=data.frame(cbind(rownames(Male_chr),getProbeType(Male_chr)
)) 
colnames(type_male)=c("Name","Type")
type_female=data.frame(cbind(rownames(Female_chr),getProbeType(Femal
e_chr))) 
colnames(type_female)=c("Name","Type")
plotBetasByType(BetaRUV_autosomes[,1], type , main="Autosomes 
BetaRUV by type", cex.legend=.8, legendPos="topright") 
mdsPlot(BetaRUV_autosomes, numPositions=1000, 
sampNames=Autosomes@phenoData$Sample_Name, 
sampGroups=Autosomes@phenoData$Batch,
        xlim=c(-14,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- RUV Autosomes")
# change variables when generating result and see if this affects 
the density plot
result_autosomes_by2= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-3, k=ceiling(ncol(mValues_autosomes)/2)) 
## perform normalization 
result_autosomes_by6= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-3, k=ceiling(ncol(mValues_autosomes)/6)) 
## perform normalization 
result_autosomes_by8= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-3, k=ceiling(ncol(mValues_autosomes)/8)) 
## perform normalization 
RUV_autosomes_by2=t(result_autosomes_by2)
BetaRUV_autosomes_by2=ilogit2(RUV_autosomes_by2)
RUV_autosomes_by6=t(result_autosomes_by6)
BetaRUV_autosomes_by6=ilogit2(RUV_autosomes_by6)
RUV_autosomes_by8=t(result_autosomes_by8)
BetaRUV_autosomes_by8=ilogit2(RUV_autosomes_by8)
par(mfrow=c(1,3))
densityPlot(BetaRUV_autosomes_by2,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data by2, Autosomes")
densityPlot(BetaRUV_autosomes_by6,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data by6, Autosomes")
densityPlot(BetaRUV_autosomes_by8,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data by8, Autosomes")
# changes the height of the graph
result_autosomes_nuCoeff_1e5= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-5, k=ceiling(ncol(mValues_autosomes)/4)) 
## perform normalization 
result_autosomes_nuCoeff_1e1= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-1, k=ceiling(ncol(mValues_autosomes)/4)) 
## perform normalization 
result_autosomes_nuCoeff_1ePos5= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e5, k=ceiling(ncol(mValues_autosomes)/4)) ## 
perform normalization 
RUV_autosomes_nuCoeff_1e5=t(result_autosomes_nuCoeff_1e5)
BetaRUV_autosomes_nuCoeff_1e5=ilogit2(RUV_autosomes_nuCoeff_1e5)
RUV_autosomes_nuCoeff_1e1=t(result_autosomes_nuCoeff_1e1)
BetaRUV_autosomes_nuCoeff_1e1=ilogit2(RUV_autosomes_nuCoeff_1e1)
RUV_autosomes_nuCoeff_1ePos5=t(result_autosomes_nuCoeff_1ePos5)
BetaRUV_autosomes_nuCoeff_1ePos5=ilogit2(RUV_autosomes_nuCoeff_1ePos
5)
par(mfrow=c(1,3))
densityPlot(BetaRUV_autosomes_nuCoeff_1e5,sampGroups=Autosomes@pheno
Data$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), 
xlab="Beta", main="Density plot RUV data nuCoeff 1e-5, Autosomes")
densityPlot(BetaRUV_autosomes_nuCoeff_1e1,sampGroups=Autosomes@pheno
Data$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), 
xlab="Beta", main="Density plot RUV data nuCoeff 1e-1, Autosomes")
densityPlot(BetaRUV_autosomes_nuCoeff_1ePos5,sampGroups=Autosomes@ph
enoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), 
xlab="Beta", main="Density plot RUV data nuCoeff 1e +5, Autosomes")
# this one is starting to look better.  Back to being biomdal 
distribution
# from the above looks like nuCoeff of ~5 and dividing by ~6 is best
result_autosomes_optimal= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e5, k=ceiling(ncol(mValues_autosomes)/6)) ## 
perform normalization 
RUV_autosomes_optimal=t(result_autosomes_optimal)
BetaRUV_autosomes_optimal=ilogit2(RUV_autosomes_optimal)
densityPlot(BetaRUV_autosomes_optimal,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 
xlab="Beta", main="Density plot RUV optimal, Autosomes")
#compare:
par(mfrow=c(1,3))
densityPlot(getBeta(Autosomes),sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), xlab="Beta", 
main="Density plot Preprocessed Autosomes")
densityPlot(BetaRUV_autosomes,sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV Autosomes")
densityPlot(BetaRUV_autosomes_optimal,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 
xlab="Beta", main="Density plot RUV optimal, Autosomes")
mdsPlot(getBeta(Autosomes), numPositions=1000, 
sampNames=Autosomes@phenoData$Sample_Name, 
sampGroups=Autosomes@phenoData$Batch,
        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- Preprocessed Autosomes")
mdsPlot(BetaRUV_autosomes, numPositions=1000, 
sampNames=Autosomes@phenoData$Sample_Name, 
sampGroups=Autosomes@phenoData$Batch,
        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- RUV Autosomes")
mdsPlot(BetaRUV_autosomes_optimal, numPositions=1000, 
sampNames=Autosomes@phenoData$Sample_Name, 
sampGroups=Autosomes@phenoData$Batch,
        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- RUV Autosomes_optimal")
# the raw and optimal look pretty similar and there is still a batch 
effect after RUV when I adjust the variables
# Male and female chr
mValues_male = getMvals(Male_chr,RGsetE2) 
ctl_male <- !(rownames(mValues_male) %in% featureNames(Male_chr))
result_male= naiveRandRuv(t(mValues_male), ctl_male, nuCoeff=1e-3, 
k=ceiling(ncol(mValues_male/4))) 
RUV_male=t(result_male)
BetaRUV_male=ilogit2(RUV_male)
mValues_female <- getMvals(Female_chr, RGsetE2)
ctl_female <- !(rownames(mValues_female) %in% 
featureNames(Female_chr))
result_female= naiveRandRuv(t(mValues_female), ctl_female, 
nuCoeff=1e-3, k=ceiling(ncol(mValues_female/4))) 
RUV_female=t(result_female)
BetaRUV_female=ilogit2(RUV_female)
# Male and female OPTIMAL
result_male_optimal= naiveRandRuv(t(mValues_male), ctl_male, 
nuCoeff=1e5, k=ceiling(ncol(mValues_male)/6)) 
RUV_male_optimal=t(result_male_optimal)
BetaRUV_male_optimal=ilogit2(RUV_male_optimal)
result_female_optimal= naiveRandRuv(t(mValues_female), ctl_female, 
nuCoeff=1e5, k=ceiling(ncol(mValues_female)/6)) 
RUV_female_optimal=t(result_female_optimal)
BetaRUV_female_optimal=ilogit2(RUV_female_optimal)
### 7. Remove failed probe sites based on detection P value ###
# compared to background.  I think 0.01 is too stringent, use 0.05 
which is the default for wateRmelon.
####
# Creates an RGset, dan't use this method on MethylSet, needs to be 
RGset
detP <- detectionP(RGsetE2_control_norm)  # from minfi
failed_detP=detP>0.05
failed_sites_0.05_1=which(rowMeans(failed_detP)>0.001) # Which 
positions failed in >1% of samples?
Raw_minfi_0.05_1=RGsetE2_control_norm[-(failed_sites_0.05_1),]
dim(Raw_minfi_0.05_1)
#Features  Samples 
#615237       52 
dim(RGsetE2_control_norm)-dim(Raw_minfi_0.05_1)
# Features  Samples 
# 7162        0   # this is the same as when you use the wateRmelon 
method below :)
# But there are less sites in Raw_filter because it has been 
converted to a methylset and this removes probes
dim(Raw_minfi_0.05_1)-dim(Raw_filter)  # Features  Samples 2450      
0
## OR:  Use pfilter method wateRmelon, removes 2450 probes, still 
RGset 
# this is still a lot less than removed when using preprocess 
(136,887)
Raw_filter  <- pfilter(mn=RGsetE2_control_norm,pn=detP)    # Can 
change threshold from default of 0.05 to 0.01 with additional 
arguments
# 0 samples having 1 % of sites with a detection p-value greater 
than 0.05 were removed 
# 719 sites were removed as beadcount <3 in 5 % of samples 
# 7162 sites having 1 % of samples with a detection p-value greater 
than 0.05 were removed
dim(Raw_filter) 
#  Features  Samples 
#  612787       52 
densityPlot(Raw_filter, sampGroups=Raw_filter@phenoData$Batch, 
pal=rainbow(3), xlim=c(-.1,1.2), ylim=c(0,3.6), xlab="Beta", 
main="Raw- pfilter")
mdsPlot(Raw_filter, numPositions=1000, 
sampNames=Raw_filter@phenoData$Sample_Name, 
sampGroups=Raw_filter@phenoData$Batch,
        xlim=c(-8.5,5), ylim=c(-5,8),legendNCol=5, legendPos = 
"bottom", main="MDS Raw_filter")
# can't plot:  Error in getGreen(rgSet)[getProbeInfo(rgSet, type = 
"II")$AddressA, ] : subscript out of bounds
# methylumi #
require(wateRmelon)
detP_methylumi <- pval.detect(MethylumiSet2)
methylumiFILTER=pfilter(mn=MethylumiSet2,pn=detP_methylumi, 
pnthresh=0.05)
# 0 samples having 1 % of sites with a detection p-value greater 
than 0.05 were removed  
# 1437 sites were removed as beadcount <3 in 5 % of samples 
# 5604 sites having 1 % of samples with a detection p-value greater 
than 0.05 were removed 
detP_methylumi_prepro=pval.detect(methylumi_prepro)
methylumiFILTER_preprop=pfilter(mn=methylumi_prepro,pn=detP_methylum
i_prepro, pnthresh=0.05)
#this removes the same number of sites, shouldnt it remove less 
since there is background correction?
# pval.detect does sfa, it just generates one value of 0.05 for all 
the data
###  8. batch correction; Combat, RUV + limma, ISVA, CpGassoc ###
library(minfi)
library(methylumi)
#library(RUVnormalize)
source("naiveRandRUV.R") 
source("missMethylRUVFunctions.R")
### Combat ###
library(sva)
ComBat_autosomes=ComBat(dat=getBeta(Autosomes), 
batch=Autosomes@phenoData$Batch,mod=1, par.prior=TRUE, 
prior.plots=FALSE)
#Found 3 batches Found 0  categorical covariate(s) Found 908 Missing 
Data Values Standardizing Data across genes Fitting L/S model and 
finding priors Finding parametric adjustments Adjusting the Data
### limma correction then RUV ###
#################################
library(limma)
mValues2 = getMvals(Autosomes,RGsetE2)  ## calculate M-values from 
intensity data, include negative control probes (NCPs)
## create design matrix, this can include additional covariates 
(i.e. it is X and Z combined)
batch <- factor(Autosomes@phenoData$Batch)
design <- model.matrix(~batch)
coef= colnames(design)[2]
fit = lmFit(mValues2, design)
fit = eBayes(fit)
result2 = topTable(fit,coef=coef,num=Inf)
ctl2 <- rownames(mValues2) %in% rownames(result2)
[ceiling(nrow(result2)*0.5):nrow(result2)]  ## select empirical 
controls
results = naiveRandRuv(t(mValues2), ctl2, nuCoeff=1e-3, 
k=ceiling(ncol(mValues2)/4)) ## perform normalization
RUV_limma=t(results)
BetaRUV_limma=ilogit2(RUV_limma)
par(mfrow=c(1,2))
densityPlot(BetaRUV_limma,sampGroups=Autosomes@phenoData$Batch, pal 
= rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot BetaRUV_limma, Autosomes")
mdsPlot(BetaRUV_limma, numPositions=1000, 
sampNames=Raw_autosomes@phenoData$Sample_Name, 
sampGroups=Raw_autosomes@phenoData$Batch,
        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_limma")
# use optimal settings as above
results_optimal = naiveRandRuv(t(mValues2), ctl2, nuCoeff=1e5, 
k=ceiling(ncol(mValues2)/6)) ## perform normalization
RUV_limma_optimal=t(results_optimal)
BetaRUV_limma_optimal=ilogit2(RUV_limma_optimal)
par(mfrow=c(1,2))
densityPlot(BetaRUV_limma_optimal,sampGroups=Raw_autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 
xlab="Beta", main="Density plot BetaRUV_limma_optimal, Autosomes")
mdsPlot(BetaRUV_limma_optimal, numPositions=1000, 
sampNames=Raw_autosomes@phenoData$Sample_Name, 
sampGroups=Raw_autosomes@phenoData$Batch,
        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_limma_optimal")
# this looks identical to RUV without limma
### ISVA ###
library(isva)
#Independent Surrogate Variable Analysis is an algorithm for feature 
selection in the presence of potential confounding factors, 
specially designed for the analysis of large-scale high-dimensional 
quantitative genomic data (e.g microarrays). It uses Independent 
Component Analysis (ICA) to model the confounding factors as 
independent surrogate variables (ISVs). These ISVs are included as 
covariates in a multivariate regression model to subsequently 
identify features that correlate with a phenotype of interest 
independently of these confounders. The ICA implementation used is 
that of the fastICA R-package.
# try NULL and 3 and 5 for the batches for potential confounders
ISVAdata <-matrix(getBeta(Autosomes), nrow=nrow(Autosomes), 
ncol=ncol(Autosomes))
rownames(ISVAdata) <- rownames(Autosomes)
colnames(ISVAdata) <- colnames(Autosomes)
pheno <- seq(from=1, to=1, length.out=52)
cf <-matrix(Autosomes$Batch)
rownames(cf) <-colnames(Autosomes)
colnames(cf) <-"Batch"
var <- Autosomes$Affected
var <- ifelse(var =="A", 1, 2)
isva<- DoISVA(data.m=ISVAdata, pheno.v=var, cf.m=NULL, pvthCF=0.01, 
th=0.05, ncomp=NULL)
# no matterv what I do :
#Error in lm.fit(x, y, offset = offset, singular.ok = 
singular.ok, ...) : 0 (non-NA) cases
isvaFn(data.m=ISVAdata, pheno.v=pheno, ncomp=NULL )
#same error as above
### CpGassoc ###
#cpg.assoc is designed to test for association between an 
independent variable and methylation at a number of CpG sites, with 
the option to include additional covariates and factors. cpg.assoc 
assesses sig- nificance with the Holm (step-down Bonferroni) and FDR 
methods. 
library(CpGassoc)
cpgAss <- cpg.assoc(beta.val=ISVAdata, indep=Autosomes$Batch, 
covariates= NULL, logit.transform=TRUE, chip.id=Autosomes$Slide, 
random=FALSE)
#use it to check if there is a batch effect still present after norm 
etc???
#Warning messages:
1: In rm(non.m.beta, sser, ssef, beta0, r.ressq) : object 'sser' not 
found
2: In rm(non.m.beta, sser, ssef, beta0, r.ressq) : object 'ssef' not 
found
3: In rm(non.m.beta, sser, ssef, beta0, r.ressq) :
  object 'beta0' not found
4: In rm(non.m.beta, sser, ssef, beta0, r.ressq) :
  object 'r.ressq' not found
### Streamlined processing ###
# ChAMP -- seems to be able to do practically everything and has an 
inbuilt all in one pipeline command 'champ.process'
library(ChAMP)
champ <- champ.process(fromIDAT=TRUE, directory="/Users/ecazaly/
Desktop/R Dec14/Raw IDATs/IDATs_passed", methValue="B", 
filterDetP=TRUE, detPcut=0.05, filterXY=TRUE, QCimages=TRUE, 
filterBeads=TRUE, beadCutoff=0.05, batchCorrect=TRUE, runSVD=TRUE, 
norm="SWAN", adjust.method="BH", runDMR=FALSE, runCNA=FALSE, 
plotBMIQ=TRUE)
# this removes practically all the proibes because of the failed 
samples.  Run only the samples that have previously passed QC
bad=c(9,17,22,24,27,29,40,42)
densityPlot(RGsetE[,bad],sampGroups=RGsetE[,bad]@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="RGsetE bad")
colnames(RGsetE[,bad])
[1] "8795207059_R05C01" "8784225156_R03C01" "8784225156_R05C02"
[4] "8784225156_R06C02" "5975827011_R03C01" "5975827011_R05C01"
[7] "9221197159_R02C02" "9221197159_R03C02"
# these have been removed form the directory "IDATs_passed" used 
above to call the champ function
# won't let me run combat with the batches as Sample_Group
# Combat failed...Your slides may be confounded with batch or with 
each other. Analysis will proceed without batch correction
# and the normalisation is pretty shit, density plots look worse 
than raw- ie. more prominent batches
# compare norm methods, have XY filter included
champ_data <- champ.load(directory="/Users/ecazaly/Desktop/R Dec14/
Raw IDATs/IDATs_passed", resultsDir="/Users/ecazaly/Desktop/R Dec14/
ChampLoad", methValue="B", filterXY=TRUE, QCimages=TRUE, 
filterDetP=TRUE, detPcut=0.05, filterBeads=TRUE, beadCutoff=0.05, 
filterNoCG=FALSE)
# creates a list of 6 objects which include: 1. minfi MethylSet 
object, 2. minfi RGset, 3.pd, 4. intensity, 5. beta, 6. detP
# removes the same DetP failed probes as other methods: Filtering 
probes with a detection p-value above 0.05 in more than one sample 
has removed 6740 probes from the analysis. If a large number of 
probes have been removed, ChAMP suggests you look at the 
failedSample.txt file to identify potentially bad samples. Filtering 
probes with a beadcount <3 in at least 5% of samples, has removed 
478 from the analysis. Zeros in your dataset have been replaced with 
0.000001 
# The analysis will proceed with 467448 probes and 52 samples.  
Takes out 10846 sex chr: 478294-467448
# it also removed sex chr
champ_Annotated<- getAnnotation(champ_data$mset)
which(champ_Annotated@listData$chr=="chrX")  #integer(0)
champ_data_withXY <- champ.load(directory="/Users/ecazaly/Desktop/R 
Dec14/Raw IDATs/IDATs_passed", resultsDir="/Users/ecazaly/Desktop/R 
Dec14/ChampLoad_withXY", methValue="B", filterXY=FALSE, 
QCimages=TRUE, filterDetP=TRUE, detPcut=0.05, filterBeads=TRUE, 
beadCutoff=0.05, filterNoCG=FALSE)
#The analysis will proceed with 478294 probes and 52 samples.
## Norm methods ##
champ_preprocess <- preprocessRaw(champ_data$rgSet)   
    
champ_StratQN <-preprocessQuantile(champ_data$mset, 
fixOutliers=TRUE, removeBadSamples=FALSE, quantileNormalize=TRUE, 
stratified=TRUE, , mergeManifest=TRUE, sex= champ_data
$mset@phenoData@data$Sex, verbose=TRUE)
champ_FunNorm <- preprocessFunnorm(champ_data$rgSet, nPCs=2, 
sex=champ_data$mset@phenoData@data$Sex, bgCorr=TRUE, dyeCorr=TRUE, 
verbose=TRUE)
champ_SWAN <-preprocessSWAN(champ_data$rgSet, mSet=champ_data$mset) 
champ_Dasen<- as.matrix(dasen(methylated(champ_data
$mset),unmethylated(champ_data$mset),onetwo= getProbeType(champ_data
$mset), fudge=100))
mValues_champ = getMvals(champ_data$mset,champ_data$rgSet) 
ctl_champ <- !(rownames(mValues_champ) %in% 
featureNames(champ_data))  
result_champ= naiveRandRuv(t(mValues_champ), ctl_champ, 
nuCoeff=1e-3, k=ceiling(ncol(mValues_champ)/4))  
champ_RUV <-t(result_champ) 
result_champ_optimal= naiveRandRuv(t(mValues_champ), ctl_champ, 
nuCoeff=1e5, k=ceiling(ncol(mValues_champ)/6)) 
RUV_champ_optimal=t(result_champ_optimal)
BetaRUV_champ_optimal=ilogit2(RUV_champ_optimal)
champ_QN <- 
normalizeMethylation.quantile(as.matrix(methylated(champ_data
$mset),unmethylated(champ_data$mset)))  #... doesn't work:Error in 
#normalizeMethylation.quantile(champ_data$rgSet) : The input should 
include 'methylated' and 'unmethylated' elements in the assayData 
slot!
design.v <- getProbeType(champ_data$mset)
design.v <- ifelse(design.v=="I", "1","2")
champ_BMIQ <- BMIQ(getBeta(champ_data$mset), design.v=design.v2))
# looks the same if I poerform the norm on dat initially leaving in 
the Xy but filtering during norm
# From minfi; Noob is a background correction method with dye-bias 
normalization for the Illumina Infinium HumanMethylation450 
platform.
champ_Noob <- preprocessNoob(champ_data$rgSet,offset=15, 
dyeCorr=TRUE, verbose=TRUE)
densityPlot(champ_Noob,sampGroups= champ_Noob@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1),ylim=c(0,4), xlab="Beta", main="Density 
plot champ_Noob data")
mdsPlot(champ_Noob, numPositions=1000, sampNames= 
champ_Noob@phenoData$Sample_Name, sampGroups= champ_Noob@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- champ_Noob")
## Chapter.3 Appendix_2:  test normalisation methods ##
## Performance Metrics ##
#1.  Density plots; to examine QC samples, batch effects and also 
type I vs II distribution z1
    plotBetasByType
#2. MDS / PCA plots: 
# a.possibly with wilcoxon test to check for associations between 
the first few PCs/dimensions and batch variable princomp= function  
# b. ANOVA to check for the proportion of CpGs associated with 
batches?  
#3. Unsupervised hierarchical clustering 
#4. Replicate samples
# a. visually examining density and MDS plots 
# b. Mean absolute difference in M values between replicates- 
may need help with an algorithm for this if I can’t find something 
in a package or supp material   
#5. Diagnostic methods in the wateRmelon package; iDMRs, XCI, 
65snps - standard error type measurement for each (DMRSE, 1-AUC, 
GCOSE)
#6. Positive Controls
##########################################
##  1. Density plots & plotBetasByType  ##
##########################################
# Raw
par(mfrow=c(1,4))
densityPlot(Raw_preprocess,sampGroups=Raw_preprocess@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="Raw_preprocess")
densityPlot(Autosomes,sampGroups=Autosomes@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Autosomes_preprocess")
densityPlot(Male_chr,sampGroups= Male_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Male_chr")
densityPlot(Female_chr,sampGroups= Female_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Female_chr")
par(mfrow=c(1,4))
plotBetasByType(Raw_preprocess[,7], main="Raw by probe, all")
plotBetasByType(Autosomes[,7], main="Raw by probe, Autosomes")
plotBetasByType(Male_chr[,7], main="Raw by probe, Male_chr")
plotBetasByType(Female_chr[,7], main="Raw by probe, Female_chr")
# Stratified QN: StratQN
par(mfrow=c(1,4))
densityPlot(getBeta(StratQN),sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Stratified QN, autosomes")
plotBetasByType(getBeta(StratQN)[,7], type_autosomes, 
main="Stratified QN, Autosomes")
densityPlot(getBeta(StratQN_all),sampGroups= 
Raw_preprocess@phenoData$Batch, pal = rainbow(3), xlim=c(-.
1,1.2),ylim=c(0,3.6), xlab="Beta", main="Stratified QN, all")
plotBetasByType(getBeta(StratQN_all)[,7], type_autosomes, 
main="Stratified QN, all")
# FunNorm:  FunNorm, only have unprocessed all chr together, 
separate?
par(mfrow=c(1,2))
densityPlot(FunNorm,sampGroups= FunNorm@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="FunNorm")
plotBetasByType(FunNorm[,7], main="FunNorm by probe, all")
#SWAN: swan, swan_autosomes, swan_maleChr, swan_femaleChr
par(mfrow=c(1,4))
densityPlot(swan,sampGroups= swan@phenoData$Batch, pal = rainbow(3), 
xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", main="swan")
densityPlot(swan_autosomes,sampGroups= swan_autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="swan_autosomes")
densityPlot(swan_maleChr,sampGroups= swan_maleChr@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="swan_maleChr")
densityPlot(swan_femaleChr,sampGroups= swan_femaleChr@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="Female_chr")
par(mfrow=c(1,4))
plotBetasByType(swan[,7], main="SWAN by probe, all")
plotBetasByType(swan_autosomes[,7], main="SWAN by probe, Autosomes")
plotBetasByType(swan_maleChr[,7], main="SWAN by probe, Male_chr")
plotBetasByType(swan_femaleChr[,7], main="SWAN by probe, 
Female_chr")
# Dasen: Dasen, Dasen_autosomes, Dasen_male, Dasen_female
par(mfrow=c(1,4))
densityPlot(Dasen,sampGroups= Raw_preprocess@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen")
densityPlot(Dasen_autosomes,sampGroups= Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen_autosomes")
densityPlot(Dasen_male,sampGroups= Male_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen_male")
densityPlot(Dasen_female,sampGroups= Female_chr@phenoData$Batch, pal 
= rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen_female")
# These last two graphs look really odd, again I think it's an issue 
in calling the probe types
par(mfrow=c(1,4))
plotBetasByType(Dasen[,7], probeType=probeTypes_Dasen , main="Dasen 
by probe, all")
plotBetasByType(Dasen_autosomes[,7], 
probeType=probeTypes_autosomes2 , main="Dasen by probe, Autosomes")
# wont plot the last 2, maybe missing too many sites 
plotBetasByType(Dasen_male[,7], 
probeType=probeTypes_autosomes2_male, main="Dasen by probe, 
Male_chr")
plotBetasByType(Dasen_female[,7], 
probeType=probeTypes_autosomes2_female, main="Dasen by probe, 
Female_chr")
#RUV: BetaRUV_autosomes, BetaRUV_autosomes_optimal, BetaRUV_male, 
BetaRUV_female, BetaRUV_male_optimal, BetaRUV_female_optimal 
par(mfrow=c(1,6))
densityPlot(BetaRUV_autosomes,sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Autosomes")
densityPlot(BetaRUV_autosomes_optimal,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Autosomes_Optimal")
densityPlot(BetaRUV_male,sampGroups=Male_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", main="Density 
plot RUV data, Male_chr")
densityPlot(BetaRUV_female,sampGroups=Female_chr@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Female_chr")
densityPlot(BetaRUV_male_optimal,sampGroups=Male_chr@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Male_chr_optimal")
densityPlot(BetaRUV_female,sampGroups=Female_chr@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Female_chr")
par(mfrow=c(1,6))
plotBetasByType(BetaRUV_autosomes[,1], type , main="Autosomes 
BetaRUV by type", cex.legend=.8, legendPos="topright") 
plotBetasByType(BetaRUV_autosomes_optimal[,1], type , 
main="Autosomes_optimal BetaRUV by type", cex.legend=.8, 
legendPos="topright") 
plotBetasByType(BetaRUV_male[,1], type_male , main="Male_chr BetaRUV 
by type", cex.legend=.8, legendPos="topright") 
plotBetasByType(BetaRUV_female[,1], type_female , main="Female_chr 
BetaRUV by type", cex.legend=.8, legendPos="topright") 
plotBetasByType(BetaRUV_male_optimal[,1], type_male , 
main="Male_chr_optimal BetaRUV by type", cex.legend=.8, 
legendPos="topright")
plotBetasByType(BetaRUV_female_optimal[,1], type_female , 
main="Female_chr_optimal BetaRUV by type", cex.legend=.8, 
legendPos="topright")
#QN: lumiQNbetas
par(mfrow=c(1,2))
densityPlot(lumiQNbetas,sampGroups=lumiQN_prepro@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot lumiQN data, All chr")
plotBetasByType(lumiQNbetas[,1], probeTypes=type_methylumi, 
main="lumiQNbetas by probe")
#BMIQ: BMIQ
par(mfrow=c(1,2))
densityPlot(BMIQ_betas,sampGroups=BMIQ@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1),ylim=c(0,4), xlab="Beta", main="Density 
plot BMIQ data, All chr")
plotBetasByType(BMIQ_betas[,1], probeTypes=type_BMIQ, main="BMIQ by 
probe")
#Limma and RUV
par(mfrow=c(1,2))
densityPlot(BetaRUV_limma,sampGroups=Autosomes@phenoData$Batch, pal 
= rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot BetaRUV_limma, Autosomes")
densityPlot(BetaRUV_limma_optimal,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 
xlab="Beta", main="Density plot BetaRUV_limma_optimal, Autosomes")
par(mfrow=c(1,2))
plotBetasByType(BetaRUV_limma[,1], probeTypes=probeTypes_autosomes2, 
main="BetaRUV_limma, Autosomes by probe")
plotBetasByType(BetaRUV_limma_optimal[,1], 
probeTypes=probeTypes_autosomes2, main="BetaRUV_limma_optimal, 
Autosomes by probe")
#Combat
par(mfrow=c(1,2))
densityPlot(ComBat_autosomes,sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot Combat, Autosomes")
plotBetasByType(ComBat_autosomes[,1], 
probeTypes=probeTypes_autosomes2, main="Combat, Autosomes by probe")
--------------------------------------------------------------------
---------------------------
####################
# 2. MDS plots   ###
####################
# Raw: Raw_preprocess, Autosomes, Male_chr, Female_chr
par(mfrow=c(1,4))
mdsPlot(Raw_preprocess, numPositions=1000, 
sampNames=Raw_preprocess@phenoData$Sample_Name, 
sampGroups=Raw_preprocess@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
Raw_preprocess")
mdsPlot(Autosomes, numPositions=1000, sampNames=Autosomes@phenoData
$Sample_Name, sampGroups=Autosomes@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- Raw 
Autosomes")
mdsPlot(Male_chr, numPositions=1000, sampNames=Male_chr@phenoData
$Sample_Name, sampGroups=Male_chr@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
Male_chr")
mdsPlot(Female_chr, numPositions=1000, 
sampNames=Female_chr@phenoData$Sample_Name, 
sampGroups=Female_chr@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
Female_chr")
# StratQN
par(mfrow=c(1,2))
mdsPlot(getBeta(StratQN), numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- StratQN")
mdsPlot(getBeta(StratQN_all), numPositions=1000, sampNames= 
Raw_preprocess@phenoData$Sample_Name, sampGroups= 
Raw_preprocess@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
StratQN_all")
# FunNorm: Raw_preprocess, need to figure out how to separate sex 
chr
mdsPlot(FunNorm_betas, numPositions=1000, 
sampNames=RGsetE2@phenoData$Sample_Name, 
sampGroups=RGsetE2@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
FunNorm")
# SWAN: swan, swan_autosomes, swan_maleChr, swan_femaleChr
par(mfrow=c(1,4))
mdsPlot(swan, numPositions=1000, sampNames=swan@phenoData
$Sample_Name, sampGroups=swan@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- SWAN")
mdsPlot(swan_autosomes, numPositions=1000, sampNames= 
swan_autosomes@phenoData$Sample_Name, sampGroups= 
swan_autosomes@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
swan_autosomes")
mdsPlot(swan_maleChr, numPositions=1000, sampNames= 
swan_maleChr@phenoData$Sample_Name, sampGroups= 
swan_maleChr@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
swan_maleChr")
mdsPlot(swan_femaleChr, numPositions=1000, 
sampNames=swan_femaleChr@phenoData$Sample_Name, 
sampGroups=swan_femaleChr@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
swan_femaleChr")
# Dasen: Dasen,Dasen_autosomes, Dasen_male, Dasen_female
par(mfrow=c(1,4))
mdsPlot(Dasen, numPositions=1000, sampNames= 
Raw_preprocess@phenoData$Sample_Name, sampGroups= 
Raw_preprocess@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- Dasen")
mdsPlot(Dasen_autosomes, numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- Dasen_autosomes")
mdsPlot(Dasen_male, numPositions=1000, sampNames= Male_chr@phenoData
$Sample_Name, sampGroups= Male_chr@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
Dasen_male")
mdsPlot(Dasen_female, numPositions=1000, sampNames= 
Female_chr@phenoData$Sample_Name, sampGroups= Female_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- Dasen_female")
# male and female separate with dasen doesn't work
# RUV: BetaRUV_autosomes, BetaRUV_autosomes_optimal, BetaRUV_male, 
BetaRUV_female, BetaRUV_male_optimal, BetaRUV_female_optimal
par(mfrow=c(1,6))
mdsPlot(BetaRUV_autosomes, numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_autosomes")
mdsPlot(BetaRUV_autosomes_optimal, numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_autosomes_optimal")
mdsPlot(BetaRUV_male, numPositions=1000, sampNames= 
Male_chr@phenoData$Sample_Name, sampGroups= Male_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_male")
mdsPlot(BetaRUV_female, numPositions=1000, sampNames= 
Female_chr@phenoData$Sample_Name, sampGroups= Female_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_female")
mdsPlot(BetaRUV_male_optimal, numPositions=1000, sampNames= 
Male_chr@phenoData$Sample_Name, sampGroups= Male_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_male_optimal")
mdsPlot(BetaRUV_female_optimal, numPositions=1000, sampNames= 
Female_chr@phenoData$Sample_Name, sampGroups= Female_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_female_optimal")
# QN - lumiQNbetas, need to figure out how to separate sex chr
mdsPlot(lumiQNbetas, numPositions=1000, sampNames= 
methylumi_prepro@phenoData$Sample_Name, sampGroups= 
methylumi_prepro@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
lumiQNbetas")
# BMIQ - BMIQ, need to figure out how to separate sex chr
mdsPlot(BMIQ_betas, numPositions=1000, sampNames= 
methylumi_prepro@phenoData$Sample_Name, sampGroups= 
methylumi_prepro@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- BMIQ")
--------------------------------------------------------------------
------------
#####################################################
## 2b. ANOVA on the PCA of the 1000 variable sites ##
#####################################################
Raw_SD<- as.matrix(apply(Raw_manual_M,1,sd))
Raw_order<- Raw_SD[rev(order(Raw_SD)),]
Raw_Top1000<-as.matrix(Raw_order[1:1000])
Raw_Top1000_cpgs <- rownames(Raw_Top1000)
StratQN_M_SD<- as.matrix(apply(StratQN_M,1,sd))
StratQN_M_SD_order<- StratQN_M_SD[rev(order(StratQN_M_SD)),]
StratQN_M_SD_Top1000<-as.matrix(StratQN_M_SD_order[1:1000])
StratQN_M_SD_Top1000_cpgs <- rownames(StratQN_M_SD_Top1000)
match(Raw_Top1000_cpgs, StratQN_M_SD_Top1000_cpgs)  # some do
length(which(StratQN_M_SD_Top1000_cpgs %in% Raw_Top1000_cpgs)) # 774 
match
Combat_StratQN_SD<- as.matrix(apply(Combat_StratQN_corrected_M,
1,sd))
Combat_StratQN_SD_order<- 
Combat_StratQN_SD[rev(order(Combat_StratQN_SD)),]
Combat_StratQN_SD_Top1000<-
as.matrix(Combat_StratQN_SD_order[1:1000])
Combat_StratQN_SD_Top1000_cpgs <- 
rownames(Combat_StratQN_SD_Top1000)
length(which(StratQN_M_SD_Top1000_cpgs %in% 
Combat_StratQN_SD_Top1000_cpgs))  # 730
length(which(Raw_Top1000_cpgs %in% Combat_StratQN_SD_Top1000_cpgs))  
#563
prcomp_Raw_Top1000 <- prcomp(t(Raw_manual_M[Raw_Top1000_cpgs,]))
anova_pc1_Raw1000_Family<- aov(prcomp_Raw_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Family))
summary(anova_pc1_Raw1000_Family)  # p-val   0.00143 **
prcomp_StratQN_Top1000 <- 
prcomp(t(StratQN_M[StratQN_M_SD_Top1000_cpgs,]))
anova_pc1_StratQN1000_Family <- aov(prcomp_StratQN_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Family))
summary(anova_pc1_StratQN1000_Family)  # p-val  0.000381
prcomp_Combat_StratQN_Top1000 <- 
prcomp(t(Combat_StratQN_corrected_M[Combat_StratQN_SD_Top1000_cpgs,]
))
anova_pc1_Combat_StratQN1000_Family <- 
aov(prcomp_Combat_StratQN_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Family))
summary(anova_pc1_Combat_StratQN1000_Family)  # p-val  0.000795 
# Now use the same method to look at how much clustering is due to 
batch
anova_pc1_Raw1000_Batch <- aov(prcomp_Raw_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Batch))
summary(anova_pc1_Raw1000_Batch)  # p-val <2e-16 ***  highly sig 
anova_pc1_StratQN1000_Batch <- aov(prcomp_StratQN_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Batch))
summary(anova_pc1_StratQN1000_Batch)  # p-val 6.04e-10 ***  less sig
anova_pc1_Combat_StratQN1000_Batch <- 
aov(prcomp_Combat_StratQN_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Batch))
summary(anova_pc1_Combat_StratQN1000_Batch)  # p-val  0.97  NOT 
SIGNIFICANT, this is what expected
# Table of ANOVA of PC1 
aov_pval_table <- matrix(c(summary(anova_pc1_Raw_manual_M)[[1]]
[["Pr(>F)"]][[1]],summary(anova_pc1_M_QN)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_StratQN_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_BMIQ_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_SWAN_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc2_FunNorm_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_Dasen_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_Noob_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_RUV_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_RUV_limma_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_ComBat_M)[[1]][["Pr(>F)"]][[1]], 
summary(anova_pc1_ComBat_StratQN_M)[[1]][["Pr(>F)"]][[1]]), nrow=12, 
ncol=1) 
colnames(aov_pval_table)= c("P-val")
rownames(aov_pval_table)= c("Raw", "Qantile Normalisation", 
"Stratified Quantile Normalisation", "BMIQ", "SWAN", "Functional 
Normalisation", "Dasen", "Noob", "RUV", "RUV with limma", "Raw with 
ComBat", "Stratified Quantile Normalisation with ComBat")
write.csv(aov_pval_table,file= "ANOVA pvals.csv")
--------------------------------------------------------------------
------------
####################################################################
#############
## 3. Unsupervised hierarchial clustering--- takes an excessive 
amount of time ##
####################################################################
#############
library(pvclust)
Raw_d_names <- getM(champ_data_mset_corrected)
colnames(Raw_d_names) <- champ_data_beta$mset@phenoData$Sample_Name
hc_Raw_names <- hclust(dist(t(Raw_d_names), method="euclidean"), 
method="single")
StratQN_d_names <- getM(champ_StratQN)
colnames(StratQN_d_names) <- champ_data_beta$mset@phenoData
$Sample_Name
hc_StratQN_names <- hclust(dist(t(StratQN_d_names), 
method="euclidean"), method="single")
StratQNcombat_d_names <- logit2(Combat_StratQN)
colnames(StratQNcombat_d_names) <- champ_data_beta$mset@phenoData
$Sample_Name
hc_StratQNcombat_names <- hclust(dist(t(StratQNcombat_d_names), 
method="euclidean"), method="single")
par(mfrow=c(1,3))
plot(hc_Raw_names, main="Cluster Dendrogram by Batch: 
Raw")
plot(hc_StratQN_names, main="Cluster Dendrogram by Batch: 
Stratified QN") 
plot(hc_StratQNcombat_names, main="Cluster Dendrogram by Batch: 
Stratified QN, ComBat corrected") 
## label by batch
Raw_d_batch <- getM(champ_data_mset_corrected)
colnames(Raw_d_batch) <- champ_data_beta$mset@phenoData$Batch
hc_Raw_batch <- hclust(dist(t(Raw_d_batch), method="euclidean"), 
method="single")
StratQN_d_batch <- getM(champ_StratQN)
colnames(StratQN_d_batch) <- champ_data_beta$mset@phenoData$Batch
hc_StratQN_batch <- hclust(dist(t(StratQN_d_batch), 
method="euclidean"), method="single")
StratQNcombat_d_batch <- logit2(Combat_StratQN)
colnames(StratQNcombat_d_batch) <- champ_data_beta$mset@phenoData
$Batch
hc_StratQNcombat_batch <- hclust(dist(t(StratQNcombat_d_batch), 
method="euclidean"), method="single")
par(mfrow=c(3,1))
plot(hc_Raw_batch, main="Cluster Dendrogram by Batch: 
Raw")
plot(hc_StratQN_batch, main="Cluster Dendrogram by Batch: 
Stratified QN") 
plot(hc_StratQNcombat_batch, main="Cluster Dendrogram by Batch: 
Stratified QN, ComBat corrected") 
--------------------------------------------------------------------
------------
############################# 
## 4. Replicate samples  ##
#############################
# Density plots and MDS to visualise effects of normalisation then 
compare the mean absolute diff in M values between diff replicates
# There are 3 different samples that have technical replicates that 
passed QC:  22-16, 22-17, 72-213
Replicates <- Raw_preprocess[,c(6,27,8,28,31,41,16,18)]
# which batches/plates do they belong to?
Replicates@phenoData$Batch  # [1] 1 2 1 2 3 3 1 1
Replicates@phenoData$Plate  # [1] 1 3 1 3 4 5 2 2
Replicates_Mvals <- getM(Replicates)
colnames(Replicates_Mvals)=Replicates@phenoData$Sample_Name
#[1] "pc22-16"        "PC22-16 (AH9)"  "pc22-17"       
#[4] "PC22-17 (AH10)" "PC22-17a"       "PC22-17b"      
#[7] "pc72-213a"      "pc72-213b"
#  M = logit(Beta) = log( Meth / Unmeth )  This formula has problems 
if either Meth or Unmeth is zero. For this reason, we can use 
betaThreshold to make sure Beta is neither 0 nor 1, before taken the 
logit. What makes sense for the offset and betaThreshold depends 
crucially on how the data was preprocessed. Do not expect the 
default values to be particular good.
# type
How are the values calculated? For getBeta setting type="Illumina" 
sets offset=100 as per Genome Studio. For getM setting type="" 
computes M-values as the logarithm of Meth/Unmeth, otherwise it is 
computed as the logit of getBeta(object).
Replicates_Mvals2 <- getM(Replicates, type="", offset=100, 
betaThreshold=TRUE)
summary(Replicates_Mvals2[,2]) 
# changing these argumenst does nothing to change the number of 
infinite values!!
beta_default  <- getBeta(Replicates)
beta_illumina <- getBeta(Replicates, type="Illumina")
beta_threshold_100 <- getBeta(Replicates, offset=100)
beta_threshold_50 <- getBeta(Replicates, offset=50)
beta_illumina[1:10] # sets offset to 100 as genome studio does
beta_default[1:10]  # these values are slightly higher than illumina 
and include 1.0000, ie no there is no offset and the M-values would 
have issues
beta_threshold_100[1:10] # same as illumina
beta_threshold_50[1:10] # slightly higher values
Mvals_default <-getM(Replicates)  #logit of getBeta(object) 
Mvals_default[1:10]  # this has inf for the 3rd value which was 1 
before
Mvals_methUnmeth <- getM(Replicates, type="")  # logarithm of Meth/
Unmeth
Mvals_methUnmeth[1:10] # same as default, inf at 3
Mvals_threshold <- getM(Replicates, type="", betaThreshold=TRUE) # 
same with or without type
Mvals_threshold[1:10]  # same as default, inf at 3 -- this shouldn't 
be the case since threshold is specified... need to do it manually
# manually 
Mvals_manual <- logit2(beta_default)
Mvals_manual[1:10]  #this is identical to Mvals_default, inf at 3 
Mvals_manual_illumina <- logit2(beta_illumina)  ## use this
Mvals_manual_illumina[1:10]  # slightly lower values, the 3rd value 
is not infinite
Mvals_manual_threshold100 <- logit2(beta_threshold_100)
Mvals_manual_threshold100[1:10] # identical to illumina one
Mvals_manual_threshold50 <- logit2(beta_threshold_50)
Mvals_manual_threshold50[1:10]  #slightly higher than threshold of 
100
# Don't use the default beta values because they contain 1s, use: 
Mvals_manual_illumina
logMethUnmeth <- logit2(getMeth(Replicates) / getUnmeth(Replicates))
logMethUnmeth[1:10]
beta_man <- getMeth(Replicates) / (getMeth(Replicates) + 
getUnmeth(Replicates) + 100)  # maybe I need to keep adjusting the 
offset so it makes the 0s big enough that their log is not -inf?? so 
a sml threshold?   no :(   no it won't make a difference what the 
threshold is if meth is 0 because the numerator will be 0... need to 
add the offset to the top!  Beta = Meth / (Meth + Unmeth + offset)
beta_man[1:10]
beta_man_M <- logit2(beta_man)
length(which(beta_man_M[,1]==-Inf))
beta_man2 <- (getMeth(Replicates) +100) / (getMeth(Replicates) + 
getUnmeth(Replicates) +100)
beta_man2[1:10]
beta_man_M2 <- logit2(beta_man2)
length(which(beta_man_M2[,1]==-Inf))  # yesssss this gets rid of the 
negative infinity values but because adding the same number top and 
bottom cancels out it creates + infinite values as beta can now be 
equal to 1. If I add an offset of 50 to the top and 100 to the 
bottom will this affect the value in a biased manner?
beta_man3 <- (getMeth(Replicates) +99.9) / (getMeth(Replicates) + 
getUnmeth(Replicates) +100)
beta_man3[1:10]
beta_man_M3 <- logit2(beta_man3)
length(which(beta_man_M3[,1]==-Inf))  # yes both are length 0 :):):) 
but has it changed values in a biased way.. if I make the difference 
between them very small, say .1
# Use
Replicates_Mvals <- beta_man_M3
# look out for infinite values:  
summary(Replicates_Mvals[,1]) 
#   Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
# -7.6320 -3.0330  0.8257  0.3039  3.0100 17.6600 
summary(Replicates_Mvals[,2])  
# Min. 1st   Qu.  Median    Mean 3rd Qu.    Max.    
# -7.2020 -2.9490  0.9983  0.3781  3.1330 16.9400
summary(Replicates_Mvals[,3]) 
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.    
#   -7.7050 -3.0970  0.9217  0.3675  3.1950 17.9200
summary(Replicates_Mvals[,4])  
#  Min.  1st Qu.  Median    Mean 3rd Qu.    Max.   
#  -7.2920 -3.1900  1.0640  0.3447  3.2780 17.2000 
summary(Replicates_Mvals[,5]) 
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.    
#  -8.87800 -3.13200  0.63340  0.08353  2.63400 18.76000   
summary(Replicates_Mvals[,6])  
#    Min. 1st Qu.  Median    Mean 3rd Qu.    Max.    
#   -7.9550 -2.9350  0.7339  0.2195  2.8100 18.1800 
summary(Replicates_Mvals[,7])  
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.   
#  -7.3840 -2.8220  0.9293  0.3257  3.0050 17.4500 
summary(Replicates_Mvals[,8])  
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.   
#   -7.4520 -2.7940  0.9521  0.3328  3.0040 17.4400  
   
# how is the data diustributed?  # skewed to the left
tail(Replicates_Mvals[,1])
hist(Replicates_Mvals[,1])  
tail(Replicates_Mvals[,2])
hist(Replicates_Mvals[,2]) 
tail(Replicates_Mvals[,3])
hist(Replicates_Mvals[,3])  
tail(Replicates_Mvals[,4])
hist(Replicates_Mvals[,4]) 
tail(Replicates_Mvals[,5])
hist(Replicates_Mvals[,5]) 
tail(Replicates_Mvals[,6])
hist(Replicates_Mvals[,6]) 
tail(Replicates_Mvals[,7])
hist(Replicates_Mvals[,7]) 
tail(Replicates_Mvals[,8])
hist(Replicates_Mvals[,8])
 
###### 
# 1: "pc22-16"  batch 1, chip 1      
# 2: "PC22-16 (AH9)" batch 2, chip 3
# 3: "pc22-17" batch 1, chip 1
# 4: "PC-17 (AH10)" batch 2, chip 3
# 5: "PC22-17a" batch 3, chip 4
# 6: "PC22-17b" batch 3, chip 5
# 7: "pc72-213a"     batch 1, chip 2
# 8: "pc72-213b"     batch 1, chip 2
# Compare:  
# 1. 22.16 (1 & 2)    diff plate, diff batch (one OS, one here)  
"pc22-16"        "PC22-16 (AH9)"
# 2. 72.213 (7 & 8)   same plate, same batch, different 
sample(array) : Expect to be smallest diff
22.17 (3,4,5,6)  all different plates, 3/4 different 
batches
# 3. 22.17 (3,4)      diff plate, diff batch
# 4. 22.17 (3,5)    diff plate, diff batch
# 5. 22.17 (3,6)   diff plate, diff batch
# 6. 22.17 (4,5)    diff plate, diff batch
# 7. 22.17 (4,6)      diff plate, diff batch
# 8. 22.17 (5,6)    diff plate, same batch  : expect 
middle diff
# 9. (1 & 3) compare diff samples same batch, same plate
#10. (3,7) diff sample, same batch , diff plate
#11. (6,7) diff sample, diff batch, diff plate
#1.
#MeanDiff_22.16=mean(abs(Replicates_Mvals[,1] - Replicates_Mvals[,
2])) #  0.6772961
MeanDiffb_22.16=abs(mean(Replicates_Mvals[,1]) - 
mean(Replicates_Mvals[,2])) # 0.07418344
# which way?
#2
MeanDiffb_72.213=abs(mean(Replicates_Mvals[,7]) - 
mean(Replicates_Mvals[,8])) # 0.007016831
#3
MeanDiffb_22.17=abs(mean(Replicates_Mvals[,3]) - 
mean(Replicates_Mvals[,4])) # 0.02274291
#4
MeanDiffb_22.17=abs(mean(Replicates_Mvals[,3]) - 
mean(Replicates_Mvals[,5])) # 0.2839539
#5
MeanDiffb_22.17=abs(mean(Replicates_Mvals[,3]) - 
mean(Replicates_Mvals[,6])) # 0.1479692
#6
MeanDiffb_22.17=abs(mean(Replicates_Mvals[,4]) - 
mean(Replicates_Mvals[,5])) # 0.261211
#7
MeanDiffb_22.17=abs(mean(Replicates_Mvals[,4]) - 
mean(Replicates_Mvals[,6])) # 0.1252263
#8
MeanDiffb_22.17=abs(mean(Replicates_Mvals[,5]) - 
mean(Replicates_Mvals[,6])) # 0.1359847
-------
#9
MeanDiffb_batch1 <- abs(mean(Replicates_Mvals[,1])-
mean(Replicates_Mvals[,3])) # 0.06358556
#10
MeanDiffb_plate <- abs(mean(Replicates_Mvals[,3])-
mean(Replicates_Mvals[,7])) # 0.04174628
#11
MeanDiffb_plate <- abs(mean(Replicates_Mvals[,6])-
mean(Replicates_Mvals[,7])) # 0.1062229
# these should be much bigger differences than the diff between the 
samples but aren't.  THis is preprocessed data so batch effects 
haven't been removed yet, thus makes sense
#1  rep 22.16:  diff plate, diff batch
table_replicate_medians_rep16 <- matrix(c(medianDiff_22.16_raw, 
medianDiff_22.16_QN, medianDiff_22.16_champ_StratQN, 
medianDiff_22.16_BMIQ, medianDiff_22.16_SWAN, 
medianDiff_22.16_FunNorm, medianDiff_22.16_Dasen, 
medianDiff_22.16_Noob, medianDiff_22.16_BetaRUV, 
medianDiff_22.16_BetaRUV_limma, medianDiff_22.16_ComBat, 
medianDiff_22.16_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep16) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep16) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep16, file="Replicate.1 Median 
Diffs.csv")
#2  72.213:  same batch, same plate
table_replicate_medians_rep72.213 <- matrix(c(medianDiff_72.213_raw, 
medianDiff_72.213_QN, medianDiff_72.213_champ_StratQN, 
medianDiff_72.213_BMIQ, medianDiff_72.213_SWAN, 
medianDiff_72.213_FunNorm, medianDiff_72.213_Dasen, 
medianDiff_72.213_Noob, medianDiff_72.213_BetaRUV, 
medianDiff_72.213_BetaRUV_limma, medianDiff_72.213_ComBat, 
medianDiff_72.213_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep72.213) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep72.213) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep72.213, file="Replicate.2 
Median Diffs.csv")
#3 22.17a:  diff plate, diff batch
table_replicate_medians_rep22.17a <- matrix(c(medianDiff_22.17a_raw, 
medianDiff_22.17a_QN, medianDiff_22.17a_champ_StratQN, 
medianDiff_22.17a_BMIQ, medianDiff_22.17a_SWAN, 
medianDiff_22.17a_FunNorm, medianDiff_22.17a_Dasen, 
medianDiff_22.17a_Noob, medianDiff_22.17a_BetaRUV, 
medianDiff_22.17a_BetaRUV_limma, medianDiff_22.17a_ComBat, 
medianDiff_22.17a_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep22.17a) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep22.17a) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep22.17a, file="Replicate.3 
Median Diffs.csv")
#4  22.17b
table_replicate_medians_rep22.17b <- matrix(c(medianDiff_22.17b_raw, 
medianDiff_22.17b_QN, medianDiff_22.17b_champ_StratQN, 
medianDiff_22.17b_BMIQ, medianDiff_22.17b_SWAN, 
medianDiff_22.17b_FunNorm, medianDiff_22.17b_Dasen, 
medianDiff_22.17b_Noob, medianDiff_22.17b_BetaRUV, 
medianDiff_22.17b_BetaRUV_limma, medianDiff_22.17b_ComBat, 
medianDiff_22.17b_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep22.17b) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep22.17b) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep22.17b, file="Replicate.4 
Median Diffs.csv")
#5 22.17c
table_replicate_medians_rep22.17c <- matrix(c(medianDiff_22.17c_raw, 
medianDiff_22.17c_QN, medianDiff_22.17c_champ_StratQN, 
medianDiff_22.17c_BMIQ, medianDiff_22.17c_SWAN, 
medianDiff_22.17c_FunNorm, medianDiff_22.17c_Dasen, 
medianDiff_22.17c_Noob, medianDiff_22.17c_BetaRUV, 
medianDiff_22.17c_BetaRUV_limma, medianDiff_22.17c_ComBat, 
medianDiff_22.17c_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep22.17c) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep22.17c) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep22.17c, file="Replicate.5 
Median Diffs.csv")
#6 22.17d
table_replicate_medians_rep22.17d <- matrix(c(medianDiff_22.17d_raw, 
medianDiff_22.17d_QN, medianDiff_22.17d_champ_StratQN, 
medianDiff_22.17d_BMIQ, medianDiff_22.17d_SWAN, 
medianDiff_22.17d_FunNorm, medianDiff_22.17d_Dasen, 
medianDiff_22.17d_Noob, medianDiff_22.17d_BetaRUV, 
medianDiff_22.17d_BetaRUV_limma, medianDiff_22.17d_ComBat, 
medianDiff_22.17d_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep22.17d) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep22.17d) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep22.17d, file="Replicate.6 
Median Diffs.csv")
#7 22.17e
table_replicate_medians_rep22.17e <- matrix(c(medianDiff_22.17e_raw, 
medianDiff_22.17e_QN, medianDiff_22.17e_champ_StratQN, 
medianDiff_22.17e_BMIQ, medianDiff_22.17e_SWAN, 
medianDiff_22.17e_FunNorm, medianDiff_22.17e_Dasen, 
medianDiff_22.17e_Noob, medianDiff_22.17e_BetaRUV, 
medianDiff_22.17e_BetaRUV_limma, medianDiff_22.17e_ComBat, 
medianDiff_22.17e_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep22.17e) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep22.17e) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep22.17e, file="Replicate.7 
Median Diffs.csv")
#8 22.17f
table_replicate_medians_rep22.17f <- matrix(c(medianDiff_22.17f_raw, 
medianDiff_22.17f_QN, medianDiff_22.17f_champ_StratQN, 
medianDiff_22.17f_BMIQ, medianDiff_22.17f_SWAN, 
medianDiff_22.17f_FunNorm, medianDiff_22.17f_Dasen, 
medianDiff_22.17f_Noob, medianDiff_22.17f_BetaRUV, 
medianDiff_22.17f_BetaRUV_limma, medianDiff_22.17f_ComBat, 
medianDiff_22.17f_Combat_StratQN), ncol=1)
rownames(table_replicate_medians_rep22.17f) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep22.17f) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep22.17f, file="Replicate.8 
Median Diffs.csv")
# 9. DiffSample1: diff samples, same batch, same plate  diffsamp1
table_replicate_medians_diffsamp1 <- 
matrix(c(medianDiff_diffsamp1_raw, medianDiff_diffsamp1_QN, 
medianDiff_diffsamp1_champ_StratQN, medianDiff_diffsamp1_BMIQ, 
medianDiff_diffsamp1_SWAN, medianDiff_diffsamp1_FunNorm, 
medianDiff_diffsamp1_Dasen, medianDiff_diffsamp1_Noob, 
medianDiff_diffsamp1_BetaRUV, medianDiff_diffsamp1_BetaRUV_limma, 
medianDiff_diffsamp1_ComBat, medianDiff_diffsamp1_Combat_StratQN), 
ncol=1)
rownames(table_replicate_medians_diffsamp1) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_diffsamp1) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_diffsamp1, file="DiffSample.1 
Median Diffs.csv")
#10. DiffSample2: diff sample, same batch , diff plate  diffsamp2
table_replicate_medians_diffsamp2 <- 
matrix(c(medianDiff_diffsamp2_raw, medianDiff_diffsamp2_QN, 
medianDiff_diffsamp2_champ_StratQN, medianDiff_diffsamp2_BMIQ, 
medianDiff_diffsamp2_SWAN, medianDiff_diffsamp2_FunNorm, 
medianDiff_diffsamp2_Dasen, medianDiff_diffsamp2_Noob, 
medianDiff_diffsamp2_BetaRUV, medianDiff_diffsamp2_BetaRUV_limma, 
medianDiff_diffsamp2_ComBat, medianDiff_diffsamp2_Combat_StratQN), 
ncol=1)
rownames(table_replicate_medians_diffsamp2) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_diffsamp2) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_diffsamp2, file="DiffSample.2 
Median Diffs.csv")
#11. DiffSample3: diff sample, diff batch, diff plate   diffsamp3
table_replicate_medians_diffsamp3 <- 
matrix(c(medianDiff_diffsamp3_raw, medianDiff_diffsamp3_QN, 
medianDiff_diffsamp3_champ_StratQN, medianDiff_diffsamp3_BMIQ, 
medianDiff_diffsamp3_SWAN, medianDiff_diffsamp3_FunNorm, 
medianDiff_diffsamp3_Dasen, medianDiff_diffsamp3_Noob, 
medianDiff_diffsamp3_BetaRUV, medianDiff_diffsamp3_BetaRUV_limma, 
medianDiff_diffsamp3_ComBat, medianDiff_diffsamp3_Combat_StratQN), 
ncol=1)
rownames(table_replicate_medians_diffsamp3) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_diffsamp3) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_diffsamp3, file="DiffSample.3 
Median Diffs.csv")
########################
### 5. Dasen metrics ###    
######################
# iDMRs, XCI, 65snps - standard error type measurement for each 
(DMRSE, 1-AUC, GCOSE)
# only iDMRs work on this data
library(wateRmelon)
############
# a) iDMRs:  
# Imprinting differentially methylated regions (iDMRs) are expected 
to be approximately half methylated, as is observed at the 227 
probes in known iDMRs. These functions calculate measures of 
dispersion for the beta values at these CpG sites, 
# Returns a standard error of the mean of betas for all samples and 
iDMR probes (dmrse) or the standard error of the mean for just the 
between sample component (dmrse_row) or between probe(dmrse_col) 
component.
# lower values are better
dmrse_row(Raw_preprocess)  / dmrse_row(Autosomes) 
# 227 iDMR data rows found
# [1] 0.004897683
dmrse_row(Male_chr) / dmrse_row(Female_chr) # don't need all probes 
as autosomes works but can't just do on sex probes 
# 0 iDMR data rows found
dmrse_row(StratQN_betas)    # 0.003342732
dmrse_row(FunNorm_betas)    # 0.005589773
dmrse_row(swan)    # 0.004925195
dmrse_row(swan_autosomes)   # 0.004920393
dmrse_row(Dasen)  # 
0.004927997
dmrse_row(Dasen_autosomes)  # 0.004956462
dmrse_row(BetaRUV_autosomes)   # 0.00422788
dmrse_row(BetaRUV_autosomes_optimal) # 0.00489734  worse than 
default setting
dmrse_row(lumiQNbetas)  # 0.005220801
dmrse_row(BMIQ)  # 
0.006240381
dmrse_row(ComBat_autosomes)  # 0.002518785
# Stratified QN looks to be the best normalisation method. Combat 
batch correction on preprocessed data is the overall best.  
# Try combat on other norm methods if possible
#############
# b) XCI - seabi
# Can only use on the objects normalised with sex CHR or just men
# Calculates an area under ROC curve - based metric for Illumina 
450K data using a t-test for male-female difference as the predictor 
for X-chromosome location of probes. The metric is 1-area so that 
small values indicate good performance,to match our other, standard 
error based metrics gcose and dmrse. Note that this requires both 
male and female samples of known sex and can be slow to compute due 
to running a t-test on every probe.
seabird_Raw<- seabi(getBeta(Raw_preprocess), sex= 
Raw_preprocess@phenoData$Sex, X=as.logical(Annotated@listData
$chr=="chrX")) # takes awhile but computes in the end
#[1] 0.09567028
seabird_StratQN<- seabi(getBeta(StratQN_all), sex= 
Raw_preprocess@phenoData$Sex, X=as.logical(Annotated@listData
$chr=="chrX"))
#
seabird_StratQN<- seabi(getBeta(swan), sex= swan@phenoData$Sex, 
X=as.logical(Annotated@listData$chr=="chrX"))
#
#############
# c) 65 SNPs:
#There are 65 well-behaved SNP genotyping probes included on the 
array. These each produce a distribution of betas with tight peaks 
for the three possible genotypes, which will be broadened by 
technical variation between samples. The spread of the peaks is thus 
usable as a performance metric.
# genki: A very simple genotype calling by one-dimensional K-means 
clustering is performed on each SNP, and for those SNPs where there 
are three genotypes, the squared deviations are summed for each 
genotype (similar to a standard deviation for each of allele A 
homozygote, heterozygote and allele B homozygote). By default these 
are further divided by the square root of the number of samples to 
get a standard error-like statistic.
# should get: a vector of 3 values for the dispersion of the three 
genotype peaks (AA, AB, BB : low, medium and high beta values)
#gcose - calculate between-sample SNP standard error
genki_Autosomes <- genki(getBeta(Autosomes), 
g=getsnp(rownames(Autosomes)), se=TRUE) 
#0SNP data rows found, Error in x[1:3, ] : incorrect number of 
dimensions
y <- preprocessRaw(RGsetE2)
rownames(y)
x <- grep("rs", rownames(y), ignore.case=TRUE,)
UNABLE TO FIND SNP PROBES
--------------------------------------------------------------------
------------
#########################
### 6. positive controls ###
#########################
# CpGs known to affect methylation, use minfi function 'plotCpg'
# CpG-SNP sites with most significant phenotype-wide correlated cis 
associations - in the brain, fromZhang etc al 2010
library(minfi)
cpgs=c("cg24920358","cg22333868","cg13926569", "cg17749961", 
"cg10106388", "cg06873352", "cg13507326", "cg01561916", 
"cg14141399", "cg18294158")
# par(mfrow=c(2,5))
# plotCpg(champ_raw_beta,cpg=cpgs, pheno=champ_data_beta
$mset@phenoData$Batch, ylim=c(0,1), mainPrefix="Raw")
# plotCpg(getBeta(champ_StratQN),cpg=cpgs, pheno=champ_data_beta
$mset@phenoData$Batch, ylim=c(0,1), mainPrefix="StratQN")
# plotCpg(Combat_StratQN_corrected,cpg=cpgs, pheno=champ_data_beta
$mset@phenoData$Batch, ylim=c(0,1), mainPrefix="StratQN with 
Combat")
# plotCpg(champ_raw_beta,cpg=cpgs, pheno=champ_data_beta
$mset@phenoData$Family, ylim=c(0,1), mainPrefix="Raw")
# plotCpg(getBeta(champ_StratQN),cpg=cpgs, pheno=champ_data_beta
$mset@phenoData$Family, ylim=c(0,1), mainPrefix="StratQN")
# plotCpg(Combat_StratQN_corrected,cpg=cpgs, pheno=champ_data_beta
$mset@phenoData$Family, ylim=c(0,1), mainPrefix="StratQN with 
Combat")
Raw_zhang <- Raw_manual_M[cpgs,]
StratQN_zhang <- StratQN_M[cpgs,]
Combat_StratQN_zhang <- Combat_StratQN_corrected_M[cpgs,]
colnames(Raw_zhang) <- champ_data_beta$mset@phenoData$Sample_Name
Raw_zhang <- t(Raw_zhang)
row.names(Raw_zhang)  <- gsub("..AH[1-9]+.","",row.names(Raw_zhang))
row.names(Raw_zhang)  <- 
gsub("PC22-17)","PC22-17",row.names(Raw_zhang))
row.names(Raw_zhang)  <- gsub("a","",row.names(Raw_zhang))
row.names(Raw_zhang)  <- gsub("b","",row.names(Raw_zhang))
row.names(Raw_zhang)  <- gsub("pc","PC",row.names(Raw_zhang))
row.names(Raw_zhang)  <- gsub("-",".",row.names(Raw_zhang))
mode(Raw_zhang) <- "numeric"
par(mar=c(6,4,1,1))
boxplot(Raw_zhang,las=2)
colnames(StratQN_zhang) <- champ_data_beta$mset@phenoData
$Sample_Name
StratQN_zhang <- t(StratQN_zhang)
row.names(StratQN_zhang)  <- 
gsub("..AH[1-9]+.","",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- 
gsub("PC22-17)","PC22-17",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- gsub("a","",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- gsub("b","",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- 
gsub("pc","PC",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- gsub("-",".",row.names(StratQN_zhang))
mode(StratQN_zhang) <- "numeric"
par(mar=c(6,4,1,1))
boxplot(StratQN_zhang,las=2)
colnames(Combat_StratQN_zhang) <- champ_data_beta$mset@phenoData
$Sample_Name
Combat_StratQN_zhang <- t(Combat_StratQN_zhang)
row.names(Combat_StratQN_zhang) <- row.names(StratQN_zhang)
mode(Combat_StratQN_zhang) <- "numeric"
par(mar=c(6,4,1,1))
boxplot(Combat_StratQN_zhang,las=2)
### Replace this with new meth data, ie. will need to repeat loop 3x
Raw_zhang 
StratQN_zhang 
Combat_StratQN_zhang 
chr <- c(1,12,10,2,1,17,14,2,19,7)
pos <- 
c(39991652,78121579,89408710,30530779,159099485,59216916,77233176,42
876472,56919728,103657263)
cpgnames <- colnames(Raw_zhang)
for (cpg in 1:length(chr)) {
system(paste(c("/Applications/plink-1.07-mac-intel/plink --
noweb --file ~/Documents/GENEPI/prostate/illumina/PCillumina/data --
chr ",chr[cpg]," --from-bp ",pos[cpg]-10^6," --to-bp ",pos[cpg]
+10^6," --recode --out ~/Users/ecazaly/Desktop/R Dec14/NormPaper/
cpg",cpg),collapse=""))
}
#for (cpg in 1:length(chr)) { 
 cpg=4
system(paste(c("/Applications/plink-1.07-mac-intel/plink --
noweb --file /Users/ecazaly/Desktop/R\\ Dec14/NormPaper/
PLINK_PCnoerrors_MAF05/PCnoerrors_MAF05 --chr ",chr[cpg]," --from-bp 
",pos[cpg]-10^6," --to-bp ",pos[cpg]+10^6," --recode --out /Users/
ecazaly/Desktop/R\\ Dec14/NormPaper/cpg",cpg),collapse=""))
for (cpg in 1:length(chr)) {
PPIEgeno <- read.table("PPIE.ped",header=F)
PPIEgeno <- 
read.table(paste(c("cpg",cpg,".ped"),collapse=""),header=F,as.is=T)
row.names(PPIEgeno) <- 
gsub("Tas-","",as.character(PPIEgeno[,1]))
row.names(PPIEgeno) <- gsub("_",".",row.names(PPIEgeno))
row.names(PPIEgeno) <- gsub("Tas","",row.names(PPIEgeno))
map <- read.table("PPIE.map",as.is=T)
map <- 
read.table(paste(c("cpg",cpg,".map"),collapse=""),as.is=T)
nsnps <- nrow(map)
log10pv <- vector(length=nsnps)
for (i in 1:nsnps) {
geno <- PPIEgeno[,(i*2+5):(i*2+6)]
geno <- geno[rowSums(geno=="0")==0,]
geno <- 
geno[match(row.names(Raw_zhang),row.names(geno)),]
als <- levels(factor(unlist(geno)))
if (length(als)<=1 | 
sum(geno[1]==geno[2],na.rm=T)==0) {
next
}
gc <- rowSums(geno==als[1])
fit = lm(Raw_zhang[,cpg] ~ gc)   #need to account 
for kinship
pv <- summary(fit)$coef[2,4]
log10pv[i] <- -1*log10(pv)
}
?lm  # figure out where to put kinship as a covariate in model -- 
need to use the GenABEL model to account for kinship
# first need to create kinship object
png(paste(cpgnames[cpg],".png",sep=""),pointsize=12,units="mm",width
=137.6,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map[,
4]*10^-6,log10pv,type="b",main=cpgnames[cpg],xlab="Position 
(Mb)",ylab="-1*log10(p-value)",xlim=c(map[1,4]*10^-6,map[nsnps,
4]*10^-6+0.4),ylim=c(-0.5,4))
abline(h=-1*log10(0.05),lty=2)
text(map[nsnps,4]*10^-6+0.15,-1*log10(0.05)+0.13,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.13,"adjusted p-value",font=3)
points(pos[cpg]*10^-6,-0.2,pch=17)
text(pos[cpg]*10^-6,-0.4,cpgnames[cpg])
#segments(40.16,3,40.23,3,lwd=2)
#segments(c(40.16,40.23),2.9,c(40.16,40.23),3.1,lwd=2)
#text(40.195,2.6,"PPIE",cex=1.2)
dev.off()
}#cg17749961
#gene = LYCAT
#chr2:30670137-30830712
poss <- read.csv("10Cpgs2.csv",as.is=T)
cpgs <- poss[1:11,4]  # this is where the cpg order gets messed up.  
These are the 10 closest cpgs to "cg01561916" but have unfortunately 
been given the same name as the first bunch of CpGs so when I reran 
the code it messed it up
# oldcpgs: "cg24920358" "cg22333868" "cg13926569" "cg17749961" 
"cg10106388" "cg06873352" "cg13507326" "cg01561916" "cg14141399"
# [10] "cg18294158"
poss <- poss[1:11,5]
cpg=4
PPIEgeno <- 
read.table(paste(c("cpg",cpg,".ped"),collapse=""),header=F,as.is=T)
row.names(PPIEgeno) <- 
gsub("Tas-","",as.character(PPIEgeno[,1]))
row.names(PPIEgeno) <- gsub("_",".",row.names(PPIEgeno))
row.names(PPIEgeno) <- gsub("Tas","",row.names(PPIEgeno))
#map <- read.table("PPIE.map",as.is=T)
map <- 
read.table(paste(c("cpg",cpg,".map"),collapse=""),as.is=T)
nsnps <- nrow(map)
log10pv <- vector(length=nsnps)
for (i in 1:nsnps) {
geno <- PPIEgeno[,(i*2+5):(i*2+6)]
geno <- geno[rowSums(geno=="0")==0,]
geno <- 
geno[match(row.names(Raw_zhang),row.names(geno)),]
als <- levels(factor(unlist(geno)))
if (length(als)<=1 | 
sum(geno[1]==geno[2],na.rm=T)==0) {
next
}
gc <- rowSums(geno==als[1])
fit = lm(Raw_zhang[,cpg] ~ gc)
pv <- summary(fit)$coef[2,4]
log10pv[i] <- -1*log10(pv)
}
png(paste(cpgnames[cpg],"_Raw.png",sep=""),pointsize=12,units="mm",w
idth=137.6,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map[,4]*10^-6,log10pv,type="o",main="Association 
between methylation and SNPs:
Raw",xlab="Position (Mb)",ylab="-1*log10(p-
value)",xlim=c(map[1,4]*10^-6,map[nsnps,
4]*10^-6+0.4),ylim=c(-1.5,10),cex=0.2)
abline(h=-1*log10(0.05),lty=2)
text(map[nsnps,4]*10^-6+0.2,-1*log10(0.05)+0.5,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.5,"adjusted p-value",font=3)
points(pos[cpg]*10^-6,-0.2,pch=17)
text(pos[cpg]*10^-6,-1,cpgnames[cpg])
#points(as.numeric(poss)*10^-6,rep(-0.2,11),pch=2)
segments(30.67,9,30.83,9,lwd=2)
segments(c(30.67,9,30.83),8.7,c(30.67,9,30.83),9.3,lwd=2)
text(30.83,8,"LYCAT",cex=1)
dev.off()
# this works for raw now try on other data, ie stratQN and COmBat
#StratQN  
for (i in 1:nsnps) {
geno <- PPIEgeno[,(i*2+5):(i*2+6)]
geno <- geno[rowSums(geno=="0")==0,]
geno <- 
geno[match(row.names(StratQN_zhang),row.names(geno)),]
als <- levels(factor(unlist(geno)))
if (length(als)<=1 | 
sum(geno[1]==geno[2],na.rm=T)==0) {
next
}
gc <- rowSums(geno==als[1])
fit = lm(StratQN_zhang[,cpg] ~ gc)
pv <- summary(fit)$coef[2,4]
log10pv[i] <- -1*log10(pv)
}
png(paste(cpgnames[cpg],"_StratQN.png",sep=""),pointsize=12,units="m
m",width=137.6,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map[,4]*10^-6,log10pv,type="o",main="Association 
between methylation and SNPs:
Stratified QN",xlab="Position (Mb)",ylab="-1*log10(p-
value)",xlim=c(map[1,4]*10^-6,map[nsnps,
4]*10^-6+0.4),ylim=c(-1.5,10),cex=0.2)
abline(h=-1*log10(0.05),lty=2)
text(map[nsnps,4]*10^-6+0.2,-1*log10(0.05)+0.5,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.5,"adjusted p-value",font=3)
points(pos[cpg]*10^-6,-0.2,pch=17)
text(pos[cpg]*10^-6,-1,cpgnames[cpg])
#points(as.numeric(poss)*10^-6,rep(-0.2,11),pch=2)
segments(30.67,9,30.83,9,lwd=2)
segments(c(30.67,9,30.83),8.7,c(30.67,9,30.83),9.3,lwd=2)
text(30.83,8,"LYCAT",cex=1)
dev.off()
## There is a big jump in significance!!! 
# Combat_StratQN
for (i in 1:nsnps) {
geno <- PPIEgeno[,(i*2+5):(i*2+6)]
geno <- geno[rowSums(geno=="0")==0,]
geno <- 
geno[match(row.names(Combat_StratQN_zhang),row.names(geno)),]
als <- levels(factor(unlist(geno)))
if (length(als)<=1 | 
sum(geno[1]==geno[2],na.rm=T)==0) {
next
}
gc <- rowSums(geno==als[1])
fit = lm(Combat_StratQN_zhang[,cpg] ~ gc)
pv <- summary(fit)$coef[2,4]
log10pv[i] <- -1*log10(pv)
}
png(paste(cpgnames[cpg],"_Combat_StratQN.png",sep=""),pointsize=12,u
nits="mm",width=137.6,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map[,4]*10^-6,log10pv,type="o",main="Association 
between methylation and SNPs: 
Stratified QN with Combat",xlab="Position 
(Mb)",ylab="-1*log10(p-value)",xlim=c(map[1,4]*10^-6,map[nsnps,
4]*10^-6+0.4),ylim=c(-1.5,10),cex=0.2)
abline(h=-1*log10(0.05),lty=2)
text(map[nsnps,4]*10^-6+0.2,-1*log10(0.05)+0.5,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.5,"adjusted p-value",font=3)
points(pos[cpg]*10^-6,-0.2,pch=17)
text(pos[cpg]*10^-6,-1,cpgnames[cpg])
#points(as.numeric(poss)*10^-6,rep(-0.2,11),pch=2)
segments(30.67,9,30.83,9,lwd=2)
segments(c(30.67,9,30.83),8.7,c(30.67,9,30.83),9.3,lwd=2)
text(30.83,8,"LYCAT",cex=1)
dev.off()
# this one is in between raw and StratQN, expected as batch and 
family are confounded you may actually be taking out real 
information
********************************************************************
# which were the samples used in this analysis?
rownames(Raw_zhang)[row.names(Raw_zhang) %in% row.names(geno)]
 # [1] "PC11.3"   "PC22.2"   "PC11.4"   "PC22.3"   "PC11.9"   
"PC22.16" 
 # [7] "PC11.147" "PC22.17"  "PC22.21"  "PC22.416" "PC72.4"   
"PC9.1"   
# [13] "PC9.4"    "PC9.12"   "PC9.477"  "PC22.16"  "PC22.17"  
"PC22.17" 
# [19] "PC22.4"   "PC11.180" "PC22.17"  "PC9.338" 
samples_both_geno_meth <- rownames(Raw_zhang)[row.names(Raw_zhang) 
%in% row.names(geno)]
write.csv(samples_both_geno_meth, file="samples_both_geno_meth.csv")
********************************************************************
#### Redo plots with KINSHIP and new omni data###
##  Use the association model from the GenABEL package to account 
for kinship.  Then plot as above
# take out the replicate samples:  [,-c(27,28,31,41,16)]
Raw_zhang <- Raw_zhang[-c(27,28,31,41,16),]
StratQN_zhang <- StratQN_zhang[-c(27,28,31,41,16),] 
Combat_StratQN_zhang <- Combat_StratQN_zhang[-c(27,28,31,41,16),] 
# Fix the sample names
rownames(Raw_zhang) <- gsub(".", "_", rownames(Raw_zhang), 
fixed=TRUE)
rownames(Raw_zhang) <- gsub("_3", "_03", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_1", "_01", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_2", "_02", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_4", "_04", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_9", "_09", rownames(Raw_zhang))
rownames(Raw_zhang)[c(6:15,17,19,22:28,30:36,38:47)] <- gsub("_0", 
"_", rownames(Raw_zhang)[c(6:15,17,19,22:28,30:36,38:47)])
rownames(Raw_zhang)[8]  <- "PC22_17_a" #add 'a' to match genotyping 
files
rownames(Raw_zhang)[16] <- "PC72_04_a"
# genotype data
chr <- c(1,12,10,2,1,17,14,2,19,7)
cpg=4
system(paste(c("/Applications/plink-1.07-mac-intel/plink --
noweb --bfile /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/cutoff_15_final --chr ", 
chr[cpg]," --from-bp ",pos[cpg]-10^6," --to-bp ",pos[cpg]+10^6," --
recode --transpose --out /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/cpg",cpg),collapse=""))
poss <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/R/
NormPaper_2015/10Cpgs2.csv",as.is=T)
cpgs <- poss[1:11,4] 
poss <- poss[1:11,5]
library(GenABEL)
convert.snp.tped(tpedfile="Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/cpg4.tped", 
tfamfile="Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cpg4.tfam", outfile="Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/cpg4.raw")
cpg4_tfam=read.table("Ass_genetic_input/cpg4.tfam", header=FALSE)
# match pheno data to genotype  
length(which(cpg4_tfam$V2 %in% rownames(Raw_zhang)))  #39 -- takes 
out 8
Raw_zhang_b <- Raw_zhang[c(which(rownames(Raw_zhang) %in% cpg4_tfam
$V2, arr.ind=TRUE)),]
removed <- Raw_zhang[-c(which(rownames(Raw_zhang) %in% cpg4_tfam$V2, 
arr.ind=TRUE)),]
rows_removed <- rownames(removed)
#  Create pheno file
ID_Raw_zhang <- matrix(rownames(Raw_zhang))
colnames(ID_Raw_zhang) <- "id"
sex_Raw_zhang <- matrix(champ_data_beta$mset@phenoData$Sex[-
c(27,28,31,41,16)])
colnames(sex_Raw_zhang) <- "sex"
sex_Raw_zhang <- gsub("M", "1", sex_Raw_zhang)
sex_Raw_zhang <- gsub("F", "0", sex_Raw_zhang)
pheno_Raw_zhang <- cbind(ID_Raw_zhang, sex_Raw_zhang, Raw_zhang)
pheno_Raw_zhang_b <- pheno_Raw_zhang[c(which(rownames(Raw_zhang) %in
% cpg4_tfam$V2, arr.ind=TRUE)),]
write.table(pheno_Raw_zhang_b, file="pheno_Raw_zhang.txt")
remove<- which(!(rownames(pheno_Raw_zhang) %in% 
rownames(pheno_Raw_zhang_b)))
length(remove)
# Now need to make the genotype file match the samples on the array
famID <- matrix(c(49,33,4, 43, 6, 48, 7, 8, 10, 12, 52, 15, 18, 21, 
38, 30, 51, 53, 25, 22, 39, 34, 47, 5, 9, 28, 29, 36, 26, 17, 13, 
45, 27, 11, 37, 14, 31, 50, 44))
# check
length(unique(famID)) # 39
Samples_zhang <- cbind(famID, rownames(pheno_Raw_zhang_b))
write.table(Samples_zhang, file="Samples_zhang.txt", 
row.names=FALSE, col.names=FALSE, quote=FALSE)
chr <- c(1,12,10,2,1,17,14,2,19,7)
cpg=4
system(paste(c("/Applications/plink-1.07-mac-intel/plink --
noweb --bfile /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/cutoff_15_final --keep /
Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Samples_zhang.txt --chr ", chr[cpg]," --from-bp ", pos[cpg]-10^6," 
--to-bp ",pos[cpg]+10^6," --recode --transpose --out /Users/ecazaly/
Desktop/PhD_Analysis/Association_2015april/Ass_genetic_input/
cpg_b",cpg),collapse=""))
# create new .raw file
convert.snp.tped(tpedfile="Ass_genetic_input/cpg_b4.tped", 
tfamfile="Ass_genetic_input/cpg_b4.tfam", 
outfile="Ass_genetic_input/cpg_b4.raw")
# create gwaa object
gwaa_cpg4=load.gwaa.data(phenofile="pheno_Raw_zhang.txt", 
genofile="Ass_genetic_input/cpg_b4.raw", force=TRUE)
# create kinship coefficient object
kinship <- read.csv("Ass_genetic_input/kinship_coefficient.csv", 
header=TRUE)
# work out which ones I need
Raw_zhang_c <- Raw_zhang_b
rownames(Raw_zhang_c) <- gsub("PC", "PCTAS", rownames(Raw_zhang_c))
rownames(Raw_zhang_c)  <- gsub("_", "-", rownames(Raw_zhang_c) )
kinship$decoded.1 <- gsub("PC22-", "", kinship$decoded.1, 
fixed=TRUE)
kinship$decoded.1<- gsub("PC11-", "",kinship$decoded.1, fixed=TRUE)
kinship$decoded.1<- gsub("PC72-", "", kinship$decoded.1, fixed=TRUE)
kinship$decoded.1<- gsub("PC9-", "", kinship$decoded.1, fixed=TRUE)
kinship$decoded.2 <- gsub("PC22-", "", kinship$decoded.2, 
fixed=TRUE)
kinship$decoded.2 <- gsub("PC11-", "", kinship$decoded.2, 
fixed=TRUE)
kinship$decoded.2 <- gsub("PC72-", "", kinship$decoded.2, 
fixed=TRUE)
kinship$decoded.2 <- gsub("PC9-", "", kinship$decoded.2, fixed=TRUE)
length(which(kinship$decoded.1 %in% rownames(Raw_zhang_c)))  #5654
name=rownames(Meth_B_cg13387643_b)
name <- gsub("PC", "PCTAS", name)
name  <- gsub("_", "-", name )
name <- gsub("-a", "", name)
length(which(kinship$decoded.1 %in% name)))
kinship_1_zhang <- kinship[c(kinship$decoded.1 %in% 
rownames(Raw_zhang_c), arr.ind=TRUE),]
dim(kinship_1_zhang) # 5655   4  good
kinship_2_zhang <- kinship_1_zhang[c(kinship_1_zhang$decoded.2 %in% 
rownames(Raw_zhang_c), arr.ind=TRUE),]
dim(kinship_2_zhang) # 181 4
head(kinship_2_zhang)
kinship_3_zhang <- kinship_2_zhang[-181,c(1,3,4)]
kinship_3_zhang$decoded.1 <- gsub("PCTAS", "PC", kinship_3_zhang
$decoded.1, fixed=TRUE)
kinship_3_zhang$decoded.2 <- gsub("PCTAS", "PC", kinship_3_zhang
$decoded.2, fixed=TRUE)
# make matrix
kinship_4_zhang <- kinship_3_zhang
library(reshape2)
acast(kinship_4_zhang, kinship_4_zhang$decoded.1 ~ kinship_4_zhang
$decoded.2 , value.var=1)
tmp2 <- xtabs(kinship_4_zhang$decoded.1~kinship_4_zhang$decoded.
2+kinship_4_zhang$Kinship.Coefficient, data= kinship_4_zhang)
head(kinship_4_zhang)
# check kinship by Identity-By-State function ibs() in GenABEL
# Create gwaa object with all SNPs, pulling out subjects of interest
library(GenABEL)
system("/Applications/plink-1.07-mac-intel/plink --noweb --bfile /
Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Samples_zhang.txt --recode --
transpose --out /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/all")
# After frequency and genotyping pruning, there are 1616835 SNPs
# After filtering, 32 males, 7 females, and 0 of unspecified sex
convert.snp.tped(tpedfile="Ass_genetic_input/all.tped", 
tfamfile="Ass_genetic_input/all.tfam", outfile="Ass_genetic_input/
all.raw")
gwaa_all=load.gwaa.data(phenofile="pheno_Raw_zhang.txt", 
genofile="Ass_genetic_input/all.raw", force=TRUE)
#Perform IBS
ibs <- ibs(gwaa_all, weight="freq")
colnames(ibs) <- gsub("_", "-", colnames(ibs))
rownames(ibs) <- gsub("_", "-", rownames(ibs))
# if don't specify weight="freq" then the values are off, with some 
values like 0.781 and others like 1609264.  Identical samples do not 
= 1
# try SNPRelate package
library(SNPRelate)
# Calculate IBD coefficients by KING method of moment.  
snpgdsIBDKING {SNPRelate}
ibd <- snpgdsIBDKING()  # looks like a bit of data manipulation 
first
head(ibs)
# perform association
library(GenABEL)
# as before, data seemed to need to be altered
gt_cpg4=as.data.frame(as.numeric(gtdata(gwaa_cpg4))) 
gwaa_cpg4b <- gwaa_cpg4
gwaa_cpg4b@gtdata@gtps=gt_cpg4  
gwaa_cpg4b@phdata$id=gsub("_","-",gwaa_cpg4b@phdata$id)
rownames(gwaa_cpg4b@phdata)=gsub("_", "-", 
rownames(gwaa_cpg4b@phdata))
gwaa_cpg4b@gtdata@idnames=gsub("_", "-", gwaa_cpg4b@gtdata@idnames)
rownames(gwaa_cpg4b@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa_cpg4b@gtdata@gtps))           
modelnum=1
name=vector()
coefs_cpg4=vector()
pvals_cpg4=vector() 
log10pvps_cpg4=vector()              
for(i in colnames(beta_gwaa_cpg4b@phdata[6])) {
  for(j in colnames(beta_gwaa_cpg4b@gtdata@gtps)){ 
   if(sum(beta_gwaa_cpg4b@gtdata@gtps[j],na.rm=T)==0) {   
  next
  } 
    name[modelnum]= paste(i, j, sep= "/")   
    formula_cpg4=as.formula(paste(beta_gwaa_cpg4b@phdata[i], "~", 
beta_gwaa_cpg4b@gtdata@gtps[j]))
    association_cpg4=polygenic_hglm(formula_cpg4, ibs, 
beta_gwaa_cpg4b)
    coefs_cpg4[modelnum] = summary(association_cpg4$hglm)
$FixCoefMat[2,1]
    pvals_cpg4[modelnum] = summary(association_cpg4$hglm)
$FixCoefMat[2,4]
    log10pvps_cpg4[modelnum]= -1*log10(pvals_cpg4[modelnum])
    modelnum= modelnum + 1
    }
    }
length(which(pvals_cpg4=="NaN"))   #1163
length(pvals_cpg4)    #1661
# so using b-values produces 261 less NaN errors
# Good ones: 498  -- how does this compare to the number of snps in 
the old 370k window?
length(pvals_cpg4)-length(which(pvals_cpg4=="NaN"))
length(beta_gwaa_cpg4b@gtdata@gtps) - length(pvals_cpg4)
# 46 removed due to all 0s
 # something is still not right because the first few are NA but 
worked before..  There is something wrong with the CpG as the loop 
works on other CpGs.  Maybe it is the M-val being negative.  Will 
try on the B-val
 # Warning messages:
# 1: In log(eigen(Sigma, only.values = TRUE)$values) : NaNs produced
# 2: In pt(abs(as.numeric(FixCoefMat[, 3])), object$dfReFe, 
lower.tail = FALSE) :
  # NaNs produced
# 3: In pt(abs(as.numeric(FixCoefMat[, 3])), object$dfReFe, 
lower.tail = FALSE) :
  # NaNs produced
#ilogit2()  # from minfi
beta_gwaa_cpg4b <- gwaa_cpg4b
beta_gwaa_cpg4b@phdata$cg17749961 <- ilogit2(beta_gwaa_cpg4b@phdata
$cg17749961)
# this seems to work but still get a warning but gives a value not 
NaN 
# Warning message:
# In log(eigen(Sigma, only.values = TRUE)$values) : NaNs produced
# I guess this makes sense as this was the first warning msg above 
and talks about logs which is what the M-values are.  So looks like 
I've sorted the second two and maybe an offset is needed to fix the 
log issue
## when the loop runs on all snps the same 3 errors come up
# so it works on 97 but not 98, whats different
beta_gwaa_cpg4b@gtdata@gtps[,97] #3 x1s
beta_gwaa_cpg4b@gtdata@gtps[,98] # only 2x 1s -- is this below some 
MAF??
beta_gwaa_cpg4b@gtdata@gtps[,9]  # this has heaps of values but the 
loop dpesn't work..
# the coef for this is negative and small and then the p-val is 
NaN..; maybe just need to exclude these ones, see hwo many there are 
 
# otherwise take out log p-val part and see if that changes it  
length(which(log10pvps_cpg4=="NaN"))
length(which(pvals_cpg4[1]=="NaN"))
# [1] 1424
length(log10pvps_cpg4)
# [1] 1661
# seems like a large proportion    
    
# the model doesn't like it when a snp is 0 for everyone, it 
produces NAs and then an error when working out the p-val and messes 
the whole loop up.  The if line says if the column adds up to 0 then 
skip the rest of the loop and go onto the next snp.  Must add 
na.rm=T as some fo the rows have an NA value
# may need to remove monomorphic alleles, ie those that appear in 
only one individual.  see if get an error with this.
     
# Errors being prodiced:  
# Error in GLM.MME(Augy = Augy, AugXZ = AugXZ, starting.delta = 
c(b.hat,  : 
  # GLM.MME diverged! Try different starting values.
# In addition: Warning message:
# In .coef.trunc(qr, .Call(sparseQR_coef, qr, y), drop = TRUE) :
  # sparseQR_coef(): structurally rank deficient case: possibly 
WRONG zeros
# maybe some of the snps come up as all 0s?? try analysis in chunks 
to find culprit
# first 10 are ok
# 11:20 ok
# 21:40 ok
# 41:70 ok
# 71:90 ok
# 91:99 error
# 91:95 ok
# 96, 97, 98 ok
# 99 error, yes this is where the whole column is 0.  Could just 
mean all are homo, or error. 
# remove 
    
# Now PLOT
# log10pvps_cpg4
chr <- c(1,12,10,2,1,17,14,2,19,7)
map <- read.table("Ass_genetic_input/cpg_b4.map", as.is=T)
# cut down map to the 1661 snps that didn't have all 0
name_keep <- gsub("cg17749961/", "", name)
head(map)
map_b <- map[c(which(name_keep %in% map$V2)),]
nsnps <- nrow(map_b)
pos <- 
c(39991652,78121579,89408710,30530779,159099485,59216916,77233176,42
876472,56919728,103657263)
png("cg17749961_Raw_OMNI.png",pointsize=12,units="mm",width=137.6,he
ight=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map_b[,4]*10^-6, 
log10pvps_cpg4,type="o",main="Association between methylation and 
SNPs:
Raw",xlab="Position (Mb)",ylab="-1*log10(p-
value)",xlim=c(map_b[1,4]*10^-6,map_b[nsnps,
4]*10^-6+0.4),ylim=c(-1.5,10),cex=0.2)
abline(h=-1*log10(0.05),lty=2)
text(map_b[nsnps,4]*10^-6+0.2,-1*log10(0.05)+0.5,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map_b[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.5,"adjusted p-value",font=3)
points(pos[4]*10^-6,-0.2,pch=17)
text(pos[4]*10^-6,-1,"cg17749961")
#points(as.numeric(poss)*10^-6,rep(-0.2,11),pch=2)
segments(30.67,9,30.83,9,lwd=2)
segments(c(30.67,9,30.83),8.7,c(30.67,9,30.83),9.3,lwd=2)
text(30.83,8,"LYCAT",cex=1)
dev.off()
# This it works.  Although it looks like the SNP picked up in the 
previous data is njot on this array or had a NaN value because there 
are now 2 sig SNPs but they are a fair bit further downstream that 
the cpg site.  Which may be good in the fact that the snp would not 
be in the probe body unless it's a reverse probe and even then 
surely its miles and miles away
# try on the normalised and batch corrected data
# Raw_zhang <- Raw_zhang[-c(27,28,31,41,16),]
# StratQN_zhang <- StratQN_zhang[-c(27,28,31,41,16),] 
# Combat_StratQN_zhang <- Combat_StratQN_zhang[-c(27,28,31,41,16),] 
rownames(pheno_Raw_zhang_b)
StratQN_zhang_b <- StratQN_zhang
StratQN_zhang_b <- StratQN_zhang_b[-c(remove),]
rownames(StratQN_zhang_b) <- rownames(pheno_Raw_zhang_b)
StratQN_zhang_gwaa <- gwaa_cpg4b
StratQN_zhang_gwaaB <-StratQN_zhang_gwaa
StratQN_zhang_gwaaB@phdata$cg17749961 <- 
ilogit2(StratQN_zhang_b[,"cg17749961"])
modelnum=1
name_stratQN=vector()
coefs_stratQN=vector()
pvals_stratQN=vector() 
log10pvps_stratQN=vector()              
for(i in colnames(StratQN_zhang_gwaaB@phdata[6])) {
  for(j in colnames(StratQN_zhang_gwaaB@gtdata@gtps)){ 
   if(sum(StratQN_zhang_gwaaB@gtdata@gtps[j],na.rm=T)==0) {   
  next
  } 
    name_stratQN[modelnum]= paste(i, j, sep= "/")   
    formula_stratQN=as.formula(paste(StratQN_zhang_gwaaB@phdata[i], 
"~", StratQN_zhang_gwaaB@gtdata@gtps[j]))
    association_stratQN=polygenic_hglm(formula_stratQN, ibs, 
StratQN_zhang_gwaaB)
    coefs_stratQN[modelnum] = summary(association_stratQN$hglm)
$FixCoefMat[2,1]
    pvals_stratQN[modelnum] = summary(association_stratQN$hglm)
$FixCoefMat[2,4]
    log10pvps_stratQN[modelnum]= -1*log10(pvals_stratQN[modelnum])
    modelnum= modelnum + 1
    }
    }
length(which(pvals_stratQN=="NaN"))   # this is now 0, as opposed to 
1163.  Must be the offset etc in Strat
length(pvals_stratQN)   # all 1661 
included
png("cg17749961_StratQN_OMNI.png",pointsize=12,units="mm",width=137.
6,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map_b[,4]*10^-6, 
log10pvps_stratQN,type="o",main="Association between methylation and 
SNPs:
StratQN_OMNI",xlab="Position (Mb)",ylab="-1*log10(p-
value)",xlim=c(map_b[1,4]*10^-6,map_b[nsnps,
4]*10^-6+0.4),ylim=c(-1.5,10),cex=0.2)
abline(h=-1*log10(0.05),lty=2)
text(map_b[nsnps,4]*10^-6+0.2,-1*log10(0.05)+0.5,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map_b[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.5,"adjusted p-value",font=3)
points(pos[4]*10^-6,-0.2,pch=17)
text(pos[4]*10^-6,-1,"cg17749961")
#points(as.numeric(poss)*10^-6,rep(-0.2,11),pch=2)
segments(30.67,9,30.83,9,lwd=2)
segments(c(30.67,9,30.83),8.7,c(30.67,9,30.83),9.3,lwd=2)
text(30.83,8,"LYCAT",cex=1)
dev.off()
Combat_zhang <- Combat_StratQN_zhang
Combat_zhang <- Combat_zhang[-c(remove),]
rownames(Combat_zhang) <- rownames(pheno_Raw_zhang_b)
Combat_zhang_gwaa  <- gwaa_cpg4b
Combat_zhang_gwaaB <- Combat_zhang_gwaa
Combat_zhang_gwaaB@phdata$cg17749961 <- 
ilogit2(Combat_zhang[,"cg17749961"])
modelnum=1
name_combat=vector()
coefs_combat=vector()
pvals_combat=vector() 
log10pvps_combat=vector()              
for(i in colnames(Combat_zhang_gwaaB@phdata[6])) {  
  for(j in colnames(Combat_zhang_gwaaB@gtdata@gtps)){ 
   
if(sum(Combat_zhang_gwaaB@gtdata@gtps[j],na.rm=T)==0) {   
  next
  } 
    name_combat[modelnum]= paste(i, j, sep= "/")   
    
formula_combat=as.formula(paste(Combat_zhang_gwaaB@phdata[i], "~", 
Combat_zhang_gwaaB@gtdata@gtps[j]))
    association_combat=polygenic_hglm(formula_combat, ibs, 
Combat_zhang_gwaaB)
    coefs_combat[modelnum] = summary(association_combat
$hglm)$FixCoefMat[2,1]
    pvals_combat[modelnum] = summary(association_combat
$hglm)$FixCoefMat[2,4]
    log10pvps_combat[modelnum]= 
-1*log10(pvals_combat[modelnum])
    modelnum= modelnum + 1
    }
    }
length(which(pvals_combat=="NaN"))   # 0
length(pvals_combat)    #1661
length(pvals_combat)-length(which(pvals_combat=="NaN")) #1661
length(Combat_zhang_gwaaB@gtdata@gtps) - length(pvals_combat) #46
png("cg17749961_combat_OMNI.png",pointsize=12,units="mm",width=137.6
,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map_b[,4]*10^-6, 
log10pvps_combat,type="o",main="Association between methylation and 
SNPs:
Combat_OMNI",xlab="Position (Mb)",ylab="-1*log10(p-
value)",xlim=c(map_b[1,4]*10^-6,map_b[nsnps,
4]*10^-6+0.4),ylim=c(-1.5,10),cex=0.2)
abline(h=-1*log10(0.05),lty=2)
text(map_b[nsnps,4]*10^-6+0.2,-1*log10(0.05)+0.5,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map_b[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.5,"adjusted p-value",font=3)
points(pos[4]*10^-6,-0.2,pch=17)
text(pos[4]*10^-6,-1,"cg17749961")
#points(as.numeric(poss)*10^-6,rep(-0.2,11),pch=2)
segments(30.67,9,30.83,9,lwd=2)
segments(c(30.67,9,30.83),8.7,c(30.67,9,30.83),9.3,lwd=2)
text(30.83,8,"LYCAT",cex=1)
dev.off()
# also try with the original model with the new OMNI data
# for (i in 1:nsnps) {
# geno <- PPIEgeno[,(i*2+5):(i*2+6)]
# geno <- geno[rowSums(geno=="0")==0,]
# geno <- 
geno[match(row.names(StratQN_zhang),row.names(geno)),]
# als <- levels(factor(unlist(geno)))
# if (length(als)<=1 | 
sum(geno[1]==geno[2],na.rm=T)==0) {
# next
# }
# gc <- rowSums(geno==als[1])
# fit = lm(StratQN_zhang[,cpg] ~ gc)
# pv <- summary(fit)$coef[2,4]
# log10pv[i] <- -1*log10(pv)
# }
  for(i in 1:length(Combat_zhang_gwaaB@gtdata@gtps)){ i=1
   if(sum(gwaa10@gtdata@gtps[i],na.rm=T)==0) {   
  next
  }
fit = lm(gwaa10@phdata[,6] ~ 
gwaa10@gtdata@gtps[,i])
pv <- summary(fit)$coef[2,4]
log10pv[i] <- -1*log10(pv)
} 
length(log10pv) # this is giving a pval length of 64779
chr <- c(1,12,10,2,1,17,14,2,19,7)
map <- read.table("Ass_genetic_input/cpg_b4.map", as.is=T)
# cut down map to the 1661 snps that didn't have all 0
name_keep <- gsub("cg17749961/", "", name)
head(map)
map_b <- map[c(which(name_keep %in% map$V2)),]
nsnps <- nrow(map_b)
pos <- 
c(39991652,78121579,89408710,30530779,159099485,59216916,77233176,42
876472,56919728,103657263)
png("test.png",pointsize=12,units="mm",width=137.6,height=137.6*2/3,
res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map_b[,4]*10^-6, log10pv,type="o",main="Association 
between methylation and SNPs:
Combat_OMNI_oldMODEL",xlab="Position 
(Mb)",ylab="-1*log10(p-value)",xlim=c(map_b[1,4]*10^-6,map_b[nsnps,
4]*10^-6+0.4),ylim=c(-1.5,10),cex=0.2)
abline(h=-1*log10(0.05),lty=2)
text(map_b[nsnps,4]*10^-6+0.2,-1*log10(0.05)+0.5,"p-value = 
0.05",font=3)
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map_b[nsnps,4]*10^-6+0.15,-1*log10(0.05/nsnps)
+0.5,"adjusted p-value",font=3)
points(pos[4]*10^-6,-0.2,pch=17)
text(pos[4]*10^-6,-1,"cg17749961")
#points(as.numeric(poss)*10^-6,rep(-0.2,11),pch=2)
segments(30.67,9,30.83,9,lwd=2)
segments(c(30.67,9,30.83),8.7,c(30.67,9,30.83),9.3,lwd=2)
text(30.83,8,"LYCAT",cex=1)
dev.off()
# Use the kinship calculated for a subset of samples 
samples <- c('PC9-1 (AH1)',"PC9-4 (AH2)","PC9-12 (AH4)", "PC9-24 
(AH6)", "PC9-121 (AH7)", "PC9-477 (AH8)", "PC22-16 (AH9)", "PC22-17 
(AH10)", "PC22-210 (AH11)", "PC22-393 (AH12)", "pc11-3", "pc22-2", 
"pc11-4", "pc22-3", "pc11-9", "pc22-16", "pc11-147", "pc22-17", 
"pc22-21", "PC22-468", "pc22-203", "pc22-387", "pc72-136", 
"pc22-416", "pc72-188", "pc72-4", "pc72-77", "pc72-126")
# have removed # 26 and 28 not present pc72-213, pc72-213 
Raw_d <- getM(champ_data_mset_corrected)
colnames(Raw_d) <- champ_data_beta$mset@phenoData$Sample_Name
Raw_d2 <- Raw_d[,samples]
meth_dist_raw <- as.matrix(dist(t(Raw_d2)))
dimnames(meth_dist_raw)=list(colnames(Raw_d2), colnames(Raw_d2))
write.csv(meth_dist_raw, file="meth_dist_raw.csv") # use the 
distances in matrix to fill in kinship vs meth excel table, then 
reload
StratQN_d_M <- getM(champ_StratQN)
colnames(StratQN_d_M) <- champ_data_beta$mset@phenoData$Sample_Name
StratQN_d_M <- StratQN_d_M[,samples]
meth_dist_StratQN_d_M <- as.matrix(dist(t(StratQN_d_M)))
write.csv(meth_dist_StratQN_d_M, file="meth_dist_StratQN.csv")
StratQNcombat_d_M <- as.matrix(Combat_StratQN_corrected_M)
colnames(StratQNcombat_d_M) <-champ_data_beta$mset@phenoData
$Sample_Name
StratQNcombat_d_M <- StratQNcombat_d_M[,samples]
meth_dist_StratQNcombat <- as.matrix(dist(t(StratQNcombat_d_M)))
write.csv(meth_dist_StratQNcombat, 
file="meth_dist_StratQNcombat.csv") 
meth_dist_kinship <- read.csv('NormPaper/Kinship vs 
Methdis_Mar15.csv')
par(mfrow=c(1,3))
plot(meth_dist_kinship$Meth.Dist.Raw..Mval~meth_dist_kinship
$Kinship..Coefficient, col=meth_dist_kinship$Family, pch=16, 
ylim=c(200,1000), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Raw Data 
Methylation Distance vs Kinship Coefficient")
legend('topleft', col=1:3, pch=16, legend=levels(meth_dist_kinship
$Family)) 
plot(meth_dist_kinship$Meth.Dist.StratQN..Mval~meth_dist_kinship
$Kinship..Coefficient, col=meth_dist_kinship$Family, pch=16, 
ylim=c(200,1000), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Stratified QN 
Methylation Distance vs Kinship Coefficient")
legend('topleft', col=1:3, pch=16, legend=levels(meth_dist_kinship
$Family)) 
plot(meth_dist_kinship
$Meth.Dist.Combat.StratQN..Mval.~meth_dist_kinship
$Kinship..Coefficient, col=meth_dist_kinship$Family, pch=16, 
ylim=c(200,1000), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Stratified QN, ComBat corrected 
Methylation Distance vs Kinship Coefficient")
legend('topleft', col=1:3, pch=16, legend=levels(meth_dist_kinship
$Family)) 
plot(meth_dist_kinship
$Meth.Dist.Combat.StratQN..Mval.~meth_dist_kinship
$Kinship..Coefficient, col=meth_dist_kinship$Family, 
pch=meth_dist_kinship$Individual.1, ylim=c(200,400), 
ylab='Methylation Distance: M-vals', xlab='Kinship Coefficient 
(absolute Log)', main="Stratified QN, ComBat corrected 
Methylation Distance vs Kinship Coefficient")
legend('topleft', col=1:3, pch=16, legend=levels(meth_dist_kinship
$Family)) 
# Perhaps just look at those closely related as the relationship 
tends to drop off after that
close_kinship <- meth_dist_kinship[meth_dist_kinship
$Kinship..Coefficient <1.0,]
Family_coef <- close_kinship$Family
Family_coef <- gsub("Family 9", "3", Family_coef)
Family_coef <- gsub("Family 22", "1", Family_coef)
Family_coef <- gsub("Family 11", "2", Family_coef)
par(mfrow=c(1,3))
plot(close_kinship$Meth.Dist.Raw..Mval~close_kinship
$Kinship..Coefficient, cex=1.5, pch=Family_coef, col=Family_coef, 
ylim=c(200,810), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Methylation Distance vs Kinship 
Coefficient: 
 Raw Data") 
plot(close_kinship$Meth.Dist.StratQN..Mval~close_kinship
$Kinship..Coefficient, cex=1.5,pch=Family_coef, col=Family_coef, 
ylim=c(200,810), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Methylation Distance vs Kinship 
Coefficient:
Stratified QN") 
plot(close_kinship$Meth.Dist.Combat.StratQN..Mval.~close_kinship
$Kinship..Coefficient, cex=1.5, pch=Family_coef, col=Family_coef, 
ylim=c(200,810), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Methylation Distance vs Kinship 
Coefficient:
Stratified QN, ComBat corrected")
correlation_Raw <- cor(x=close_kinship$Meth.Dist.Raw..Mval, 
y=close_kinship$Kinship..Coefficient, method="pearson")
# -0.6517868
correlation_StratQN <- cor(x=close_kinship$Meth.Dist.StratQN..Mval, 
y=close_kinship$Kinship..Coefficient, method="pearson")
# -0.3562952
correlation_Combat_StratQN <- cor(x=close_kinship
$Meth.Dist.Combat.StratQN..Mval., y=close_kinship
$Kinship..Coefficient, method="pearson")
# 0.2796014
#### Positive Control 2 :  QQ plots ####
# creat 3 QQ plots looking at methylation vs age, before and after 
normalisation and with Combat
# Run a regression between methylation and age and pull out the p-
value for methylation at a given row.
## For Raw methylation values  ##
rawmeth_age_pv <- function(row) {
  summary(lm(Raw_manual_M_3[row,]~Age_numeric))$coef[2,4]
}
# Test first 100 rows:
pvals <- sapply(1:100,rawmeth_age_pv)
# Obtain p-values for all 
pvals_raw <- sapply(1:nrow(Raw_manual_M_3),rawmeth_age_pv)
## For StratQN ##
StratQN_age_pv <- function(row) {
  summary(lm(StratQN_M_2[row,]~Age_numeric))$coef[2,4]
}
# Test first 100 rows:
pvals_StratQN_test <- sapply(1:100,StratQN_age_pv)
# Obtain p-values for all 
pvals_StratQN <- sapply(1:nrow(StratQN_M_2), StratQN_age_pv)
## For Combat/StratQN ##
CombatStratQN_age_pv <- function(row) {
  summary(lm(Combat_StratQN_corrected_M[row,]~Age_numeric))
$coef[2,4]
}
# Test first 100 rows:
pvals_CombatStratQN_test <- sapply(1:100, CombatStratQN_age_pv)
# Obtain p-values for all 
pvals_CombatStratQN <- sapply(1:nrow(Combat_StratQN_corrected_M), 
CombatStratQN_age_pv)
#### Then generate expected pvals for each  ####
m=length(pvals_raw) #all 3 have same length
expect.stats=-log10(seq(1/(m+1),m/(m+1),length.out=m))
png("QQplot Raw.png")
qqplot(x=expect.stats, y=-log10(pvals_raw), plot.it=TRUE, xlab = 
"expected -log10(pvalues)", ylab ="observed -log10(pvalues)", 
main="Raw Q-Q Plot", ylim=c(0,14))
abline(a=0,b=1,lwd=2)
lambda_raw=median(-log10(pvals_raw))/median(expect.stats)
text(0,10,bquote(lambda==.(round(lambda_raw,3))),adj=0,cex=2)
dev.off()
png("QQplot StratQN.png")
qqplot(x=expect.stats, y=-log10(pvals_StratQN), plot.it=TRUE, xlab 
="expected -log10(pvalues)", ylab ="observed -log10(pvalues)", 
main="StratQN Q-Q Plot", ylim=c(0,14))
abline(a=0,b=1,lwd=2)
lambda_strat=median(-log10(pvals_StratQN))/median(expect.stats)
text(0,10,bquote(lambda==.(round(lambda_strat,3))),adj=0,cex=2)
dev.off()
png("QQplot Combat.png")
qqplot(x=expect.stats, y=-log10(pvals_CombatStratQN), plot.it=TRUE, 
xlab = "expected -log10(pvalues)", ylab = "observed -
log10(pvalues)", main="Combat Q-Q Plot", ylim=c(0,14))
abline(a=0,b=1,lwd=2)
lambda_combat=median(-log10(pvals_CombatStratQN))/
median(expect.stats)
text(0,10,bquote(lambda==.(round(lambda_combat,3))),adj=0,cex=2)
dev.off()
# these plots show that after normalisation there are a lot more 
sites significantly associated with age.  
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Abstract
Background: Human methylome mapping in health and disease states has largely relied on Illumina Human
Methylation 450k array (450k array) technology. Accompanying this has been the necessary evolution of analysis
pipelines to facilitate data processing. The majority of these pipelines, however, cater for experimental designs
where matched ‘controls’ or ‘normal’ samples are available. Experimental designs where no appropriate ‘reference’
exists remain challenging. Herein, we use data generated from our study of the inheritance of methylome profiles
in families to evaluate the performance of eight normalisation pre-processing methods. Fifty individual samples
representing four families were interrogated on five 450k array BeadChips. Eight normalisation methods were tested
using qualitative and quantitative metrics, to assess efficacy and suitability.
Results: Stratified quantile normalisation combined with ComBat were consistently found to be the most
appropriate when assessed using density, MDS and cluster plots. This was supported quantitatively by ANOVA on
the first principal component where the effect of batch dropped from p < 0.01 to p = 0.97 after stratified QN and
ComBat. Median absolute differences between replicated samples were the lowest after stratified QN and ComBat
as were the standard error measures on known imprinted regions. Biological information was preserved after
normalisation as indicated by the maintenance of a significant association between a known mQTL and
methylation (p = 1.05e-05).
Conclusions: A strategy combining stratified QN with ComBat is appropriate for use in the analyses when no
reference sample is available but preservation of biological variation is paramount. There is great potential for use
of 450k array data to further our understanding of the methylome in a variety of similar settings. Such advances will
be reliant on the determination of appropriate methodologies for processing these data such as established here.
Keywords: Familial data, 450k, Array, Methylation, Pre-processing pipeline, Normalisation
Background
DNA methylation, the covalent addition of a methyl group
to a cytosine base, usually in a cytosine-guanine pair
(CpG), remains the most widely studied epigenetic modifi-
cation in disease. While around 70 % of CpG dinucleotides
are methylated in mammals, when clustered in groups or
‘islands’ (CGIs) they are generally unmethylated [1]. These
islands occur often at promoter regions, where methylation
has been traditionally associated with transcriptional re-
pression [2]. Less extensively studied, but potentially more
interesting, is the regulatory role of methylation at CpG
shores and within gene bodies, as these regions have been
found to be more variably methylated between tissue types
and in cancer compared to normal tissue [3, 4].
Deepening the complexities surrounding the regulatory
roles of CpG dinucleotides located in regions adjacent to
promoters, ‘shores’ and gene bodies is the knowledge that
sequence variation has a strong influence on methylation.
Gertz et al. [5] examined methylation patterns in a three
generation family and have estimated that genotype
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explains around 80 % of the variation in methylation.
Methylation quantitative trait loci or meQTLs refer to se-
quence variants across the genome driving methylation
patterns [6] and these have been mapped in a variety of
different tissues and at different stages of development in
various organisms [7–10]. Smith et al. [9] have compared
sequence variants influencing methylation patterns across
different human tissues and identified sets of meQTLs
that are tissue specific but also others that are consistent
across different tissue types and indeed across popula-
tions. Further, inherited genetic variants have been linked
to methylation changes observed in disease. Shen et al.
[11] have demonstrated that susceptibility SNPs at the
HNF1B locus in ovarian cancer are associated with altered
methylation and consequent expression of HNF1B. Also,
it has been proposed that at least a proportion of unex-
plained Lynch syndrome cases are likely to be due to epi-
genetic silencing of mismatch repair genes. Indeed, it has
been shown that the inheritance of the c.-27C>A germ-line
variant in the 5′ UTR leads to epigenetic silencing MLH1
in Lynch syndrome [12]. Thus, there is now considerable
interest in mapping inherited methylation changes influen-
cing disease susceptibility and disease course.
Genome-wide epigenetic studies have thus far largely fo-
cused on epigenetic alterations that occur in diseased tis-
sues, where epigenetic changes across the genome are
mapped through comparing ‘normal’ and affected tissues
from the same individual. Indeed, epigenetic drugs, cur-
rently in clinical use, are designed to correct the epigenetic
alterations acquired during disease development [13]. The
assumption being that these acquired epigenetic alterations
are driven by the disease process itself. More recently, it
has been hypothesised that inherited genetic variation can
drive epigenetic alterations and further that these contrib-
ute to disease susceptibility or disease course. To date, the
large majority of genome-wide methylation studies and
consequently the bioinformatic pipelines used to interpret
these data have been designed to compare diseased with
‘normal’ tissue, in order to map epigenetic changes in the
disease tissue itself. This analysis may screen out inherited
epigenetic changes that are evident both in the normal tis-
sue and the diseased tissue of the same affected individual.
There remains a need to explore inter-individual variation
of the epigenome and its contribution to disease. A power-
ful approach to examining the role of inherited variation
drivers of epigenetic change is to examine large families
where inheritance of variation driving epigenetic alter-
ations can be tracked through generations.
A number of challenges exist in the analysis of
genome-wide methylation mapping in samples and these
include technical challenges dealing with batch effects
and the underlying biochemistry employed by the array
methods. This has necessitated the development of nu-
merous pre-processing quality control methods to ensure
reliable, high-quality data generation. As most studies
examining epigenetic profiles have typically examined dif-
ferences between two distinct groups (normal vs tumour
tissue or case vs control), the majority of normalisation
methods for the 450k array are designed for these types of
data, frequently requiring two data groups to normalise
negative and positive control probes or genomic regions.
Such methods are incompatible with pedigree data, which
lack a distinct second group for normalisation. In re-
sponse to the absence of appropriate strategies, we have
developed a pipeline for optimal normalisation and pre-
processing of familial-based methylation array data.
Methods
DNA isolation and preparation
Fifty peripheral blood samples were collected from indi-
viduals representing clusters of densely aggregated cases
of affected men and close relatives from the Tasmanian
Familial Prostate Cancer study. A diagrammatic repre-
sentation of the family pedigrees is shown in Fig. 1, with
disease status indicated. Individuals are of Caucasian
descent, ranging in age from 23 to 89 years. See
Additional file 1: Table S1 for more detailed information
on clinical data and sample handling where available.
DNA was extracted from whole blood using the Nucleon
BACC3 (GE Healthcare) DNA extraction kit, following
the manufacturer’s instructions. DNA was initially quan-
tified on the Nanodrop 8000 (Thermo Scientific) and
samples with a 260:280 ratio of less than 1.80 were fur-
ther purified using the Zymo Clean & Concentrator
(TM)-5 Kit. DNA was then quantified using a Qubit®
Flourometer. One microgram of DNA was bisulphite
converted using the EZ DNA Methylation-Gold (TM)
kit (ZYmo Research), according to the manufacturer’s
instructions. Bisulphite-converted DNA (400 ng) was
then used for analysis of DNA methylation using the
450k array, according to the manufacturer’s instructions.
Data extraction, pre-processing and initial quality control
IDAT files containing the raw intensity signals from red
and green colour channels were generated using Illumi-
na’s iControl software, with all further analysis carried
out in the R environment [14]. A combination of three R
packages, minfi [15], methylumi [16] and ChAMP [17],
were used to load IDAT files into R and perform basic
quality control. Different normalisation methods require
the data to be in different formats which cannot be sub-
sequently modified once loaded into R. As such, a num-
ber of different packages were used to load data, with
the chosen package dependent on the normalisation
method tested. Methylumi was used to read data into R
in the correct format for quantile normalisation in the
lumi R package. The minfi package provides a quality
control report based on inbuilt control probes on the
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array (such as staining, hybridization, bisulfite conver-
sion and negative controls) as well as the ability to ex-
clude probes and samples based on probe signal
intensity. Samples failing this initial quality control were
excluded from further analysis. Replicate samples across
batches were included on the beadchips to allow assess-
ment of quality control and technical bias. Of the 50
unique samples and 8 replicates initially interrogated, 45
unique and 5 replicate samples passed quality control
metrics and were used for further analysis. Following
sample quality control, the recommended quality thresh-
olds in ChAMP were employed to exclude poor quality
probes, with a minimum detection p value of 0.05 in
more than one sample removing 6740 probes and a bead
count threshold of <3 in 5 % of samples removing a fur-
ther 478 probes. To account for sex differences in
methylation, driven particularly by dosage compensation
by X-inactivation, probes on the sex chromosomes were
removed prior to normalisation. While ChAMP includes
this option as default when loading data, most packages re-
quire manual separation, normalisation and recombination
of sex chromosomes or their complete manual removal.
Thus, to permit appropriate comparison of normalisation
methods, a homogenous set of loci across all packages was
required; therefore, sex chromosomes were removed at this
stage of analysis and not re-introduced.
Normalisation
Eight normalisation techniques were applied to the
whole dataset, as detailed in Table 1 with each method
evaluating the same samples. The probe subset chosen
for each analysis was selected following the instructions
of each individual normalisation package, which had dif-
ferent requirements. This dictated whether normalisa-
tion methods were compatible and could be used in
conjunction.
Data are presented for each method except RUV, for
which the results were not resolvable using the data gen-
erated in this study. These methods involve various de-
grees of type I and II probe scaling to account for
underlying technical differences between the probe types,
background and dye bias correction and initial between
array batch correction. Depending on the normalisation
method, data was either used in the red/green signal for-
mat (RGset), converted into methylated and unmethylated
values (MethylSet) or converted to β values by the func-
tion β =M/(M +U + 100), where M is the methylated
(See figure on previous page.)
Fig. 1 Selected pedigree clusters from four families from the Tasmanian Familial Prostate Cancer study. Four clusters were chosen from family 9
(a), two from family 11 (b), four from family 22 (c) and five from family 72 (d). Circles represent women and squares men, with individuals affected
by prostate cancer filled in black, those unaffected unfilled and individuals affected by other cancers quarter filled. Samples interrogated on the 450k array are
indicated by a red arrow head. Replicate samples are indicated by square brackets around the sample name, while the batch is indicated underneath the
sample name. Orange stars indicate samples for which good-quality Omni2.5 genotype and 450k methylation data were available
Table 1 Normalisation methods tested. The table includes a
brief description of each method, the relevant R package and
reference for further information
Normalisation method Package Reference
Quantile normalisation
The distributions of probe intensities for
different samples are made identical. Often
used in microarray analysis.
lumi [33]
Stratified quantile normalisation
Probes are stratified by genomic region then
quantile normalised with sex chromosomes
normalised separately when male and female
samples are present. No background
correction, zeros removed by outlier
function. Not recommended for cancer-
normal comparisons or other groups with
global differences.
minfi [15]
Beta-mixture quantile dilation (BMIQ)
Adjusts type II probes to type I distribution.
Recommended for all datasets.
ChAMP [27]
Subset-quantile within array normalisation
(SWAN)
A quantile distribution is created using a
subset of probes, with subsetting based on
the number of CpGs in the probe body.
Separate subsets are created for type I and II
probes. The remaining probes are then
adjusted to the subsets.
minfi [34]
Functional normalisation (FunNorm)
Uses control probes to remove unwanted
technical variation. Also diminishes batch
effects in some datasets. Suitable for use in
cancer-normal studies or where global
methylation changes occur.
minfi [29]
Dasen
Background adjustment and between array
normalisation are performed separately on
type I and II probes.
wateRmelon [20]
Noob
Uses type I probe design to measure non-
specific fluorescence in the opposite colour
channel.
minfi [35]
Remove unwanted variation (RUV)
Previously used with microarray data to
normalise via negative control genes.
Requires distinct groups such as cancer-
normal to normalise on.
RUVnormalize [36]
Batch correction: ComBat
Adjusts for known or unknown batches
using an empirical Bayesian framework.
sva [19]
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signal and U unmethylated. In some normalisation
methods, the offset of 100 is included to regularise scores
when both methylated and unmethylated values are very
low. While the β value is more biologically intuitive (it
ranges from 0 to 1 indicating the proportion of methyla-
tion at that site for the population of cells analysed), it suf-
fers from severe heteroskedasticity at very high or low
values [18]. Logit transforming to anM value removes this
unequal variance. Thus wherever possible, calculations in
this study have been performed on the M values and
transformed back to β values if required for biological in-
terpretation. Eight performance metrics were then used to
compare methods and determine the optimal normalisa-
tion approach for familial datasets. Visual tools such as
density and MDS plots and unsupervised hierarchical
clustering were used to compare the various methods be-
tween all samples and particularly replicate samples. See
Table 2 for a description of each metric.
Table 2 Qualitative and Quantitative metrics used to assess normalisation efficacy. The table includes a brief description of each
metric and which figures describe the results for that method
Method Description Figure
1 Density plot: all samples Bimodal distribution of Beta values as methylated and unmethylated
signals. Each sample is represented by a single line. A batch effect
is indicated when samples performed in the same batch have
a similar distribution.
Fig. 2a, c, e
Additional file 5: Figure S4
Density plot: three groups of
replicate samples
Bimodal distribution of Beta values as methylated and unmethylated
signals. Samples are coloured by replicate group. As each replicate
group contain the same biological information, differences in sample
distribution within groups indicate technical bias.
Additional file 3: Figure S2 (A, C, E)
Density plot: probe I and II
distribution
Bimodal distribution of Beta values as methylated and unmethylated
signals separated by Infinium I and II probe types. Provides information
about probe normalisation which is required for Infinium I and II signals
to be combined in the same analysis.
Fig. 2b, d, f
2 MDS plot: all samples Multidimensional scaling plots show a 2D projection of distances
between samples. For these plots the 1000 most variable sites have
been selected as they are the most biologically relevant for this type
of analysis. Samples cluster by similarity and as such batch effects and
familial clustering can be clearly discerned.
Fig. 3
Additional file 8: Figure S5
MDS plot: three groups of
replicate samples
1000 most variable sites are again selected, with samples coloured
by replicate group. As each replicate group contains the same biological
information, close within group clustering indicates minimal technical
bias while distantly clustered replicate samples indicate heightened
technical bias.
Additional file 3: Figure S2 (B, D, F)
3 ANOVA of the first principal
component for MDS plots
Provides a quantitative value for MDS plots. A lower p value indicates the
clustering is more significantly explained by batch. Ie. a larger p value after
normalisation indicates a reduction in batch effect.
p values displayed on Fig. 3
4 Median absolute differences
between replicate samples
For each replicate group the median M value (log of Beta values) across
all probes was calculated and the absolute difference compared between
replicate groups after various normalisation methods. A smaller absolute
difference indicates improved normalisation as more technical bias
is removed.
Additional file 6: Table S2
5 Imprinted regions:
density plots
227 probes mapping known imprinted hemi-methylated regions can
be used as a standard to measure changes in methylation levels after
normalisation. Density plots have a single distribution peak since there
is roughly 50 % methylation at these sites.
Additional file 4: Figure S3
Differentially methylated region
standard error (DMRSE)
The DMRSE measures how each sample varies from the expected
50 % methylation. Smaller error/deviation from 50 % indicates less
technical bias.
Additional file 1: Table S1
Additional file 4: Figure S3 (A, C, E)
6 Cluster dendrogram Another tool to measure clustering by sample similarity. Samples are
labelled by batch with batch effects clearly seen before normalisation
and diminished after. Red stars indicate replicate samples that are
expected to cluster most closely.
Additional file 2: Figure S1
7 meQTL association Association between methylation at cg17749961 and SNPs in a
2-Mb window.
A significant association is maintained after normalisation and
batch correction.
Additional file 5: Figure S4
8 Epigenome-wide methylation
association with age
QQ plots depicting the association between epigenome-wide
methylation and age.
Plots are performed on raw, normalised and batch-corrected data.
Additional file 9: Figure S6
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Batch correction
Since an obvious batch effect remained after normalisa-
tion, the ComBat function from the sva package [19] was
used to further remove technical bias introduced by inter-
rogating samples on the 450k array in different batches.
Genotype data
DNA from a subset of samples was extracted as described
above and interrogated on Illumina’s HumanOmni2.5-8
Beadchip according to the manufacturer’s instructions.
Quality control was performed with Illumina’s GenomeS-
tudio Software.
Statistical analysis
Eight methods, as described in Table 2, were used to com-
pare the efficacy of the various normalisation methods. In
addition to density and MDS plots, the ANOVA test and
quantitative measures, mean absolute difference between
replicates and the differentially methylated region stand-
ard error (DMRSE) measures were used. Additionally, two
approaches were taken to test the underlying biological in-
formation was preserved between samples; namely, an as-
sociation analysis between genotype and methylation at a
previously identified meQTL and an epigenome-wide as-
sociation analysis with age.
For a qualitative measure to examine effectiveness of be-
tween array normalisation, hierarchical cluster dendrograms
were generated using all probes with the hclust function
using the Euclidean distance between from the default R
package, stats. Cluster dendrograms group samples by dif-
ferences, with similar samples grouping together.
MDS plots were clustered by batch or family; then,
analysis of variance was performed on the first principal
component from a PCA on the 1000 most variable beta
values using the aov and prcomp functions in the stats
core R package. p values are displayed on the MDS plots
in Fig. 2. A lower p value indicates that clustering is
more significantly explained by batch or family, with a
larger p value after normalisation indicating a reduction
in technical bias.
Six replicate sample pairs were used to quantitatively
assess the performance of the normalisation methods, as
one sample from each pair was interrogated on a separ-
ate batch. The median absolute difference between each
pair was calculated by first taking the absolute difference
at each probe between the two replicates and then tak-
ing the median of the differences. A lower median differ-
ence indicates less technical bias, as the samples are
biologically identical.
There are 227 known imprinted regions (iDMRs) on
the 450k array, and these have previously been employed
in analysis packages such as wateRmelon as a quality
control metric [20]. These regions are expected to have
allele-specific methylation and a β value of 0.5, and
therefore deviation from this value can be examined as a
standard error-type measure, denoted DMRSE in the
wateRmelon package. The dmrse_row function was used
to measure dispersion of methylation between samples
for each normalisation method. A lower value indicates
methylation values are more tightly aligned with ex-
pected methylation levels.
While evidence of clustering according to familial rela-
tionships following normalisation correction provides
some confidence that biological integrity of the data is
preserved, to further test the preservation of biologically
relevant information, we examined detectable associa-
tions of known meQTLs in our data. Shoemaker and
colleagues have previously identified 736 CpG sites to be
associated with SNPs in cis [21]. Here, we examined
cg17749961, one of the ten most significant hits re-
ported by Shoemaker et al., in the 22 individuals, for
whom both methylation and genotyping SNP data was
available. Association analysis was performed between
this probe site and SNPs located within a 2-Mb window
adjacent to this site, using linear regression, and assum-
ing an additive disease model. Relatedness was adjusted
for by fitting a linear mixed model on the methylation of
cg17749961 and a kinship matrix, determined by the
identity-by-state function in the GenABEL R package
[22]. The residuals from this model were then used as
the outcome variable in the linear regression model with
SNPs drawn from a 370 K Illumina array. Bonferroni
correction was used to correct for multiple testing error.
To further demonstrate biological information is pre-
served after normalisation and batch correction, the as-
sociation between age and epigenome-wide methylation
was compared for raw data, stratified QN normalised
data and ComBat-corrected stratified QN data. Linear
regression models were fitted with age as the explana-
tory variable and methylation as the outcome variable,
with −log10 p values of the models plotted against
−log10 expected p values as QQ plots.
Results
Evaluation of normalisation methods to address technical
bias
Data generated from whole genome methylation analysis
employing array technology generates an output necessi-
tating application of normalisation methods to correct
for possible bias arising from within and between array
variation. Herein eight different methodologies (Table 1)
were examined and visual and quantitative metrics were
employed to evaluate their comparative performance.
High-quality methylation data was generated for 45
unique and five replicate samples from four families
using the 450k array in three separate batches (see Fig. 1
for further details). A minimum of one sample in each
of the three batches was replicated, providing five
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technical replicates in addition to the three unique sam-
ples on each batch, to permit generation of data from
analysis of the same biological sample. In data lacking
technical bias, replicate samples would be expected to
generate the most similar methylation profiles, while
methylation profiles generated from closely related
individuals should also cluster tightly compared to dis-
tantly or unrelated individuals. However, if technical bias
such as a batch effect has been introduced, this distorts
the profiles and samples no longer cluster by biological
similarity but instead the most evident grouping would
be by batch.
A B
C D
E F
Fig. 2 Multidimensional scaling plots of M values by batch and family. Multidimensional scaling plots for raw (a, b), stratified QN (c, d) and
ComBat stratified QN (e, f) M values. For each plot, the 1000 most variable probes were selected. In a, c and e, numbers represent batches and
are coloured accordingly, with clustering by batch clearly seen in a, to a lesser extent in c and removed in e. In b, d and f, numbers represent
family groups and are coloured accordingly with the clearest clustering present in f after the batch effect has been removed. p values are from an
ANOVA test for significance of batch (a, c and e) or family (b, d and f) on the first principal component from a PCA on the beta values
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Batch effect (between array variation) was examined
and the density distribution plot (Fig. 3a) of the raw β
values from all three batches reveals significant bias. The
greatest contributor to batch effect was the date on
which the BeadChips were processed, with bisulphite
conversion performed on the same day as BeadChip pro-
cessing. Employing a stratified QN (Fig. 3b) and/or
ComBat normalisation (Fig. 3c) dramatically reduced
Fig. 3 Density distribution of β values. Density plot and probe distribution of β values for raw pre-normalisation data (a, b), after stratified QN (c, d)
and with stratified QN and ComBat batch correction (e, f). For density plots (a, c, e), a single line represents a sample, with samples coloured by batch. A
clear batch effect is present in a, lessened in c and removed in e. For the probe distribution (b, d, f), one sample has been chosen with the red dashed
line indicating type I probe distribution, the blue dashed line type II and the solid black line the combined probe distribution. The probe type distribution
is also improved after normalisation, as types I and II are more closely aligned in d and f compared to b
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this observed effect. For between array biases, Fig. 3
shows the density distribution of β values for raw data
samples (A), after stratified QN (C) and after stratified
QN combined with ComBat correction (E). This is par-
ticularly evident when comparing the β value density
plots of three groups of replicate samples (Additional file 2:
Figure S1A, C and E).
Stratified QN also performs best at removing within
array biases as the distribution of probe I and II types
become more uniform (Fig. 3b, d, f ). This bias is driven
by the differing biochemistry of the probes, with type I
employing a single colour channel with a different bead
for methylated and unmethylated DNA and type II con-
taining one bead in two colour channels. The underlying
biology targeted by each probe is confounded by this
technical bias, as type I measures CpG-dense regions
(such as islands) while type II can only tolerate three
CpGs in the length of the probe. As such, type I interro-
gates a greater proportion of unmethylated to methyl-
ated DNA, while type II performs the opposite.
Removing the probe bias is imperative for accurate com-
parisons between these probe types when pooling probe
I and II data, which is necessary for accurate genome-
wide methylation information of both CpG rich and
poor regions.
In contrast, the density plots of β values for other nor-
malisation (SWAN and FunNorm) methods do not im-
prove to the same degree and in some cases greater
variation is introduced (Additional file 3: Figure S2C–G).
For example, a worsening of the batch effect is seen for
SWAN normalisation (Additional file 3: Figure S2D), com-
pared to raw data (Additional file 2: Figure S1A) and the
distribution of methylated and unmethylated signals is
inverted following FunNorm (Additional file 3: Figure S2E).
The second approach employed to examine the per-
formance of the normalisation methods was to generate
multidimensional scaling (MDS) plots. These permitted
the visualisation of the two-dimensional projection of
the differences between samples. For each plot, the 1000
most variable probes were selected, as these represent
the most pertinent biological differences between sam-
ples. M values were used as opposed to β values, the lat-
ter of which have been shown to suffer severe
heteroskedasticity at very high and low values [18].
Again, a strong batch effect is observed in the raw data
(Fig. 2a) as expected and this is removed or significantly
reduced following normalisation using stratified QN
(Fig. 2c) and ComBat (Fig. 2e) corrected data. The
strong batch effect masks the familial relationships in
the raw data; however, following the correction, cluster-
ing according to kinship is clearly evident. Similarly, the
replicate samples (in Additional file 2: Figure S1), which
group disparately in the raw data (A, B), co-locate or
cluster tightly following stratified QN (C, D) and
ComBat (E, F). The MDS plots for each normalisation
method (Additional file 4: Figure S3) also show stratified
QN followed by ComBat to be the most effective
method for removing clustering by batch.
This efficacy of normalisation methods in reducing
clustering of samples by batch was assessed quantita-
tively by ANOVA to test the effect of batch on the first
principal component. The ANOVA was repeated for
each normalisation method, using M values from the top
1000 most variable sites. Consistent with the visualised
MDS plot, the p value was highly significant demonstrat-
ing the significant association of batch in M value in raw
and stratified QN data (p < 0.01) but was not significant
following correction using ComBat (p = 0.97).
For a final qualitative measure to examine effective-
ness of between array normalisation, hierarchical cluster
dendrograms were generated. Application of stratified
QN and ComBat (Additional file 5: Figure S4) again
demonstrated superior normalisation when visualised by
this method; with raw data samples clearly clustering
into three distinct groups (Additional file 5: Figure S4A),
stratified QN resulting in improved clustering (B) while
ComBat batch correction following stratified QN com-
pletely removes the batch effect (C) permitting the de-
sired outcome with related individuals clustering
together in familial groups. Furthermore, replicate sam-
ples cluster more clearly after ComBat normalisation (C,
red stars) indicating removal of batch effects without
perturbing biologically relevant information.
To quantitatively assess the performance of these nor-
malisation methods, the median absolute difference in
M values was calculated for six replicate pairs, with one
sample from each pair interrogated on a separate batch.
With the exception of one pair, stratified QN with Com-
Bat was found to have the lowest absolute median differ-
ence between technical replicate pairs, corresponding to
the highest correlation between replicate pairs (see Add-
itional file 6: Table S2). While others such as SWAN in-
troduced an increase in the error rate relative to the raw
data values.
Finally, standard error measures for imprinted re-
gions were calculated and compared between methods
as described in the statistical analysis section of the
methods. Smaller values indicate lower errors and
more reliable data. A DMRSE of 0.0048 was calcu-
lated for the raw data, with this value increasing with
following normalisations using QN (0.0052), noob
(0.0052) and functional normalisation (0.0056). The
remaining normalisation methods generated reduced
DMSRE values with stratified QN with ComBat batch
correction again producing the smallest error values
at 0.0012. See Additional file 7: Table S3 for a full list
of DMRSE values and Additional file 8: Figure S5 for
the density plots of these probes.
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Increased power for determining true biological
associations
Critical to any normalisation method is the maintenance
of true biological differences between samples. As de-
scribed in the statistical analysis section of the methods,
a previously identified meQTL was selected to perform
association analysis with prior to and following normal-
isation. Following Bonferroni correction, a significant asso-
ciation was detected in the raw data (Fig. 4a, p value =
7.29e-06), increasing markedly after stratified QN (Fig. 4b,
p value = 3.53e-07). After ComBat (C), there was a drop in
significance compared to stratified QN and raw, yet the p
value was still highly significant (p value = 1.05e-05) indicat-
ing preservation of the biological information of interest.
The drop in significance after batch correction may be ex-
plained as confounding between batch and family, which
is removed after ComBat. Ideally, samples would be
randomised across experiments; however, the nature of fa-
milial studies is such that this is not always possible, as
samples are collected at different time points, often across
generations. To maintain maximum power, the inclusion
of all available samples is essential and, therefore, data
processing methods capable of dealing with non-ideal
datasets are required.
Epigenome-wide methylation has long been shown to
drift with age, specifically global hypomethylation and
region-specific hypermethylation are observed [23]. The
association between age and epigenome-wide methylation
was compared for raw data, stratified QN normalised data
and ComBat-corrected stratified QN data to demonstrate
that this biological information was preserved after nor-
malisation and batch correction. After normalisation
(Additional file 9: Figure S6B), there are many more sig-
nificant associations with age than in the raw data (Add-
itional file 9: Figure S6A), indicated by a greater number
of points above the expected line and a much greater
Lambda value (median of observed −log10 p values di-
vided by the median of expected −log10 p values), with an
increase from 0.838 to 1.402. There is another small in-
crease in significance after ComBat batch correction
(Additional file 9: Figure S6C) to 1.448, again indicating
improved strength in testing biological associations.
Discussion
There is currently a plethora of pre-processing methods
and R packages available for analysis of 450k array data,
and comprehensive review articles evaluating their utility
have been published [24–26]. The majority of these are
designed for specific types of sample sets, particularly
those comprised of two distinct groups such as case–
control or cancer-normal with substantial methylation
differences between the two groups. For different data-
sets, such as those from familial studies, which include
complex pedigree structures instead of two distinct
groups, these methods may be ineffective or worse, det-
rimental in that they introduce technical bias, as identi-
fied with selected methods in this paper. To correctly
normalise data, it is critical to choose the most appropri-
ate method; yet there has been little focus on developing
appropriate processing pipelines for familial methylation
array analysis, despite the current interest in inherited
drivers of methylation patterns. Further barriers are the
various format requirements and the lack of integration
to provide a seamless processing pipeline. Here, we have
Fig. 4 Association plot between SNPs and methylation. Association
between methylation at cg17749961 and SNPs in a 2-Mb window.
There is a significant association in the raw data (a, p value = 7.29e-06)
which increases after stratified QN (b, p value = 3.53e-07) and drops
slightly after ComBat correction (c, p value = 1.05e-05)
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tested eight different methods and presented a prelimin-
ary pre-processing pipeline for familial data (depicted in
Fig. 5). This pipeline creates a template to guide and ex-
pedite the analysis of familial datasets, particularly gen-
erated using the 450k array data. Sample size (n = 50) is
a limitation of this study, therefore additional familial
studies would aid in validating the pipeline.
A fundamental requirement for processing methyla-
tion array data is effective adjustment for technical bias,
including batch effects and adjusting for the two-probe
biochemistry of the array. Batch effects may be intro-
duced through bisulphite conversion or downstream
processing or variation in array quality. Various methods
have been developed to adjust for these effects, mostly
involving variations in quantile normalisation, a tech-
nique commonly used in analysis of microarray datasets
to align two different distributions so they result in iden-
tical statistical properties [26–29].
BMIQ and functional normalisation have been advo-
cated as the preferred methods for cancer studies as they
are more specific in design than quantile normalisation
and have been shown to be more effective at removing
unwanted technical bias [27, 29]. However, these
methods work most effectively on case–control or
tumour-normal datasets respectively and to the best of
our knowledge, optimal pre-processing methods for
Fig. 5 Pipeline for familial data processed on the 450k array. Each box indicates a stage of the pipeline including the R package and the data
format required/created in italics
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familial-based data, such as performed here, have not
been reported. Normalisation methods necessarily make
assumptions about data, with the accuracy of these as-
sumptions varying for different datasets. Thus, the same
normalisation method can have a vastly different effect
on different types of data and conversely, as shown here,
different normalisation methods can have vastly different
effects on the same data. It is therefore a key to select
the right normalisation method for the dataset of inter-
est. Of the eight methods tested, stratified QN was con-
sistently identified as the best normalisation method
across all visual and quantitative evaluation metrics for
use in this context. The principle underpinning this nor-
malisation is stratification by genomic region and is thus
ideal for data where the differences between adjacent
genomic loci are maintained. This is in contrast to
tumour-normal tissue datasets where there are large
blocks of dramatically altered methylation patterns
throughout the tumour genome [30]. Again not surpris-
ingly, packages that utilise differences in negative control
methylation patterns between cases and controls such as
FunNorm were not found to be effective on familial
datasets where no ‘normal’ control is available.
The inherent strengths of familial data could be further
exploited by a normalisation technique that accounts for
known relationships between samples. Such a method
could draw on pedigree information to ensure normalisa-
tion has effectively removed technical bias while maintain-
ing known biologically relevant information such as
relatedness and familial clustering by methylation. A diag-
nostic metric accounting for a known relationship could
be used to test the efficacy of pre-processing methods in a
similar manner to the standard error associated with
iDMRs from the wateRmelon package.
It may also be of importance for researchers to con-
sider the undesirable effect of non-specific binding and
the presence of SNPs in the probe body. A study from
the Weksberg lab found around 6 % of probes on the
array cross-hybridised to non-targeted genomic regions
[31]. They have catalogued these probes and suggest re-
moving them prior to downstream analysis. Their study
also demonstrates that SNPs in the probe body can
interfere with probe binding, altering the methylation
signal at around 14 % of sites. Illumina recommends all
probes containing a SNP within 10 bp of the interro-
gated CpG site ought to be removed, while others sug-
gest the ‘probe effect’ continues to the entire 50-bp
length of the probe [31, 32]. The removal of all such
probes would be undesirable for studies examining the
effect of genotype on methylation, as evidence suggests
the vast majority of these SNPs occur either at the CpG
site itself (meSNPs) or close by [32].
To overcome this issue, Zhi and colleagues suggest an
elegant approach to examine the effect of meSNPs on
methylation without the potential bias introduced by
SNPs altering probe binding [32]. The type II probes
contain only one bead type for both methylated and
unmethylated sites of interest, with the methylation sta-
tus of the loci designated by the addition of a different
coloured nucleotide (red or green) at the single base ex-
tension. As type II probes terminate one base pair before
the cytosine of the CpG dinucleotide, a mutation at the
cytosine itself would not affect probe binding. As such,
probes without SNPs in the probe body but present at
the single base extension can reliably be used to examine
the effect of meSNPs on methylation, a very useful tech-
nique for examining the effect of inherited variation on
methylation patterns.
Conclusions
Preservation of the biological integrity of information
from methylation array data is imperative and requires ap-
propriate pre-processing to minimise technical errors,
which will be dictated by the type of data. Stratified QN in
combination with ComBat batch correction performed
the best of those methods tested for normalising familial
data interrogated on 450k array. This method was ob-
served to remove technical biases while maintaining bio-
logically relevant information; allowing true biological
differences and similarities to inform our search for the
role of methylation patterns driving disease processes. The
workflow presented in this paper (highlighted in Fig. 5)
provides a streamlined methodology to pre-process famil-
ial data and may also be instructive for other datasets in-
cluding longitudinal studies where the same individuals
are repeatedly measured over time.
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Additional file 1: Table S1. Clinical data and sample extraction and
storage information. (DOCX 20 kb)
Additional file 2: Figure S1. Hierarchical cluster dendrogram for raw,
stratified QN and ComBat-corrected data. Samples are clustered by
similarity and labelled by batch. Raw data samples (A) clearly cluster into
three distinct batches while stratified QN (B) partially adjusts clustering by
batch and stratified QN combined with ComBat considerably diminishes
the batch effect (C). Red stars indicate replicate samples which cluster
more clearly in (C), indicating removal of batch effects. (PDF 449 kb)
Additional file 3: Figure S2. Density distribution of β values and
multidimensional scaling plots of M values for replicate samples. Density
(A, C, E) and MDS (B, D, F) plots of three replicate sample groups for raw
(A, B), stratified QN (C, D) and stratified QN ComBat-corrected (E, F) data.
For all plots, samples are coloured by batch 1–3 as labelled. Density plots
show the distribution of β values, which become more uniform after stratified
QN (C) and stratified QN plus ComBat (E). MDS plots show clustering of the
1000 most variable sites by M value, highlighting the decreasing variance
between replicate groups after stratified QN and ComBat (F). (PDF 7387 kb)
Additional file 4: Figure S3. Density distribution of β values for
imprinted differentially methylated regions. Density plots for raw (A),
stratified QN (C) and stratified QN with ComBat (E) for 227 probes
mapping known imprinted differentially methylated regions. Each line
represents a sample, with samples coloured by batch. As methylation at
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these loci is allele-specific there is a single density distribution rather than
the bimodal distribution seen in Additional file 3: Figure S2. The standard
error-type measure (DMRSE) diminishes with Stratified QN and ComBat,
indicating more reliable data. B, D and F show the Infinium I and II probe
distributions, which becomes more uniform with stratified QN and
ComBat. (PDF 4133 kb)
Additional file 5: Figure S4. Density distribution of β values for all
normalisation methods. Density plots of β values for various normalisation
methods: raw pre-normalisation data (A), quantile normalisation (B), BMIQ
(C), SWAN (D), FunNorm (E), Dasen (F), noob (G), stratified QN (H), raw with
ComBat correction (I) and stratified QN with ComBat correction (J). A single
line represents a sample with samples coloured by batch. The batch effect
present in the raw data (A) remains after the majority of normalisation
methods with Dasen (F) and stratified QN (H) showing the most uniform
distributions. Some methods such as quantile normalisation (B) and
FunNorm (E) flip the methylated and unmethylated signal distribution.
ComBat is effective at removing batch effects in both raw (I) and normalised
(J) data, with the best outcome seen with stratified QN with ComBat batch
correction (J). (PDF 260 kb)
Additional file 6: Table S2. Median absolute difference between
technical replicate pairs. (DOCX 14 kb)
Additional file 7: Table S3. Standard error measures for imprinted
differentially methylated regions for the various normalisation methods.
(DOCX 13 kb)
Additional file 8: Figure S5. Multidimensional scaling plots of M values
by batch for all normalisation methods. Multidimensional scaling plots for
raw (A), quantile normalisation (B), BMIQ (C), SWAN (D), FunNorm (E),
Dasen (F), noob (G), stratified QN (H), raw with ComBat correction (I) and
stratified QN with ComBat correction (J). For each plot, the 1000 most
variable probes were selected. Batches are numbered and coloured, with
clustering by batch clearly seen in the raw data (A) and removed to
varying degrees with different normalisation methods. ComBat correction
following stratified QN provides optimal batch correction removal as the
samples no longer cluster according to batch. (PDF 559 kb)
Additional file 9: Figure S6. QQ plots for the association of age and
epigenome-wide methylation. QQ plots with −log10 p values from the
linear model of methylation and age plotted against expected −log10
p values. Raw data (A), data normalised by stratified QN (B) and data
normalised by stratified QN then corrected with ComBat (C). (PDF 85 kb)
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Appendix	  4.1	  Linkage	  regions	  with	  the	  highest	  LOD	  scores	  previously	  identified	  through	  the	  
SNP Chr Position LOD	  Score SNP Chr Position LOD	  Score SNP Chr Position LOD	  Score
RS2600776 2 237263622 3.09 RS4714457 6 41485970 2.26 RS1722791 15 21503831 2.17
RS2600793 2 237269550 3.25 RS814836 6 41497306 2.2 RS1524842 15 21505342 2.43
RS7585432 2 237291473 3.44 RS814839 6 41502190 2.2 RS1717839 15 21525066 2.36
RS975919 2 237293119 3.44 RS13219238 6 41506909 2.16 RS11632341 15 21540364 2.36
RS10929183 2 237293840 3.61 RS13196762 6 41512003 2.22 RS1628195 15 21551731 2.41
RS7556982 2 237308938 3.67 RS766389 6 41514764 2.08 RS824205 15 21559164 2.27
RS13419340 2 237325521 3.67 RS11962670 6 41520542 2.04 RS8182040 15 21569096 2.25
RS1549869 2 237335771 3.7 RS9381065 6 41522528 2.02 RS1722842 15 21582049 2.38
RS999031 2 237355157 3.58 RS912881 6 41523715 2.02 RS12439817 15 21582093 2.41
RS1897464 2 237363415 3.61 RS1970923 6 41525198 1.98 RS7181322 15 21583164 3.16
RS934397 2 237371678 3.61 RS9357362 6 41541193 2.02 RS940595 15 21589360 3.13
RS1344762 2 237373226 3.73 RS2496635 6 41542795 2.11 RS8038234 15 21597810 3.13
RS10929194 2 237385373 3.73 RS7762551 6 41545237 2.35 RS824211 15 21598281 3.16
RS13000320 2 237388433 3.73 RS728825 6 41551451 2.43 RS7180295 15 21601351 3.01
RS1368202 2 237395901 3.85 RS728826 6 41551593 2.58 RS2352765 15 21606718 3.01
RS10166334 2 237405247 3.91 RS2477831 6 41551667 2.58 RS844033 15 21609833 3.01
RS1000007 2 237416793 3.88 RS10947972 6 41554327 2.58 RS824162 15 21609981 2.99
RS7565608 2 237425567 4.03 RS4714468 6 41560974 2.58 RS1524845 15 21612590 3.04
RS11694315 2 237435644 4.03 RS2496637 6 41563034 2.35 RS824167 15 21614609 3.01
RS3888913 2 237444863 3.41 RS721313 6 41563275 2.31 RS2177077 15 21618739 3.01
RS30105 2 237459284 3.43 RS3800282 6 41568265 2.35 RS8031166 15 21633826 2.68
RS6737351 2 237464699 3.52 RS6913778 6 41572879 2.44 RS11633486 15 21639815 2.68
RS10169105 2 237470609 3.37 RS6907558 6 41575838 2.59 RS8038712 15 21647999 2.65
Tasmanian	  Familial	  Prostate	  Cancer	  Study	  
RS12463648 2 237475305 3.37 RS2495232 6 41582705 2.77 RS1459958 15 21649687 2.45
RS4663682 2 237481662 3.37 RS2495233 6 41583425 2.77 RS10519445 15 21657901 2.47
RS7603272 2 237486328 3.48 RS2477842 6 41597419 2.85 RS4778341 15 21663374 2.47
RS7581699 2 237496143 3.48 RS2496652 6 41612104 2.95 RS1459985 15 21668350 2.47
RS10929201 2 237497105 3.6 RS4714484 6 41639201 2.95 RS2883186 15 21680981 2.21
RS729454 2 237516077 3.65 RS913074 6 41646523 3.1 RS4778346 15 21686776 2.11
RS1435847 2 237527888 3.56 RS4714487 6 41655290 3.07
RS7600637 2 237538697 3.45 RS13362583 6 41671135 3.07
RS2701323 2 237550613 3.28 RS913075 6 41676884 2.91
RS4663691 2 237565291 3.25 RS9381084 6 41678328 2.75
RS2701336 2 237571642 3.2 RS9369298 6 41684618 2.75
RS4663692 2 237573371 3.14 RS2842639 6 41690967 2.75 SNP Chr Position LOD	  Score
RS755512 2 237575821 3.12 RS6928533 6 41701974 2.8 RS738092 22 19190931 3.03
RS2573718 2 237582343 3.2 RS1973920 6 41711172 2.77 RS7291930 22 19206509 4.64
RS2318131 2 237598705 3.14 RS2495229 6 41713808 2.73 RS1110462 22 19211385 4.6
RS7591958 2 237608324 3.12 RS2268408 6 41718697 2.77 RS5995708 22 19217080 4.47
RS7576705 2 237612027 3.14 RS2842658 6 41727028 2.89 RS7292126 22 19226926 4.47
RS7597414 2 237622493 3.26 RS4714501 6 41727341 2.94 RS886319 22 19233410 4.51
RS7589198 2 237632354 3.21 RS2230088 6 41729249 2.97 RS177421 22 19243757 4.51
RS12620999 2 237701106 3.18 RS2143678 6 41731011 2.67 RS165674 22 19258809 4.6
RS10172321 2 237730202 3.35 RS1474762 6 41735030 2.56 RS361646 22 19277274 4.8
RS6714237 2 237734087 3.32 RS1474761 6 41735041 2.68 RS165626 22 19284760 4.7
RS7599969 2 237734970 3.32 RS4714503 6 41741250 2.63 RS552823 22 19286906 3.87
RS12613316 2 237740231 3.18 RS6458234 6 41746737 2.46 RS561595 22 19290707 3.9
RS4527163 2 237765225 3.15 RS1011101 6 41751364 2.12 RS680548 22 19295555 3.87
RS4663242 2 237767644 3.15 RS1883816 6 41752419 2.14 RS473304 22 19297450 3.64
RS4233629 2 237768857 3.08 RS654526 22 19303386 3.64
CpG	  Name
Significant	  
Associations
Highest	  
-­‐log10(p-­‐value)
CpG	  Name
Significant	  
Associations
Highest	  
-­‐log10(p-­‐value)
1 cg13387643 10 33.80 51 cg19300401 18 20.91
2 cg20592836 44 30.25 52 cg05161773 18 20.68
3 cg25203245 37 28.94 53 cg23052585 29 20.67
4 cg13928473 18 28.86 54 cg18618432 28 20.59
5 cg15083522 42 28.34 55 cg11251367 9 20.42
6 cg03075889 27 27.84 56 cg25543264 36 20.29
7 cg07414487 66 27.73 57 cg11585022 34 20.28
8 cg05792312 10 27.68 58 cg18527716 25 19.70
9 cg09281805 10 27.00 59 cg02113055 33 19.63
10 cg08146865 42 26.84 60 cg18572898 138 19.57
11 cg10724632 20 26.55 61 cg09993319 9 19.40
12 cg09084244 31 26.38 62 cg18709904 29 19.26
13 cg21927991 20 26.25 63 cg18088486 29 19.05
14 cg25013753 15 26.25 64 cg04610028 14 18.94
15 cg08210706 24 25.90 65 cg22851875 12 18.85
16 cg16490124 29 25.56 66 cg05338731 33 18.81
17 cg19393008 23 25.53 67 cg12551908 20 18.80
18 cg20205188 12 25.39 68 cg26128129 8 18.64
19 cg05809586 22 25.11 69 cg07686394 29 18.61
20 cg17723206 11 24.96 70 cg04028540 9 18.48
21 cg23098789 6 24.48 71 cg05059349 24 17.93
22 cg04145681 46 24.42 72 cg27341708 29 17.10
23 cg27481428 23 24.24 73 cg05509228 9 16.97
24 cg23681001 17 24.23 74 cg12186981 36 16.95
Appendix	  4.2	  Significant	  me-­‐QTL	  Associations	  for	  the	  Variable	  Methylation	  Approach	  using	  
25 cg07240846 7 24.10 75 cg25593194 37 16.73
26 cg06330797 14 23.95 76 cg09533869 14 16.57
27 cg00231519 27 23.87 77 cg06032337 59 16.29
28 cg26705599 11 23.81 78 cg02658043 18 16.26
29 cg19360212 27 23.77 79 cg21498547 8 15.76
30 cg00257789 32 23.74 80 cg17056069 12 15.69
31 cg18828306 24 23.73 81 cg02533724 8 15.52
32 cg18624102 29 23.64 82 cg00345083 12 15.03
33 cg25674027 32 23.39 83 cg16748433 26 14.23
34 cg04998327 13 23.33 84 cg20536971 27 14.03
35 cg10530344 20 22.90 85 cg26365090 6 12.53
36 cg06318935 25 22.73 86 cg12195446 19 12.48
37 cg05134736 12 22.59 87 cg17662493 31 12.33
38 cg22274273 9 22.58 88 cg08238375 45 12.04
39 cg01127608 4 22.29 89 cg14797147 15 11.59
40 cg15567368 1 22.03 90 cg13232075 20 11.50
41 cg02978201 19 22.00 91 cg10507965 13 10.84
42 cg15765638 12 21.88 92 cg07501029 7 10.56
43 cg01341801 31 21.53 93 cg20086657 28 10.09
44 cg01891583 12 21.53 94 cg00704664 9 9.69
45 cg24009806 8 21.48 95 cg03796003 11 9.43
46 cg16791832 13 21.35 96 cg24925741 9 8.04
47 cg09856996 5 21.34 97 cg03224005 14 7.98
48 cg12342501 15 21.30 98 cg26642774 8 7.76
49 cg02890259 23 21.18 99 cg25465065 26 6.85
50 cg12657416 13 21.02 100 cg09289202 11 6.21
Mean	  Number	  of	  Significant	  hits:	  21.94
Mean	  log	  p-­‐value:	  22.06
Appendix	  4.3	  Significant	  me-­‐QTL	  Associations	  for	  the	  Variable	  Methylation	  Approach	  using	  95%-­‐Reference	  Range
CpG	  Name
Significant	  
Associations
Highest	  
-­‐log10(p-­‐value)
CpG	  Name
Significant	  
Associations
Highest	  
-­‐log10(p-­‐value)
1 cg20592836 44 30.25 49 cg13885788 7 19.76
2 cg25203245 37 28.94 50 cg18527716 25 19.70
3 cg15083522 42 28.34 51 cg02113055 33 19.63
4 cg07414487 66 27.73 52 cg18572898 138 19.57
5 cg02464073 9 27.35 53 cg08049519 35 19.55
6 cg08146865 42 26.84 54 cg09993319 9 19.40
7 cg10724632 20 26.55 55 cg00474373 7 19.39
8 cg23698271 7 26.33 56 cg18709904 29 19.26
9 cg21927991 20 26.25 57 cg18088486 29 19.05
10 cg06464078 22 25.81 58 cg04610028 14 18.94
11 cg16490124 29 25.56 59 cg05338731 33 18.81
12 cg19393008 23 25.53 60 cg07686394 29 18.61
13 cg17723206 11 24.96 61 cg05059349 24 17.93
14 cg24801230 57 24.70 62 cg27341708 29 17.10
15 cg23098789 6 24.48 63 cg07498088 42 16.99
16 cg04145681 46 24.42 64 cg12186981 36 16.95
17 cg27481428 23 24.24 65 cg04131969 19 16.73
18 cg23681001 17 24.23 66 cg09533869 14 16.57
19 cg07240846 7 24.10 67 cg06032337 59 16.29
20 cg06330797 14 23.95 68 cg02658043 18 16.26
21 cg26705599 11 23.81 69 cg24534774 35 16.22
22 cg19360212 27 23.77 70 cg21498547 8 15.76
23 cg00257789 32 23.74 71 cg17056069 12 15.69
24 cg18828306 24 23.73 72 cg04627110 59 15.61
25 cg25674027 32 23.39 73 cg02533724 8 15.52
26 cg04998327 13 23.33 74 cg10140678 12 14.62
27 cg10530344 20 22.90 75 cg25755428 6 14.43
28 cg06318935 25 22.73 76 cg16748433 26 14.23
29 cg22274273 9 22.58 77 cg04657146 1 13.44
30 cg01127608 4 22.29 78 cg23603995 26 13.25
31 cg04003990 15 22.03 79 cg03075889 21 13.16
32 cg15567368 1 22.03 80 cg26365090 6 12.53
33 cg16963093 3 22.00 81 cg12195446 19 12.48
34 cg21463262 7 21.92 82 cg17662493 31 12.33
35 cg05331763 10 21.83 83 cg14797147 15 11.59
36 cg01891583 12 21.53 84 cg07501029 7 10.56
37 cg16791832 13 21.35 85 cg20086657 28 10.09
38 cg09856996 5 21.34 86 cg00704664 9 9.69
39 cg12342501 15 21.30 87 cg03796003 11 9.43
40 cg02890259 23 21.18 88 cg27126508 13 9.03
41 cg12657416 13 21.02 89 cg24925741 9 8.04
42 cg19300401 18 20.91 90 cg03224005 14 7.98
43 cg05161773 18 20.68 91 cg11607219 22 7.75
44 cg23052585 29 20.67 92 cg25465065 26 6.85
45 cg18618432 28 20.59 93 cg02100397 2 6.73
46 cg05111645 115 20.46 94 cg09289202 11 6.21
47 cg11251367 9 20.42 95 cg21550016 30 5.86
48 cg10528424 4 20.26 96 cg01201512 13 5.64
Mean	  Number	  of	  Significant	  hits:	  22.77
Mean	  log	  p-­‐value:	  18.9
Chr Genomic	  Position CpG	  Name
1 chr15 24125985 cg12151888
2 chr6 41407766 cg26223899
3 chr15 24043142 cg26261358
4 chr6 41383225 cg10863737
5 chr6 41528198 cg03036702
6 chr2 237992612 cg16995742
B)	  Risk	  Loci	  identified	  through	  published	  familial	  prostate	  cancer	  studies
Chr Genomic	  Position CpG	  Name
1 chr1 235292369 cg16490124
2 chr1 241800323 cg03964373
3 chr1 240620177 cg11251367
4 chr1 233089275 cg00069771
5 chr1 233518998 cg16675926
6 chr1 232086152 cg23209941
7 chr1 231820076 cg07134368
8 chr1 242002464 cg24361198
C)	  Risk	  Loci	  identified	  through	  published	  prostate	  cancer	  GWAS	  
Chr Genomic	  Position CpG	  Name
1 chr8 128079561 cg11123619
2 chr19 51362954 cg04741880
3 chr2 121684535 cg26075039
4 chr10 101910498 cg20720056
5 chr1 154839813 cg06221963
6 chr1 154839909 cg09359103
7 chr6 6543402 cg23069046
8 chr6 153455993 cg02956194
9 chr6 41528198 cg03036702
10 chr5 1298644 cg12474444
11 chr8 143751801 cg24634471
12 chr8 143757498 cg04035553
13 chr8 143751796 cg10596483
14 chr19 51336166 cg14773235
15 chr12 47353065 cg18468917
16 chr1 117487269 cg16060930
Appendix	  4.4	  The	  most	  significant	  associations	  from	  the	  risk	  loci	  approach
A)	  Risk	  loci	  identified	  through	  the	  Tasmanian	  Familial	  Prostate	  Cancer	  Study	  
17 chr6 32186049 cg00366603
18 chr6 32188822 cg10158182
19 chr6 32202844 cg17239008
20 chr6 32186244 cg17351927
21 chr6 32415210 cg06281714
22 chr5 1325588 cg06550200
23 chr10 100167465 cg26690318
24 chr10 126700684 cg14375985
25 chr10 126686762 cg09349613
26 chr20 62387416 cg13301327
27 chr20 61660810 cg08564027
28 chr11 2211939 cg19586845
29 chr11 2243973 cg01452169
30 chr11 2222912 cg07146321
31 chr11 2212225 cg08241307
32 chr1 38180356 cg06437931
33 chr2 238410067 cg14271023
34 chr2 238380390 cg14458575
35 chr2 238392110 cg16989719
36 chr3 113254986 cg13284789





Variable Methylation Approach to Identify meQTLs    
 1. Identify most variable CpGs  
2. Draw SNPs in 250kb surrounds   
3. Perform association analysis in windows     
4. Sort and organise most significant associations   
 
#############################################################
# Methods of determining the most variable CpG sites between 
individuals
load("/Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_meth_input/R_workspaces_scripts_Meth/Methylation.RData") # load 
clean data
# use the object Meth_M which contains normalised and batch 
corrected M values (logit of Beta values) for 47 samples at 467263 
CpG sites.  M values are used to determine which CpGs are the most 
variable as this measure is less vulnerable to heteroskedasticity 
than  Beta values. Once CpG sites are identified, Beta values can 
then be used for more biologically interpretable plots
## Initial Comparison of variability methods ##
# check the difference between using M and Beta values in the SD 
approach
length(which(rownames(Top100_SD_M) %in% rownames(Top100_SD))) # 71 
cross over 
# check which aren't in overlap and see what plots look like, some 
look messy 
non_overlap <- as.matrix(Top100_SD[which(!(rownames(Top100_SD_M) %in
% rownames(Top100_SD))),])
length(non_overlap) #29
rownames(non_overlap)
## Top 100/500 variable by 95% reference range, only sbe SNPs, no 
probe SNPs
quantile_95_M_sbeSNP <- apply(Meth_M_sbeSNP,1, quantile, 
probs=c(0, .025, 0.5, 0.975, 1))
range_95_M_sbeSNP <- as.matrix(quantile_95_M_sbeSNP[4,]-
quantile_95_M_sbeSNP[2,])
ord_range_95_M_sbeSNP <- range_95_M_sbeSNP[order(range_95_M_sbeSNP, 
decreasing=TRUE),]
Top100_range_M_sbeSNP <- as.matrix(ord_range_95_M_sbeSNP[1:100])
Top500_range_M_sbeSNP <- as.matrix(ord_range_95_M_sbeSNP[1:500])
# check the difference between different methods
length(which(rownames(Top100_SD) %in% rownames(Top100_range_M))) # 
51, 51% 
length(which(rownames(Top100_SD_M) %in% rownames(Top100_range_M))) # 
67, 67%
length(which(rownames(Top500_SD_M) %in% rownames(Top500_range_M))) # 
407, 81%
length(which(rownames(Top100_SD_Meth_M_sbeSNP) %in% 
rownames(Top100_range_M_sbeSNP))) # 73, 73%
length(which(rownames(Top500_SD_Meth_M_sbeSNP) %in% 
rownames(Top500_range_M_sbeSNP))) # 428, 86%
# check the difference between CpGs with a SNP at the sbe and the 
ones without taking this into account
length(which(rownames(Top100_SD_M) %in% 
rownames(Top100_SD_Meth_M_sbeSNP))) # 80, 80%
length(which(rownames(Top500_SD_M) %in% 
rownames(Top500_SD_Meth_M_sbeSNP))) # 396, 79%
length(which(rownames(Top100_range_M) %in% 
rownames(Top100_range_M_sbeSNP))) # 90, 90%  # these have the 
greatest overlap
length(which(rownames(Top500_range_M) %in% 
rownames(Top500_range_M_sbeSNP))) # 415, 83%
# Thus, the range is better at pulling out the sbe SNPs rather than 
SD, especially in the most variable sites (Top100) where its 10% 
more than the Top500
# write a csv with 4 columns listing 100s/500s and the overlap 
between
Tops_100 <- cbind(rownames(Top100_SD_M), rownames(Top100_range_M), 
rownames(Top100_SD_Meth_M_sbeSNP), rownames(Top100_range_M_sbeSNP))
colnames(Tops_100) <- c("Top100_SD_M", "Top100_range_M", 
"Top100_SD_Meth_M_sbeSNP", "Top100_range_M_sbeSNP")
write.csv(Tops_100, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_meth_input/Tops_100.csv")
Tops_500 <- cbind(rownames(Top500_SD_M), rownames(Top500_range_M), 
rownames(Top500_SD_Meth_M_sbeSNP), rownames(Top500_range_M_sbeSNP))
colnames(Tops_500) <- c("Top500_SD_M", "Top500_range_M", 
"Top500_SD_Meth_M_sbeSNP", "Top500_range_M_sbeSNP")
write.csv(Tops_500, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_meth_input/Tops_500.csv")
### Chose M over Beta values due to heteroskedasticity, chose a 
combination of SD and 95%-range to give wider coverage and chose a 
combination of only sbe SNP CpGs (SD) and CpGs unfiltered for sbe 
SNPs (95%-range) ###
############################
## 1. Standard Deviation  ##
############################
# Prioritise the CpGs that are TypeII and have a SNP at the sbe as 
methylation at these sites are the most likely to be affected by 
SNPs but those SNPs will not affect the pribe binding.  Also check 
for SNPs in probe body as these may affect the binding of the probe
load("/Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_meth_input/R_workspaces_scripts_Meth/Methylation.RData")
# Which are type II probes?
typeII <- Annotated_meth[which(Annotated_meth$Type=="II"),]
dim(typeII)  #336539     33
# Which of these have a SNP at the sbe?
typeII_sbeSNP <- typeII[which(!(typeII$SBE_rs=="NA")),]
dim(typeII_sbeSNP)  #7049   33
#What are the CpG names for these sites?
names_typeII_sbeSNP <- rownames(typeII_sbeSNP)
length(names_typeII_sbeSNP)  #7049
# Which ones also have a snp in the probe body?
typeII_sbeSNP_probeSNP <- typeII_sbeSNP[which(!(typeII_sbeSNP
$Probe_rs=="NA")),] 
dim(typeII_sbeSNP_probeSNP) # none
# Which are the most variable between samples by Standard Deviation?
# First, get the CpG names and ensure they match the Meth_M info
length(which(names_typeII_sbeSNP %in% rownames(Meth_M)))  #only 
6920, other 69 may be control probes
keep_typeII_sbeSNP <- typeII_sbeSNP[which(names_typeII_sbeSNP %in% 
rownames(Meth_M)),]
dim(keep_typeII_sbeSNP)  #6920  33
keep_names_typeII_sbeSNP <- 
rownames(typeII_sbeSNP[which(names_typeII_sbeSNP %in% 
rownames(Meth_M)),])
length(keep_names_typeII_sbeSNP)
# check
identical(rownames(keep_typeII_sbeSNP), keep_names_typeII_sbeSNP)  
#TRUE, good
# Pull out these CpGs from the Meth_M data
Meth_M_sbeSNP <- Meth_M[keep_names_typeII_sbeSNP,]
dim(Meth_M_sbeSNP)  # 6920   47
identical(keep_names_typeII_sbeSNP,rownames(Meth_M_sbeSNP))  #TRUE
# Order by Standard Deviation
SD_Meth_M_sbeSNP <- as.matrix(apply(Meth_M_sbeSNP,1,sd))
ord_SD_Meth_M_sbeSNP <- 
SD_Meth_M_sbeSNP[rev(order(SD_Meth_M_sbeSNP)),]
Top100_SD_Meth_M_sbeSNP <- as.matrix(ord_SD_Meth_M_sbeSNP[1:100])
par(mfrow=c(3,4))
plotCpg(Meth_B, rownames(Top100_SD_Meth_M_sbeSNP)[1:20], 
pheno=Meth_info@phenoData@data$Family, measure="beta", ylim= c(0,1))
# the pheno is wrong here, need to match up with the correct data 
frame but for these purposes it doesn't matter as I don't currently 
care how they segregate, just as long as there are 3 groups
# Also have plotted as B than M as this is more biologically 
interpretable 
# These look quite variable.  There are some that appear randomly 
vriable though, ie. may need to perfect the kmeans cluster method to 
get three nice clusters rather than just random variation
# Now go back and pull the top 100 variable out of the 6920 sbeSNP
top100sbeSNP <- 
keep_typeII_sbeSNP[rownames(Top100_SD_Meth_M_sbeSNP),]
# check
top100sbeSNP$Type  # yes all II
top100sbeSNP$pos
top100sbeSNP$chr  # yes all diff chr
# Now pull the actual methylation values to use in the association 
model
top100Meth_M <- Meth_M[rownames(Top100_SD_Meth_M_sbeSNP),]
# check
identical(rownames(top100Meth_M), rownames(top100sbeSNP)) # TRUE
# Subset Meth_B for biologically relevant values and to use in the 
assoication model if the top100Meth_M does not work as has been a 
problem in the past because low values generate NaNs
top100Meth_B <- Meth_B[rownames(Top100_SD_Meth_M_sbeSNP),]
# Use top100sbeSNP as the object for annotation info and 
top100Meth_M or top100Meth_B as the actual methylation data for the 
model
########################
## 2. K-means Cluster ##
########################
# This method was not as efficient as SD or 95%-range as it requires 
extensive optimisation of the parameters for within and between sum 
of squares so clusters are generated in three regions. For example 
adjustment of within ss cut offs indicate which samples are to be 
included in the cluster and adjustment of between ss indicates the 
distance between clusters, optinmally clustered in three distinct 
groups, not random variation across the possible beta value range of 
0:1.  If not performed in parallel the function is also 
computationally slow and requires the data to be broken into to 
chunks 
# for examples trying a totss >1 and withinss <0.15 was much more 
effective than default metrics but still required further 
optimisation for similar efficacy as SD or 95%-range
# totss >1  and withinss <0.15
Meth_M=t(Meth_M)
betweenSS1=vector()
modelnum=1
for(i in colnames(Meth_M)){
  cluster=kmeans(Meth_M[,i],3)
  betweenSS1[modelnum]=if(cluster$totss>1 && cluster$withinss<0.15) 
cluster$betweenss/cluster$totss else "NA"
  modelnum= modelnum +1 }
############################
## 3. 95%-reference range ##
############################
# The difference between the most and least methylated individuals, 
among 95% of the individuals forming the central distribution of 
methylation values.  This approach is less sensitive to outliers 
than the full range and more readily interpretable than SD
dim(Meth_M) # [1] 467263     47
quantile(Meth_M[1,], probs=c(0, .025, 0.5, 0.975, 1))  # Test the 
quantile function on one CpG site, dividing the distribution into 
quintiles and selecting the lower 2.5% and upper 97.5% as the 2nd 
and 4th quantiles
      # 0%     2.5%      50%    97.5%     100% 
# 2.096701 2.211459 2.819828 3.769314 3.914120 
quantile_95_M <- apply(Meth_M,1, quantile, probs=c(0, .025, 0.5, 
0.975, 1))  # apply to all CpG sites
range_95_M <- as.matrix(quantile_95_M[4,]-quantile_95_M[2,]) # 
calculate the 95%-range for each CpG site by subtracting the 2nd 
quantile from the 4th
ord_range_95 <- range_95_M[order(range_95_M, decreasing=TRUE),] # 
order the 95% range in decreasing order so those CpGs with the 
greatest range are first
Top100_range_M <- as.matrix(ord_range_95_M[1:100]) # select the 
first 100 CpG sites with the greatest 95%-range
Top500_range_M <- as.matrix(ord_range_95_M[1:500]) # select the 
first 500 CpG sites with the greatest 95%-range
## Top 100/500 variable by 95% reference range, only sbe SNPs, no 
probe SNPs
quantile_95_M_sbeSNP <- apply(Meth_M_sbeSNP,1, quantile, 
probs=c(0, .025, 0.5, 0.975, 1))
range_95_M_sbeSNP <- as.matrix(quantile_95_M_sbeSNP[4,]-
quantile_95_M_sbeSNP[2,])
ord_range_95_M_sbeSNP <- range_95_M_sbeSNP[order(range_95_M_sbeSNP, 
decreasing=TRUE),]
Top100_range_M_sbeSNP <- as.matrix(ord_range_95_M_sbeSNP[1:100])
Top500_range_M_sbeSNP <- as.matrix(ord_range_95_M_sbeSNP[1:500])
length(which(rownames(Top100_range_M) %in% 
rownames(Top100_range_M_sbeSNP))) # 90, 90%
# Do association analysis for Top100_range_M because 90/100 of them 
were sbe SNPs so wanted to know what the other 10 looked like, ie do 
they have lower log p-vals like I suspect
# Use Top100_range_M in the model, if Beta values are required used 
the CpG names from this object to pull the correct Beta values
#########################
## Perform Association ##
#########################
## Data required for both analysis ##
# a) Selecting samples
colnames(top100Meth_M)  # good quality samples on methylation array
 # [1] "PC11.3"   "PC22.2"   "PC11.4"   "PC22.3"   "PC11.9"  
 # [6] "PC22.16"  "PC11.147" "PC22.17"  "PC22.21"  "PC22.468"
# [11] "PC22.203" "PC22.387" "PC72.136" "PC22.416" "PC72.188"
# [16] "PC72.4"   "PC72.213" "PC72.77"  "PC72.126" "PC9.1"   
# [21] "PC9.4"    "PC9.12"   "PC9.24"   "PC9.121"  "PC9.477" 
# [26] "PC22.210" "PC22.393" "PC22.414" "PC22.4"   "PC22.162"
# [31] "PC22.195" "PC11.415" "PC22.418" "PC11.234" "PC22.476"
# [36] "PC11.180" "PC72.03"  "PC22.388" "PC9.338"  "PC22.386"
# [41] "PC9.357"  "PC22.274" "PC9.129"  "PC72.106" "PC9.29"  
# [46] "PC72.187" "PC9.286" 
# create a text file with these samples so they can be pulled from 
the plink file
# Create a fam file with all the samples from the genotyping data 
then match these to the ones that have methylation data.  NB, have 
used the position of the first variable CpG site plus 1Mb to make it 
fast as I don't need all the information.
system("/Applications/plink-1.07-mac-intel/plink --noweb --bfile /
Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --chr 1 --from-bp 33292126 --to-bp 
34292126 --transpose --recode --out /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
geno_sampleNames") 
# Use the .tfam file generated by this command to look at samples
geno_samples <- read.table("geno_sampleNames.tfam")  # sample names 
are V2 column. There are 51 samples
# change the format of methylation names so they can be compared
topVariable_samples <-  colnames(top100Meth_M)
topVariable_samples <- gsub(".", "_",topVariable_samples, fixed=T)
topVariable_samples[20] <- gsub("_1", "_01",topVariable_samples[20], 
fixed=T)
topVariable_samples[2] <- gsub("_2", "_02",topVariable_samples[2], 
fixed=T)
topVariable_samples[c(1,4)] <- gsub("_3", 
"_03",topVariable_samples[c(1,4)], fixed=T)
topVariable_samples[c(3,16,21,29)] <- gsub("_4", 
"_04",topVariable_samples[c(3,16,21,29)], fixed=T)
topVariable_samples[5] <- gsub("_9", "_09",topVariable_samples[5], 
fixed=TRUE)
topVariable_samples[16] <- gsub("04","04_a", 
topVariable_samples[16], fixed=TRUE) 
topVariable_samples[8] <- gsub("17","17_a", topVariable_samples[8], 
fixed=TRUE)
write.table(topVariable_samples, file="meth_samplesNames.txt", 
col.names=FALSE, quote=FALSE)
meth_samplesNames <- read.table("meth_samplesNames.txt")
# match the two sample files to see which to keep
length(geno_samples$V2)  #51
length(meth_samplesNames$V2) #47
length(which(geno_samples$V2 %in% meth_samplesNames$V2)) #39, agrees 
with previous scripts
# create new text file with just these names to pull out desired 
samples from plink
keep_sampleNames <- geno_samples[which(geno_samples$V2 %in% 
meth_samplesNames$V2),]
# make sure keep V1 as this is the family ID.  I didn't put a proper 
family ID in the genotyping file so it's just a number 1-51 
write.table(keep_sampleNames[,1:2], col.names=FALSE, 
row.names=FALSE, quote=FALSE, file="keep_samples.txt")
# b) creating a kinship coefficient matrix to include how samples 
are related in the association model 
# Use the ibs (identity by state) function from the GenABEL package. 
Here I've created the ibs_no object by choosing "no" for the weight 
argument in the ibs function, this allows direct IBS computaitons.  
I tested an alternative method, "weight=freq" which takes into 
account allelic frequency assuming HWE but this method was not 
sucessful in the association model, possibly because the assumption 
did not hold for my familial data where the allelic frequencies may 
not be in HWE
gwaa_all_omni=load.gwaa.data(phenofile="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/SBE_snp/
pheno_cg13387643.txt", genofile="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/SBE_snp/
all_omni.raw", force=TRUE)
ibs_no <- ibs(gwaa_all_omni, weight="no") 
colnames(ibs_no) <- gsub("_", "-", colnames(ibs_no))
rownames(ibs_no) <- gsub("_", "-", rownames(ibs_no))
####################################
## 1. Standard Deviation Method  ##
###################################
# Use top 100 variable as determined by SD with no probe SNPs and 
all sbe SNPs in Type II probes
# Export genotype data from PLINK and create R object with 250Kb 
window, 125Kb (50^3) either side (tested 200kb/400kb/500kb/1Mb, 
there was only 1-5 snps in the 200Kb-400Kb for the first cpg but 
increasing to 2MB gave 704 SNPs in the 1st Cpg window but some other 
cpgs had far too many at a couple of thousand)
library(GenABEL)
library(hglm)
chr <- top100sbeSNP$chr
chr <- as.integer(gsub("chr", "", chr))
pos <- top100sbeSNP$pos
cpgNames <- rownames(top100sbeSNP)
cpg <- 1:length(chr)
for(cpg in 1:length(chr)){
system(paste(c("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
keep_samples.txt --chr ", chr[cpg]," --from-bp ",pos[cpg]-50^3," --
to-bp ",pos[cpg]+50^3," --recode --transpose --out /Users/ecazaly/
Desktop/PhD_Analysis/Association_2015april/Perform_Ass/
Top100variable/",cpgNames[cpg]),collapse=""))
} # Files should be in .tped and .tmap format for the GenABEL R 
package;  add in --transpose line 
# Create genotype .raw file
library(GenABEL)
cpg <- 1:length(cpgNames)
for(cpg in 1:length(cpgNames)){
convert.snp.tped(tpedfile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/
Top100variable/",cpgNames[cpg],".tped", sep=""), tfamfile=paste("/
Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Perform_Ass/Top100variable/",cpgNames[cpg],".tfam", sep=""), 
outfile=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/
Top100variable/",cpgNames[cpg],".raw", sep=""))
}
# Create phenotype file from 'top100Meth_B' data.  Tried 
top100Meth_M but this fails in the model
colnames(top100Meth_B) <- topVariable_samples
length(which(colnames(top100Meth_B) %in% keep_sampleNames$V2))
keep_top100Meth_B <-top100Meth_B[,which(colnames(top100Meth_B) %in% 
keep_sampleNames$V2)]
dim(keep_top100Meth_B) 
colnames(keep_top100Meth_B)
ID <- matrix(colnames(keep_top100Meth_B))
colnames(ID) <- "id"
female <- keep_sampleNames[keep_sampleNames$V5==2,]
female$V2  
sex <- matrix(c(rep(1,17),0,1,1,0,0,0,rep(1,11),0,1,0,0,1))
colnames(sex) <- "sex"
pheno <- cbind(ID, sex, t(keep_top100Meth_B))
write.table(pheno, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100variable/
pheno.txt",quote=FALSE)
for(cpg in 1:length(cpgNames)){  
require(GenABEL)
gwaa=load.gwaa.data(phenofile="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100variable/pheno.txt", 
genofile=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100variable/",cpgInfo[cpg,
3],".raw", sep=""),  force=TRUE)
gt=as.data.frame(as.numeric(gtdata(gwaa))) 
gwaa@gtdata@gtps=gt 
gwaa@phdata$id=gsub("_","-",gwaa@phdata$id)
rownames(gwaa@phdata)=gsub("_", "-", rownames(gwaa@phdata))
gwaa@gtdata@idnames=gsub("_", "-", gwaa@gtdata@idnames)
rownames(gwaa@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa@gtdata@gtps))           
modelnum=1
name=vector()
coefs=vector()
pvals=vector() 
log10pvps=vector() 
Number_Sig_Hits=vector() 
Highest_pval=vector() 
details=matrix(nrow=1, ncol=2)
colnames(details)=c("Number_Sig_Hits","Highest_pval")
rownames(details)=cpgInfo[cpg,3]
for(i in colnames(gwaa@phdata[(cpgInfo[cpg,4])+2])) {
  for(j in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[j], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(i, j, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[i], "~", 
gwaa@gtdata@gtps[j]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum= modelnum + 1
    }} 
#plot   
system(paste("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
keep_samples.txt --chr ", cpgInfo[cpg,1]," --from-bp ",cpgInfo[cpg,
2]-50^3," --to-bp ",cpgInfo[cpg,2]+50^3," --recode --out /Users/
ecazaly/Desktop/PhD_Analysis/Association_2015april/Perform_Ass/
Top100variable/", cpgInfo[cpg,3], sep=""))
 # don't transpose to get .map file  
map <- read.table(paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100variable/",cpgInfo[cpg,
3],".map",sep=""), as.is=T)  
# cut down map to the snps that have pvals
name_keep <- gsub(paste(cpgInfo[cpg,3], "/", sep=""),"", name, 
fixed=TRUE)
map_b <- map[c(which(name_keep %in% map$V2)),]
nsnps <- nrow(map_b)    
png(filename=paste("PNGs_IBS_no/", cpgInfo[cpg,
3],"_ibs",".png",sep=""),pointsize=12,units="mm",width=137.6,height=
137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map_b[,4]*10^-6, 
log10pvps,type="o",main=NULL,xlab=c("Position (Mb)", 
cex=2),ylab="-1*log10(p-value)",xlim=c(map_b[1,4]*10^-6,map_b[nsnps,
4]*10^-6),ylim=c(-3,35),cex=0.2)
title(main=list(paste("Association between ",cpgInfo[cpg,
3], " and ", nsnps, " SNPs in a 250Kb window", sep=""), cex=.95))
abline(h=-1*log10(0.05),lty=2)
text(map_b[nsnps,4]*10^-6-0.005,-1*log10(0.05)+1,"p-value = 
0.05",font=3, cex=0.4, col="red")
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map_b[nsnps,4]*10^-6-0.005,-1*log10(0.05/nsnps)
+1.2,"adjusted p-value",font=3, cex=0.4, col="red")
text(map_b[nsnps,4]*10^-6-0.033, 35, paste("Significant 
associations: ", length(which(log10pvps> -1*log10(0.05/nsnps))), 
spe=""), cex=0.6)
dev.off()    
# significant hit info   
Number_Sig_Hits=length(which(log10pvps>-1*log10(0.05/nsnps)))
Highest_pval=max(log10pvps, na.rm=T)
details[,1]=Number_Sig_Hits
details[,2]=Highest_pval
write.csv(details, file=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100variable/Hits_ibs_no/", 
cpgInfo[cpg,3], ".csv", sep="")) 
}    
# then read in and bind all csvs
filenames <- list.files(path="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100variable/Hits_ibs_no/", 
full.names=T)
library(plyr)
import.list <- llply(filenames, read.csv, header=T)
details_all <- matrix(nrow=100, ncol=3)
library(reshape)
details_all <- merge_recurse(import.list)
colnames(details_all) <- c("CpG_Name", "Number_Sig_Hits", 
"Highest_pval")
write.csv(details_all, file="hits_ibs_no.csv")
hits_ibs_no <- read.csv("hits_ibs_no.csv")
# then add annotation info using the minfi package and it's add ons
Genomic_Position <- cpgInfo[,2]
Chromosome <- cpgInfo[,1]
Associated_gene <- top100sbeSNP[,"UCSC_RefGene_Name"]
rs_name <- top100sbeSNP[,"SBE_rs"]
CpG_location <- top100sbeSNP[,"Relation_to_Island"]
MAF <- top100sbeSNP[,"SBE_maf"] # for these it is the same as  
top100sbeSNP[,"CpG_maf"]
identical(top100sbeSNP[,"SBE_maf"], top100sbeSNP[,"CpG_maf"])  #TRUE
CPG_detail_100 <- matrix(nrow=100, ncol=11)
row.names(CPG_detail_100)=cpgNames
colnames(CPG_detail_100)=COLnames
CPG_detail_100[,1] <- Genomic_Position
CPG_detail_100[,2] <- Chromosome
CPG_detail_100[,5] <- Associated_gene
CPG_detail_100[,7] <- rs_name
CPG_detail_100[,8] <- MAF
rs_onOMNI_100 <- conversion[conversion$RsID %in% CPG_detail_100[,
7],]
for(i in rownames(CPG_detail_100)){ 
CPG_detail_100[i,9] <- if(CPG_detail_100[i,7] %in% 
rs_onOMNI_100$RsID) "yes" else "no"
}
CPG_detail_100[,10] <- CpG_location
write.csv(CPG_detail_100, file="CPG_detail_100.csv")
#########################
## 2. 95%-range Method ##
#########################
# make new cpgInfo file
cpgNames_range <- rownames(Top100_range_M)
Annotated_range <- Annotated_meth[cpgNames_range,]
identical(rownames(Meth_M_100range), rownames(Annotated_range)) 
#TRUE
Meth_M_100range <- Meth_M[cpgNames_range,]
identical(rownames(Annotated_range), cpgNames_range)  #TRUE
identical(rownames(Meth_M_100range), cpgNames_range)  #TRUE
chr_range <- Annotated_range$chr
chr_range <- as.integer(gsub("chr", "", chr_range))
pos_range <- Annotated_range$pos
cpgNumber_range <- 1:length(chr_range)
cpgInfo_range <- data.frame(chr_range, pos_range, cpgNames_range, 
cpgNumber_range)
cpgInfo_range$cpgNames_range <- as.character(cpgInfo_range
$cpgNames_range)
# Create .tped files
for(cpg in 1:length(chr_range)){
system(paste(c("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
keep_samples.txt --chr ", chr_range[cpg]," --from-bp 
",pos_range[cpg]-50^3," --to-bp ",pos_range[cpg]+50^3," --recode --
transpose --out /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/", 
cpgNames_range[cpg]),collapse=""))}
# Create .raw file
library(GenABEL)
for(cpg in 1:length(cpgNames_range)){
convert.snp.tped(tpedfile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100_range/", 
cpgNames_range[cpg],".tped", sep=""), tfamfile=paste("/Users/
ecazaly/Desktop/PhD_Analysis/Association_2015april/Perform_Ass/
Top100_range/", cpgNames_range[cpg],".tfam", sep=""), 
outfile=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/", 
cpgNames_range[cpg],".raw", sep=""))}
# Create phenotype file, try with Meth_M 
Meth_M_100range
# select only the samples that have geno data for
colnames(Meth_M_100range) <- colnames(top100Meth_B)
length(which(colnames(Meth_M_100range) %in% keep_sampleNames$V2)) 
#39, keep the samples which have both methylation and Omni2.5 SNP 
genotyping data 
keep_Meth_M_100range <- 
Meth_M_100range[,which(colnames(Meth_M_100range) %in% 
keep_sampleNames$V2)]
dim(keep_Meth_M_100range) 
ID <- matrix(colnames(keep_Meth_M_100range))
colnames(ID) <- "id"
female <- keep_sampleNames[keep_sampleNames$V5==2,]
female$V2  
sex <- matrix(c(rep(1,17),0,1,1,0,0,0,rep(1,11),0,1,0,0,1))
colnames(sex) <- "sex"
pheno_range <- cbind(ID, sex, t(keep_Meth_M_100range))
write.table(pheno_range, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/
pheno.txt",quote=FALSE)
# the association model did not work with these M-values as the 
pheno input, try with Beta values and see if that works
Meth_B_100range <- Meth_B[cpgNames_range,]
colnames(Meth_B_100range) <- colnames(top100Meth_B)
length(which(colnames(Meth_B_100range) %in% keep_sampleNames$V2)) 
#39
keep_Meth_B_100range <- 
Meth_B_100range[,which(colnames(Meth_B_100range) %in% 
keep_sampleNames$V2)]
ID <- matrix(colnames(keep_Meth_B_100range))
colnames(ID) <- "id"
female <- keep_sampleNames[keep_sampleNames$V5==2,]
female$V2  
sex <- matrix(c(rep(1,17),0,1,1,0,0,0,rep(1,11),0,1,0,0,1))
colnames(sex) <- "sex"
pheno_range_B <- cbind(ID, sex, t(keep_Meth_B_100range))
write.table(pheno_range_B, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100_range/
pheno_B.txt",quote=FALSE)
# Association
for(cpg in 1:length(cpgNames_range)){  
require(GenABEL)
gwaa=load.gwaa.data(phenofile="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/pheno_B.txt", 
genofile=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/", cpgInfo_range[cpg,
3],".raw", sep=""),  force=TRUE)
gt=as.data.frame(as.numeric(gtdata(gwaa))) 
gwaa@gtdata@gtps=gt 
gwaa@phdata$id=gsub("_","-",gwaa@phdata$id)
rownames(gwaa@phdata)=gsub("_", "-", rownames(gwaa@phdata))
gwaa@gtdata@idnames=gsub("_", "-", gwaa@gtdata@idnames)
rownames(gwaa@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa@gtdata@gtps))           
modelnum=1
name=vector()
coefs=vector()
pvals=vector() 
log10pvps=vector() 
Number_Sig_Hits=vector() 
Highest_pval=vector() 
details_range=matrix(nrow=1, ncol=2)
colnames(details_range)=c("Number_Sig_Hits","Highest_pval")
rownames(details_range)=cpgInfo_range[cpg,3]
 
for(i in colnames(gwaa@phdata[(cpgInfo_range[cpg,4])+2])) {
  for(j in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[j], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(i, j, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[i], "~", 
gwaa@gtdata@gtps[j]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum= modelnum + 1
    }} 
# plot 
 system(paste("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
keep_samples.txt --chr ", cpgInfo_range[cpg,1]," --from-bp 
",cpgInfo_range[cpg,2]-50^3," --to-bp ",cpgInfo_range[cpg,2]+50^3," 
--recode --out /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/", cpgInfo_range[cpg,
3], sep=""))
 # don't transpose to get .map file  
map <- read.table(paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/", cpgInfo_range[cpg,
3],".map",sep=""), as.is=T)  
# cut down map to the snps that have pvals
name_keep <- gsub(paste(cpgInfo_range[cpg,3], "/", sep=""),"", name, 
fixed=TRUE)
map_b <- map[c(which(name_keep %in% map$V2)),]
nsnps <- nrow(map_b)  
png(filename=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/PNGs_range/", 
cpgInfo_range[cpg,
3],".png",sep=""),pointsize=12,units="mm",width=137.6,height=137.6*2
/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))
plot(map_b[,4]*10^-6, 
log10pvps,type="o",main=NULL,xlab=c("Position (Mb)", 
cex=2),ylab="-1*log10(p-value)",xlim=c(map_b[1,4]*10^-6,map_b[nsnps,
4]*10^-6),ylim=c(-3,35),cex=0.2)
title(main=list(paste("Association between 
",cpgInfo_range[cpg,3], " and ", nsnps, " SNPs in a 250Kb window", 
sep=""), cex=.95))
abline(h=-1*log10(0.05),lty=2)
text(map_b[nsnps,4]*10^-6-0.005,-1*log10(0.05)+1,"p-value = 
0.05",font=3, cex=0.4, col="red")
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map_b[nsnps,4]*10^-6-0.005,-1*log10(0.05/nsnps)
+1.2,"adjusted p-value",font=3, cex=0.4, col="red")
text(map_b[nsnps,4]*10^-6-0.033, 35, paste("Significant 
associations: ", length(which(log10pvps> -1*log10(0.05/nsnps))), 
spe=""), cex=0.6)
dev.off()    
  
Number_Sig_Hits=length(which(log10pvps>-1*log10(0.05/nsnps)))
Highest_pval=max(log10pvps, na.rm=T)
details_range[,1]=Number_Sig_Hits
details_range[,2]=Highest_pval
write.csv(details_range, file=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100_range/
Hits_range/", cpgInfo_range[cpg,3], ".csv", sep="")) 
}    
# then read in and bind all csvs
filenames <- list.files(path="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/Hits_range/", 
full.names=T)
library(plyr)
import.list <- llply(filenames, read.csv, header=T)
details_all_range <- matrix(nrow=100, ncol=3)
library(reshape)
details_all_range <- merge_recurse(import.list)
colnames(details_all_range) <- c("CpG_Name", "Number_Sig_Hits", 
"Highest_pval")
write.csv(details_all_range, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100_range/
all_hits_range.csv")
#get info on the hits
range_sigHits_annotated <- Annotated_meth[details_all_range
$CpG_Name,]
dim(range_sigHits_annotated)  # [1] 98  33
# 96 sig hits from the 98 ass that worked, 85 of these are >10log 
pval
# check these for CpG_rs
range_10log <- details_all_range[which(details_all_range
$Highest_pval>=10),]
dim(range_10log)  #85  3
range_10log_cpgs <- range_10log$CpG_Name
range_10log_annotated <- Annotated_meth[range_10log_cpgs, 
c(1,2,4,9,12,14,15,16,17,18,19,24,28,29,33)]
range_10log_annotated$CpG_rs  # all but 4 have CpG_rs
length(which(!(is.na(range_10log_annotated$CpG_rs))))  #81
length(which(!(is.na(range_sigHits_annotated$CpG_rs))))  #90 
# check overlap with SD
length(which(rownames(range_sigHits_annotated) %in% 
rownames(Top100_SD_M))) #66 
rownames(range_sigHits_annotated[rownames(range_sigHits_annotated) 
%in% rownames(Top100_SD_M),])
length(which(rownames(range_sigHits_annotated) %in% 
rownames(Top500_SD_M))) #98
# write range signifcant hits to a csv with annotaion details and 
log pvals etc to be used to prioritising CpGs for validation and 
follow up
range_sigHits_detail <- 
range_sigHits_annotated[,c(1,2,4,9,10,12,14,15,16,19,24,29)]
head(range_sigHits_detail)
identical(as.character(details_all_range$CpG_Name), 
rownames(range_sigHits_detail)) # TRUE
range_sigHits_detail$num_hits <- details_all_range$Number_Sig_Hits
range_sigHits_detail$highest_pval <- details_all_range$Highest_pval
write.csv(range_sigHits_detail, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/Hits_combined/range_sigHits_detail.csv")
# Use the csv files with genome annotations and log p-vals to 
prioritise CpGs for validation and further follow up. 
###############################################################
##  Prostate Cancer Risk Loci Approach to Identify meQ 3QTLs ##
###############################################################
# generate prostate cancer rick genomic windows to examine the 
association between SNPs in the region and methylation 
# For our linkage regions and GWAS, a 50KB window was taken around 
the hit SNP.  For published linkage regions a sliding window 
approach was used as described below
# Sliding windows were created by selecting a core region of 30KB 
with an additional 10KB either side which overlaps with wondows 
either side. This size window was chosen as (Smith et al 2014, Zhi 
et al 2013) have found 15KB/10KB to be average distance for 
association, this gives a little extra incase.  Larger windows were 
not chosen as (Luijk et al 2015) have suggested that windows of 
hundreds of KB are much too large due to high FDR, they suggest 
10-50KB.  These windows are much less than the 250KB windows used in 
the methylation approach as that method examines only one CpG per 
window and thus has a lower number of tests and FDR.
# if ROI are greater than 50KB then take a few 50KB windows with an 
overlap of 10KB each side, if less than 50KB then take whole region 
and add however many KBs to each side to make the total window 50KB
library(minfi)
library(GenABEL)
library(doParallel)
library(foreach)
numCores <- detectCores()-1
cl <- makeCluster(numCores)
registerDoParallel(cl)
## Data required for all analysis ##
# the same files/R objects generated for the methylation apparoach 
were used to:
# a) Select samples
# b) Kinship coefficient matrix
####################################################################
#########################
## 1. Familial Prostate Cancer risk regions identified in our lab 
through linkage analysis ##
####################################################################
#########################
# In a familial prostate cancer linkage analysis performed in our 
lab (REFERENCE), 4 regions with high LOD scores were identified as 
possible prostate cancer risk regions. Within these regions 143 SNPs 
were identified (ask Nick about exactly how he did this) on four 
chromosomes (2,6,15,22)
# The regions were then converted to the hg19 genome annotation via 
SNPnexus 
PCrisk_list <- read.csv(file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/
genomic_riskLoci_Leisel_geneNames.csv", header=T)
PCrisk_list$Liesel_LinkageROI_List # look at genes
genes_Leisel <- annotated_genes[which(annotated_genes
$UCSC_RefGene_Name %in% PCrisk_list$Liesel_LinkageROI_List),] 
dim(genes_Leisel)
# [1] 1428   33    
genes_Leisel$UCSC_RefGene_Name  # gene names, there are duplicates 
as some genes have more than one cpg
genes_Leisel$Name  # these are the cpg sites
# pull these from Meth_B
genes_Leisel_Meth_B <- Meth_B[which(rownames(Meth_B) %in% 
genes_Leisel$Name),]
dim(genes_Leisel_Meth_B)
# [1] 1427  47
genes_Leisel_info <- Meth_info[genes_Leisel$Name,
genes_Leisel_info_annotation <-getAnnotation(genes_Leisel_info)
check_gene_Leisel_Names <- genes_Leisel_info_annotation[genes_Leisel
$Name, "UCSC_RefGene_Name"]
length(check_gene_Leisel_Names %in% PCrisk_list
$Liesel_LinkageROI_List) # 1428 
# any of these CpGs in the TopVariable?
which(genes_Leisel$Name %in% rownames(top100sbeSNP))  #1:  1298
# Top 500 ?
which(rownames(Top500_SD_Meth_M_sbeSNP) %in% genes_Leisel$Name) # 
same 1 1298 / 71
Top500_SD_Meth_M_sbeSNP[71,]
genes_Leisel[1298,]
# this is cg20205188 the one that was pulled out at the top of the 
script, no more by looking at top 500.
# what about looking at CpGs within the region.. may not necessarily 
be associated with the gene..
# but also positions themselves 
chrAll_risk$chr
chrAll_risk$pos # maybe pull cpgs within range?
chrAll_risk$chrPos <- paste(chrAll_risk$chr, ":", chrAll_risk$pos, 
sep="")
colnames(chrAll_risk)
write.csv(chrAll_risk, file="Leisel_list.csv")
leisel <- read.csv(file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Leisel_risk/
Leisel_list.csv")
leisel <- leisel[,c(2,5,6,7)]
colnames(leisel) <- c("snp", "chr", "pos", "LOD")
leisel$start_50KB <- leisel$pos-25000
leisel$end_50KB <- leisel$pos+25000
leisel$end_50KB - leisel$start_50KB # check
leisel$chr <- as.numeric(gsub("chr", "", leisel$chr, fixed=T))
# no Xchr to remove
length(leisel$snp)  #143
foreach(i=1:length(leisel$snp)) %dopar% {
system(paste(c("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
keep_samples.txt --chr ", leisel$chr[i]," --from-bp ", leisel
$start_50KB[i]," --to-bp ", leisel$end_50KB[i]," --recode --
transpose --out /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
windows_leisel/", as.character(leisel$snp[i])),collapse=""))
foreach(i=1:length(leisel$snp)) %dopar% {
require(GenABEL)
convert.snp.tped(tpedfile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_leisel/", as.character(leisel
$snp[i]),".tped", sep=""), tfamfile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_leisel/",as.character(leisel
$snp[i]),".tfam", sep=""), outfile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_leisel/", as.character(leisel
$snp[i]),".raw", sep=""))
# create .map file by not transposing  
system(paste(c("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
keep_samples.txt --chr ", leisel$chr[i]," --from-bp ", leisel
$start_50KB[i]," --to-bp ", leisel$end_50KB[i]," --recode --out /
Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/Genetic_riskLoci/windows_leisel/", 
as.character(leisel$snp[i])),collapse=""))
}
cpgs_leisel <- vector()
foreach(i=1:length(leisel$snp)) %dopar% {
require(minfi)
cpgs_leisel <- rownames(Annotated_meth[which(Annotated_chr==leisel
$chr[i] & Annotated_meth$pos <leisel$end_50KB[i] & Annotated_meth
$pos >leisel$start_50KB[i]),])
cpgs_leisel <- cpgs_leisel[which(cpgs_leisel %in% 
rownames(Meth_B))]
Meth_B_leisel <- data.frame(Meth_B[cpgs_leisel,])
Meth_B_leisel <- if(length(cpgs_leisel)==1) 
t(Meth_B_leisel) else Meth_B_leisel
colnames(Meth_B_leisel) <- topVariable_samples
rownames(Meth_B_leisel) <- cpgs_leisel 
keep_leisel <- 
data.frame(Meth_B_leisel[,which(colnames(Meth_B_leisel) %in% 
keep_sampleNames$V2)])
keep_leisel <- if(length(cpgs_leisel)==1) t(keep_leisel) 
else keep_leisel
rownames(keep_leisel) <- if(length(cpgs_leisel)==1) 
cpgs_leisel else rownames(keep_leisel)
dim(keep_leisel) # 1 39
ID <- matrix(colnames(keep_leisel))
colnames(ID) <- "id"
female <- keep_sampleNames[keep_sampleNames$V5==2,]
female$V2 
sex <- matrix(c(rep(1,17),0,1,1,0,0,0,rep(1,11),0,1,0,0,1))
colnames(sex) <- "sex"
dim(keep_leisel) # 39 1
pheno_leisel <- cbind(ID, sex, t(keep_leisel))
colnames(pheno_leisel)
write.table(pheno_leisel, file=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_leisel/pheno_",as.character(leisel$snp[i]), 
".txt", sep=""), quote=FALSE)
}
foreach(i=1:length(leisel$snp))  %dopar% {
require(GenABEL)
gwaa=load.gwaa.data(phenofile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_leisel/pheno_",as.character(leisel$snp[i]), 
".txt", sep=""), genofile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_leisel/", as.character(leisel
$snp[i]),".raw", sep=""),  force=TRUE)
gt=as.data.frame(as.numeric(gtdata(gwaa))) 
gwaa@gtdata@gtps=gt 
gwaa@phdata$id=gsub("_","-",gwaa@phdata$id)
rownames(gwaa@phdata)=gsub("_", "-", rownames(gwaa@phdata))
gwaa@gtdata@idnames=gsub("_", "-", gwaa@gtdata@idnames)
rownames(gwaa@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1,2)])) { 
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1
    }}  
#plot
map_b <- read.table(paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
windows_leisel/", as.character(leisel$snp[i]),".map",sep="", 
collapse=""), as.is=T)
nsnps  <- ncol(gwaa@gtdata@gtps) 
nCPGs <-  ncol(gwaa@phdata[-c(1:2)])
ntests <- length(name)
Number_Sig_Hits=length(which(log10pvps>-1*log10(0.05/nsnps)))
Number_Sig_Hits_stringent <- length(which(log10pvps>-1*log10(0.05/
ntests)))
stringent_cpgs <- name[which(log10pvps>-1*log10(0.05/ntests))]
stringent_log_pvals <- log10pvps[which(log10pvps>-1*log10(0.05/
ntests))]
Highest_pval=max(log10pvps, na.rm=T)
window_name <- as.character(leisel$snp[i])
hits_leisel_detailed <- data.frame(window_name, nsnps, nCPGs, 
ntests, Number_Sig_Hits, Number_Sig_Hits_stringent, Highest_pval, 
stringent_cpgs, stringent_log_pvals)
write.csv(hits_leisel_detailed, file=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/hits_leisel/Detail_hits/Detail_hits_",  
as.character(leisel$snp[i]),".csv", collapse=""))  
}
# this gives 53 files, the amount with stringent sig hits
# bind these in one csv
filenames <- list.files(path="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
hits_leisel/Detail_hits/", full.names=T)
library(plyr)
import.list <- llply(filenames, read.csv, header=T)
Detail_hits_all_leisel <- matrix(nrow=200, ncol=10)
library(reshape)
Detail_hits_all_leisel <- merge_recurse(import.list)
head(Detail_hits_all_leisel)
dim(Detail_hits_all_leisel) # [1] 163  10
write.csv(Detail_hits_all_leisel, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/hits_leisel/Detail_hits/
Detail_hits_all_leisel.csv")
# A lot of repetition in the CpGs because of the overlapping sliding 
window and this spreadsheet also lists the significant hits of each 
SNP with a CpG so that the most significant one can be determined.  
IN the methylation approach, only the ..
####################################################################
###########################
## 2. Prostate Cancer risk regions identified in published studies 
through linkage analysis  ##
####################################################################
###########################
# A list of 32 prostate cancer risk linkage regions from published 
familial studies was generated on OMIM (www.ncbi.nlm.nih.gov/omim).  
These regions were already annotated to the hg19 genome build so it 
was not necessary to perform conversion by SNPnexus.
linkage_region <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/Familial/
Familial_lit_regions_pos.csv", header=T)
linkage_region$range <- (linkage_region$start -linkage_region
$end)*-1
write.csv(linkage_region, "/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/Familial/
Familial_lit_regions_pos2.csv")
# Create sliding windows for association analysis
linkage_region <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/Familial/
Familial_lit_regions_pos2.csv", header=T)
# Create data frame with the new windows:  50KB total 
linkage_windows_50KB <- data.frame(linkage_region$Region_Identifier, 
linkage_region$hg19_chr, linkage_region$range, linkage_region
$start-10000, linkage_region$end+10000)
colnames(linkage_windows_50KB) <- c("window_name", "chr", 
"ROI_range", "window_start", "window_end")
linkage_windows_50KB$window_range <- (linkage_windows_50KB
$window_start - linkage_windows_50KB$window_end)*-1 
# need to adjust so this is 50Kb for smaller windows
write.csv(linkage_windows_50KB, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
linkage_windows_50KB")
# do the first and second window manually then the thirs onwards in 
a loop.  For the largest region of 44000000 bp there should be 
44000000/40000 = 1100 windows? it's not too worrying that there are 
a lot as long as there are not too many significant hits, just need 
to be aware of controlling FDR or keeping the cut off p-vals very 
stringent
first_window_start <- vector()
first_window_end <- vector()
first_window_range <- vector()
for(i in 1:32){
first_window_start[i] <- if(linkage_region$range[i]< 30000) 
linkage_region$start[i] - ((50000-linkage_region$range[i])/2) else 
linkage_region$start[i]-10000
first_window_end[i] <- if(linkage_region$range[i]< 30000) 
linkage_region$start[i] + ((50000-linkage_region$range[i])/2) + 
linkage_region$range[i] else linkage_region$start[i]+40000 #then the 
next window starts 10kb in of that end
first_window_range[i] <- first_window_end[i] -first_window_start[i] 
}
first_window <- data.frame(linkage_region$Region_Identifier, 
rep(1,32), linkage_region$range, linkage_region$hg19_chr, 
first_window_start, first_window_end, first_window_range)
colnames(first_window) <- c("ROI", "windows_window", "ROI_range", 
"chr", "windows_start", "windows_end", "windows_range")
# Keep creating these windows until all regions are broken down to 
50KB windows, then rbind all the windows and sort by 
Region_Identifier then window
second_window_start <- vector()
second_window_end <- vector()
second_window_range <- vector()
for(i in 1:32){
second_window_start[i] <- if(linkage_region$range[i]> 30000) 
first_window_end[i]-10000 else NA
second_window_end[i] <- if(linkage_region$range[i]> 30000) 
(first_window_end[i]+ 40000) else NA
second_window_range[i] <- if(is.na(second_window_end[i])) NA else 
second_window_end[i] - second_window_start[i] }
second_window <- data.frame(linkage_region$Region_Identifier, 
rep(2,32), linkage_region$range, linkage_region$hg19_chr, 
second_window_start, second_window_end, second_window_range)
colnames(second_window) <- c("ROI", "windows_window", "ROI_range", 
"chr", "windows_start", "windows_end", "windows_range")
# how do you know when to stop the windows? for the 3rd if original 
ROI >60 ? that covers 2 x30 unique windows plus overlap?  just keep 
adding 30 on each time as that's the unique window part?
third_window_start <- vector()
third_window_end <- vector()
third_window_range <- vector()
for(i in 1:32){
third_window_start[i] <- if(!(is.na(second_window_range[i])) & 
linkage_region$range[i]> 60000) second_window_end[i]-10000 else NA
third_window_end[i] <- if(linkage_region$range[i]> 60000) 
(second_window_end[i]+ 40000) else NA
third_window_range[i] <- if(is.na(third_window_end[i])) NA else 
third_window_end[i] - third_window_start[i] 
}
third_window <- data.frame(linkage_region$Region_Identifier, 
rep(3,32), linkage_region$range, linkage_region$hg19_chr, 
third_window_start, third_window_end, third_window_range)
colnames(third_window) <-c("ROI", "windows_window", "ROI_range", 
"chr", "windows_start", "windows_end", "windows_range")
fourth_window_start <- vector()
fourth_window_end <- vector()
fourth_window_range <- vector()
for(i in 1:32){
fourth_window_start[i] <- if(!(is.na(third_window_range[i])) & 
linkage_region$range[i]> 90000) third_window_end[i]-10000 else NA
fourth_window_end[i] <- if(linkage_region$range[i]> 90000) 
(third_window_end[i]+ 40000) else NA
fourth_window_range[i] <- if(is.na(fourth_window_end[i])) NA else 
fourth_window_end[i] - fourth_window_start[i] 
}
fourth_window <- data.frame(linkage_region$Region_Identifier, 
rep(4,32), linkage_region$range, linkage_region$hg19_chr, 
fourth_window_start, fourth_window_end, fourth_window_range)
colnames(fourth_window) <- c("ROI", "windows_window", "ROI_range", 
"chr", "windows_start", "windows_end", "windows_range")
# write the first few windows in a csv, check, then combine first 
two with others
oneTo4 <- rbind(first_window, second_window, third_window, 
fourth_window)
oneTo4 <- oneTo4[with(oneTo4, order(oneTo4$ROI, 
oneTo4$windows_window)),]
write.csv(oneTo4, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/windows/oneTo4.csv")
# loop the remaining windows (start from the 3rd window, can then 
doubke check the third and fourth against the manual windows from 
above)
linkage_region$Region_Identifier <- as.character(linkage_region
$Region_Identifier)
linkage_region$Region_Identifier[1] <- gsub("1", "01", 
linkage_region$Region_Identifier[1], fixed=T)
linkage_region$Region_Identifier[2] <- gsub("2", "02", 
linkage_region$Region_Identifier[2], fixed=T)
linkage_region$Region_Identifier[3] <- gsub("3", "03", 
linkage_region$Region_Identifier[3], fixed=T)
linkage_region$Region_Identifier[4] <- gsub("4", "04", 
linkage_region$Region_Identifier[4], fixed=T)
linkage_region$Region_Identifier[5] <- gsub("5", "05", 
linkage_region$Region_Identifier[5], fixed=T)
linkage_region$Region_Identifier[6] <- gsub("6", "06", 
linkage_region$Region_Identifier[6], fixed=T)
linkage_region$Region_Identifier[7] <- gsub("7", "07", 
linkage_region$Region_Identifier[7], fixed=T)
linkage_region$Region_Identifier[8] <- gsub("8", "08", 
linkage_region$Region_Identifier[8], fixed=T)
linkage_region$Region_Identifier[9] <- gsub("9", "09", 
linkage_region$Region_Identifier[9], fixed=T)
windows_start <- vector()
windows_end <- vector()
windows_range <- vector()
windows_window <- vector()
ROI <- vector()
ROI_range <- vector()
chr <- vector()
for(i in 1:32){ 
for(j in 1:35200){ 
windows_start[j] <- if(linkage_region$range[i]> 30000*j) 
linkage_region$start[i]+30000+40000*j else NA
windows_end[j] <- if(linkage_region$range[i]> 30000*j) 
(linkage_region$start[i]+30000+40000*j)+50000 else NA
windows_end[j] <- if(!(is.na(windows_end[j])) & windows_start[j] < 
linkage_region$end[i]) windows_end[j] else NA
windows_range[j] <- if(is.na(windows_end[j])) NA else windows_end[j] 
- windows_start[j]
windows_window[j] <- j+02 # j+2 reflects that the loop starts at the 
third window
ROI[j] <- rep(linkage_region
$Region_Identifier[i],length(windows_window[j]))
chr[j] <- rep(linkage_region$hg19_chr[i],length(windows_window[j]))
ROI_range[j] <- rep(linkage_region
$range[i],length(windows_window[j]))
}
windows <- data.frame(ROI, windows_window, ROI_range, chr, 
windows_start, windows_end, windows_range)
windows <- windows[1:(length(windows_range)-
length(which(is.na(windows_range)))),]
dim(windows)
write.csv(windows, file=(paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/windows/", "windows_ROI_",i, 
".csv", sep="")))
}
# This works. Then combine the oneTo4 and order by ROI, 
windows_window, check then remove then manual 3&4 windows
# Needed to change window.1 etc to just 1,2,3... because when it 
came to ordering had the issue of 01 vs 1 in alphanumeric ordering
filenames <- list.files(path="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/windows/", full.names=T)
library(plyr)
import.list <- llply(filenames, read.csv, header=T)
library(reshape)
windows_all <- merge_recurse(import.list)
dim(windows_all) # 5797    8
head(windows_all)
windows_all[1:20,1:6]
# order by ROI, window
windows_all <- windows_all[with(windows_all, order(windows_all$ROI, 
windows_all$windows_window)),]
# remove duplicate windows
windows_all$X <- paste(windows_all$ROI, "_", windows_all
$windows_window, sep="")
dim(windows_all)-dim(windows_all[unique(windows_all$X),]) # should 
take out 2x32=64 but only 52 because .. 64-52=12 /2 = 6... 5 only 
had one window?
rownames(windows_all) <- 1:length(windows_all$X)
windows_all <- windows_all[which(!(duplicated(windows_all$X))),]
dim(windows_all) #5745  8  (5797-52)
# remove NAs
length(windows_all$windows_start) - length(which(is.na(windows_all
$windows_start))) #5723
# there are 22 rows with NAs
windows_all <- windows_all[which(!(is.na(windows_all
$windows_start))),]
dim(windows_all)
colnames(windows_all)[1] <- "ROI_window"
write.csv(windows_all[,-c(2,3)], file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/windows/
windows_all.csv")
windows_all2 <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/windows/windows_all.csv")
head(windows_all2)
# save the workspace, script and plink files and move over to Hydra 
for faster computation
load("/home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/
Genomic_sites.RData")
# perform association in parallel
library(minfi)
library(GenABEL)
library(foreach)
library(doParallel)
library(parallel)
numCores <- 35  # detectCores()
cl <- makeCluster(numCores)
registerDoParallel(cl)
cpgs_genomic <- vector()
foreach(i=1:length(windows_all2$ROI_window)) %dopar% { #
system(paste(c("/opt/apps/plink-1.07-x86_64/plink --noweb --bfile /
home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/cutoff_15_final 
--keep /home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/
keep_samples.txt --chr ", windows_all2$chr[i]," --from-bp ", 
windows_all2$windows_start[i]," --to-bp ", 
windows_all2$windows_end[i]," --recode --transpose --out /home/
ecazaly/Data/Aug2015_onwards/Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i])),collapse=""))
# Create .raw file
convert.snp.tped(tpedfile=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i]),".tped", sep=""), 
tfamfile=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i]),".tfam", sep=""), 
outfile=paste("/home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/
windows/", as.character(windows_all2$ROI_window[i]),".raw", sep=""))
system(paste(c("/opt/apps/plink-1.07-x86_64/plink --noweb --bfile /
home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/cutoff_15_final 
--keep /home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/
keep_samples.txt --chr ", windows_all2$chr[i]," --from-bp ", 
windows_all2$windows_start[i]," --to-bp ", 
windows_all2$windows_end[i]," --recode --out /home/ecazaly/Data/
Aug2015_onwards/Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i])),collapse=""))
cpgs_genomic <- 
rownames(Annotated_meth[which(Annotated_chr==windows_all2$chr[i] & 
Annotated_meth$pos <windows_all2$windows_end[i] & Annotated_meth$pos 
>windows_all2$windows_start[i]),])
# if(length(cpgs_genomic)<=1) { next  # no cpgs in the 
window
# }
cpgs_genomic <- cpgs_genomic[which(cpgs_genomic %in% 
rownames(Meth_B))]
Meth_B_genomic <- data.frame(Meth_B[cpgs_genomic,])
Meth_B_genomic <- if(length(cpgs_genomic)==1) 
t(Meth_B_genomic) else Meth_B_genomic
colnames(Meth_B_genomic) <- topVariable_samples
rownames(Meth_B_genomic) <- cpgs_genomic 
keep_genomic <- 
data.frame(Meth_B_genomic[,which(colnames(Meth_B_genomic) %in% 
keep_sampleNames$V2)])
keep_genomic <- if(length(cpgs_genomic)==1) t(keep_genomic) 
else keep_genomic
rownames(keep_genomic) <- if(length(cpgs_genomic)==1) 
cpgs_genomic else rownames(keep_genomic)
dim(keep_genomic) # 1 39ID <- 
matrix(colnames(keep_genomic))
ID <- matrix(colnames(keep_genomic))
colnames(ID) <- "id"
female <- keep_sampleNames[keep_sampleNames$V5==2,]
female$V2 
sex <- matrix(c(rep(1,17),0,1,1,0,0,0,rep(1,11),0,1,0,0,1))
colnames(sex) <- "sex"
pheno <- cbind(ID, sex, t(keep_genomic))
write.table(pheno, file=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/Phenos/
pheno_",as.character(windows_all2$ROI_window[i]), ".txt", sep=""), 
quote=FALSE)
}
gwaa=load.gwaa.data(phenofile=paste("/home/ecazaly/Data/
Aug2015_onwards/Ass_genetic_input/windows/Phenos/
pheno_",windows_all2$ROI_window[i], ".txt", sep=""), 
genofile=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i]),".raw", sep=""),  
force=TRUE)
gt=as.data.frame(as.numeric(gtdata(gwaa))) 
gwaa@gtdata@gtps=gt 
gwaa@phdata$id=gsub("_","-",gwaa@phdata$id)
rownames(gwaa@phdata)=gsub("_", "-", rownames(gwaa@phdata))
gwaa@gtdata@idnames=gsub("_", "-", gwaa@gtdata@idnames)
rownames(gwaa@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1:2)])) {  
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1
    }}
# plot, will not plot at this stage, just generate significant hit 
data
# create .map file by not transposing  
map_b <- read.table(paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i]),".map",sep="", 
collapse=""), as.is=T)  
# cut down map to the snps that have pvals
# name_keep <- gsub(paste(colnames(gwaa@phdata[,-c(1:2)]), "/", 
sep="")[i], "", name, fixed=TRUE) 
# map_b <- map[c(which(name_keep %in% map$V2)),] 
# should correct by /ntests not /nsnps but see if any are sig first 
because may use Simes procedure rather than Bonferroni to correct if 
some look possibly sig
nsnps  <- ncol(gwaa@gtdata@gtps) 
nCPGs <-  ncol(gwaa@phdata[-c(1:2)])
ntests <- ncol(gwaa@gtdata@gtps) *  ncol(gwaa@phdata[-c(1:2)])
Number_Sig_Hits=length(which(log10pvps>-1*log10(0.05/nsnps)))
Number_Sig_Hits_stringent <- length(which(log10pvps>-1*log10(0.05/
ntests)))
Highest_pval=max(log10pvps, na.rm=T)
window_name <- windows_all2$ROI_window[i]
hits <- data.frame(window_name, nsnps, nCPGs, ntests, 
Number_Sig_Hits, Number_Sig_Hits_stringent, Highest_pval)
write.csv(hits, file=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/hits/hits_", 
as.character(windows_all2$ROI_window[i]),".csv", collapse="")) 
  } 
  
# Then bind together csvs   
filenames <- list.files(path="/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/hits/hits_batch2", full.names=T)
library(plyr)
import.list <- llply(filenames, read.csv, header=T)
Hits_all_linkage <- matrix(nrow=2061, ncol=7)
library(reshape)
Hits_all_linkage_a <- 
Hits_all_linkage_b <- merge_recurse(import.list)  # still too big
colnames(Hits_all_linkage) <- c("window_name", "nsnps", "nCPGs", 
"ntests", "Number_Sig_Hits", "Number_Sig_Hits_stringent", 
"Highest_pval")
write.csv(Hits_all_linkage, file="/home/ecazaly/Data/
Aug2015_onwards/Ass_genetic_input/hits2/Hits_all_linkage.csv")
# There are too many for the memory to handle.  Need to be more 
stingent with the cut offs for significance, or the ones I choose to 
bind.  Choose those with just log10 pvals >10 as for familial 
associations
foreach(i=1:length(windows_all2$ROI_window)) %dopar% { 
require(GenABEL)
gwaa=load.gwaa.data(phenofile=paste("/home/ecazaly/Data/
Aug2015_onwards/Ass_genetic_input/windows/Phenos/
pheno_",windows_all2$ROI_window[i], ".txt", sep=""), 
genofile=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i]),".raw", sep=""),  
force=TRUE)
gt=as.data.frame(as.numeric(gtdata(gwaa))) 
gwaa@gtdata@gtps=gt 
gwaa@phdata$id=gsub("_","-",gwaa@phdata$id)
rownames(gwaa@phdata)=gsub("_", "-", rownames(gwaa@phdata))
gwaa@gtdata@idnames=gsub("_", "-", gwaa@gtdata@idnames)
rownames(gwaa@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1:2)])) {  
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1
    }}
nsnps  <- ncol(gwaa@gtdata@gtps) 
nCPGs <-  ncol(gwaa@phdata[-c(1:2)])
ntests <- length(name)
Number_Sig_Hits=length(which(log10pvps>-1*log10(0.05/nsnps)))
Number_Sig_Hits_stringent <- length(which(log10pvps>-1*log10(0.05/
ntests)))
Highest_pval=max(log10pvps, na.rm=T)
window_name <- windows_all2$ROI_window[i]
stringent_cpgs <- name[which(log10pvps>-1*log10(0.05/ntests))]
stringent_log_pvals <- log10pvps[which(log10pvps>-1*log10(0.05/
ntests))]
Highest_pval=max(log10pvps, na.rm=T)
hits_linkage_detailed <- data.frame(window_name, nsnps, nCPGs, 
ntests, Number_Sig_Hits, Number_Sig_Hits_stringent, Highest_pval, 
stringent_cpgs, stringent_log_pvals)
if (log10pvps[which(log10pvps>-1*log10(0.05/ntests))] <= 10) 
write.csv(hits_linkage_detailed, file=paste("/home/ecazaly/Data/
Aug2015_onwards/Ass_genetic_input/hits/Detailed_hits_", 
as.character(windows_all2$ROI_window[i]),".csv", collapse="")) # 
Create excel files for just the ones with log pvals >10
  } 
# The code works but not the if line as it writes csvs for hits with 
lower log pvals than 10. I've upped the CPUs to 35 from 25, should 
only take a few hours
# there are 231
# merge
filenames <- list.files(path="/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/hits/detailed/", full.names=T)
library(plyr)
import.list <- llply(filenames, read.csv, header=T)
Detail_hits_all_linkage <- matrix(nrow=400, ncol=10)
library(reshape)
Detail_hits_all_linkage <- merge_recurse(import.list)
head(Detail_hits_all_linkage)
dim(Detail_hits_all_linkage) # 573  10  The proportion with 
significant hits is a lot less than the other methods, therefore not 
an issue with FDRs??
# order by pval
Detail_hits_all_linkage_ord <- 
Detail_hits_all_linkage[with(Detail_hits_all_linkage, 
order(Detail_hits_all_linkage$stringent_log_pvals, decreasing=T)),]
write.csv(Detail_hits_all_linkage_ord, file="/home/ecazaly/Data/
Aug2015_onwards/Ass_genetic_input/hits/detailed/
Detail_hits_all_linkage_ord.csv")
# only 37 are above log pval of 10, manageable
hits_linkage <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
hits_linkage/Detail_hits_all_linkage_ord.csv")
# which have stringent pval hits?
hits_linkage_cpgs <- gsub("/..+", "", hits_linkage$stringent_cpgs)
length(hits_linkage_cpgs) #573
length(unique(hits_linkage_cpgs))  # 228, most out of all three but 
not too huge considering how many started with
hits_linkage_cpgs_unique <- hits_linkage_cpgs[which(!
(duplicated(hits_linkage_cpgs)))]
# check how many have CpG_rs sites
Annotated_meth_hits_linkage <- 
Annotated_meth[hits_linkage_cpgs_unique,]
hits_linkage_cpgs_rs <- Annotated_meth_hits_linkage[(which(!
(is.na(Annotated_meth_hits_linkage$CpG_rs)))),]
dim(hits_linkage_cpgs_rs) 
# only 16, so much smaller proportion than the other 2  (6/13, 
30/131)
hits_linkage_cpgs_rs$CpG_rs
# are any of these the original rs picked up in previous studies? 
can't look at for this as it's regions but can with other two.  None 
in the other two.   but could be in LD, look further into the 
locations/proximites
rownames(hits_linkage_cpgs_rs)  
# what proportion of sig pvals and >10 log pvals were these?
# 16/228 for sig hits.  
 # [1] "cg16490124" "cg03964373" "cg11251367"
 # [4] "cg00069771" "cg16675926" "cg23209941"
 # [7] "cg07134368" "cg01021334" "cg00382740"
# [10] "cg20267322" "cg03224005" "cg04910228"
# [13] "cg13081429" "cg03272499" "cg24412204"
# [16] "cg02262873"
# 8/228 had log pvals >10 these are probably the most interesting.  
7/8 of these had CpG_rs
# "cg16490124"
# "cg03964373"
# "cg11251367"
# "cg00069771"
# "cg16675926"
# "cg23209941"
# "cg07134368"
# the one that doesn't had quite a high log pval of 19.942  
"cg24361198"
Annotated_meth_hits_linkage["cg24361198",]
# no probe SNPs, OpenSea, type II, chr1:242002464, quite far at the 
end of q arm of chr1
# check genes within 1500 bases, as 450k annotation doesn't give any 
there shouldn't be anything
242002464-1500   # chr1: 242000964
242002464+1500   # chr1: 242003964
# UCSC tell you if that CpG site has previously been found to be 
methylated, unmethylated, partially methylated
# out of 6 diff cell lines 5 were methylated and 1 was unmethylated 
in HepG2 (liver carcinoma cell line)
# Overlap with top[100 and top500] 95%-Range variable
length(which(hits_linkage_cpgs_unique %in% cpgInfo_range
$cpgNames_range))  #3
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% cpgInfo_range$cpgNames_range),])
# "cg16490124" "cg11251367" "cg03224005"
# these all have CpG_rs
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% cpgInfo_range$cpgNames_range),]) %in% 
rownames(hits_linkage_cpgs_rs)  #[1] TRUE TRUE TRUE
length(which(hits_linkage_cpgs_unique %in% 
cpgInfo_range_500$cpgNames_range_500)) #5 
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% cpgInfo_range_500$cpgNames_range_500),])
#[1] "cg16490124" "cg11251367" "cg00069771" "cg23209941" 
"cg03224005"  
# these don't overlap with the gwas ones
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% cpgInfo_range_500$cpgNames_range_500),]) %in% 
rownames(hits_linkage_cpgs_rs)  #[1] TRUE TRUE TRUE TRUE TRUE
# not overly surprising since 90/100 range were CpG_rs.. what about 
500 proportion?
# what about overlap with Standard Deviation
length(which(hits_linkage_cpgs_unique %in% rownames(Top100_SD_M))) 
#3, the same ones
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% rownames(Top100_SD_M)),])
[1] "cg16490124" "cg11251367" "cg03224005"
length(which(hits_linkage_cpgs_unique %in% rownames(Top500_SD_M))) 
#4 same as above but missing one
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% rownames(Top500_SD_M)),])
[1] "cg16490124" "cg11251367" "cg00069771" "cg03224005"
# save all the proportions to /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/proportions.xlsx
# Follow up the 8 CpGs with >10 log pvals, ie. check what genes 
they're near and for the 7 that are CpG_rs if that snp has been 
linked to disease risk etc
linkage_FollowUp_cpgs <- c("cg16490124", "cg03964373", "cg11251367", 
"cg00069771", "cg16675926", "cg23209941", "cg07134368", 
"cg24361198")
linkage_FollowUp <- Annotated_meth[linkage_FollowUp_cpgs, 
c(1,2,4,9,12,14,15,16,17,18,19,24,28,29,33)]
# All on chr1.  They are all from ROI_8  230700000-243700000 Look 
into this region/past studies more
write.csv(linkage_FollowUp, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/Hits_combined/linkage_FollowUp.csv")
# check any overlap with previously annotated variability by SD for 
CpG_rs
linkage_FollowUp_cpgs  %in% rownames(top100sbeSNP) # two are
linkage_FollowUp_cpgs[which(linkage_FollowUp_cpgs  %in% 
rownames(top100sbeSNP))]
[1] "cg16490124" "cg11251367"
# excel doc with gene info found at:
/Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Perform_Ass/Top100variable/CPG_detail_long.xlsx
 save(linkage_FollowUp_cpgs, linkage_FollowUp, hits_linkage, 
Annotated_meth_hits_linkage, hits_linkage_cpgs_rs, cpgInfo_range, 
cpgInfo_range_500, ibs_no, Meth_B, Annotated_meth, Annotated_chr, 
keep_sampleNames, topVariable_samples, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genomic_PCrisk_linkage.RData")
 
 
 
####################################################################
########
## 3. Prostate Cancer risk loci identified through published GWAS 
studies ##
####################################################################
########
# GWAS published PC risk loci generated from GWAS Catalog, then 
generated windows of 25KB either side of risk SNP to create a 50KB 
window of interest to perform association
# A list of 320 prostate cancer risk SNPs from published GWAS 
studies was generated using the GWAS catalogue (https://
www.ebi.ac.uk/gwas/).  63 duplicate SNPs from multiple studies were 
removed, along with 1 SNP with no information on UCSC, leaving 256 
unique SNPs.  
gwas_catalog <- read.delim("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/gwas_risk/
GWAS_catalog_PROSTATE.tsv", header=T)
head(gwas_catalog)
dim(gwas_catalog)  # 320 variants, 33 data info columns
# column 22 "SNPs" has the rs numbers
# column 13 has the position as per genome build h38
gwas_catalog_lessINFO <- gwas_catalog[,c(11,12,13,22)]
gwas_catalog_lessINFO$db <- gsub("rs", "dbsnp  rs", 
gwas_catalog_lessINFO$SNPs, fixed=T)
gwas_catalog_lessINFO$hg19_pos <- 
c(rep("TBA",nrow(gwas_catalog_lessINFO)))
write.csv(gwas_catalog_lessINFO, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/PCrisk/Lit_risk/
gwas_risk/gwas_catalog_lessINFO.csv")
# when I put this into SNP nexus only got 254 back under "Genomic 
Coordinates and External Links" and 
# 494 under "Consequences on UCSC"
# Checked which were unique rs names:
length(unique(gwas_catalog_lessINFO$SNPs))  #[1] 257, still 3 more 
than turned up in SNP nexus..
# but #25 is NA so that takes it down to 256
length(gwas_catalog_lessINFO$SNPs)  # [1] 320
# So there are 63 SNPs that double up in some studies?
length(gwas_catalog_lessINFO$SNPs) - 
length(unique(gwas_catalog_lessINFO$SNPs)) #63
length(which(duplicated(gwas_catalog_lessINFO$SNPs))) #63
which(duplicated(gwas_catalog_lessINFO$SNPs))
unique_gwas <- gwas_catalog_lessINFO[-
c(which(duplicated(gwas_catalog_lessINFO$SNPs))),]
dim(unique_gwas) #257 6
length(unique(unique_gwas$SNPs)) #257
duplicated(unique_gwas$SNPs) # all FALSE
# remove row 23 as no info
unique_gwas <- unique_gwas[-23,]
write.csv(unique_gwas, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/gwas_risk/
gwas_catalog_unique.csv")
# As these SNPs have been annotated to the latest genome build hg38, 
I ran them through SNP nexus, to generate hg19 annotations so that 
they can be compared to 450K data and other other PC risk info.  
# Again got 254 out so went through ths excel file to find the two 
missing ones, they are rs115457135 and rs11530697
# rs115457135 has now been 'merged' with rs7767188, replaced on 
excel spreadsheet and looked up position
#  rs11530697 has now been 'merged' with rs3129859 , replaced on 
excel spreadsheet and looked up position 
# read back in and create window
unique_gwas2 <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/gwas_risk/
gwas_catalog_unique.csv", head=T)
unique_gwas2$chromPosition
unique_gwas2$window <- paste(unique_gwas2$chromPosition-50000, ":", 
unique_gwas2$chromPosition+50000, sep="")
write.csv(unique_gwas2, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/gwas_risk/
gwas_catalog_unique2.csv")
# added to All_PCrisk_info spreadsheet
# generate windows for analysis
gwas <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/PCrisk/Lit_risk/gwas_risk/
gwas_catalog_unique2.csv")
dim(gwas) # 256 11
gwas <- gwas[,c(8,9,10)]
colnames(gwas) <- c("snp", "chr", "pos")
gwas$start_50KB <- gwas$pos-25000
gwas$end_50KB <- gwas$pos+25000
gwas$end_50KB - gwas$start_50KB # check
gwas$chr <- as.numeric(gsub("chr", "", gwas$chr, fixed=T))
# remove those on the X chr, I have no meth data for these
length(which(!(is.na(gwas$chr)))) #242 
length(which(is.na(gwas$chr))) #14
gwas <- gwas[which(!(is.na(gwas$chr))),] 
dim(gwas) # 242 5
gwas$snp
# Create .tped files
library(GenABEL)
for(snp in 1:length(gwas$snp)){
system(paste(c("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
keep_samples.txt --chr ", gwas$chr[snp]," --from-bp ", gwas
$start_50KB[snp]," --to-bp ", gwas$end_50KB[snp]," --recode --
transpose --out /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
windows_gwas/", as.character(gwas$snp[snp])),collapse=""))
convert.snp.tped(tpedfile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_gwas/", as.character(gwas
$snp[snp]),".tped", sep=""), tfamfile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_gwas/",as.character(gwas$snp[snp]),".tfam", 
sep=""), outfile=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
windows_gwas/", as.character(gwas$snp[snp]),".raw", sep=""))
# create .map file by not transposing  
system(paste(c("/Applications/plink-1.07-mac-intel/plink --noweb --
bfile /Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --keep /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
keep_samples.txt --chr ", gwas$chr[i]," --from-bp ", gwas
$start_50KB[i]," --to-bp ", gwas$end_50KB[i]," --recode --out /
Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/Genetic_riskLoci/windows_gwas/", as.character(gwas
$snp[i])),collapse=""))
}
# make pheno file
cpgs_genomic <- rownames(Annotated_meth[which(Annotated_chr==gwas
$chr[i] & Annotated_meth$pos <gwas$end_50KB[i] & Annotated_meth$pos 
>gwas$start_50KB[i]),])
# if(length(cpgs_genomic)<=1) { next  # no cpgs in the window
# }
cpgs_genomic <- cpgs_genomic[which(cpgs_genomic %in% 
rownames(Meth_B))]
Meth_B_genomic <- data.frame(Meth_B[cpgs_genomic,])
Meth_B_genomic <- if(length(cpgs_genomic)==1) t(Meth_B_genomic) else 
Meth_B_genomic
colnames(Meth_B_genomic) <- topVariable_samples
rownames(Meth_B_genomic) <- cpgs_genomic 
keep_genomic <- 
data.frame(Meth_B_genomic[,which(colnames(Meth_B_genomic) %in% 
keep_sampleNames$V2)])
keep_genomic <- if(length(cpgs_genomic)==1) t(keep_genomic) else 
keep_genomic
rownames(keep_genomic) <- if(length(cpgs_genomic)==1) cpgs_genomic 
else rownames(keep_genomic)
dim(keep_genomic) # 1 39
ID <- matrix(colnames(keep_genomic))
colnames(ID) <- "id"
female <- keep_sampleNames[keep_sampleNames$V5==2,]
female$V2 
sex <- matrix(c(rep(1,17),0,1,1,0,0,0,rep(1,11),0,1,0,0,1))
colnames(sex) <- "sex"
dim(keep_genomic) # 39 1
pheno <- cbind(ID, sex, t(keep_genomic))
colnames(pheno)
write.table(pheno, file=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
windows_gwas/pheno_",as.character(gwas$snp[i]), ".txt", sep=""), 
quote=FALSE)
# Perform association
foreach(i=1:length(gwas$snp)) %dopar% { 
require(GenABEL)
gwaa=load.gwaa.data(phenofile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_gwas/pheno_",as.character(gwas$snp[i]), 
".txt", sep=""), genofile=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/windows_gwas/", as.character(gwas$snp[i]),".raw", 
sep=""),  force=TRUE)
gt=as.data.frame(as.numeric(gtdata(gwaa))) 
gwaa@gtdata@gtps=gt 
gwaa@phdata$id=gsub("_","-",gwaa@phdata$id)
rownames(gwaa@phdata)=gsub("_", "-", rownames(gwaa@phdata))
gwaa@gtdata@idnames=gsub("_", "-", gwaa@gtdata@idnames)
rownames(gwaa@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1,2)])) {  
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1
    }}  
nsnps  <- ncol(gwaa@gtdata@gtps) 
nCPGs <-  ncol(gwaa@phdata[-c(1:2)])
ntests <- length(name)
Number_Sig_Hits=length(which(log10pvps>-1*log10(0.05/nsnps)))
Number_Sig_Hits_stringent <- length(which(log10pvps>-1*log10(0.05/
ntests)))
Highest_pval=max(log10pvps, na.rm=T)
window_name <- as.character(gwas$snp[i]) 
stringent_cpgs <- name[which(log10pvps>-1*log10(0.05/ntests))]
stringent_log_pvals <- log10pvps[which(log10pvps>-1*log10(0.05/
ntests))]
Highest_pval=max(log10pvps, na.rm=T)
window_name <- as.character(gwas$snp[i])
hits_gwas_detailed <- data.frame(window_name, nsnps, nCPGs, ntests, 
Number_Sig_Hits, Number_Sig_Hits_stringent, Highest_pval, 
stringent_cpgs, stringent_log_pvals)
write.csv(hits_gwas_detailed, file=paste("/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/hits_gwas/Detail_gwas_hits_",  as.character(gwas
$snp[i]),".csv", collapse=""))  
}
# there are 79
# bind these together in one csv
filenames <- list.files(path="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/hits_gwas/
Detail_hits/", full.names=T)
library(plyr)
import.list <- llply(filenames, read.csv, header=T)
Detail_hits_all_gwas <- matrix(nrow=400, ncol=10)
library(reshape)
Detail_hits_all_gwas <- merge_recurse(import.list)
head(Detail_hits_all_gwas)
dim(Detail_hits_all_gwas) # 745  10
write.csv(Detail_hits_all_gwas, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genetic_riskLoci/hits_gwas/Detail_hits/Detail_hits_all_gwas.csv")
# These associations have one CpG with multiple SNPs, pull all the 
CpGs that have at least one association greater than log10 pval of 
10
hits_gwas <- read.csv("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/hits_gwas/
Detail_hits/Detail_hits_all_gwas.csv")
head(hits_gwas)
# Need hits_gwas$stringent_cpgs
hits_gwas_cpgs <- gsub("/..+", "", hits_gwas$stringent_cpgs)
length(hits_gwas_cpgs) #745
length(unique(hits_gwas_cpgs))  # 131, so 131 separate CpGs
hits_gwas_cpgs_unique <- hits_gwas_cpgs[which(!
(duplicated(hits_gwas_cpgs)))]
# ones with log pval >10
hits_gwas_10plus <- hits_gwas[hits_gwas$stringent_log_pvals >=10,]
dim(hits_gwas_10plus) #155
hits_gwas_cpgs_10plus <- gsub("/..+", "", hits_gwas_10plus
$stringent_cpgs)
length(unique(hits_gwas_cpgs_10plus))  # 36, only 36 separate CpGs 
with a log10 pval >10
 # [1] "cg11123619" "cg04741880" "cg26075039" "cg20720056" 
"cg06221963"
 # [6] "cg09359103" "cg23069046" "cg02956194" "cg03036702" 
"cg12474444"
# [11] "cg24634471" "cg04035553" "cg10596483" "cg14773235" 
"cg18468917"
# [16] "cg16060930" "cg00366603" "cg10158182" "cg17239008" 
"cg17351927"
# [21] "cg06281714" "cg06550200" "cg26690318" "cg14375985" 
"cg09349613"
# [26] "cg13301327" "cg08564027" "cg19586845" "cg01452169" 
"cg07146321"
# [31] "cg08241307" "cg06437931" "cg14271023" "cg14458575" 
"cg16989719"
# [36] "cg13284789"
# which of these are GpG_rs
Annotated_meth_hits_gwas <- Annotated_meth[hits_gwas_cpgs_unique,]
hits_gwas_cpgs_rs <- Annotated_meth_hits_gwas[(which(!
(is.na(Annotated_meth_hits_gwas$CpG_rs)))),]
Annotated_meth_hits_gwas_10plus <- 
Annotated_meth_hits_gwas[unique(hits_gwas_cpgs_10plus),]
dim(Annotated_meth_hits_gwas_10plus ) #36, 33
# which of the >10 logpvals have CpG_rs?
gwas_cpgs_rs_10plus <- Annotated_meth_hits_gwas_10plus[(which(!
(is.na(Annotated_meth_hits_gwas_10plus$CpG_rs)))),]
dim(gwas_cpgs_rs_10plus)  
# 22 33, so 22 out of the 36 unique CpGs with a log10 >10 have a 
CpG_rs
gwas_cpgs_rs_10plus$CpG_rs
 # [1] "rs75324250"  "rs45588133"  "rs112225149" "rs4919427"   
"rs6920276"  
 # [6] "rs672341"    "rs4714482"   "rs3888705"   "rs7485236"   
"rs56209138" 
# [11] "rs3134797"   "rs8192585"   "rs438475"    "rs28895028"  
"rs12763379" 
# [16] "rs72830824"  "rs72828989"  "rs11696871"  "rs12292212"  
"rs57606101" 
# [21] "rs35847523"  "rs4508746"
#  Follow up the 36 with >10pvals, ie. follow up 22 with a CpG_rs 
and 14 that do not have CpG_rs
gwas_FollowUp_cpgs <- unique(hits_gwas_cpgs_10plus)
gwas_FollowUp <- Annotated_meth[gwas_FollowUp_cpgs, 
c(1,2,4,9,12,14,15,16,17,18,19,24,28,29,33)]
write.csv(gwas_FollowUp, file="/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
Hits_combined/gwas_FollowUp.csv")
# 6 have probe_rs sites and some are Type I probes with CpG_rs that 
are not sbe_rs. Remove these as can't be sure the signal is not an 
artifact 
# Are any of these the original rs picked up in previous studies?
which(hits_gwas_cpgs_rs$CpG_rs %in% hits_gwas$window_name) # none
# what is the overlap with top[100 and top500] 95%-range variable 
CpG sites?
length(which(hits_gwas_cpgs_unique %in% cpgInfo_range
$cpgNames_range))  #0 
length(which(hits_gwas_cpgs_unique %in% 
cpgInfo_range_500$cpgNames_range_500)) #6 
rownames(Annotated_meth_hits_gwas[which(hits_gwas_cpgs_unique %in% 
cpgInfo_range_500$cpgNames_range_500),])
[1] "cg02956194" "cg24634471" "cg10596483"
[4] "cg00366603" "cg26690318" "cg13301327"
# Overlap with Standard Deviation?
length(which(hits_gwas_cpgs_unique %in% rownames(Top100_SD_M))) #0
length(which(hits_gwas_cpgs_unique %in% rownames(Top500_SD_M))) #6
rownames(Annotated_meth_hits_gwas[which(hits_gwas_cpgs_unique %in% 
rownames(Top500_SD_M)),])
[1] "cg02956194" "cg24634471" "cg10596483" "cg00366603"
[5] "cg26690318" "cg13301327"
# identical to 95%-range as above
# Create PNGs showing associations
# need to be specific with which cpg against all snps to get n(cpg) 
plots
for(CPG in 1:ncol(gwaa@phdata[,-c(1:2)])){  # 
png(filename=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
PNGs_gwas/", colnames(gwaa@phdata[,-c(1:2)])[CPG],".png", sep=""), 
pointsize=12,units="mm",width=137.6,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))   
# I;m not sure how to subset the pvals so you just get the CPG ones 
ie, /nsnps
plot(map_b[,4]*10^-6, 
log10pvps[],type="o",main=NULL,xlab=c("Position (Mb)", 
cex=2),ylab="-1*log10(p-value)",xlim=c(map_b[1,4]*10^-6,map_b[nsnps,
4]*10^-6),ylim=c(-3,35),cex=0.2)
title(main=list(paste("Association between ", 
colnames(gwaa@phdata[,-c(1:2)])[i], " and ", nsnps, " SNPs in a 50Kb 
window", sep=""), cex=.8))
abline(h=-1*log10(0.05),lty=2)
text(map_b[nsnps,4]*10^-6-0.005,-1*log10(0.05)+1,"p-value = 
0.05",font=3, cex=0.4, col="red")
abline(h=-1*log10(0.05/nsnps),lty=2)
text(map_b[nsnps,4]*10^-6-0.005,-1*log10(0.05/nsnps)
+1.2,"adjusted p-value",font=3, cex=0.4, col="red")
text(map_b[nsnps,4]*10^-6-0.033, 35, paste("Significant 
associations: ", length(which(log10pvps[]> -1*log10(0.05/nsnps))), 
sep=""), cex=0.6)
# points(Annotated_meth[NC_info$cpgs[cpg],
2]*10^-6,-0.8,pch=17, col="red")
# text(Annotated_meth[NC_info$cpgs[cpg],2]*10^-6,-3, 
NC_info$cpgs[cpg], col="red", cex=0.8)
dev.off()    
}
save(gwas, ibs_no, Meth_B, Annotated_meth, Annotated_chr, 
keep_sampleNames, topVariable_samples, file="/Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Ass_genetic_input/
Genomic_PCrisk_gwas.RData")

Sample
ID
Resource	  
Type
Sex
Disease	  
Status
Age
*	  
1 PC1-­‐03 Familial M Affected 82
2 PC2-­‐01 Familial M Affected 52
3 PC2-­‐02 Familial M Affected 53
4 PC2-­‐03 Familial M Affected 58
5 PC4-­‐01 Familial M Affected 74
6 PC9-­‐01 Familial M Affected 64
7 PC9-­‐04 Familial M Affected 65
8 PC9-­‐12 Familial M Affected 72
9 PC9-­‐121 Familial M Unaffected 48
10 PC9-­‐129 Familial F NA 61
11 PC9-­‐24 Familial F NA 45
12 PC9-­‐286 Familial M Unaffected 47
13 PC9-­‐338 Familial M Affected 63
14 PC9-­‐357 Familial M Unaffected 42
15 PC9-­‐532 Familial M Affected 71
62
16 PC11-­‐03 Familial M Affected 89
17 PC11-­‐04 Familial M Affected 73
18 PC11-­‐09 Familial M Affected 83
19 PC11-­‐147 Familial M Affected 61
20 PC11-­‐180 Familial M Unaffected 42
21 PC11-­‐234 Familial M Unaffected 55
PC11	  Median	  Age	  at	  Collection: 67
22 PC22-­‐03 Familial M Affected 74
23 PC22-­‐04 Familial M Affected 62
24 PC22-­‐16 Familial M Affected 76
25 PC22-­‐162 Familial M Unaffected 56
26 PC22-­‐17 Familial M Affected 63
27 PC22-­‐203 Familial M Affected 75
28 PC22-­‐21 Familial M Affected 70
29 PC22-­‐210 Familial F NA 73
30 PC22-­‐274 Familial M Unaffected 45
31 PC22-­‐387 Familial M Affected 79
32 PC22-­‐388 Familial M Unaffected 73
33 PC22-­‐393 Familial F NA 44
PC9	  Median	  Age	  at	  Collection:
Apendix	  5.1	  Samples	  for	  which	  good	  quality	  bisulphite	  sequencing	  data	  was	  generated
34 PC22-­‐414 Familial F NA 66
35 PC22-­‐416 Familial M Affected 61
36 PC22-­‐418 Familial M Unaffected 54
37 PC22-­‐468 Familial M Affected 69
38 PC22-­‐476 Familial M Unaffected 36
66
39 PC27-­‐01 Familial M Affected 64
40 PC72-­‐01 Familial M Affected 71
41 PC72-­‐02 Familial M Affected 85
42 PC72-­‐03 Familial M Affected 70
43 PC72-­‐04 Familial M Affected 78
44 PC72-­‐106 Familial M Unaffected 46
45 PC72-­‐126 Familial M Affected 49
46 PC72-­‐187 Familial F NA 41
47 PC72-­‐188 Familial M Other	  Cancer 23
48 PC72-­‐77 Familial M Affected 75
70
49 PC75-­‐01 Familial M Affected 65
50 DVA1690 Case/Control M Unaffected 70
51 DVA1694 Case/Control M Unaffected 68
52 DVA1695 Case/Control M Unaffected 70
53 DVA1696 Case/Control M Unaffected 68
54 DVA1703 Case/Control M Unaffected 71
55 DVA1704 Case/Control M Unaffected 68
56 DVA1705 Case/Control M Unaffected 70
57 DVA1710 Case/Control M Unaffected 67
58 DVA1711 Case/Control M Unaffected 69
59 DVA1718 Case/Control M Unaffected 67
60 DVA1720 Case/Control M Unaffected 69
61 DVA1723 Case/Control M Unaffected 67
62 DVA1725 Case/Control M Unaffected 70
63 DVA1728 Case/Control M Unaffected 67
64 DVA1729 Case/Control M Unaffected 68
65 DVA1730 Case/Control M Unaffected 70
66 DVA1732 Case/Control M Unaffected 68
67 DVA1735 Case/Control M Unaffected 69
68 DVA1737 Case/Control M Unaffected 69
69 DVA1739 Case/Control M Unaffected 70
70 DVA1743 Case/Control M Unaffected 68
PC72	  Median	  Age	  at	  Collection:
PC22	  Median	  Age	  at	  Collection:
71 DVA1744 Case/Control M Unaffected 69
72 DVA1745 Case/Control M Unaffected 70
73 DVA1746 Case/Control M Unaffected 67
74 DVA1747 Case/Control M Unaffected 68
75 DVA1748 Case/Control M Unaffected 70
76 DVA1749 Case/Control M Unaffected 71
77 DVA505 Case/Control M Unaffected 67
78 DVA552 Case/Control M Unaffected 67
79 DVA566 Case/Control M Unaffected 70
80 DVA576 Case/Control M Unaffected 68
81 DVA599 Case/Control M Unaffected 70
Control	  Median	  Age	  at	  Collection: 69
Median	  age	  of	  affected	  individuals: 71
Median	  age	  of	  unaffected	  individuals: 69
*	  Age	  at	  DNA	  collection	  in	  years
Organge	  highlighting:	  37	  samples	  with	  good	  quality
methylation	  and	  genotype	  data	  generated	  in	  Ch.	  2-­‐4
NA:	  	  non-­‐applicable



Gene	   CpG rs chr Position 	  Size
1 CASZ1_a cg13387643 rs284310 1 10737562 930
2 CASZ1_b cg13387643 rs284310 1 10737562 913
3 CDK2AP1 cg09084244 rs1109559 12 123757860 1102
4 MCC cg08238375 rs4705795 5 112483149 1058
5 TP53INP2	   cg20592836 rs2378256 20 33292126 1217
6 ITGB2 cg02464073 rs1721 21 46349496 1217
7 RPS6KA2 cg06330797 rs7357046 6 167195910 1230
8 USP7_a cg01891583 rs2304466 16 8995926 817
9 USP7_b cg01891583 rs2304466 16 8995926 822
10 S	  EPT9	   cg05161773 rs426439 17 75378036 1183
11 MGMT	   cg09993319 rs7898151 10 131529435 945
12 FOXP4 cg03036702 rs4714482 6 41528198 958
13 ARHGAP22 cg25013753 rs1051508 10 49654342 1109
14 C10orf46 cg00231519 rs36101953 10 120516119 946
15 AJAP1_a cg00345083 rs7517857 1 4725584 735
16 AJAP1_b cg00345083 rs7517857 1 4725584 864
17 NME6 cg08146865 rs3197223 3 48335857 751
18 ZFAT	   cg21927991 rs5025124 8 135494242 1110
19 NSMCE4A	   cg19360212 rs11200296 10 123731471 1296
20 FOXK2_a cg05331763 rs79974293 17 80535367 905
21 FOXK2_b cg05331763 rs79974293 17 80535367 880
22 FMN2	   cg11251367 rs12403072 1 240620177 1180
23 TOX2 cg26365090 rs11700304 20 42574362 1201
24 SMC1B	   cg17662493 rs6006744 22 45806309 1060
25 PRM1_a cg02978201 rs737008 16 11374865 680
26 PRM1_b cg02978201 rs737008 16 11374865 785
27 RAB11B_a cg04610028 rs2967607 19 8464538 782
28 RAB11B_b cg04610028 rs2967607 19 8464538 865
29 STK25 cg09289202 rs6757649 2 242443982 1000
Appendix	  5.2	  Primers	  for	  bisulphite	  sequencing
Primer	  L Primer	  R
TTTTTTTTATTTTGGTGTTTGTTTT ATAACTATCCCCTATCCCAAAATAC
GTGGGTAAATAGGGAAGTAGTTGTT ACTACTCAAACCCTCCACAAAAC
ATGTTTATTTAGGTTTGTTTTTTTT ATTTCAAACAATTCTCCTATCTCAAC
TTATAGATTTTTAGTTTGAAAGGAAAAGAA AAATATATCAAACAAACTTATAAACCC
TTTTTTTATATTTTTAGATGTTTTT TAAAATCCCATACAACCCTAAACTC
TTTTATGGGGGTTTTTTAAGTTTAG ACCCCCTACCTAACAAATACCTAAC
AAATTGGGAATTTTTTTGAGGATAG ATAACCTCCATAATCACCCAAAAC
AATAGTTTAATGATAAGTGAAATGATAGTT CTTAAACAATATTCCTAAAAACAATT
GGAAGAAGGTTTAATTTTGTGTGTT ATTTCAAACAATTCTCCTACCTCAA
AGTTGGTTTTAAGTAGGGATTTTTG TACCTCTCTCCCACCTAAATTATTT
TTTTTGTAGGTTTTTTTAAGTTTGTGTT TAAACAACAATACCACTCTCCTCAA
TGGAAATTAGTTTGGGTAATAAAGTG AAACCTAAAAACTCCTACAAATACC
AGAGTTAGGGTTATGGTGGAAAGTT AAATCACAAACCCAAAAAAACTAAA
GTGTTTGTTGTTTTAGTTAGTTG TCCAAAATAATCTTCTCATCTCAAAA
AAGTTAGTATTTTGTTGTGGATTTAATTTT TCTTCCCAAAACATCAAACTTCTATA
ATTTTGGAGGGTTTTTTTGAATAT CTACCCTACCCTCCTCCTAAATAAA
TTAAATGTTGTTTGGAGTTATTGTAT AAAAATTACAACCTTCTTCCCTAAC
TTGGGTTATGGTATTATTTTGTGG AAAAACATACTTCTCAAAAAAACTTCTC
TTAGGATTTTTTATTGGATTAAAAA AAATAAAACAAACAAACACAAAATAC
TTGTTTTATTTTTATGGTGTTGTAATGT ATAATCACAACAATTATCTCAATTCTAAAT
GGTGGAGGAGAAAGATAGTATAAAGTTT TATTTCCTCACCCAACCCTAAATA
TAGATTTTTTTGATAGTGTTATGTT CTACTCTATTTTTCCTTAAAACTTC
GGTTTTAGAAGAGTGGAAAGGAATTA CTAACCCTACTCTCCAAAAAACAAC
TTTTTTGAGGAAGGTTTGGTTTA CTTATCCATATACACTATCTTACAATAACC
TTAAGAGTTTGGAATAATGGTTAGG TTCTTAATCTCACCAAAATACTACC
GTAGGTTTTTGATTTTTATTGGATG AATAATACTTCTTAACAAAAACATATC
TGAGTAGTTGGGGTTATAGTAGTTATTA AACAAACTCCTACCTTCCAAAAAC
TATTAGGTTGTAGGTGGAGGTTTAG CAAATATAAACACCAATAAAAAAAA
TTTTTTTGTAGGTTTTTTTAAGTTTGTG AACCCAACTATCTTCCACTAAAACA
Appendix	  5.3	  Optimal	  PCR	  conditions	  for	  meQTL	  regions
Gene	   CpG Chr* Position Size Temp** Q	  solution Cycles Amplified
1 CASZ1_a cg13387643 1 10737562 930 58 None 40 Yes
2 CASZ1_b cg13387643 1 10737562 913 62 	  0.5uL 40 Yes
3 MCC cg08238375 5 112483149 1058 56 None 40 Yes
4 S	  EPT9	   cg05161773 17 75378036 1183 58 None 45 Yes
5 AJAP1_a cg00345083 1 4725584 735 58 None 40 Yes
6 AJAP1_b cg00345083 1 4725584 864 61 	  0.5uL 40 Yes
7 ZFAT	   cg21927991 8 135494242 1110 61 	  0.5uL 45 Yes
8 SMC1B	   cg17662493 22 45806309 1060 56 	  0.5uL 45 Yes
9 PRM1_a cg02978201 16 11374865 680 58 None 40 Yes
10 PRM1_b cg02978201 16 11374865 785 58 None 40 Yes
11 NME6 cg08146865 3 48335857 751 61 	  0.5uL 45 Yes
12 FOXP4 cg03036702 6 41528198 958 62 	  0.5uL 45 Yes
13 C10orf46 cg00231519 10 120516119 946 60 	  0.5uL 45 Yes
14 RPS6KA2 cg06330797 6 167195910 1230 60 	  0.5uL 45 Yes
15 MGMT	   cg09993319 10 131529435 945 62 	  0.5uL 45 Yes
16 STK25 cg09289202 242443982 1000 62 	  0.5uL 45 Yes
17 ARHGAP22 cg25013753 10 49654342 1109 60 	  0.5uL 45 Yes
18 USP7_a cg01891583 16 8995926 817 54 None 40 Yes
19 FOXK2_b cg05331763 17 80535367 880 62 None 45 Yes
20 RAB11B_a cg04610028 19 8464538 782 62 	  0.5uL 40 Yes
21 USP7_b cg01891583 16 8995926 822 60 	  0.5uL 45 No
22 FOXK2_a cg05331763 17 80535367 905 60 	  0.5uL 45 No
23 RAB11B_b cg04610028 19 8464538 865 56 	  0.5uL 45 No
24 ITGB2 cg02464073 21 46349496 1217 60 	  0.5uL 45 No
25 NSMCE4A	   cg19360212 10 123731471 1296 55 	  0.5uL 45 No
26 TP53INP2	   cg20592836 20 33292126 1217 55 	  0.5uL 45 No
27 TOX2 cg26365090 20 42574362 1201 54 	  0.5uL 45 No
28 FMN2	   cg11251367 1 240620177 1180 58 	  0.5uL 45 No
29 CDK2AP1 cg09084244 12 123757860 1102 60 	  0.5uL 45 No
*	  Chromosome
**	  Reaction	  Temperature
# Quality Control Pipeline for Bisulphite Sequencing data: 
Based on the Epigenesis guide http://www.epigenesys.eu/images/
stories/protocols/pdf/20120720103700_p57.pdf  
# Key steps: 
# 1. QC
# 2. Alignment
# 3. Extract Methylation data
# 4. Load Data in R
# 5. Perform QC with BiSeq
# 1. Quality Control:  FastQC (java):  via command line or 
using a GUI
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
ssh ...
module avail FastQC
module load FastQC/11.4
cd /gd/apps/FastQC-11.4
./fastqc ~/Emma_home/BiSeq_wd/WD/*fastq.gz --o ~/Emma_home/
BiSeq_wd/WD/FastQC_output
# Quality and Adapter trimming:  Trim Galore 
# This works on paired-end files, so both files per sample at 
the same time.  Default: removes base calls with Phred score 
20 or lower, removes Illumina adapter sequence form 3’ end, 
removes sequences shorter than 20bp
cd ~/Emma_home/BiSeq_wd/trim_galore_zip
./trim_galore --paired --trim1 ~/Emma_home/BiSeq_wd/WD/
*.fastq.gz --o ~/Emma_home/BiSeq_wd/test_2 --path_to_cutadapt 
~/Emma_home/BiSeq_wd/cutadapt-1.9.1/bin/cutadapt
# Generate a FastQC report for each trimmed read 
cd /gd/apps/FastQC-11.4
./fastqc ~/Emma_home/BiSeq_wd/test_2/*.fq.gz --o ~/Emma_home/
BiSeq_wd/FastQC_trimmed
2. Alignment to bisulphite reference:  Bismark
# Requires a working version of Perl, Bowtie2 and samtools 
# Sequencing data needs to be FastA format, either .fa 
or .fasta
# download reference genome from Ensemble:  http://
asia.ensembl.org/info/data/ftp/index.html/   
# Genome build Hg19
# Path to UCSC reference genome:  /gd/Genome_Reference/gatk-
bundle/hg19/ucsc.hg19.fasta
# Copied over to my folder
cd /gd/apps/bowtie2-2.2.6
module load bowtie2 
cd ~/Emma_home/BiSeq_wd/bismark_v0.15.0
chmod +x bismark
chmod +x bismark_genome_preparation  
# Prepare the reference genome
./bismark_genome_preparation --path_to_bowtie /gd/apps/
bowtie2-2.2.6 --bowtie2 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome/
# Align the genome, use --multicore to process in parallel
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-291_S90_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-291_S90_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC75-01_S74_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC75-01_S74_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-541_S33_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-541_S33_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-532_S75_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-532_S75_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-477_S2_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-477_S2_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-357_S62_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-357_S62_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-338_S14_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-338_S14_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-29_S4_L001_R1_001_val_1.fq.gz -2 
~/Emma_home/BiSeq_wd/test_2/PC9-29_S4_L001_R2_001_val_2.fq.gz 
--output_dir ~/Emma_home/BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-286_S26_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-286_S26_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-24_S78_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-24_S78_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-12_S83_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-12_S83_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-129_S86_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-129_S86_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-121_S36_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-121_S36_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-04_S32_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-04_S32_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC9-01_S22_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC9-01_S22_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-94_S84_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-94_S84_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-77_S29_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-77_S29_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-75_S9_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-75_S9_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-291_S90_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-291_S90_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-213_S73_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-213_S73_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-188_S16_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-188_S16_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-187_S8_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-187_S8_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-136_S52_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-136_S52_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-126_S79_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-126_S79_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-106_S3_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-106_S3_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-04_S25_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-04_S25_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-03_S5_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-03_S5_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-02_S94_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-02_S94_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC72-01_S50_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC72-01_S50_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC4-01_S7_L001_R1_001_val_1.fq.gz -2 
~/Emma_home/BiSeq_wd/test_2/PC4-01_S7_L001_R2_001_val_2.fq.gz 
--output_dir ~/Emma_home/BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC27-01_S82_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC27-01_S82_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-476_S54_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-476_S54_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-468_S34_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-468_S34_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-418_S6_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-418_S6_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-416_S48_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-416_S48_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-414_S55_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-414_S55_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-393_S91_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-393_S91_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-388_S31_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-388_S31_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-387_S93_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-387_S93_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-386_S41_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-386_S41_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-274_S87_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-274_S87_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-21_S89_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-21_S89_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-210_S64_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-210_S64_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-203_S30_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-203_S30_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-195_S19_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-195_S19_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-17_S95_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-17_S95_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-16_S72_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-16_S72_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-162_S28_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-162_S28_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-04_S47_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-04_S47_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC22-03_S53_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC22-03_S53_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC2-03_S18_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC2-03_S18_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC2-02_S80_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC2-02_S80_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC2-01_S20_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC2-01_S20_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC12-01_S61_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC12-01_S61_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-415_S44_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-415_S44_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-234_S38_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-234_S38_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-233_S92_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-233_S92_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-180_S23_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-180_S23_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-147_S59_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-147_S59_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-09_S43_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-09_S43_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-04_S37_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-04_S37_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC11-03_S46_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC11-03_S46_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/PC1-03_S10_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
PC1-03_S10_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/NTC_S60_L001_R1_001_val_1.fq.gz -2 
~/Emma_home/BiSeq_wd/test_2/NTC_S60_L001_R2_001_val_2.fq.gz --
output_dir ~/Emma_home/BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA720_S77_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA720_S77_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA711_S76_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA711_S76_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA599_S42_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA599_S42_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA586_S96_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA586_S96_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA576_S85_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA576_S85_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA566_S67_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA566_S67_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA552_S24_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA552_S24_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA505_S45_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA505_S45_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1749_S71_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1749_S71_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1748_S1_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1748_S1_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1747_S27_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1747_S27_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1746_S11_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1746_S11_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1745_S56_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1745_S56_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1744_S68_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1744_S68_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1743_S40_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1743_S40_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1739_S17_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1739_S17_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1737_S15_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1737_S15_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1735_S51_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1735_S51_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1732_S66_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1732_S66_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1730_S58_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1730_S58_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1729_S63_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1729_S63_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1728_S70_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1728_S70_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1725_S65_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1725_S65_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1723_S13_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1723_S13_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1718_S57_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1718_S57_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1710_S88_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1710_S88_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1705_S39_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1705_S39_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1704_S81_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1704_S81_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1703_S21_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1703_S21_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1696_S35_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1696_S35_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1695_S12_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1695_S12_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1694_S49_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1694_S49_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
Ref_genome  --path_to_bowtie /gd/apps/bowtie2-2.2.6 -1 ~/
Emma_home/BiSeq_wd/test_2/DVA1690_S69_L001_R1_001_val_1.fq.gz 
-2 ~/Emma_home/BiSeq_wd/test_2/
DVA1690_S69_L001_R2_001_val_2.fq.gz --output_dir ~/Emma_home/
BiSeq_wd/Alignment/alignment_output
# Creates two files (BAM and txt report file) for each of the 
96 samples 
3. Extract Methylation data
cd ~/Emma_home/BiSeq_wd/bismark_v0.15.0
chmod +x bismark_methylation_extractor  # makes this command 
executable on the server
 
./bismark_methylation_extractor -s ~/Emma_home/BiSeq_wd/
Alignment/alignment_output/
DVA566_S67_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.bam -p --
no_overlap --o ~/Emma_home/BiSeq_wd/extracted_methylation_data
# makes 15 files per sample
# Do all
./bismark_methylation_extractor -s ~/Emma_home/BiSeq_wd/
Alignment/alignment_output/*.fq.gz_bismark_bt2_pe.bam -p --
no_overlap --o ~/Emma_home/BiSeq_wd/extracted_methylation_data
# Use the --comprehensive command so that it combines the 4 
reads
./bismark_methylation_extractor -s --comprehensive ~/
Emma_home/BiSeq_wd/Alignment/alignment_output/
*.fq.gz_bismark_bt2_pe.bam -p --no_overlap --o ~/Emma_home/
BiSeq_wd/extracted_meth_comp
# Use bismark2bedGraph to get the required .cov files for R
chmod +x bismark2bedGraph
cd ~/Emma_home/BiSeq_wd/bismark_v0.15.0
./bismark2bedGraph --output DVA1748.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context/ ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1748_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-477.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-477_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-106.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-106_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC9-29.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-29_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-03.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-03_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-418.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-418_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC4-01.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC4-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-187.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-187_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC72-75.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-75_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC1-03.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC1-03_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1746.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1746_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1695.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1695_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1723.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1723_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-338.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-338_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1737.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1737_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-188.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-188_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA1739.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1739_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC2-03.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC2-03_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-195.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-195_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC2-01.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC2-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1703.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1703_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-01.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC11-180.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-180_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA552.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA552_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-04.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-04_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-286.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-286_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1747.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1747_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-162.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-162_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC72-77.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-77_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-203.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-203_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC22-388.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-388_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC9-04.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-04_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-541.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-541_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-468.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-468_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA1696.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1696_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-121.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-121_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC11-04.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-04_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC11-234.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-234_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA1705.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1705_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1743.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1743_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-386.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-386_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA599.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA599_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC11-09.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-09_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC11-415.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-415_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA505.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA505_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC11-03.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-03_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-04.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-04_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-416.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-416_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA1694.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1694_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-01.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1735.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1735_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-136.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-136_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC22-03.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-03_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-476.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-476_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC22-414.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-414_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA1745.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1745_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1718.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1718_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1730.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1730_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC11-147.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-147_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output NTC.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_NTC_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC12-01.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC12-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-357.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-357_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1729.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1729_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-210.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-210_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA1725.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1725_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1732.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1732_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA566.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA566_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1744.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1744_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1690.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1690_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1728.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1728_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1749.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1749_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-16.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-16_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-213.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-213_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC75-01.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC75-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-532.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-532_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA711.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA711_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA720.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA720_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-24.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-24_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-126.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-126_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC2-02.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC2-02_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA1704.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1704_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC27-01.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC27-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-12.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-12_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-94.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-94_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA576.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA576_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-129.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC9-129_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-274.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-274_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output DVA1710.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_DVA1710_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-21.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-21_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC72-291.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-291_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC22-393.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-393_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC11-233.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC11-233_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC22-387.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-387_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.tx
t
./bismark2bedGraph --output PC72-02.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC72-02_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC22-17.bedGraph --dir ~/
Emma_home/BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/
CpG_context/
CpG_context_PC22-17_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA586.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA586_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
#######################
## 4. Load Data in R ##
#######################
library(BiSeq)
sample_sheet <- read.csv("SampleSheet_2.csv", header=T)  
sample_names <- as.character(sample_sheet$Sample_ID) 
# load all files
files <- list.files("~/Emma_home/BiSeq_wd/R/cov_files/")
file_path <- paste("~/Emma_home/BiSeq_wd/R/cov_files/", files, 
sep="")
biseqRaw <- readBismark(file_path, colData=sample_names) 
biseqRel <- rawToRel(biseqRaw) # create relative data
##############################
## 5. Perform QC with BiSeq ##
##############################
# Subset object to contain only regions of interest
# Currently 104,302 CpGs, many off target regions as final 
regions of interest only 678
regions <- read.csv("/Users/ecazaly/Desktop/Thesis/Results/
Chapter_5/MiSeq/My_analysis/BiSeq_regions_r.csv")
# pull these out by row.name
biseq_regions <- biseqRaw[regions$row.name,]
# QC plots
covStats_regions <- covStatistics(biseq_regions)
covered_cpgs <- covStats_regions$Covered_CpG_sites
range(covered_cpgs) #[1]  43 389 # before 
removing off-target 118, 14375
median(covered_cpgs) #303  #old 1164
mean(covered_cpgs) #[1] 289 # before removing off-
target 1670
median <- covStats_regions$Median_coverage
range(median) #[1] 2 1472 # before removing 
off-target 2 67
mean(median)  #[1] 390  # before removing 
off-target 11.5
covBoxplots(biseq_regions, col="cornflowerblue", las=2)
png(file="/Users/ecazaly/Desktop/Thesis/Results/Chapter_5/
MiSeq/My_analysis/covBoxplots_regions.png", pointsize=12, 
units="mm", width=250, height=250*2/3, res=900)
covBoxplots(biseq_regions, col="cornflowerblue", las=2)
dev.off()
# Set QC thresholds for samples dependant on:
# 1. Median_coverage: median of the coverage of the CpG 
sites covered per sample must be above 10
samples_100 <- biseq_regions[,which(covStats_regions
$Covered_CpG_sites>=100)]
samples_100@colData$Sample_ID
covStats_samples_100 <- covStatistics(samples_100)
covStats_samples_100$Covered_CpG_sites  
# now remove any that do not have a min coverage of 10 
covStats_samples_100$Median_coverage
length(which(covStats_samples_100$Median_coverage>=10))  # 88
samples_100_10 <- 
samples_100[,which(covStats_samples_100$Median_coverage>=10)]
dim(samples_100_10) #678, 88
clean_raw_100 <- samples_100_10
clean_rel_100 <- rawToRel(clean_raw_100)
covBoxplots(clean_raw_100, col="cornflowerblue", las=2)  # 
looks slightly better?
png(file="/Users/ecazaly/Desktop/Thesis/Results/Chapter_5/
MiSeq/My_analysis/clean100_covBoxplots_regions.png", 
pointsize=12, units="mm", width=250, height=250*2/3, res=900)
covBoxplots(clean_raw, col="cornflowerblue", las=2, 
main="Coverage per sample: clean data")
dev.off()
# Set QC thresholds for CpGs:
# 1. Remove CpGs if row medians = 0
# 2. Remove CpGs if row medians = 1
# 3. Remove CpGs if NaN value is present in >90% of 
samples
length(which(rowMedians(methLevel(clean_rel_100), 
na.rm=T)==0)) #316
clean4 <- clean_raw_100[-
which(rowMedians(methLevel(clean_rel_100), na.rm=T)==1),]
clean4_rel <- rawToRel(clean4)
clean5 <- clean4[-which(rowMedians(methLevel(clean4_rel), 
na.rm=T)==0),]
#253 sites, 88 samples
clean5_rel <- rawToRel(clean5)
length_nan_5 <- function(row) {
length(which(is.nan(methLevel(clean5_rel)[row,])))
}
number_nans_5 <- sapply(1:nrow(clean5_rel), length_nan_5)
length(which(number_nans_5>75.6))  # 5
clean_raw5_90nan <- clean5[-which(number_nans_5>75.6),]
dim(clean_raw5_90nan) #248, 88  
clean_rel5_90nan <- rawToRel(clean_raw5_90nan)
# Analysis Pipeline for Bisulphite Sequencing data in R 
####################################################################
####################################################
# Key steps: 
# 1. Validate 450k data
# 2. Examine genotype-methylation association
# 3. Examine methylation levels between cancer/control groups
####################################################################
####################################################
###########################
## 1. Validate 450k data ##
###########################
# This was performed on raw data not cleaned because I wanted to 
include as many CpGs as possible when validating
# use the biseq_regions object generated in the above section
methLevel(bsRel_keyCpg)  
length(methLevel(bsRel_keyCpg))  #1248 (96x13), this includes the 
NTC + 95 samples
# remove NTC
bsRel_keyCpg2 <- bsRel_keyCpg[,-34]
length(methLevel(bsRel_keyCpg2))  #1235 (95x13)
length(which(is.nan(methLevel(bsRel_keyCpg2)))) #199  16%
# write this data to a CSV and check against methylation array data
write.csv(t(methLevel(bsRel_keyCpg2)), file="/Users/ecazaly/Desktop/
Thesis/Results/Chapter_5/MiSeq/My_analysis/
450k_biseq_validation.csv")
#################################################
## 2. Examine genotype-methylation association ##
#################################################
# Methylation Landscape Plots in 37 samples from the familial study 
with both methylation and genotype array data. These were the 
samples analysed for meQTL analysis in Chapter.4 An additional 2 
samples were removed from the analysis in this chapter as the 
bisulphite sequencing data was of poor quality
# 1. Group samples into 3 groups based on genotype at the CpG of 
interest
# 2. Within each group take the median methylation at each CpG site. 
# 3. Plot these three medians across all CpGs in the region using a 
different colour for each genotype
# 4. Is there a pattern between genotype and methylation?
# not present on Omni2.5 (8): FOXK2 (rs79974293), CASZ1 (rs284310), 
SEPT9 (rs426439), MGMT (rs7898151), MCC (rs4705795), FOXP4 
(rs4714482), C10orf46 (rs36101953), RAB11 (rs2967607)
# present on Omni2.5 (5): NME6 (rs3197223) , AJAP (rs7517857), USP7 
(kgp9608995), PRM1 (rs737008), ITGB2 (rs1721)
###  Regions with CpG-SNP present on Omni2.5  ###
# Plot with clean data:  clean_raw5_90nan
gwaa_all_omni@gtdata@idnames[4]=gsub("_a", "", 
gwaa_all_omni@gtdata@idnames[4])
gwaa_all_omni@gtdata@idnames[14]=gsub("_a", "", 
gwaa_all_omni@gtdata@idnames[14])
rownames(gwaa_all_omni@gtdata@gtps)[4]=gsub("_a", "", 
rownames(gwaa_all_omni@gtdata@gtps)[4]) 
rownames(gwaa_all_omni@gtdata@gtps)[14]=gsub("_a", "", 
rownames(gwaa_all_omni@gtdata@gtps)[14])           
gwaa_all_omni@phdata$id=gsub("_", "-", gwaa_all_omni@phdata$id)
gwaa_all_omni@gtdata@idnames=gsub("_", "-", 
gwaa_all_omni@gtdata@idnames)
rownames(gwaa_all_omni@gtdata@gtps)=gsub("_", "-", 
rownames(gwaa_all_omni@gtdata@gtps))
NME6_detail <- regions[which(regions$Gene=="NME6"),]
NME6_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
NME6_detail$row.name),]
NME6_rel <- rawToRel(NME6_raw)
**** have to remove the poor quality samples ****
rownames(ibs_no) %in% colnames(NME6_raw)  # 3 False
NME6_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(NME6_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs319722
3")]
NME6_genotype <- as.genotype.gwaa.data(NME6_gwaa) 
dim(NME6_genotype)
NME6_rel_samples <- NME6_rel[,which(colnames(NME6_rel) %in% 
rownames(NME6_genotype))]
NME6_rel_samples_ord <- 
NME6_rel_samples[,order(match(colnames(NME6_rel_samples), 
rownames(NME6_genotype)))]
colnames(NME6_rel_samples_ord)
identical(colnames(NME6_rel_samples_ord), rownames(NME6_genotype)) 
#TRUE
# work out the median methylation level per genotype
NME6_genotype$sample <- rownames(NME6_genotype)
NME6_AA <- NME6_genotype$sample[which(NME6_genotype$rs3197223=="A/
A")]
NME6_GA <- NME6_genotype$sample[which(NME6_genotype$rs3197223=="A/
G")]
NME6_GG <- NME6_genotype$sample[which(NME6_genotype$rs3197223=="G/
G")]
length(NME6_AA)  #10
length(NME6_GA)  #13, 1 less
length(NME6_GG)  #14, 1 less
# check this against general populaiton frequencies?
NME6_AA_meth <- methLevel(NME6_rel_samples_ord)[, NME6_AA]
dim(NME6_AA_meth)
NME6_AA_medians <- rowMedians(NME6_AA_meth, na.rm=T)
NME6_GA_meth <- methLevel(NME6_rel_samples_ord)[, NME6_GA]
NME6_GA_medians <- rowMedians(NME6_GA_meth, na.rm=T)
NME6_GG_meth <- methLevel(NME6_rel_samples_ord)[, NME6_GG]
NME6_GG_medians <- rowMedians(NME6_GG_meth, na.rm=T)
# are they different?  not really
NME6_AA_medians
NME6_GA_medians
NME6_GG_medians
# no longer NaNs but there are still some 1s/0s
library(gplots)
png(filename="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/NME6_landscape.png", pointsize=12, units="mm", 
width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(NME6_rel_samples_ord))*10^-6, NME6_AA_medians, 
type="o", pch=15, col="dark green", bg="dark green", xlab="", 
ylab="", main="Median Methylation by Genotype NME6
cg08146865 / rs3197223", ylim=c(0, 1.05))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(NME6_rel_samples_ord))*10^-6, NME6_GA_medians, 
type="b", pch=16, col="hotpink")
points(start(ranges(NME6_rel_samples_ord))*10^-6, NME6_GG_medians, 
type="b", pch=17, col="cornflowerblue")
abline(v=48335857*10^-6, col="black", lwd=1)
legend(48.335843,1.11, legend="CpG-SNP: UTR in open sea", 
col="black", bty="n", cex=0.8)
legend(x=48.3356, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (14)") 
legend(x=48.3356, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (10)") 
legend(x=48.3356, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(13)") 
dev.off()
### AJAP (rs7517857) ###
AJAP_detail<- regions[which(regions$Gene=="AJAP1_a_b"),]
AJAP_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
AJAP_detail$row.name),]
AJAP_rel <- rawToRel(AJAP_raw)
AJAP_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(AJAP_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs751785
7")]
AJAP_genotype <- as.genotype.gwaa.data(AJAP_gwaa) 
which(colnames(AJAP_rel) %in% rownames(AJAP_genotype))
AJAP_rel_samples <- AJAP_rel[,which(colnames(AJAP_rel) %in% 
rownames(AJAP_genotype))]
colnames(AJAP_rel_samples)
rownames(AJAP_genotype) # not the same
AJAP_rel_samples_ord <- 
AJAP_rel_samples[,order(match(colnames(AJAP_rel_samples), 
rownames(AJAP_genotype)))]
colnames(AJAP_rel_samples_ord)
identical(colnames(AJAP_rel_samples_ord), rownames(AJAP_genotype)) 
#TRUE
# work out the median methylation level per genotype
AJAP_genotype$sample <- rownames(AJAP_genotype)
AJAP_AA <- AJAP_genotype$sample[which(AJAP_genotype$rs7517857 =="A/
A")]
AJAP_GA <- AJAP_genotype$sample[which(AJAP_genotype$rs7517857 =="A/
G")]
AJAP_GG <- AJAP_genotype$sample[which(AJAP_genotype$rs7517857 =="G/
G")]
length(AJAP_AA)  #11 now 10
length(AJAP_GA)  #17 now 16
length(AJAP_GG)  #11 now 10
AJAP_AA_meth <- methLevel(AJAP_rel_samples_ord)[, AJAP_AA]
dim(AJAP_AA_meth)
AJAP_AA_medians <- rowMedians(AJAP_AA_meth, na.rm=T)
AJAP_GA_meth <- methLevel(AJAP_rel_samples_ord)[, AJAP_GA]
AJAP_GA_medians <- rowMedians(AJAP_GA_meth, na.rm=T)
AJAP_GG_meth <- methLevel(AJAP_rel_samples_ord)[, AJAP_GG]
AJAP_GG_medians <- rowMedians(AJAP_GG_meth, na.rm=T)
AJAP_AA_medians
AJAP_GA_medians
AJAP_GG_medians
png(filename="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/AJAP_landscape.png", pointsize=12, units="mm", 
width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(AJAP_rel_samples_ord))*10^-6, AJAP_AA_medians, 
type="o", pch=15, col="dark green", bg="green", xlab="", ylab="", 
main="Median Methylation by Genotype AJAP
cg00345083 / rs7517857")
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(AJAP_rel_samples_ord))*10^-6, AJAP_GA_medians, 
type="o", pch=16, col="hotpink")
points(start(ranges(AJAP_rel_samples_ord))*10^-6, AJAP_GG_medians, 
type="o", pch=17, col="cornflowerblue")
abline(v=4725584*10^-6, col="black", lwd=1)
legend(4.72513,1.062, legend="CpG-SNP: intronic in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=4.72485, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (10)") 
legend(x=4.72485, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (10)") 
legend(x=4.72485, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(16)") 
dev.off()
### USP7 (kgp9608995), cg01891583, 8995926 ###
USP7_detail <- regions[which(regions$Gene=="USP7_a"),]
USP7_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
USP7_detail$row.name),]
USP7_rel <- rawToRel(USP7_raw)
USP7_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(USP7_raw)),which(colnames(gwaa_all_omni@gtdata)=="kgp96089
95")]
USP7_genotype <- as.genotype.gwaa.data(USP7_gwaa) 
which(colnames(USP7_rel) %in% rownames(USP7_genotype))
USP7_rel_samples <- USP7_rel[,which(colnames(USP7_rel) %in% 
rownames(USP7_genotype))]
colnames(USP7_rel_samples)
rownames(USP7_genotype) # not the same
USP7_rel_samples_ord <- 
USP7_rel_samples[,order(match(colnames(USP7_rel_samples), 
rownames(USP7_genotype)))]
colnames(USP7_rel_samples_ord)
identical(colnames(USP7_rel_samples_ord), rownames(USP7_genotype)) 
#TRUE
USP7_genotype$sample <- rownames(USP7_genotype)
USP7_AA <- USP7_genotype$sample[which(USP7_genotype$kgp9608995 =="A/
A")]
USP7_GA <- USP7_genotype$sample[which(USP7_genotype$kgp9608995 =="A/
G")]
USP7_GG <- USP7_genotype$sample[which(USP7_genotype$kgp9608995 =="G/
G")]
length(USP7_AA)  #14 now 13
length(USP7_GA)  #20 now 19
length(USP7_GG)  #4
USP7_AA_meth <- methLevel(USP7_rel_samples_ord)[, USP7_AA]
dim(USP7_AA_meth)
USP7_AA_medians <- rowMedians(USP7_AA_meth, na.rm=T)
USP7_GA_meth <- methLevel(USP7_rel_samples_ord)[, USP7_GA]
USP7_GA_medians <- rowMedians(USP7_GA_meth, na.rm=T)
USP7_GG_meth <- methLevel(USP7_rel_samples_ord)[, USP7_GG]
USP7_GG_medians <- rowMedians(USP7_GG_meth, na.rm=T)
USP7_AA_medians
USP7_GA_medians
USP7_GG_medians
png(filename="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/USP7_landscape.png", pointsize=12, units="mm", 
width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(USP7_rel_samples_ord))*10^-6, USP7_AA_medians, 
type="o", pch=15, col="green", bg="green", xlab="", ylab="", 
main="Median Methylation by Genotype USP7
cg01891583 / kgp9608995", ylim=c(0, 1.06))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(USP7_rel_samples_ord))*10^-6, USP7_GA_medians, 
type="o", pch=16, col="hotpink")
points(start(ranges(USP7_rel_samples_ord))*10^-6, USP7_GG_medians, 
type="o", pch=17, col="cornflowerblue")
abline(v= 8995926*10^-6, col="black", lwd=1)
legend(8.99574,1.12, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=8.99533, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (14)") 
legend(x=8.99533, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (10)") 
legend(x=8.99533, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(13)") 
dev.off()
### PRM1 (rs737008), cg02978201, 11374865 ###
PRM1_detail <- regions[which(regions$Gene=="PRM1_a_b"),]
PRM1_raw <- clean_raw_90nan[which(rownames(clean_raw_90nan) %in% 
PRM1_detail$row.name),]
PRM1_rel <- rawToRel(PRM1_raw)
PRM1_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(PRM1_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs737008
")]
PRM1_genotype <- as.genotype.gwaa.data(PRM1_gwaa) 
which(colnames(PRM1_rel) %in% rownames(PRM1_genotype))
PRM1_rel_samples <- PRM1_rel[,which(colnames(PRM1_rel) %in% 
rownames(PRM1_genotype))]
colnames(PRM1_rel_samples)
rownames(PRM1_genotype) # not the same
PRM1_rel_samples_ord <- 
PRM1_rel_samples[,order(match(colnames(PRM1_rel_samples), 
rownames(PRM1_genotype)))]
colnames(PRM1_rel_samples_ord)
identical(colnames(PRM1_rel_samples_ord), rownames(PRM1_genotype)) 
#TRUE
PRM1_genotype$sample <- rownames(PRM1_genotype)
PRM1_AA <- PRM1_genotype$sample[which(PRM1_genotype$rs737008 =="A/
A")]
PRM1_CA <- PRM1_genotype$sample[which(PRM1_genotype$rs737008 =="A/
C")]
PRM1_CC <- PRM1_genotype$sample[which(PRM1_genotype$rs737008 =="C/
C")]
length(PRM1_AA)  #20, 19 now
length(PRM1_CA)  #17, 15 now
length(PRM1_CC)  #2
PRM1_AA_meth <- methLevel(PRM1_rel_samples_ord)[, PRM1_AA]
dim(PRM1_AA_meth)
PRM1_AA_medians <- rowMedians(PRM1_AA_meth, na.rm=T)
PRM1_CA_meth <- methLevel(PRM1_rel_samples_ord)[, PRM1_CA]
PRM1_CA_medians <- rowMedians(PRM1_CA_meth, na.rm=T)
PRM1_CC_meth <- methLevel(PRM1_rel_samples_ord)[, PRM1_CC]
PRM1_CC_medians <- rowMedians(PRM1_CC_meth, na.rm=T)
PRM1_AA_medians
PRM1_CA_medians
PRM1_CC_medians
png(filename="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/PRM1_landscape.png", pointsize=12, units="mm", 
width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(PRM1_rel_samples_ord))*10^-6, PRM1_AA_medians, 
type="o", pch=15, col="dark green", bg="green", xlab="", ylab="", 
ylim=c(0, 1.06), main="Median Methylation by Genotype PRM1
cg02978201 / rs737008")
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(PRM1_rel_samples_ord))*10^-6, PRM1_CA_medians, 
type="o", pch=16, col="hotpink")
points(start(ranges(PRM1_rel_samples_ord))*10^-6, PRM1_CC_medians, 
type="o", pch=17, col="cornflowerblue")
abline(v= 11374865*10^-6, col="black", lwd=1)
legend(11.37483,1.12, legend="CpG-SNP: coding (synonymous in open 
sea)", col="black", bty="n", cex=0.8)
legend(x=11.37425, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="CC (2)") 
legend(x=11.37425, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (19)") 
legend(x=11.37425, y=0.1, pch=16, col="hotpink", bty="n", legend="CA 
(15)") 
dev.off()
### ITGB2 (rs1721), cg02464073 ###
ITGB2_detail <- regions[which(regions$Gene=="ITGB2"),]
ITGB2_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
ITGB2_detail$row.name),]
ITGB2_rel <- rawToRel(ITGB2_raw)
ITGB2_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(ITGB2_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs1721"
)]
ITGB2_genotype <- as.genotype.gwaa.data(ITGB2_gwaa) 
which(colnames(ITGB2_rel) %in% rownames(ITGB2_genotype))
ITGB2_rel_samples <- ITGB2_rel[,which(colnames(ITGB2_rel) %in% 
rownames(ITGB2_genotype))]
colnames(ITGB2_rel_samples)
rownames(ITGB2_genotype) # not the same
ITGB2_rel_samples_ord <- 
ITGB2_rel_samples[,order(match(colnames(ITGB2_rel_samples), 
rownames(ITGB2_genotype)))]
colnames(ITGB2_rel_samples_ord)
identical(colnames(ITGB2_rel_samples_ord), rownames(ITGB2_genotype)) 
#TRUE
ITGB2_genotype$sample <- rownames(ITGB2_genotype)
ITGB2_AA <- ITGB2_genotype$sample[which(ITGB2_genotype$rs1721 =="A/
A")]
ITGB2_GA <- ITGB2_genotype$sample[which(ITGB2_genotype$rs1721 =="A/
G")]
ITGB2_GG <- ITGB2_genotype$sample[which(ITGB2_genotype$rs1721 =="G/
G")]
length(ITGB2_AA)  #2, now 1
length(ITGB2_GA)  #24, now 23
length(ITGB2_GG)  #12, now 11
ITGB2_AA_meth <- methLevel(ITGB2_rel_samples_ord)[, ITGB2_AA]
dim(ITGB2_AA_meth)
ITGB2_AA_medians <- ITGB2_AA_meth # only 1 change to meth value 
instead of rowMedians
ITGB2_GA_meth <- methLevel(ITGB2_rel_samples_ord)[, ITGB2_GA]
ITGB2_GA_medians <- rowMedians(ITGB2_GA_meth, na.rm=T)
ITGB2_GG_meth <- methLevel(ITGB2_rel_samples_ord)[, ITGB2_GG]
ITGB2_GG_medians <- rowMedians(ITGB2_GG_meth, na.rm=T)
ITGB2_AA_medians
ITGB2_GA_medians
ITGB2_GG_medians
png(filename="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/ITGB2_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(ITGB2_rel_samples_ord))*10^-6, ITGB2_AA_medians, 
type="o", pch=15, col="dark green", bg="green", xlab="", ylab="", 
main="Median Methylation by Genotype ITGB2
cg02464073 / rs1721", ylim=c(0, 1.06))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(ITGB2_rel_samples_ord))*10^-6, type="o", 
ITGB2_GA_medians, pch=16, col="hotpink")
points(start(ranges(ITGB2_rel_samples_ord))*10^-6, type="o",  
ITGB2_GG_medians, pch=17, col="cornflowerblue")
abline(v= 46349496*10^-6, col="black", lwd=1)
legend(46.349475,1.12, legend="CpG-SNP: UTR in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=46.34929, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (11)") 
legend(x=46.34929, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (1)") 
legend(x=46.34929, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(23)") 
dev.off()
###  Regions without CpG-SNP on Omni2.5  ###
# CASZ1
CASZ1_detail <- regions[which(regions$Gene=="CASZ1_a_b"),]
CASZ1_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
CASZ1_detail$row.name),]
CASZ1_rel <- rawToRel(CASZ1_raw)
# genotype at kpg1150744   or rs284307
casz1_gwaa <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="rs284307")]
casz1_genotype <- as.genotype.gwaa.data(casz1_gwaa) 
# need to convert kpg1150744 to rs
# casz1_gwaa2 <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="kpg1150744")]
# casz1_genotype2 <- as.genotype.gwaa.data(casz1_gwaa2) 
casz1_genotype$sample <- rownames(casz1_genotype)
casz1_AA <- casz1_genotype$sample[which(casz1_genotype$rs284307=="A/
A")]
casz1_GA <- casz1_genotype$sample[which(casz1_genotype$rs284307 
=="A/G")]
casz1_GG <- casz1_genotype$sample[which(casz1_genotype$rs284307 
=="G/G")]
length(casz1_AA)  #11
length(casz1_GA)  #15
length(casz1_GG)  #13
which(colnames(CASZ1_rel) %in% rownames(casz1_genotype))
CASZ1_rel_samples <- CASZ1_rel[,which(colnames(CASZ1_rel) %in% 
rownames(casz1_genotype))]
colnames(CASZ1_rel_samples)
rownames(casz1_genotype) # not the same
CASZ1_rel_samples_ord <- 
CASZ1_rel_samples[,order(match(colnames(CASZ1_rel_samples), 
rownames(casz1_genotype)))]
colnames(CASZ1_rel_samples_ord)
identical(colnames(CASZ1_rel_samples_ord), rownames(casz1_genotype)) 
#FALSE, 2 geno samples not having seq data
which(!(rownames(casz1_genotype) %in% 
colnames(CASZ1_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
casz1_geno <- casz1_genotype[which(casz1_genotype$sample %in% 
colnames(CASZ1_rel_samples_ord)),]
identical(colnames(CASZ1_rel_samples_ord), rownames(casz1_geno))  
#TRUE
casz1_AA <- casz1_geno$sample[which(casz1_geno$rs284307=="A/A")]
casz1_GA <- casz1_geno$sample[which(casz1_geno$rs284307 =="A/G")]
casz1_GG <- casz1_geno$sample[which(casz1_geno$rs284307 =="G/G")]
length(casz1_AA)  #9
length(casz1_GA)  #15
length(casz1_GG)  #13
CASZ1_AA_meth <- methLevel(CASZ1_rel_samples_ord)[, casz1_AA]
CASZ1_AA_medians <- rowMedians(CASZ1_AA_meth, na.rm=T)
CASZ1_GA_meth <- methLevel(CASZ1_rel_samples_ord)[, casz1_GA]
CASZ1_GA_medians <- rowMedians(CASZ1_GA_meth, na.rm=T)
CASZ1_GG_meth <- methLevel(CASZ1_rel_samples_ord)[, casz1_GG]
CASZ1_GG_medians <- rowMedians(CASZ1_GG_meth, na.rm=T)
library(gplots)
png(filename="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/CASZ1_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(CASZ1_rel_samples_ord))*10^-6, CASZ1_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype CASZ1", ylim=c(0, 
1.06))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(CASZ1_rel_samples_ord))*10^-6, type="b", 
CASZ1_GA_medians, pch=16, col="dark green")
points(start(ranges(CASZ1_rel_samples_ord))*10^-6, type="b", 
CASZ1_GG_medians, pch=17, col="hotpink")
abline(v=10737562*10^-6, col="black", lwd=1)
legend(10.73731,1.12, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=10.7369, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (9)") #AA
legend(x=10.7369, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (15)") #GA
legend(x=10.7369, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(13)") #GG
dev.off()
# C10orf46:   cg00231519 / rs36101953 / chr10:120516119
# rs10886296: 120522232 - 120516119  #6113
# rs4319431: 120515182 - 120516119  # -937
# Use rs4319431 genotype as this is ~1kb away and the LD plot 
indicates in LD with CpG-SNP
which(colnames(gwaa_all_omni@gtdata)=="rs4319431") # [1] 987672
C10orf46_gwaa <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="rs4319431")]
C10orf46_genotype <- as.genotype.gwaa.data(C10orf46_gwaa) 
C10orf46_genotype$sample <- rownames(C10orf46_genotype)
C10orf46_AA <- C10orf46_genotype$sample[which(C10orf46_genotype
$rs4319431 =="A/A")]
C10orf46_GA <- C10orf46_genotype$sample[which(C10orf46_genotype
$rs4319431 =="A/G")]
C10orf46_GG <- C10orf46_genotype$sample[which(C10orf46_genotype
$rs4319431 =="G/G")]
length(C10orf46_AA)  #5
length(C10orf46_GA)  #10
length(C10orf46_GG)  #24
# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
C10orf46_detail <- regions[which(regions$Gene=="C10orf46"),]
C10orf46_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) 
%in% C10orf46_detail$row.name),]
C10orf46_rel <- rawToRel(C10orf46_raw)
which(colnames(C10orf46_rel) %in% rownames(C10orf46_genotype))  #37
C10orf46_rel_samples <- C10orf46_rel[,which(colnames(C10orf46_rel) 
%in% rownames(C10orf46_genotype))]
colnames(C10orf46_rel_samples)
rownames(C10orf46_genotype) # not the same
C10orf46_rel_samples_ord <- 
C10orf46_rel_samples[,order(match(colnames(C10orf46_rel_samples), 
rownames(C10orf46_genotype)))]
colnames(C10orf46_rel_samples_ord)
identical(colnames(C10orf46_rel_samples_ord), 
rownames(C10orf46_genotype)) #FALSE, 2 geno samples not having seq 
data
which(!(rownames(C10orf46_genotype) %in% 
colnames(C10orf46_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
C10orf46_geno <- C10orf46_genotype[which(C10orf46_genotype$sample 
%in% colnames(C10orf46_rel_samples_ord)),]
identical(colnames(C10orf46_rel_samples_ord), 
rownames(C10orf46_geno))  #TRUE
C10orf46_AA <- C10orf46_geno$sample[which(C10orf46_geno$rs4319431 
=="A/A")]
C10orf46_GA <- C10orf46_geno$sample[which(C10orf46_geno$rs4319431 
=="A/G")]
C10orf46_GG <- C10orf46_geno$sample[which(C10orf46_geno$rs4319431 
=="G/G")]
length(C10orf46_AA)  # 5
length(C10orf46_GA)  # 9
length(C10orf46_GG)  # 23
C10orf46_AA_meth <- methLevel(C10orf46_rel_samples_ord)[, 
C10orf46_AA]
C10orf46_AA_medians <- rowMedians(C10orf46_AA_meth, na.rm=T)
C10orf46_GA_meth <- methLevel(C10orf46_rel_samples_ord)[, 
C10orf46_GA]
C10orf46_GA_medians <- rowMedians(C10orf46_GA_meth, na.rm=T)
C10orf46_GG_meth <- methLevel(C10orf46_rel_samples_ord)[, 
C10orf46_GG]
C10orf46_GG_medians <- rowMedians(C10orf46_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/C10orf46_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(C10orf46_rel_samples_ord))*10^-6, 
C10orf46_AA_medians, type="b", pch=15, col="cornflower blue", 
bg="green", xlab="", ylab="", main="Median Methylation by Genotype 
C10orf46
 cg00231519 / rs36101953", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(C10orf46_rel_samples_ord))*10^-6, type="b", 
C10orf46_GA_medians, pch=16, col="dark green")
points(start(ranges(C10orf46_rel_samples_ord))*10^-6, type="b", 
C10orf46_GG_medians, pch=17, col="hotpink")
abline(v=120516119*10^-6, col="black", lwd=1)
legend(120.51587, 1.12, legend="CpG-SNP: intronic in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=120.5155, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (5)") #AA
legend(x=120.5155, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (9)") #GA
legend(x=120.5155, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(23)") #GG
dev.off()
# RAB11: cg04610028 / rs2967607 / chr19:8464538 / intronic in CpG 
shore
conversion[which(conversion$Name=="kgp6405269"),] #rs2913970  
8464653 - 8464538 = 115
conversion[which(conversion$Name=="kgp9275677"),] #rs2913971  
8463460 - 8464538 = -1078
# Use genotype at kgp6405269 as this is ~100b away and the LD plot 
indicates in LD with CpG-SNP
which(colnames(gwaa_all_omni@gtdata)=="kgp6405269") #[1] 1467904
RAB11_gwaa <-
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="kgp6405269")]
RAB11_genotype <- as.genotype.gwaa.data(RAB11_gwaa) 
RAB11_genotype$sample <- rownames(RAB11_genotype)
RAB11_AA <- RAB11_genotype$sample[which(RAB11_genotype
$kgp6405269=="A/A")]
RAB11_GA <- RAB11_genotype$sample[which(RAB11_genotype
$kgp6405269=="A/G")]
RAB11_GG <- RAB11_genotype$sample[which(RAB11_genotype
$kgp6405269=="G/G")]
length(RAB11_AA)  # 2
length(RAB11_GA)  # 11
length(RAB11_GG)  # 26
RAB11_detail <- regions[which(regions$Gene=="RAB11_a"),]
RAB11_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
RAB11_detail$row.name),]
RAB11_rel <- rawToRel(RAB11_raw)
which(colnames(RAB11_rel) %in% rownames(RAB11_genotype))  #37
RAB11_rel_samples <- RAB11_rel[,which(colnames(RAB11_rel) %in% 
rownames(RAB11_genotype))]
colnames(RAB11_rel_samples)
rownames(RAB11_genotype) # not the same
RAB11_rel_samples_ord <- 
RAB11_rel_samples[,order(match(colnames(RAB11_rel_samples), 
rownames(RAB11_genotype)))]
colnames(RAB11_rel_samples_ord)
identical(colnames(RAB11_rel_samples_ord), rownames(RAB11_genotype)) 
#FALSE, 2 geno samples not having seq data
which(!(rownames(RAB11_genotype) %in% 
colnames(RAB11_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
RAB11_geno <- RAB11_genotype[which(RAB11_genotype$sample %in% 
colnames(RAB11_rel_samples_ord)),]
identical(colnames(RAB11_rel_samples_ord), rownames(RAB11_geno))  
#TRUE
RAB11_AA <- RAB11_geno$sample[which(RAB11_geno$kgp6405269 =="A/A")]
RAB11_GA <- RAB11_geno$sample[which(RAB11_geno$kgp6405269 =="A/G")]
RAB11_GG <- RAB11_geno$sample[which(RAB11_geno$kgp6405269 =="G/G")]
length(RAB11_AA)  # 2
length(RAB11_GA)  # 10
length(RAB11_GG)  # 25
RAB11_AA_meth <- methLevel(RAB11_rel_samples_ord)[, RAB11_AA]
RAB11_AA_medians <- rowMedians(RAB11_AA_meth, na.rm=T)
RAB11_GA_meth <- methLevel(RAB11_rel_samples_ord)[, RAB11_GA]
RAB11_GA_medians <- rowMedians(RAB11_GA_meth, na.rm=T)
RAB11_GG_meth <- methLevel(RAB11_rel_samples_ord)[, RAB11_GG]
RAB11_GG_medians <- rowMedians(RAB11_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/RAB11_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(RAB11_rel_samples_ord))*10^-6, RAB11_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype RAB11
cg04610028 / rs2967607", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(RAB11_rel_samples_ord))*10^-6, type="b", 
RAB11_GA_medians, pch=16, col="dark green")
points(start(ranges(RAB11_rel_samples_ord))*10^-6, type="b", 
RAB11_GG_medians, pch=17, col="hotpink")
abline(v=8464538*10^-6, col="black", lwd=1)
legend(8.46432, 1.13, legend="CpG-SNP: intronic in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=8.463937, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (2)") #AA
legend(x=8.463937, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (10)") #GA
legend(x=8.463937, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(25)") #GG
dev.off()
# SEPT9: cg05161773 / rs426439 / chr17:75378036
conversion[which(conversion$Name=="kgp9468443"),]  #rs67129266
75381103 - 75378036 = 3067
conversion[which(conversion$Name=="kgp9643238"),]  #rs312828   
75373938 - 75378036 = -4098
# Use genotype at kgp9468443 as this is ~3kb away and the LD plot 
indicates in LD with CpG-SNP
which(colnames(gwaa_all_omni@gtdata)=="")
SEPT9_gwaa <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="kgp9468443")]
SEPT9_genotype <- as.genotype.gwaa.data(SEPT9_gwaa) 
SEPT9_genotype$sample <- rownames(SEPT9_genotype)
SEPT9_AA <- SEPT9_genotype$sample[which(SEPT9_genotype$kgp9468443 
=="A/A")]
SEPT9_GA <- SEPT9_genotype$sample[which(SEPT9_genotype$kgp9468443 
=="A/G")]
SEPT9_GG <- SEPT9_genotype$sample[which(SEPT9_genotype$kgp9468443 
=="G/G")]
length(SEPT9_AA)  #17
length(SEPT9_GA)  #13
length(SEPT9_GG)  #9
# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
SEPT9_detail <- regions[which(regions$Gene=="SEPT_9"),]
SEPT9_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
SEPT9_detail$row.name),]
SEPT9_rel <- rawToRel(SEPT9_raw)
which(colnames(SEPT9_rel) %in% rownames(SEPT9_genotype))  #37
SEPT9_rel_samples <- SEPT9_rel[,which(colnames(SEPT9_rel) %in% 
rownames(SEPT9_genotype))]
colnames(SEPT9_rel_samples)
rownames(SEPT9_genotype) # not the same
SEPT9_rel_samples_ord <- 
SEPT9_rel_samples[,order(match(colnames(SEPT9_rel_samples), 
rownames(SEPT9_genotype)))]
colnames(SEPT9_rel_samples_ord)
identical(colnames(SEPT9_rel_samples_ord), rownames(SEPT9_genotype)) 
#FALSE, 2 geno samples not having seq data
which(!(rownames(SEPT9_genotype) %in% 
colnames(SEPT9_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
SEPT9_geno <- SEPT9_genotype[which(SEPT9_genotype$sample %in% 
colnames(SEPT9_rel_samples_ord)),]
identical(colnames(SEPT9_rel_samples_ord), rownames(SEPT9_geno))  
#TRUE
SEPT9_AA <- SEPT9_geno$sample[which(SEPT9_geno$kgp9468443 =="A/A")]
SEPT9_GA <- SEPT9_geno$sample[which(SEPT9_geno$kgp9468443 =="A/G")]
SEPT9_GG <- SEPT9_geno$sample[which(SEPT9_geno$kgp9468443 =="G/G")]
length(SEPT9_AA)  #16
length(SEPT9_GA)  #12
length(SEPT9_GG)  #9
SEPT9_AA_meth <- methLevel(SEPT9_rel_samples_ord)[, SEPT9_AA]
SEPT9_AA_medians <- rowMedians(SEPT9_AA_meth, na.rm=T)
SEPT9_GA_meth <- methLevel(SEPT9_rel_samples_ord)[, SEPT9_GA]
SEPT9_GA_medians <- rowMedians(SEPT9_GA_meth, na.rm=T)
SEPT9_GG_meth <- methLevel(SEPT9_rel_samples_ord)[, SEPT9_GG]
SEPT9_GG_medians <- rowMedians(SEPT9_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/SEPT9_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(SEPT9_rel_samples_ord))*10^-6, SEPT9_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype SEPT9
cg05161773 / rs426439", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(SEPT9_rel_samples_ord))*10^-6, type="b", 
SEPT9_GA_medians, pch=16, col="dark green")
points(start(ranges(SEPT9_rel_samples_ord))*10^-6, type="b", 
SEPT9_GG_medians, pch=17, col="hotpink")
abline(v=75378036*10^-6, col="black", lwd=1)
legend(75.378020, 1.13, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=75.3776, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (16)") #AA
legend(x= 75.3776, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (12)") #GA
legend(x= 75.3776, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(9)") #GG
dev.off()
# MGMT:  cg09993319 / rs7898151 / chr10:131529435 / intronic in open 
sea
conversion[which(conversion$Name=="kgp8599981"),] #rs12571103    
131530307 - 131529435 = 872
# Use genotype at as this is ~1kb away. However this may not be in 
LD with CpG-SNP as haplotype block right on the site where the 
nearest SNP is.  The plot looks like it is though
which(colnames(gwaa_all_omni@gtdata)=="kgp8599981")  
MGMT_gwaa <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="kgp8599981")]
MGMT_genotype <- as.genotype.gwaa.data(MGMT_gwaa) 
MGMT_genotype$sample <- rownames(MGMT_genotype)
MGMT_AA <- MGMT_genotype$sample[which(MGMT_genotype$kgp8599981 =="A/
A")]
MGMT_GA <- MGMT_genotype$sample[which(MGMT_genotype$kgp8599981 =="A/
G")]
MGMT_GG <- MGMT_genotype$sample[which(MGMT_genotype$kgp8599981 =="G/
G")]
length(MGMT_AA)  #3
length(MGMT_GA)  #19
length(MGMT_GG)  #17
# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
MGMT_detail <- regions[which(regions$Gene=="MGMT"),]
MGMT_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MGMT_detail$row.name),]
MGMT_rel <- rawToRel(MGMT_raw)
which(colnames(MGMT_rel) %in% rownames(MGMT_genotype))  #37
MGMT_rel_samples <- MGMT_rel[,which(colnames(MGMT_rel) %in% 
rownames(MGMT_genotype))]
colnames(MGMT_rel_samples)
rownames(MGMT_genotype) # not the same
MGMT_rel_samples_ord <- 
MGMT_rel_samples[,order(match(colnames(MGMT_rel_samples), 
rownames(MGMT_genotype)))]
colnames(MGMT_rel_samples_ord)
identical(colnames(MGMT_rel_samples_ord), rownames(MGMT_genotype)) 
#FALSE, 2 geno samples not having seq data
which(!(rownames(MGMT_genotype) %in% 
colnames(MGMT_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
MGMT_geno <- MGMT_genotype[which(MGMT_genotype$sample %in% 
colnames(MGMT_rel_samples_ord)),]
identical(colnames(MGMT_rel_samples_ord), rownames(MGMT_geno))  
#TRUE
MGMT_AA <- MGMT_geno$sample[which(MGMT_geno$kgp8599981 =="A/A")]
MGMT_GA <- MGMT_geno$sample[which(MGMT_geno$kgp8599981 =="A/G")]
MGMT_GG <- MGMT_geno$sample[which(MGMT_geno$kgp8599981 =="G/G")]
length(MGMT_AA)  #3
length(MGMT_GA)  #18
length(MGMT_GG)  #16
MGMT_AA_meth <- methLevel(MGMT_rel_samples_ord)[, MGMT_AA]
MGMT_AA_medians <- rowMedians(MGMT_AA_meth, na.rm=T)
MGMT_GA_meth <- methLevel(MGMT_rel_samples_ord)[, MGMT_GA]
MGMT_GA_medians <- rowMedians(MGMT_GA_meth, na.rm=T)
MGMT_GG_meth <- methLevel(MGMT_rel_samples_ord)[, MGMT_GG]
MGMT_GG_medians <- rowMedians(MGMT_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/MGMT_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(MGMT_rel_samples_ord))*10^-6, MGMT_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype MGMT
cg09993319 / rs7898151", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(MGMT_rel_samples_ord))*10^-6, type="b", 
MGMT_GA_medians, pch=16, col="dark green")
points(start(ranges(MGMT_rel_samples_ord))*10^-6, type="b", 
MGMT_GG_medians, pch=17, col="hotpink")
abline(v=131529435*10^-6, col="black", lwd=1)
legend(131529420*10^-6, 1.12, legend="CpG-SNP: intronic in open 
sea", col="black", bty="n", cex=0.8)
legend(x= 131.52948, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (3)") #AA
legend(x= 131.52948, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (18)") #GA
legend(x= 131.52948, y=0.1, pch=17, col="hotpink", bty="n", 
legend="GG (16)") #GG
dev.off()
# MCC: cg08238375 / rs4705795 / chr5:112483149  / intronic in open 
sea
conversion[which(conversion$Name=="kgp1825521"),]  #rs57297544  
112482136  - 112483149 = -1013
# 112482033 -  112483149 = -1116
# 112483604 -  112483149 = 455 rs2416305
# Use genotype at rs2416305 as this is ~.5 kb away and the LD plot 
indicates in LD with CpG-SNP
which(colnames(gwaa_all_omni@gtdata)=="")
MCC_gwaa <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="rs2416305")]
MCC_genotype <- as.genotype.gwaa.data(MCC_gwaa) 
MCC_genotype$sample <- rownames(MCC_genotype)
MCC_AA <- MCC_genotype$sample[which(MCC_genotype$rs2416305 =="A/A")]
MCC_GA <- MCC_genotype$sample[which(MCC_genotype$rs2416305 =="A/G")]
MCC_GG <- MCC_genotype$sample[which(MCC_genotype$rs2416305 =="G/G")]
length(MCC_AA)  #29
length(MCC_GA)  #10
length(MCC_GG)  #0
# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
MCC_detail <- regions[which(regions$Gene=="MCC"),]
MCC_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MCC_detail$row.name),]
MCC_rel <- rawToRel(MCC_raw)
which(colnames(MCC_rel) %in% rownames(MCC_genotype))  #37
MCC_rel_samples <- MCC_rel[,which(colnames(MCC_rel) %in% 
rownames(MCC_genotype))]
colnames(MCC_rel_samples)
rownames(MCC_genotype) # not the same
MCC_rel_samples_ord <- 
MCC_rel_samples[,order(match(colnames(MCC_rel_samples), 
rownames(MCC_genotype)))]
colnames(MCC_rel_samples_ord)
identical(colnames(MCC_rel_samples_ord), rownames(MCC_genotype)) 
#FALSE, 2 geno samples not having seq data
which(!(rownames(MCC_genotype) %in% colnames(MCC_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
MCC_geno <- MCC_genotype[which(MCC_genotype$sample %in% 
colnames(MCC_rel_samples_ord)),]
identical(colnames(MCC_rel_samples_ord), rownames(MCC_geno))  #TRUE
MCC_AA <- MCC_geno$sample[which(MCC_geno$rs2416305 =="A/A")]
MCC_GA <- MCC_geno$sample[which(MCC_geno$rs2416305 =="A/G")]
MCC_GG <- MCC_geno$sample[which(MCC_geno$rs2416305 =="G/G")]
length(MCC_AA)  # 27
length(MCC_GA)  # 10 
length(MCC_GG)  # 0  only genotype to have 0 so far
MCC_AA_meth <- methLevel(MCC_rel_samples_ord)[, MCC_AA]
MCC_AA_medians <- rowMedians(MCC_AA_meth, na.rm=T)
MCC_GA_meth <- methLevel(MCC_rel_samples_ord)[, MCC_GA]
MCC_GA_medians <- rowMedians(MCC_GA_meth, na.rm=T)
MCC_GG_meth <- methLevel(MCC_rel_samples_ord)[, MCC_GG]
MCC_GG_medians <- rowMedians(MCC_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/MCC_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(MCC_rel_samples_ord))*10^-6, MCC_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype MCC
cg08238375 / rs4705795", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(MCC_rel_samples_ord))*10^-6, type="b", 
MCC_GA_medians, pch=16, col="dark green")
#points(start(ranges(MCC_rel_samples_ord))*10^-6, type="b", 
MCC_GG_medians, pch=17, col="hotpink")
abline(v=112483149*10^-6, col="black", lwd=1)
legend(112.48314, 1.12, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=112.48323, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (27)") #AA
legend(x=112.48323, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (10)") #GA
legend(x=112.48323, y=0.1, pch=17, col="hotpink", bty="n", 
legend="GG (0)") #GG
dev.off()
#################################################################
## 3. Examine methylation levels between cancer/control groups ##
#################################################################
# Methylation Landscape Plots --> colour methylation values by case/
control status 
# Clean data generated in above section
clean_raw5_90nan
clean_rel5_90nan
cancer <- clean_raw5_90nan[, which(clean_raw5_90nan@colData
$Disease=="A")] 
# 248, 31
control <- clean_raw5_90nan[, which(clean_raw5_90nan@colData
$Disease=="DVA_control")]
# 248, 32
# subset this data by meQTL region
AJAP_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
AJAP_detail$row.name),]
AJAP_rel <- rawToRel(AJAP_raw)
CASZ1_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
CASZ1_detail$row.name),]
CASZ1_rel <- rawToRel(CASZ1_raw)
NME6_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
NME6_detail$row.name),]
NME6_rel <- rawToRel(NME6_raw)
MCC_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MCC_detail$row.name),]
MCC_rel <- rawToRel(MCC_raw)
C10orf46_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) 
%in% C10orf46_detail$row.name),]
C10orf46_rel <- rawToRel(C10orf46_raw)
MGMT_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MGMT_detail$row.name),]
MGMT_rel <- rawToRel(MGMT_raw)
USP7_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
USP7_detail$row.name),]
USP7_rel <- rawToRel(USP7_raw)
PRM1_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
PRM1_detail$row.name),]
PRM1_rel <- rawToRel(PRM1_raw)
FOXK2_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
FOXK2_detail$row.name),]
FOXK2_rel <- rawToRel(FOXK2_raw)
SEPT9_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
SEPT9_detail$row.name),]
SEPT9_rel <- rawToRel(SEPT9_raw)
RAB11_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
RAB11_detail$row.name),]
RAB11_rel <- rawToRel(RAB11_raw)
ITGB2_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
ITGB2_detail$row.name),]
ITGB2_rel <- rawToRel(ITGB2_raw)
# AJAP
median_AJAP_cancer <- rowMedians(methLevel(AJAP_rel[, 
which(AJAP_rel@colData$Disease=="A")]), na.rm=T)
median_AJAP_control <- rowMedians(methLevel(AJAP_rel[, 
which(AJAP_rel@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
AJAP_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1)  #c(bottom, left, top, 
right), default is c(5, 4, 4, 2) + 0.1.
plot(rep(start(ranges(AJAP_rel))*10^-6,ncol(cancer)), 
methLevel(AJAP_rel[, which(AJAP_rel@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="AJAP: 
Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(AJAP_rel))*10^-6, ncol(control)), 
methLevel(AJAP_rel[, which(AJAP_rel@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at AJAP by cancer 
status")
points(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=4725584*10^-6, col="black", lwd=1.5)
legend(x=(4725584*10^-6)-0.00004, y=1.16, legend="CpG-SNP: intronic 
in CpG Shore", bty="n", cex=.8)
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)-0.00006, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="AJAP: 
Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=4725584*10^-6, col="black", lwd=1.5)
legend(x=(4725584*10^-6)-0.00004, y=1.16, legend="CpG-SNP; intronic 
in CpG Shore", bty="n", cex=.8)
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)-0.00006, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
dev.off()
# CASZ1
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
CASZ1_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(CASZ1_rel))*10^-6,ncol(cancer)), 
methLevel(CASZ1_rel[, which(CASZ1_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="CASZ1: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(CASZ1_rel))*10^-6, ncol(control)), 
methLevel(CASZ1_rel[, which(CASZ1_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at CASZ1 by cancer 
status")
points(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=10737562*10^-6, col="black", lwd=1)
legend(x=(10737562*10^-6)-0.00027, y=1.16, legend="CpG-SNP; intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)-0.000009, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
median_CASZ1_cancer <- rowMedians(methLevel(CASZ1_rel[, 
which(CASZ1_raw@colData$Disease=="A")]), na.rm=T)
median_CASZ1_control <- rowMedians(methLevel(CASZ1_rel[, 
which(CASZ1_raw@colData$Disease=="DVA_control")]), na.rm=T)
plot(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="CASZ1: Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=10737562*10^-6, col="black", lwd=1)
legend(x=(10737562*10^-6)-0.00027, y=1.16, legend="CpG-SNP; intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)-0.000009, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
 
# PRM1
median_PRM1_cancer <- rowMedians(methLevel(PRM1_rel[, 
which(PRM1_raw@colData$Disease=="A")]), na.rm=T)
median_PRM1_control <- rowMedians(methLevel(PRM1_rel[, 
which(PRM1_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
PRM1_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(PRM1_rel))*10^-6,ncol(cancer)), 
methLevel(PRM1_rel[, which(PRM1_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="PRM1: 
Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(PRM1_rel))*10^-6, ncol(control)), 
methLevel(PRM1_rel[, which(PRM1_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at PRM1 by cancer 
status", ylim=c(0,1.1))
points(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=11374865*10^-6, col="black", lwd=1)
legend(x=(11374865*10^-6)+0.000006, y=1.16, legend="CpG-SNP: coding 
(synonymous) in open sea", bty="n", cex=.8)
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)+0.00014,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)-0.00002, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="PRM1: 
Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=11374865*10^-6, col="black", lwd=1)
legend(x=(11374865*10^-6)+0.000006, y=1.16, legend="CpG-SNP: coding 
(synonymous) in open sea", bty="n", cex=.8)
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)+0.00014,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)-0.00002, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
dev.off()
# USP7  
median_USP7_cancer <- rowMedians(methLevel(USP7_rel[, 
which(USP7_raw@colData$Disease=="A")]), na.rm=T)
median_USP7_control <- rowMedians(methLevel(USP7_rel[, 
which(USP7_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
USP7_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(USP7_rel))*10^-6,ncol(cancer)), 
methLevel(USP7_rel[, which(USP7_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="USP7: 
Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(USP7_rel))*10^-6, ncol(control)), 
methLevel(USP7_rel[, which(USP7_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(USP7_rel))*10^-6), median_USP7_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at USP7 by cancer 
status")
points(rep(start(ranges(USP7_rel))*10^-6), median_USP7_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=8995926*10^-6, col="black", lwd=1)
legend(x=(8995926*10^-6)-0.00025, y=1.16, legend="CpG-SNP: 
intragenic in open sea", bty="n", cex=.8)
legend(x=(start(ranges(USP7_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(USP7_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(USP7_rel))*10^-6), median_USP7_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="USP7: 
Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(USP7_rel))*10^-6), median_USP7_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=8995926*10^-6, col="black", lwd=1)
legend(x=(8995926*10^-6)-0.00025, y=1.16, legend="CpG-SNP: 
intragenic in open sea", bty="n", cex=.8)
legend(x=(start(ranges(USP7_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(USP7_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
dev.off()
# FOXK2
median_FOXK2_cancer <- rowMedians(methLevel(FOXK2_rel[, 
which(FOXK2_raw@colData$Disease=="A")]), na.rm=T)
median_FOXK2_control <- rowMedians(methLevel(FOXK2_rel[, 
which(FOXK2_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
FOXK2_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(FOXK2_rel))*10^-6,ncol(cancer)), 
methLevel(FOXK2_rel[, which(FOXK2_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="FOXK2: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(FOXK2_rel))*10^-6, ncol(control)), 
methLevel(FOXK2_rel[, which(FOXK2_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=80535367*10^-6, col="black", lwd=1)
legend(x=(80535367*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
points(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at FOXK2 by cancer 
status", ylim=c(0,1.1))
points(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00003, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="ITBG2: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=80535367*10^-6, col="black", lwd=1)
legend(x=(80535367*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00003, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# NME6
median_NME6_cancer <- rowMedians(methLevel(NME6_rel[, 
which(NME6_raw@colData$Disease=="A")]), na.rm=T)
median_NME6_control <- rowMedians(methLevel(NME6_rel[, 
which(NME6_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
NME6_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(NME6_rel))*10^-6,ncol(cancer)), 
methLevel(NME6_rel[, which(NME6_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="NME6: 
Individual Methylation Level", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(NME6_rel))*10^-6, ncol(control)), 
methLevel(NME6_rel[, which(NME6_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(NME6_rel))*10^-6), median_NME6_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Position (Mb)", 
ylab="methylation", main="Median Methylation at NME6 by cancer 
status")
points(rep(start(ranges(NME6_rel))*10^-6), median_NME6_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
abline(v=48335857*10^-6, col="black", lwd=1)
legend(x=(48335857*10^-6)-0.000009, y=1.16, legend="CpG-SNP: UTR in 
open sea", bty="n", cex=.8)
plot(rep(start(ranges(NME6_rel))*10^-6), median_NME6_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="NME6: 
Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(NME6_rel))*10^-6), median_NME6_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
abline(v=48335857*10^-6, col="black", lwd=1)
legend(x=(48335857*10^-6)-0.000009, y=1.16, legend="CpG-SNP: UTR in 
open sea", bty="n", cex=.8)
dev.off()
# MCC
median_MCC_cancer <- rowMedians(methLevel(MCC_rel[, 
which(MCC_raw@colData$Disease=="A")]), na.rm=T)
median_MCC_control <- rowMedians(methLevel(MCC_rel[, 
which(MCC_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
MCC_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(MCC_rel))*10^-6,ncol(cancer)), 
methLevel(MCC_rel[, which(MCC_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="MCC: 
Individual Methylation Level", ylim=c(0,1.1), xlim=c(112.4830999, 
112.4837))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MCC_rel))*10^-6, ncol(control)), 
methLevel(MCC_rel[, which(MCC_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(MCC_rel))*10^-6), median_MCC_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Position (Mb)", 
ylab="methylation", main="Median Methylation at MCC by cancer 
status")
points(rep(start(ranges(MCC_rel))*10^-6), median_MCC_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=112483149*10^-6, col="black", lwd=1)
legend(x=(112483149*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00005, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(MCC_rel))*10^-6), median_MCC_cancer, type="o", 
pch=16, cex=0.5, col="red", xlab="", ylab="", main="MCC: Median 
Methylation by Group", ylim=c(0,1.1), xlim=c(112.4830999, 
112.4837))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MCC_rel))*10^-6), median_MCC_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=112483149*10^-6, col="black", lwd=1)
legend(x=(112483149*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00005, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
dev.off()
# C10orf46
median_C10orf46_cancer <- rowMedians(methLevel(C10orf46_rel[, 
which(C10orf46_rel@colData$Disease=="A")]), na.rm=T)
median_C10orf46_control <- rowMedians(methLevel(C10orf46_rel[, 
which(C10orf46_rel@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
C10orf46_cancer.png", pointsize=12, units="mm", width=200, 
height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(C10orf46_rel))*10^-6,ncol(cancer)), 
methLevel(C10orf46_rel[, which(C10orf46_rel@colData
$Disease=="A")]), type="p", pch=16, cex=0.5, col="red", xlab="", 
ylab="", main="C10orf46: Individual Methylation Levels", 
ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(C10orf46_rel))*10^-6, ncol(control)), 
methLevel(C10orf46_rel[, which(C10orf46_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=120516119*10^-6, col="black", lwd=1)
legend(x=(120516119*10^-6)-0.00025, y=1.16, legend="CpG-SNP; 
intronic in CpG shore", bty="n", cex=.8)
points(rep(start(ranges(C10orf46_rel))*10^-6), 
median_C10orf46_cancer, type="o", pch=16, cex=0.5, col="red", 
xlab="Genomic Position (Mb)", ylab="Methylation", main="Median 
Methylation at C10orf46 by cancer status")
points(rep(start(ranges(C10orf46_rel))*10^-6), 
median_C10orf46_control, pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)+0.0001,y=1.17, 
pch=16, col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)-0.00002, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(C10orf46_rel))*10^-6), median_C10orf46_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="C10orf46: Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(C10orf46_rel))*10^-6), 
median_C10orf46_control, pch=17, col="blue", cex=0.5, type="o")
abline(v=120516119*10^-6, col="black", lwd=1)
legend(x=(120516119*10^-6)-0.00025, y=1.16, legend="CpG-SNP; 
intronic in CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)+0.0001,y=1.17, 
pch=16, col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)-0.00002, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
 
## MGMT
median_MGMT_cancer <- rowMedians(methLevel(MGMT_rel[, 
which(MGMT_raw@colData$Disease=="A")]), na.rm=T)
median_MGMT_control <- rowMedians(methLevel(MGMT_rel[, 
which(MGMT_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
MGMT_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(MGMT_rel))*10^-6,ncol(cancer)), 
methLevel(MGMT_rel[, which(MGMT_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="MGMT: 
Individual Methylation Level", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MGMT_rel))*10^-6, ncol(control)), 
methLevel(MGMT_rel[, which(MGMT_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=131529435*10^-6, col="black", lwd=1)
legend(x=(131529435*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
points(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at MGMT by cancer 
status")
points(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.0002,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.000115, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="MGMT: 
Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=131529435*10^-6, col="black", lwd=1)
legend(x=(131529435*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.0002,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.000115, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# SEPT9
median_SEPT9_cancer <- rowMedians(methLevel(SEPT9_rel[, 
which(SEPT9_raw@colData$Disease=="A")]), na.rm=T)
median_SEPT9_control <- rowMedians(methLevel(SEPT9_rel[, 
which(SEPT9_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
SEPT9_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(SEPT9_rel))*10^-6,ncol(cancer)), 
methLevel(SEPT9_rel[, which(SEPT9_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="SEPT9: Individual Methylation Level", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(SEPT9_rel))*10^-6, ncol(control)), 
methLevel(SEPT9_rel[, which(SEPT9_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=75378036*10^-6, col="black", lwd=1)
legend(x=(75378036*10^-6)-0.000015, y=1.16, legend="CpG-SNP: 
intronic in open sea", bty="n", cex=.8)
points(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at SEPT9 by cancer 
status")
points(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)+0.00012,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)-0.00002, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="SEPT9: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=75378036*10^-6, col="black", lwd=1)
legend(x=(75378036*10^-6)-0.000015, y=1.16, legend="CpG-SNP: 
intronic in open sea", bty="n", cex=.8)
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)+0.00012,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)-0.00002, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# RAB11
median_RAB11_cancer <- rowMedians(methLevel(RAB11_rel[, 
which(RAB11_raw@colData$Disease=="A")]), na.rm=T)
median_RAB11_control <- rowMedians(methLevel(RAB11_rel[, 
which(RAB11_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
RAB11_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(RAB11_rel))*10^-6,ncol(cancer)), 
methLevel(RAB11_rel[, which(RAB11_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="RAB11: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(RAB11_rel))*10^-6, ncol(control)), 
methLevel(RAB11_rel[, which(RAB11_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=8464538*10^-6, col="black", lwd=1)
legend(x=(8464538*10^-6)-0.00023, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
points(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at RAB11 by cancer 
status")
points(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)-0.00001, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="RAB11: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=8464538*10^-6, col="black", lwd=1)
legend(x=(8464538*10^-6)-0.00023, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)-0.00001, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# ITGB2 
median_ITGB2_cancer <- rowMedians(methLevel(ITGB2_rel[, 
which(ITGB2_raw@colData$Disease=="A")]), na.rm=T)
median_ITGB2_control <- rowMedians(methLevel(ITGB2_rel[, 
which(ITGB2_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
ITGB2_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1) 
plot(rep(start(ranges(ITGB2_rel))*10^-6,ncol(cancer)), 
methLevel(ITGB2_rel[, which(ITGB2_raw@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="ITGB2: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(ITGB2_rel))*10^-6, ncol(control)), 
methLevel(ITGB2_rel[, which(ITGB2_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=46349496*10^-6, col="black", lwd=1)
legend(x=(46349496*10^-6)+0.000002, y=1.16, legend="CpG-SNP: UTR in 
CpG shore", bty="n", cex=.8)
points(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at ITGB2 by cancer 
status")
points(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)-0.000015, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="ITGB2: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=46349496*10^-6, col="black", lwd=1)
legend(x=(46349496*10^-6)+0.000002, y=1.16, legend="CpG-SNP: UTR in 
CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)-0.000015, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
